assay_description,canonical_smiles,document_chembl_id,relation,standard_relation,standard_type,standard_units,standard_value,type,units,value,SMILES,year
Binding affinity to K-Ras G12D mutant-GDP complex,Nc1ccc2nc(Cc3c[nH]c4ccccc34)[nH]c2c1,CHEMBL2086330,=,=,Kd,nM,1300000.0,Kd,uM,1300.0,Nc1ccc2nc(Cc3c[nH]c4ccccc34)[nH]c2c1,2012
Binding affinity to K-Ras G12D mutant-GDP complex,CC[C@H](C)[C@H](N)C(=O)Nc1ccc2nc(Cc3c[nH]c4ccccc34)[nH]c2c1,CHEMBL2086330,=,=,Kd,nM,190000.0,Kd,uM,190.0,CC[C@H](C)[C@H](N)C(=O)Nc1ccc2nc(Cc3c[nH]c4ccccc34)[nH]c2c1,2012
Binding affinity to K-Ras G12D mutant-GDP complex,O=C(Nc1ccc2nc(Cc3c[nH]c4ccccc34)[nH]c2c1)[C@@H]1CCCN1,CHEMBL2086330,=,=,Kd,nM,340000.0,Kd,uM,340.0,O=C(Nc1ccc2nc(Cc3c[nH]c4ccccc34)[nH]c2c1)[C@@H]1CCCN1,2012
Inhibition of Ki-Ras,N#Cc1ccc2cc1Oc1ccc(CCC3CCCCC3)c(c1)CN1CCN(CC1=O)Cc1cncn1C2,CHEMBL2203227,=,=,EC50,nM,1065.0,EC50,nM,1065.0,N#Cc1ccc2cc1Oc1ccc(CCC3CCCCC3)c(c1)CN1CCN(CC1=O)Cc1cncn1C2,2011
Inhibition of Ki-Ras,N#Cc1ccc2cc1Oc1ccc3cccc(c3c1)N1CCN(CC1=O)Cc1cncn1C2,CHEMBL2203227,>,>,EC50,nM,10000.0,EC50,uM,10.0,N#Cc1ccc2cc1Oc1ccc3cccc(c3c1)N1CCN(CC1=O)Cc1cncn1C2,2011
Inhibition of full-length human KRas4B (amino acids 1 to 188)-SOS interaction assessed as inhibition of SOS-mediated nucleotide release activity,Cc1[nH]c2cc(Cl)cc(Cl)c2c1CCN,CHEMBL2396593,=,=,IC50,nM,155000.0,IC50,uM,155.0,Cc1[nH]c2cc(Cl)cc(Cl)c2c1CCN,2013
Inhibition of full-length human KRas4B (amino acids 1 to 188)-SOS interaction assessed as inhibition of nucleotide exchange activity,Cc1[nH]c2cc(Cl)cc(Cl)c2c1CCN,CHEMBL2396593,=,=,IC50,nM,342000.0,IC50,uM,342.0,Cc1[nH]c2cc(Cl)cc(Cl)c2c1CCN,2013
Binding affinity to KRAS G12D mutant (unknown origin),O=C(Nc1ccc2[nH]c(Cc3c[nH]c4ccccc34)nc2c1)[C@H]1CCCN1,CHEMBL2396593,=,=,Activity,uM,340.0,Activity,uM,340.0,O=C(Nc1ccc2[nH]c(Cc3c[nH]c4ccccc34)nc2c1)[C@H]1CCCN1,2013
Binding affinity to KRAS G12D mutant (unknown origin),CC[C@H](C)[C@H](N)C(=O)Nc1ccc2nc(Cc3c[nH]c4ccccc34)[nH]c2c1,CHEMBL2396593,=,=,Activity,uM,190.0,Activity,uM,190.0,CC[C@H](C)[C@H](N)C(=O)Nc1ccc2nc(Cc3c[nH]c4ccccc34)[nH]c2c1,2013
Binding affinity to KRAS G12D mutant (unknown origin),Cc1[nH]c2ccccc2c1Cc1nc2ccccc2[nH]1,CHEMBL2396593,=,=,Activity,mM,1.3,Activity,mM,1.3,Cc1[nH]c2ccccc2c1Cc1nc2ccccc2[nH]1,2013
Binding affinity to K-Ras (unknown origin) assessed as SOS-mediated nucleotide exchange by fluorescence assay relative to control,CC(C)(c1ccc(O)cc1)c1ccc(O)cc1,CHEMBL3108714,=,=,FC,,1.6,FC,,1.6,CC(C)(c1ccc(O)cc1)c1ccc(O)cc1,2013
Binding affinity to human K-RAS by NMR analysis,CC(C)(c1ccc(O)cc1)c1ccc(O)cc1,CHEMBL3108714,=,=,Kd,nM,600000.0,Kd,uM,600.0,CC(C)(c1ccc(O)cc1)c1ccc(O)cc1,2013
Binding affinity to human K-RAS by NMR analysis,Oc1ccc(-c2ccc(O)cc2)cc1,CHEMBL3108714,,,Inhibition,%,,INH,,,Oc1ccc(-c2ccc(O)cc2)cc1,2013
Inhibition of recombinant HA-tagged K-Ras G12V mutant (unknown origin) assessed as disruption of interaction with GST-tagged Raf-RBD after overnight incubation by HTRF assay,CC(C)[C@@H]1NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CCC(N)=O)NC(=O)C[C@@H](CCc2ccccc2)NC(=O)[C@@H]2CCCCN2C(=O)C(=O)C(C)(C)COC1=O,CHEMBL3217533,=,=,IC50,nM,1200.0,IC50,uM,1.2,CC(C)[C@@H]1NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CCC(N)=O)NC(=O)C[C@@H](CCc2ccccc2)NC(=O)[C@@H]2CCCCN2C(=O)C(=O)C(C)(C)COC1=O,2013
Inhibition of recombinant HA-tagged K-Ras G12V mutant (unknown origin) assessed as disruption of interaction with GST-tagged Raf-RBD after overnight incubation by HTRF assay,CCCC[C@H]1NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)[C@@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](CCC(N)=O)NC(=O)C[C@@H](CCc2ccccc2)NC(=O)[C@@H]2CCCCN2C(=O)C(=O)C(C)(C)COC1=O,CHEMBL3217533,=,=,IC50,nM,10000.0,IC50,uM,10.0,CCCC[C@H]1NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)[C@@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](CCC(N)=O)NC(=O)C[C@@H](CCc2ccccc2)NC(=O)[C@@H]2CCCCN2C(=O)C(=O)C(C)(C)COC1=O,2013
Inhibition of recombinant HA-tagged K-Ras G12V mutant (unknown origin) assessed as disruption of interaction with GST-tagged Raf-RBD after overnight incubation by HTRF assay,CC1(C)COC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](CCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)C[C@@H](CCc2ccccc2)NC(=O)[C@@H]2CCCCN2C(=O)C1=O,CHEMBL3217533,=,=,IC50,nM,1800.0,IC50,uM,1.8,CC1(C)COC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](CCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)C[C@@H](CCc2ccccc2)NC(=O)[C@@H]2CCCCN2C(=O)C1=O,2013
Inhibition of recombinant HA-tagged K-Ras G12V mutant (unknown origin) assessed as disruption of interaction with GST-tagged Raf-RBD after overnight incubation by HTRF assay,CC(C)C[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)C[C@@H](CCc2ccccc2)NC(=O)[C@@H]2CCCCN2C(=O)C(=O)C(C)(C)COC1=O,CHEMBL3217533,=,=,IC50,nM,200.0,IC50,uM,0.2,CC(C)C[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)C[C@@H](CCc2ccccc2)NC(=O)[C@@H]2CCCCN2C(=O)C(=O)C(C)(C)COC1=O,2013
Inhibition of recombinant HA-tagged K-Ras G12V mutant (unknown origin) assessed as disruption of interaction with GST-tagged Raf-RBD after overnight incubation by HTRF assay,CC1(C)COC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CCC(N)=O)NC(=O)C[C@@H](CCc2ccccc2)NC(=O)[C@@H]2CCCCN2C(=O)C1=O,CHEMBL3217533,=,=,IC50,nM,10000.0,IC50,uM,10.0,CC1(C)COC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CCC(N)=O)NC(=O)C[C@@H](CCc2ccccc2)NC(=O)[C@@H]2CCCCN2C(=O)C1=O,2013
Inhibition of recombinant HA-tagged K-Ras G12V mutant (unknown origin) assessed as disruption of interaction with GST-tagged Raf-RBD after overnight incubation by HTRF assay,CC(C)C[C@@H]1NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](c2ccccc2)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CCCN)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCC(N)=O)NC(=O)C[C@@H](CCc2ccccc2)NC(=O)[C@@H]2CCCCN2C(=O)C(=O)C(C)(C)COC1=O,CHEMBL3217533,=,=,IC50,nM,10000.0,IC50,uM,10.0,CC(C)C[C@@H]1NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](c2ccccc2)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CCCN)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCC(N)=O)NC(=O)C[C@@H](CCc2ccccc2)NC(=O)[C@@H]2CCCCN2C(=O)C(=O)C(C)(C)COC1=O,2013
Inhibition of recombinant HA-tagged K-Ras G12V mutant (unknown origin) assessed as disruption of interaction with GST-tagged Raf-RBD after overnight incubation by HTRF assay,CCCC[C@H]1NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)C[C@@H](CCc2ccccc2)NC(=O)[C@@H]2CCCCN2C(=O)C(=O)C(C)(C)COC1=O,CHEMBL3217533,=,=,IC50,nM,700.0,IC50,uM,0.7,CCCC[C@H]1NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)C[C@@H](CCc2ccccc2)NC(=O)[C@@H]2CCCCN2C(=O)C(=O)C(C)(C)COC1=O,2013
Inhibition of recombinant HA-tagged K-Ras G12V mutant (unknown origin) assessed as disruption of interaction with GST-tagged Raf-RBD after overnight incubation by HTRF assay,CC1(C)COC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)C[C@@H](CCc2ccccc2)NC(=O)[C@@H]2CCCCN2C(=O)C1=O,CHEMBL3217533,=,=,IC50,nM,1100.0,IC50,uM,1.1,CC1(C)COC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)C[C@@H](CCc2ccccc2)NC(=O)[C@@H]2CCCCN2C(=O)C1=O,2013
Inhibition of recombinant HA-tagged K-Ras G12V mutant (unknown origin) assessed as disruption of interaction with GST-tagged Raf-RBD after overnight incubation by HTRF assay,CC(C)C[C@@H]1NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)C[C@@H](CCc2ccccc2)NC(=O)[C@@H]2CCCCN2C(=O)C(=O)C(C)(C)COC1=O,CHEMBL3217533,=,=,IC50,nM,2000.0,IC50,uM,2.0,CC(C)C[C@@H]1NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)C[C@@H](CCc2ccccc2)NC(=O)[C@@H]2CCCCN2C(=O)C(=O)C(C)(C)COC1=O,2013
Inhibition of recombinant HA-tagged K-Ras G12V mutant (unknown origin) assessed as disruption of interaction with GST-tagged Raf-RBD after overnight incubation by HTRF assay,C[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]([C@H](C)O)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)C[C@@H](CCc2ccccc2)NC(=O)[C@@H]2CCCCN2C(=O)C(=O)C(C)(C)COC(=O)[C@H](Cc2ccccc2)NC1=O,CHEMBL3217533,=,=,IC50,nM,2300.0,IC50,uM,2.3,C[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]([C@H](C)O)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)C[C@@H](CCc2ccccc2)NC(=O)[C@@H]2CCCCN2C(=O)C(=O)C(C)(C)COC(=O)[C@H](Cc2ccccc2)NC1=O,2013
Binding affinity to K-Ras G12V mutant (unknown origin) after 2 hrs by fluorescence polarization-based spectrofluorimetric analysis,CC(C)C[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)C[C@@H](CCc2ccccc2)NC(=O)[C@@H]2CCCCN2C(=O)C(=O)C(C)(C)COC1=O,CHEMBL3217533,,,Activity,,,Activity,,,CC(C)C[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)C[C@@H](CCc2ccccc2)NC(=O)[C@@H]2CCCCN2C(=O)C(=O)C(C)(C)COC1=O,2013
Binding affinity to K-Ras G12V mutant (unknown origin) after 2 hrs by fluorescence polarization-based spectrofluorimetric analysis,CCCC[C@H]1NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)C[C@@H](CCc2ccccc2)NC(=O)[C@@H]2CCCCN2C(=O)C(=O)C(C)(C)COC1=O,CHEMBL3217533,=,=,Kd,nM,830.0,Kd,uM,0.83,CCCC[C@H]1NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)C[C@@H](CCc2ccccc2)NC(=O)[C@@H]2CCCCN2C(=O)C(=O)C(C)(C)COC1=O,2013
Binding affinity to K-Ras G12V mutant (unknown origin) by surface plasmon resonance assay,CCCC[C@H]1NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)C[C@@H](CCc2ccccc2)NC(=O)[C@@H]2CCCCN2C(=O)C(=O)C(C)(C)COC1=O,CHEMBL3217533,,,Activity,,,Activity,,,CCCC[C@H]1NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)C[C@@H](CCc2ccccc2)NC(=O)[C@@H]2CCCCN2C(=O)C(=O)C(C)(C)COC1=O,2013
Inhibition of K-Ras G12V mutant (unknown origin) assessed as disruption of interaction with GST-tagged Raf-RBD at 10 uM after 60 mins by fluorescence microscopic-based bead binding assay,CCCC[C@H]1NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)C[C@@H](CCc2ccccc2)NC(=O)[C@@H]2CCCCN2C(=O)C(=O)C(C)(C)COC1=O,CHEMBL3217533,,,Inhibition,%,,INH,,,CCCC[C@H]1NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)C[C@@H](CCc2ccccc2)NC(=O)[C@@H]2CCCCN2C(=O)C(=O)C(C)(C)COC1=O,2013
Inhibition of K-Ras G12V mutant (unknown origin) assessed as disruption of interaction with Myc-tagged Ral-GDS at 10 uM after 60 mins by fluorescence microscopic-based bead binding assay,CCCC[C@H]1NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)C[C@@H](CCc2ccccc2)NC(=O)[C@@H]2CCCCN2C(=O)C(=O)C(C)(C)COC1=O,CHEMBL3217533,,,Inhibition,%,,INH,,,CCCC[C@H]1NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)C[C@@H](CCc2ccccc2)NC(=O)[C@@H]2CCCCN2C(=O)C(=O)C(C)(C)COC1=O,2013
Inhibition of K-Ras G12V mutant (unknown origin) assessed as disruption of interaction with Tiam1 at 10 uM after 60 mins by fluorescence microscopic-based bead binding assay,CCCC[C@H]1NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)C[C@@H](CCc2ccccc2)NC(=O)[C@@H]2CCCCN2C(=O)C(=O)C(C)(C)COC1=O,CHEMBL3217533,,,Inhibition,%,,INH,,,CCCC[C@H]1NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)C[C@@H](CCc2ccccc2)NC(=O)[C@@H]2CCCCN2C(=O)C(=O)C(C)(C)COC1=O,2013
Inhibition of K-Ras G12V mutant in human H358 cells assessed as decrease in Mek phosphorylation up to 16 hrs,CCCC[C@H]1NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)C[C@@H](CCc2ccccc2)NC(=O)[C@@H]2CCCCN2C(=O)C(=O)C(C)(C)COC1=O,CHEMBL3217533,,,Inhibition,%,,INH,,,CCCC[C@H]1NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)C[C@@H](CCc2ccccc2)NC(=O)[C@@H]2CCCCN2C(=O)C(=O)C(C)(C)COC1=O,2013
Inhibition of K-Ras G12V mutant in human H358 cells assessed as decrease in Erk phosphorylation up to 16 hrs,CCCC[C@H]1NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)C[C@@H](CCc2ccccc2)NC(=O)[C@@H]2CCCCN2C(=O)C(=O)C(C)(C)COC1=O,CHEMBL3217533,,,Inhibition,%,,INH,,,CCCC[C@H]1NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)C[C@@H](CCc2ccccc2)NC(=O)[C@@H]2CCCCN2C(=O)C(=O)C(C)(C)COC1=O,2013
Inhibition of K-Ras G12V mutant in human A549 cells assessed as decrease in Mek phosphorylation up to 16 hrs,CCCC[C@H]1NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)C[C@@H](CCc2ccccc2)NC(=O)[C@@H]2CCCCN2C(=O)C(=O)C(C)(C)COC1=O,CHEMBL3217533,,,Inhibition,%,,INH,,,CCCC[C@H]1NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)C[C@@H](CCc2ccccc2)NC(=O)[C@@H]2CCCCN2C(=O)C(=O)C(C)(C)COC1=O,2013
Inhibition of K-Ras G12V mutant in human A549 cells assessed as decrease in Erk phosphorylation up to 16 hrs,CCCC[C@H]1NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)C[C@@H](CCc2ccccc2)NC(=O)[C@@H]2CCCCN2C(=O)C(=O)C(C)(C)COC1=O,CHEMBL3217533,,,Inhibition,%,,INH,,,CCCC[C@H]1NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)C[C@@H](CCc2ccccc2)NC(=O)[C@@H]2CCCCN2C(=O)C(=O)C(C)(C)COC1=O,2013
Inhibition of K-Ras G12V mutant (unknown origin) assessed as disruption fluorescein-labeled Raf binding to beads immobilized with K-Ras G12V mutant at 10 uM after 60 mins by fluorescence microscopic-based bead binding assay,CCCC[C@H]1NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)C[C@@H](CCc2ccccc2)NC(=O)[C@@H]2CCCCN2C(=O)C(=O)C(C)(C)COC1=O,CHEMBL3217533,,,Inhibition,%,,INH,,,CCCC[C@H]1NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)C[C@@H](CCc2ccccc2)NC(=O)[C@@H]2CCCCN2C(=O)C(=O)C(C)(C)COC1=O,2013
Binding affinity to K-Ras G12V mutant (unknown origin),CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCCN1C(=O)CN)C(C)(C)C)[C@@H](C)CC)C(C)(C)C)C(=O)N[C@H](C(=O)NCC(=O)N1[C@H](C(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O)CSC1(C)C)[C@@H](C)O,CHEMBL3351816,,,Activity,,,Activity,,,CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCCN1C(=O)CN)C(C)(C)C)[C@@H](C)CC)C(C)(C)C)C(=O)N[C@H](C(=O)NCC(=O)N1[C@H](C(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O)CSC1(C)C)[C@@H](C)O,2014
Inhibition of biotinylated KRas-GDP (unknown origin) at 200 uM incubated for 2.5 hrs followed by SOS addition measured after 4 hrs by HTRF method,O=C1C=CC(=O)N1C1CCS(=O)(=O)C1,CHEMBL3414570,,,Inhibition,%,,INH,,,O=C1C=CC(=O)N1C1CCS(=O)(=O)C1,2015
Inhibition of biotinylated KRas-GDP (unknown origin) at 200 uM incubated for 2.5 hrs followed by SOS addition measured after 4 hrs by HTRF method,CCN1C(=O)C=C(c2cccc(CN)c2)C1=O,CHEMBL3414570,,,Inhibition,%,,INH,,,CCN1C(=O)C=C(c2cccc(CN)c2)C1=O,2015
Inhibition of biotinylated KRas-GDP (unknown origin) at 200 uM incubated for 2.5 hrs followed by SOS addition measured after 4 hrs by HTRF method,CCN1C(=O)C=C(c2cccc(C(N)=O)c2)C1=O,CHEMBL3414570,,,Inhibition,%,,INH,,,CCN1C(=O)C=C(c2cccc(C(N)=O)c2)C1=O,2015
Inhibition of biotinylated KRas-GDP (unknown origin) at 200 uM incubated for 2.5 hrs followed by SOS addition measured after 4 hrs by HTRF method,CCN1C(=O)C=C(c2cc(C#N)cc(C(=O)O)c2)C1=O,CHEMBL3414570,,,Inhibition,%,,INH,,,CCN1C(=O)C=C(c2cc(C#N)cc(C(=O)O)c2)C1=O,2015
Inhibition of biotinylated KRas-GDP (unknown origin) at 200 uM incubated for 2.5 hrs followed by SOS addition measured after 4 hrs by HTRF method,CCN1C(=O)C=C(c2cc(Cl)cc(C(N)=O)c2)C1=O,CHEMBL3414570,,,Inhibition,%,,INH,,,CCN1C(=O)C=C(c2cc(Cl)cc(C(N)=O)c2)C1=O,2015
Time dependent inhibition of wild-type KRas (unknown origin) assessed as SOS-mediated MANT-dGDP displacement at 200 uM by microplate reader analysis,CCN1C(=O)C=C(c2cccc(C(N)=O)c2)C1=O,CHEMBL3414570,,,Inhibition,%,,INH,,,CCN1C(=O)C=C(c2cccc(C(N)=O)c2)C1=O,2015
Time dependent inhibition of KRas G12V mutant (unknown origin) assessed as SOS-mediated MANT-dGDP displacement at 200 uM by microplate reader analysis,CCN1C(=O)C=C(c2cccc(C(N)=O)c2)C1=O,CHEMBL3414570,,,Inhibition,%,,INH,,,CCN1C(=O)C=C(c2cccc(C(N)=O)c2)C1=O,2015
Time dependent inhibition of KRas G12C mutant (unknown origin) assessed as SOS-mediated MANT-dGDP displacement at 200 uM by microplate reader analysis,CCN1C(=O)C=C(c2cccc(C(N)=O)c2)C1=O,CHEMBL3414570,,,Inhibition,%,,INH,,,CCN1C(=O)C=C(c2cccc(C(N)=O)c2)C1=O,2015
Binding affinity to KRas (unknown origin),CC[C@H](C)[C@H](N)C(=O)Nc1ccc2nc(Cc3c[nH]c4ccccc34)[nH]c2c1,CHEMBL3425399,=,=,Kd,nM,190000.0,Kd,uM,190.0,CC[C@H](C)[C@H](N)C(=O)Nc1ccc2nc(Cc3c[nH]c4ccccc34)[nH]c2c1,2015
Binding affinity to KRas (unknown origin),O=C(Nc1ccc2nc(Cc3c[nH]c4ccccc34)[nH]c2c1)[C@@H]1CCCN1,CHEMBL3425399,=,=,Kd,nM,340000.0,Kd,uM,340.0,O=C(Nc1ccc2nc(Cc3c[nH]c4ccccc34)[nH]c2c1)[C@@H]1CCCN1,2015
Binding affinity to KRas (unknown origin),Cc1[nH]c2ccccc2c1Cc1nc2ccccc2[nH]1,CHEMBL3425399,=,=,Kd,nM,2000000.0,Kd,mM,2.0,Cc1[nH]c2ccccc2c1Cc1nc2ccccc2[nH]1,2015
Inhibition of KRas (unknown origin) by nucleotide release assay,Cc1[nH]c2cc(Cl)cc(Cl)c2c1CCN,CHEMBL3425399,=,=,IC50,nM,155000.0,IC50,uM,155.0,Cc1[nH]c2cc(Cl)cc(Cl)c2c1CCN,2015
Inhibition of KRAS G13D mutant in human HCT116 cells assessed as inhibition of ERK phosphorylation by ELISA,CCn1c(=O)c(-c2cc(NC(=O)NCCC(C)(C)C)c(F)cc2C)cc2cnc(NC)cc21,CHEMBL3576847,=,=,IC50,nM,120.0,IC50,uM,0.12,CCn1c(=O)c(-c2cc(NC(=O)NCCC(C)(C)C)c(F)cc2C)cc2cnc(NC)cc21,2015
Inhibition of KRAS G13D mutant in human HCT116 cells assessed as inhibition of ERK phosphorylation by ELISA,CCn1c(=O)c(-c2ccc(F)c(NC(=O)Nc3cc(C(C)(C)C)no3)c2)cc2cnc(NC)cc21,CHEMBL3576847,=,=,IC50,nM,91.0,IC50,uM,0.091,CCn1c(=O)c(-c2ccc(F)c(NC(=O)Nc3cc(C(C)(C)C)no3)c2)cc2cnc(NC)cc21,2015
Inhibition of KRAS G13D mutant in human HCT116 cells assessed as inhibition of ERK phosphorylation by ELISA,CNc1cc2c(cn1)cc(-c1ccc(F)c(NC(=O)Nc3cc(C(C)(C)C)no3)c1)c(=O)n2[C@H]1CCOC1,CHEMBL3576847,=,=,IC50,nM,57.0,IC50,uM,0.057,CNc1cc2c(cn1)cc(-c1ccc(F)c(NC(=O)Nc3cc(C(C)(C)C)no3)c1)c(=O)n2[C@H]1CCOC1,2015
Inhibition of KRAS G13D mutant in human HCT116 cells assessed as inhibition of ERK phosphorylation by ELISA,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1,CHEMBL3576847,=,=,IC50,nM,5880.0,IC50,uM,5.88,CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1,2015
Inhibition of KRAS G13D mutant in human HCT116 cells assessed as inhibition of ERK phosphorylation by ELISA,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F,CHEMBL3576847,=,=,IC50,nM,16600.0,IC50,uM,16.6,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F,2015
Inhibition of KRAS G13D mutant in human HCT116 cells assessed as inhibition of ERK phosphorylation by ELISA,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1,CHEMBL3576847,=,=,IC50,nM,150.0,IC50,uM,0.15,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1,2015
Inhibition of KRAS G13D mutant in human HCT116 cells assessed as inhibition of ERK phosphorylation by ELISA,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)cnc2n1,CHEMBL3576847,=,=,IC50,nM,16.0,IC50,uM,0.016,CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)cnc2n1,2015
Inhibition of KRAS G13D mutant in human HCT116 cells assessed as inhibition of ERK phosphorylation by ELISA,CNc1cc2nc(C)c(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)cc2cn1,CHEMBL3576847,=,=,IC50,nM,120.0,IC50,uM,0.12,CNc1cc2nc(C)c(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)cc2cn1,2015
Inhibition of KRAS G13D mutant in human HCT116 cells assessed as inhibition of ERK phosphorylation by ELISA,CNc1cc2nc(C)c(-c3ccc(F)c(NC(=O)NCCC(C)(C)C)c3)cc2cn1,CHEMBL3576847,=,=,IC50,nM,46.0,IC50,uM,0.046,CNc1cc2nc(C)c(-c3ccc(F)c(NC(=O)NCCC(C)(C)C)c3)cc2cn1,2015
Inhibition of KRAS G13D mutant in human HCT116 cells assessed as inhibition of ERK phosphorylation by ELISA,CNc1ncc2cc(-c3ccc(F)c(NC(=O)NCCC(C)(C)C)c3)c(C)nc2n1,CHEMBL3576847,=,=,IC50,nM,48.0,IC50,uM,0.048,CNc1ncc2cc(-c3ccc(F)c(NC(=O)NCCC(C)(C)C)c3)c(C)nc2n1,2015
Inhibition of KRAS G13D mutant in human HCT116 cells assessed as inhibition of ERK phosphorylation by ELISA,CNc1cc2nc(C)c(-c3cc(NC(=O)NCCC(C)(C)C)ccc3C)cc2cn1,CHEMBL3576847,=,=,IC50,nM,270.0,IC50,uM,0.27,CNc1cc2nc(C)c(-c3cc(NC(=O)NCCC(C)(C)C)ccc3C)cc2cn1,2015
Inhibition of KRAS G13D mutant in human HCT116 cells assessed as inhibition of ERK phosphorylation by ELISA,CNc1cc2nc(C)c(-c3cc(NC(=O)NC[C@@H](O)C(C)(C)C)c(F)cc3C)cc2cn1,CHEMBL3576847,=,=,IC50,nM,160.0,IC50,uM,0.16,CNc1cc2nc(C)c(-c3cc(NC(=O)NC[C@@H](O)C(C)(C)C)c(F)cc3C)cc2cn1,2015
Binding affinity to K-Ras (unknown origin),C[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@H]2CCCCN2C(=O)[C@@H]([C@H](C)O)NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@@H](Cc2ccc(F)cc2)NC(=O)c2cc3cc(c2)C(=O)NC[C@H](NC(=O)[C@@H](C)NC1=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc2ccccc2c1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)O)CNC3=O,CHEMBL3588828,,,Activity,,,Activity,,,C[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@H]2CCCCN2C(=O)[C@@H]([C@H](C)O)NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@@H](Cc2ccc(F)cc2)NC(=O)c2cc3cc(c2)C(=O)NC[C@H](NC(=O)[C@@H](C)NC1=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc2ccccc2c1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)O)CNC3=O,2015
Binding affinity to KRAS (unknown origin),OC1CCN(C(=S)c2c[nH]c3ccccc23)CC1,CHEMBL3745594,=,=,Kd,nM,420000.0,Kd,uM,420.0,OC1CCN(C(=S)c2c[nH]c3ccccc23)CC1,2015
Binding affinity to KRAS (unknown origin),O=C(Nc1ccc2nc(Cc3c[nH]c4ccccc34)[nH]c2c1)[C@@H]1CCCN1,CHEMBL3745594,=,=,Kd,nM,190000.0,Kd,uM,190.0,O=C(Nc1ccc2nc(Cc3c[nH]c4ccccc34)[nH]c2c1)[C@@H]1CCCN1,2015
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) assessed as ratio of Kinact to Ki using desthiobiotin-GTP probe by alphascreen assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CP(=O)(O)OC3CCN(C(=O)CCl)C3)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,Ratio,/min/microM,2.4,Ratio,/min/microM,2.4,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CP(=O)(O)OC3CCN(C(=O)CCl)C3)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) assessed as inactivation constant using desthiobiotin-GTP probe by alphascreen assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CP(=O)(O)O[C@@H]3CC[C@@H](NC(=O)CCl)C3)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,Kinact,/min,2.3,Kinact,/min,2.3,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CP(=O)(O)O[C@@H]3CC[C@@H](NC(=O)CCl)C3)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) using desthiobiotin-GTP probe by alphascreen assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COC(=O)CS(=O)(=O)NCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,>,>,Ki,nM,10000.0,Ki,uM,10.0,Nc1nc2c(ncn2[C@@H]2O[C@H](COC(=O)CS(=O)(=O)NCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) using desthiobiotin-GTP probe by alphascreen assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)C(F)(F)P(=O)(O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,Ki,nM,380.0,Ki,uM,0.38,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)C(F)(F)P(=O)(O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to recombinant GDP-loaded KRAS G12C mutant (unknown origin) assessed as half life at 115 uM by CPM-probe based fluorescence assay,CC(C)(CNC(=O)CCl)COP(=O)(O)CP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(=O)[nH]c(N)nc32)[C@H](O)[C@@H]1O,CHEMBL3870358,=,=,T1/2,hr,20.0,t1/2,hr,20.0,CC(C)(CNC(=O)CCl)COP(=O)(O)CP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(=O)[nH]c(N)nc32)[C@H](O)[C@@H]1O,2017
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) assessed as ratio of Kinact to Ki using desthiobiotin-GTP probe by alphascreen assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)C(F)(F)P(=O)(O)OCCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,Ratio,/min/microM,0.8,Ratio,/min/microM,0.8,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)C(F)(F)P(=O)(O)OCCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) assessed as inactivation constant using desthiobiotin-GTP probe by alphascreen assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CP(=O)(O)O[C@@H]3CC[C@H](NC(=O)CCl)C3)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,Kinact,/min,1.0,Kinact,/min,1.0,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CP(=O)(O)O[C@@H]3CC[C@H](NC(=O)CCl)C3)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) using desthiobiotin-GTP probe by alphascreen assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CS(=O)(=O)NCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,Ki,nM,1600.0,Ki,uM,1.6,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CS(=O)(=O)NCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) using desthiobiotin-GTP probe by alphascreen assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CP(=O)(O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,Ki,nM,2700.0,Ki,uM,2.7,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CP(=O)(O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to recombinant GDP-loaded KRAS G12C mutant (unknown origin) assessed as half life at 115 uM by CPM-probe based fluorescence assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CP(=O)(O)OCCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,T1/2,hr,2.5,t1/2,hr,2.5,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CP(=O)(O)OCCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) assessed as ratio of Kinact to Ki using desthiobiotin-GTP probe by alphascreen assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CP(=O)(O)OCCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,Ratio,/min/microM,0.2,Ratio,/min/microM,0.2,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CP(=O)(O)OCCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) assessed as inactivation constant using desthiobiotin-GTP probe by alphascreen assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CP(=O)(O)OC3CCN(C(=O)CCl)C3)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,Kinact,/min,2.2,Kinact,/min,2.2,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CP(=O)(O)OC3CCN(C(=O)CCl)C3)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) using desthiobiotin-GTP probe by alphascreen assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COC(=O)CP(=O)(O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,Ki,nM,2200.0,Ki,uM,2.2,Nc1nc2c(ncn2[C@@H]2O[C@H](COC(=O)CP(=O)(O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) using desthiobiotin-GTP probe by alphascreen assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,Ki,nM,9.0,Ki,uM,0.009,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to recombinant GDP-loaded KRAS G12C mutant (unknown origin) assessed as half life at 115 uM by CPM-probe based fluorescence assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)C(F)(F)P(=O)(O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,T1/2,hr,4.2,t1/2,hr,4.2,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)C(F)(F)P(=O)(O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) assessed as ratio of Kinact to Ki using desthiobiotin-GTP probe by alphascreen assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COS(=O)(=O)NC(=O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,Ratio,/min/microM,0.05,Ratio,/min/microM,0.05,Nc1nc2c(ncn2[C@@H]2O[C@H](COS(=O)(=O)NC(=O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) assessed as ratio of Kinact to Ki using desthiobiotin-GTP probe by alphascreen assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)C(F)(F)P(=O)(O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,Ratio,/min/microM,0.9,Ratio,/min/microM,0.9,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)C(F)(F)P(=O)(O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) assessed as inactivation constant using desthiobiotin-GTP probe by alphascreen assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)C(F)(F)P(=O)(O)OCCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,Kinact,/min,0.3,Kinact,/min,0.3,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)C(F)(F)P(=O)(O)OCCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) using desthiobiotin-GTP probe by alphascreen assay,COC(=O)/C=C/CCCOP(=O)(O)CP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(=O)[nH]c(N)nc32)[C@H](O)[C@@H]1O,CHEMBL3870358,>,>,Ki,nM,20000.0,Ki,uM,20.0,COC(=O)/C=C/CCCOP(=O)(O)CP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(=O)[nH]c(N)nc32)[C@H](O)[C@@H]1O,2017
Binding affinity to recombinant GDP-loaded KRAS G12C mutant (unknown origin) assessed as half life at 115 uM by CPM-probe based fluorescence assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COC(=O)CS(=O)(=O)NCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,T1/2,hr,24.0,t1/2,hr,24.0,Nc1nc2c(ncn2[C@@H]2O[C@H](COC(=O)CS(=O)(=O)NCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to recombinant GDP-loaded KRAS G12C mutant (unknown origin) assessed as half life at 115 uM by CPM-probe based fluorescence assay,C=CC(=O)NCCOP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(=O)[nH]c(N)nc32)[C@H](O)[C@@H]1O,CHEMBL3870358,=,=,T1/2,hr,0.6,t1/2,hr,0.6,C=CC(=O)NCCOP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(=O)[nH]c(N)nc32)[C@H](O)[C@@H]1O,2017
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) assessed as ratio of Kinact to Ki using desthiobiotin-GTP probe by alphascreen assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CS(=O)(=O)NCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,Ratio,/min/microM,0.2,Ratio,/min/microM,0.2,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CS(=O)(=O)NCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) assessed as ratio of Kinact to Ki using desthiobiotin-GTP probe by alphascreen assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CP(=O)(O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,Ratio,/min/microM,0.02,Ratio,/min/microM,0.02,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CP(=O)(O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) assessed as inactivation constant using desthiobiotin-GTP probe by alphascreen assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CP(=O)(O)OCCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,Kinact,/min,0.07,Kinact,/min,0.07,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CP(=O)(O)OCCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) using desthiobiotin-GTP probe by alphascreen assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CP(=O)(O)O[C@@H]3CC[C@H](NC(=O)CCl)C3)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,Ki,nM,50000.0,Ki,uM,50.0,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CP(=O)(O)O[C@@H]3CC[C@H](NC(=O)CCl)C3)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to recombinant GDP-loaded KRAS G12C mutant (unknown origin) assessed as half life at 115 uM by CPM-probe based fluorescence assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CS(=O)(=O)NCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,T1/2,hr,2.3,t1/2,hr,2.3,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CS(=O)(=O)NCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) assessed as ratio of Kinact to Ki using desthiobiotin-GTP probe by alphascreen assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CC(=O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,Ratio,/min/microM,0.003,Ratio,/min/microM,0.003,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CC(=O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) assessed as ratio of Kinact to Ki using desthiobiotin-GTP probe by alphascreen assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,Ratio,/min/microM,95.0,Ratio,/min/microM,95.0,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) assessed as inactivation constant using desthiobiotin-GTP probe by alphascreen assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)C(F)(F)P(=O)(O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,Kinact,/min,0.365,Kinact,/min,0.365,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)C(F)(F)P(=O)(O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) using desthiobiotin-GTP probe by alphascreen assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CP(=O)(O)OC3CCN(C(=O)CCl)C3)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,Ki,nM,920.0,Ki,uM,0.92,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CP(=O)(O)OC3CCN(C(=O)CCl)C3)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to recombinant GDP-loaded KRAS G12C mutant (unknown origin) assessed as half life at 115 uM by CPM-probe based fluorescence assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CC(=O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,T1/2,hr,84.0,t1/2,hr,84.0,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CC(=O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) assessed as ratio of Kinact to Ki using desthiobiotin-GTP probe by alphascreen assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CP(=O)(O)O[C@@H]3CC[C@@H](NC(=O)CCl)C3)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,Ratio,/min/microM,0.06,Ratio,/min/microM,0.06,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CP(=O)(O)O[C@@H]3CC[C@@H](NC(=O)CCl)C3)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) assessed as inactivation constant using desthiobiotin-GTP probe by alphascreen assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COS(=O)(=O)NC(=O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,Kinact,/min,0.24,Kinact,/min,0.24,Nc1nc2c(ncn2[C@@H]2O[C@H](COS(=O)(=O)NC(=O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) assessed as inactivation constant using desthiobiotin-GTP probe by alphascreen assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CP(=O)(O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,Kinact,/min,0.06,Kinact,/min,0.06,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CP(=O)(O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) using desthiobiotin-GTP probe by alphascreen assay,CC(C)(CNC(=O)CCl)COP(=O)(O)CP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(=O)[nH]c(N)nc32)[C@H](O)[C@@H]1O,CHEMBL3870358,=,=,Ki,nM,5000.0,Ki,uM,5.0,CC(C)(CNC(=O)CCl)COP(=O)(O)CP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(=O)[nH]c(N)nc32)[C@H](O)[C@@H]1O,2017
Binding affinity to recombinant GDP-loaded KRAS G12C mutant (unknown origin) assessed as half life at 115 uM by CPM-probe based fluorescence assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CP(=O)(O)O[C@@H]3CC[C@@H](NC(=O)CCl)C3)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,T1/2,hr,64.0,t1/2,hr,64.0,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CP(=O)(O)O[C@@H]3CC[C@@H](NC(=O)CCl)C3)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) assessed as ratio of Kinact to Ki using desthiobiotin-GTP probe by alphascreen assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CP(=O)(O)OC3CCCN(C(=O)CCl)C3)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,Ratio,/min/microM,0.16,Ratio,/min/microM,0.16,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CP(=O)(O)OC3CCCN(C(=O)CCl)C3)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) assessed as inactivation constant using desthiobiotin-GTP probe by alphascreen assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COC(=O)CP(=O)(O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,Kinact,/min,0.053,Kinact,/min,0.053,Nc1nc2c(ncn2[C@@H]2O[C@H](COC(=O)CP(=O)(O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) assessed as inactivation constant using desthiobiotin-GTP probe by alphascreen assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,Kinact,/min,0.86,Kinact,/min,0.86,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) using desthiobiotin-GTP probe by alphascreen assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CP(=O)(O)OCCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,Ki,nM,374.0,Ki,uM,0.374,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CP(=O)(O)OCCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to recombinant GDP-loaded KRAS G12C mutant (unknown origin) assessed as half life at 115 uM by CPM-probe based fluorescence assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CP(=O)(O)OC3CCCN(C(=O)CCl)C3)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,T1/2,hr,12.0,t1/2,hr,12.0,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CP(=O)(O)OC3CCCN(C(=O)CCl)C3)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) assessed as ratio of Kinact to Ki using desthiobiotin-GTP probe by alphascreen assay,CC(C)(CNC(=O)CCl)COP(=O)(O)CP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(=O)[nH]c(N)nc32)[C@H](O)[C@@H]1O,CHEMBL3870358,=,=,Ratio,/min/microM,0.028,Ratio,/min/microM,0.028,CC(C)(CNC(=O)CCl)COP(=O)(O)CP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(=O)[nH]c(N)nc32)[C@H](O)[C@@H]1O,2017
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) using desthiobiotin-GTP probe by alphascreen assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COS(=O)(=O)NC(=O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,Ki,nM,5000.0,Ki,uM,5.0,Nc1nc2c(ncn2[C@@H]2O[C@H](COS(=O)(=O)NC(=O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to recombinant GDP-loaded KRAS G12C mutant (unknown origin) assessed as half life at 115 uM by CPM-probe based fluorescence assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)C(F)(F)P(=O)(O)OCCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,T1/2,hr,1.06,t1/2,hr,1.06,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)C(F)(F)P(=O)(O)OCCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) assessed as inactivation constant using desthiobiotin-GTP probe by alphascreen assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CP(=O)(O)OC3CCCN(C(=O)CCl)C3)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,Kinact,/min,0.55,Kinact,/min,0.55,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CP(=O)(O)OC3CCCN(C(=O)CCl)C3)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) using desthiobiotin-GTP probe by alphascreen assay,C=CC(=O)NCCOP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(=O)[nH]c(N)nc32)[C@H](O)[C@@H]1O,CHEMBL3870358,=,=,Ki,nM,280.0,Ki,uM,0.28,C=CC(=O)NCCOP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(=O)[nH]c(N)nc32)[C@H](O)[C@@H]1O,2017
Binding affinity to recombinant GDP-loaded KRAS G12C mutant (unknown origin) assessed as half life at 115 uM by CPM-probe based fluorescence assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)C(F)P(=O)(O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,T1/2,hr,6.6,t1/2,hr,6.6,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)C(F)P(=O)(O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) assessed as ratio of Kinact to Ki using desthiobiotin-GTP probe by alphascreen assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)C(F)P(=O)(O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,Ratio,/min/microM,0.03,Ratio,/min/microM,0.03,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)C(F)P(=O)(O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) assessed as inactivation constant using desthiobiotin-GTP probe by alphascreen assay,CC(C)(CNC(=O)CCl)COP(=O)(O)CP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(=O)[nH]c(N)nc32)[C@H](O)[C@@H]1O,CHEMBL3870358,=,=,Kinact,/min,0.14,Kinact,/min,0.14,CC(C)(CNC(=O)CCl)COP(=O)(O)CP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(=O)[nH]c(N)nc32)[C@H](O)[C@@H]1O,2017
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) using desthiobiotin-GTP probe by alphascreen assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CC(=O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,Ki,nM,15200.0,Ki,uM,15.2,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CC(=O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to recombinant GDP-loaded KRAS G12C mutant (unknown origin) assessed as half life at 115 uM by CPM-probe based fluorescence assay,Nc1nc2c(ncn2[C@@H]2O[C@H](CNc3c(NCCCNC(=O)CCl)c(=O)c3=O)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,T1/2,hr,13.0,t1/2,hr,13.0,Nc1nc2c(ncn2[C@@H]2O[C@H](CNc3c(NCCCNC(=O)CCl)c(=O)c3=O)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to recombinant GDP-loaded KRAS G12C mutant (unknown origin) assessed as half life at 115 uM by CPM-probe based fluorescence assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CP(=O)(O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,T1/2,hr,2.1,t1/2,hr,2.1,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CP(=O)(O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) using desthiobiotin-GTP probe by alphascreen assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CP(=O)(O)O[C@@H]3CC[C@@H](NC(=O)CCl)C3)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,Ki,nM,36000.0,Ki,uM,36.0,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CP(=O)(O)O[C@@H]3CC[C@@H](NC(=O)CCl)C3)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to recombinant GDP-loaded KRAS G12C mutant (unknown origin) assessed as half life at 115 uM by CPM-probe based fluorescence assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COS(=O)(=O)NC(=O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,T1/2,hr,9.5,t1/2,hr,9.5,Nc1nc2c(ncn2[C@@H]2O[C@H](COS(=O)(=O)NC(=O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to recombinant GDP-loaded KRAS G12C mutant (unknown origin) assessed as half life at 115 uM by CPM-probe based fluorescence assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,T1/2,hr,0.68,t1/2,hr,0.68,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) assessed as ratio of Kinact to Ki using desthiobiotin-GTP probe by alphascreen assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COC(=O)CP(=O)(O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,Ratio,/min/microM,0.02,Ratio,/min/microM,0.02,Nc1nc2c(ncn2[C@@H]2O[C@H](COC(=O)CP(=O)(O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) assessed as ratio of Kinact to Ki using desthiobiotin-GTP probe by alphascreen assay,C=CC(=O)NCCOP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(=O)[nH]c(N)nc32)[C@H](O)[C@@H]1O,CHEMBL3870358,=,=,Ratio,/min/microM,7.6,Ratio,/min/microM,7.6,C=CC(=O)NCCOP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(=O)[nH]c(N)nc32)[C@H](O)[C@@H]1O,2017
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) assessed as inactivation constant using desthiobiotin-GTP probe by alphascreen assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)C(F)P(=O)(O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,Kinact,/min,0.21,Kinact,/min,0.21,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)C(F)P(=O)(O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) using desthiobiotin-GTP probe by alphascreen assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CP(=O)(O)OC3CCCN(C(=O)CCl)C3)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,Ki,nM,3500.0,Ki,uM,3.5,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CP(=O)(O)OC3CCCN(C(=O)CCl)C3)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to recombinant GDP-loaded KRAS G12C mutant (unknown origin) assessed as half life at 115 uM by CPM-probe based fluorescence assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COC(=O)CP(=O)(O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,T1/2,hr,47.0,t1/2,hr,47.0,Nc1nc2c(ncn2[C@@H]2O[C@H](COC(=O)CP(=O)(O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to recombinant GDP-loaded KRAS G12C mutant (unknown origin) assessed as half life at 115 uM by CPM-probe based fluorescence assay,COC(=O)/C=C/CCCOP(=O)(O)CP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(=O)[nH]c(N)nc32)[C@H](O)[C@@H]1O,CHEMBL3870358,=,=,T1/2,hr,120.0,t1/2,hr,120.0,COC(=O)/C=C/CCCOP(=O)(O)CP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(=O)[nH]c(N)nc32)[C@H](O)[C@@H]1O,2017
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) assessed as ratio of Kinact to Ki using desthiobiotin-GTP probe by alphascreen assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CP(=O)(O)O[C@@H]3CC[C@H](NC(=O)CCl)C3)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,Ratio,/min/microM,0.02,Ratio,/min/microM,0.02,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CP(=O)(O)O[C@@H]3CC[C@H](NC(=O)CCl)C3)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) assessed as inactivation constant using desthiobiotin-GTP probe by alphascreen assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CS(=O)(=O)NCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,Kinact,/min,0.33,Kinact,/min,0.33,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CS(=O)(=O)NCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) assessed as inactivation constant using desthiobiotin-GTP probe by alphascreen assay,C=CC(=O)NCCOP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(=O)[nH]c(N)nc32)[C@H](O)[C@@H]1O,CHEMBL3870358,=,=,Kinact,/min,2.124,Kinact,/min,2.124,C=CC(=O)NCCOP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(=O)[nH]c(N)nc32)[C@H](O)[C@@H]1O,2017
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) using desthiobiotin-GTP probe by alphascreen assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)C(F)(F)P(=O)(O)OCCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,Ki,nM,382.0,Ki,uM,0.382,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)C(F)(F)P(=O)(O)OCCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to recombinant GDP-loaded KRAS G12C mutant (unknown origin) assessed as half life at 115 uM by CPM-probe based fluorescence assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CP(=O)(O)O[C@@H]3CC[C@H](NC(=O)CCl)C3)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,T1/2,hr,42.0,t1/2,hr,42.0,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CP(=O)(O)O[C@@H]3CC[C@H](NC(=O)CCl)C3)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) assessed as inactivation constant using desthiobiotin-GTP probe by alphascreen assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CC(=O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,Kinact,/min,0.055,Kinact,/min,0.055,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CC(=O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) using desthiobiotin-GTP probe by alphascreen assay,Nc1nc2c(ncn2[C@@H]2O[C@H](CNc3c(NCCCNC(=O)CCl)c(=O)c3=O)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,>,>,Ki,nM,25000.0,Ki,uM,25.0,Nc1nc2c(ncn2[C@@H]2O[C@H](CNc3c(NCCCNC(=O)CCl)c(=O)c3=O)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to GMP-stabilized FLAG-tagged KRAS G12C mutant (unknown origin) using desthiobiotin-GTP probe by alphascreen assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)C(F)P(=O)(O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,Ki,nM,8000.0,Ki,uM,8.0,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)C(F)P(=O)(O)OCCNC(=O)CCl)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to recombinant GDP-loaded KRAS G12C mutant (unknown origin) assessed as half life at 115 uM by CPM-probe based fluorescence assay,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CP(=O)(O)OC3CCN(C(=O)CCl)C3)[C@@H](O)[C@H]2O)c(=O)[nH]1,CHEMBL3870358,=,=,T1/2,hr,1.1,t1/2,hr,1.1,Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)CP(=O)(O)OC3CCN(C(=O)CCl)C3)[C@@H](O)[C@H]2O)c(=O)[nH]1,2017
Binding affinity to His-tagged KRAS (1 to 169 residues) G12C mutant (unknown origin) at 10 to 100 uM after 24 hrs by mass spectrometric method,C=CC(=O)NC[C@H]1C[C@@H]2O[C@H](CO)[C@@H](OCc3ccccc3)[C@@H]2O1,CHEMBL3880441,=,=,Activity,%,0.5,Activity,%,0.5,C=CC(=O)NC[C@H]1C[C@@H]2O[C@H](CO)[C@@H](OCc3ccccc3)[C@@H]2O1,2014
Binding affinity to His-tagged KRAS (1 to 169 residues) G12C mutant (unknown origin) at 10 to 100 uM after 24 hrs by mass spectrometric method,C=CC(=O)NC[C@@H]1C[C@@H]2O[C@H](CO)[C@@H](OCc3ccccc3)[C@@H]2O1,CHEMBL3880441,=,=,Activity,%,0.5,Activity,%,0.5,C=CC(=O)NC[C@@H]1C[C@@H]2O[C@H](CO)[C@@H](OCc3ccccc3)[C@@H]2O1,2014
Binding affinity to His-tagged KRAS (1 to 169 residues) G12C mutant (unknown origin) at 10 to 100 uM after 24 hrs by mass spectrometric method,C=CC(=O)NC[C@H]1C[C@@H]2O[C@H](COCc3ccccc3)[C@@H](OCc3ccccc3)[C@@H]2O1,CHEMBL3880441,=,=,Activity,%,0.5,Activity,%,0.5,C=CC(=O)NC[C@H]1C[C@@H]2O[C@H](COCc3ccccc3)[C@@H](OCc3ccccc3)[C@@H]2O1,2014
Binding affinity to His-tagged KRAS (1 to 169 residues) G12C mutant (unknown origin) at 10 to 100 uM after 24 hrs by mass spectrometric method,C=CC(=O)NC[C@@H]1C[C@@H]2O[C@H](COCc3ccccc3)[C@@H](OCc3ccccc3)[C@@H]2O1,CHEMBL3880441,=,=,Activity,%,0.5,Activity,%,0.5,C=CC(=O)NC[C@@H]1C[C@@H]2O[C@H](COCc3ccccc3)[C@@H](OCc3ccccc3)[C@@H]2O1,2014
Binding affinity to His-tagged KRAS (1 to 169 residues) G12C mutant (unknown origin) at 10 to 100 uM after 24 hrs by mass spectrometric method,C=CS(=O)(=O)NC[C@@H]1C[C@@H]2O[C@H](COCc3ccccc3)[C@@H](OCc3ccccc3)[C@@H]2O1,CHEMBL3880441,=,=,Activity,%,10.0,Activity,%,10.0,C=CS(=O)(=O)NC[C@@H]1C[C@@H]2O[C@H](COCc3ccccc3)[C@@H](OCc3ccccc3)[C@@H]2O1,2014
Binding affinity to His-tagged KRAS (1 to 169 residues) G12C mutant (unknown origin) at 10 to 100 uM after 24 hrs by mass spectrometric method,C=CS(=O)(=O)NC[C@H]1C[C@@H]2O[C@H](COCc3ccccc3)[C@@H](OCc3ccccc3)[C@@H]2O1,CHEMBL3880441,=,=,Activity,%,10.0,Activity,%,10.0,C=CS(=O)(=O)NC[C@H]1C[C@@H]2O[C@H](COCc3ccccc3)[C@@H](OCc3ccccc3)[C@@H]2O1,2014
Binding affinity to His-tagged KRAS (1 to 169 residues) G12C mutant (unknown origin) at 10 to 100 uM after 24 hrs by mass spectrometric method,C=CS(=O)(=O)NC[C@H]1C[C@@H]2O[C@H](CO)[C@@H](OCc3ccccc3)[C@@H]2O1,CHEMBL3880441,=,=,Activity,%,5.0,Activity,%,5.0,C=CS(=O)(=O)NC[C@H]1C[C@@H]2O[C@H](CO)[C@@H](OCc3ccccc3)[C@@H]2O1,2014
Binding affinity to His-tagged KRAS (1 to 169 residues) G12C mutant (unknown origin) at 10 to 100 uM after 24 hrs by mass spectrometric method,C=Cc1ccc(S(=O)(=O)NC[C@H]2C[C@@H]3O[C@H](CO)[C@@H](OCc4ccccc4)[C@@H]3O2)cc1,CHEMBL3880441,=,=,Activity,%,10.0,Activity,%,10.0,C=Cc1ccc(S(=O)(=O)NC[C@H]2C[C@@H]3O[C@H](CO)[C@@H](OCc4ccccc4)[C@@H]3O2)cc1,2014
Binding affinity to His-tagged KRAS (1 to 169 residues) G12C mutant (unknown origin) at 10 to 100 uM after 24 hrs by mass spectrometric method,C=Cc1ccc(S(=O)(=O)NC[C@H]2C[C@@H]3O[C@H](COCc4ccccc4)[C@@H](OCc4ccccc4)[C@@H]3O2)cc1,CHEMBL3880441,>,>,Activity,%,15.0,Activity,%,15.0,C=Cc1ccc(S(=O)(=O)NC[C@H]2C[C@@H]3O[C@H](COCc4ccccc4)[C@@H](OCc4ccccc4)[C@@H]3O2)cc1,2014
Binding affinity to His-tagged KRAS (1 to 169 residues) G12C mutant (unknown origin) at 10 to 100 uM after 24 hrs by mass spectrometric method,C=Cc1cccc(S(=O)(=O)NC[C@H]2C[C@@H]3O[C@H](COCc4ccccc4)[C@@H](OCc4ccccc4)[C@@H]3O2)c1,CHEMBL3880441,=,=,Activity,%,5.0,Activity,%,5.0,C=Cc1cccc(S(=O)(=O)NC[C@H]2C[C@@H]3O[C@H](COCc4ccccc4)[C@@H](OCc4ccccc4)[C@@H]3O2)c1,2014
Binding affinity to His-tagged KRAS (1 to 169 residues) G12C mutant (unknown origin) at 10 to 100 uM after 24 hrs by mass spectrometric method,C=Cc1ccccc1S(=O)(=O)NC[C@H]1C[C@@H]2O[C@H](COCc3ccccc3)[C@@H](OCc3ccccc3)[C@@H]2O1,CHEMBL3880441,=,=,Activity,%,10.0,Activity,%,10.0,C=Cc1ccccc1S(=O)(=O)NC[C@H]1C[C@@H]2O[C@H](COCc3ccccc3)[C@@H](OCc3ccccc3)[C@@H]2O1,2014
Binding affinity to His-tagged KRAS (1 to 169 residues) G12C mutant (unknown origin) at 10 to 100 uM after 24 hrs by mass spectrometric method,C=Cc1cccc(S(=O)(=O)NC[C@@H]2C[C@@H]3O[C@H](COCc4ccccc4)[C@@H](OCc4ccccc4)[C@@H]3O2)c1,CHEMBL3880441,>,>,Activity,%,15.0,Activity,%,15.0,C=Cc1cccc(S(=O)(=O)NC[C@@H]2C[C@@H]3O[C@H](COCc4ccccc4)[C@@H](OCc4ccccc4)[C@@H]3O2)c1,2014
Binding affinity to His-tagged KRAS (1 to 169 residues) G12C mutant (unknown origin) at 10 to 100 uM after 24 hrs by mass spectrometric method,C=Cc1ccc(S(=O)(=O)NC[C@@H]2C[C@@H]3O[C@H](COCc4ccccc4)[C@@H](OCc4ccccc4)[C@@H]3O2)cc1,CHEMBL3880441,=,=,Activity,%,10.0,Activity,%,10.0,C=Cc1ccc(S(=O)(=O)NC[C@@H]2C[C@@H]3O[C@H](COCc4ccccc4)[C@@H](OCc4ccccc4)[C@@H]3O2)cc1,2014
Binding affinity to His-tagged KRAS (1 to 169 residues) G12C mutant (unknown origin) at 10 to 100 uM after 24 hrs by mass spectrometric method,C=Cc1ccccc1S(=O)(=O)NC[C@@H]1C[C@@H]2O[C@H](COCc3ccccc3)[C@@H](OCc3ccccc3)[C@@H]2O1,CHEMBL3880441,=,=,Activity,%,10.0,Activity,%,10.0,C=Cc1ccccc1S(=O)(=O)NC[C@@H]1C[C@@H]2O[C@H](COCc3ccccc3)[C@@H](OCc3ccccc3)[C@@H]2O1,2014
Binding affinity to His-tagged KRAS (1 to 169 residues) G12C mutant (unknown origin) at 10 to 100 uM after 24 hrs by mass spectrometric method,C=Cc1cccc(S(=O)(=O)NC[C@H]2C[C@@H]3O[C@H](CO)[C@@H](OCc4ccccc4)[C@@H]3O2)c1,CHEMBL3880441,=,=,Activity,%,5.0,Activity,%,5.0,C=Cc1cccc(S(=O)(=O)NC[C@H]2C[C@@H]3O[C@H](CO)[C@@H](OCc4ccccc4)[C@@H]3O2)c1,2014
Binding affinity to His-tagged KRAS (1 to 169 residues) G12C mutant (unknown origin) at 10 to 100 uM after 24 hrs by mass spectrometric method,C=Cc1ccccc1S(=O)(=O)NC[C@@H]1C[C@@H]2O[C@H](CO)[C@@H](OCc3ccccc3)[C@@H]2O1,CHEMBL3880441,>,>,Activity,%,15.0,Activity,%,15.0,C=Cc1ccccc1S(=O)(=O)NC[C@@H]1C[C@@H]2O[C@H](CO)[C@@H](OCc3ccccc3)[C@@H]2O1,2014
Binding affinity to His-tagged KRAS (1 to 169 residues) G12C mutant (unknown origin) at 10 to 100 uM after 24 hrs by mass spectrometric method,C=Cc1ccccc1S(=O)(=O)NC[C@H]1C[C@@H]2O[C@H](CO)[C@@H](OCc3ccccc3)[C@@H]2O1,CHEMBL3880441,=,=,Activity,%,10.0,Activity,%,10.0,C=Cc1ccccc1S(=O)(=O)NC[C@H]1C[C@@H]2O[C@H](CO)[C@@H](OCc3ccccc3)[C@@H]2O1,2014
Binding affinity to His-tagged KRAS (1 to 169 residues) G12C mutant (unknown origin) at 10 to 100 uM after 24 hrs by mass spectrometric method,C=Cc1ccc(S(=O)(=O)NC[C@@H]2C[C@@H]3O[C@H](CO)[C@@H](OCc4ccccc4)[C@@H]3O2)cc1,CHEMBL3880441,=,=,Activity,%,5.0,Activity,%,5.0,C=Cc1ccc(S(=O)(=O)NC[C@@H]2C[C@@H]3O[C@H](CO)[C@@H](OCc4ccccc4)[C@@H]3O2)cc1,2014
Binding affinity to His-tagged KRAS (1 to 169 residues) G12C mutant (unknown origin) at 10 to 100 uM after 24 hrs by mass spectrometric method,C=Cc1cccc(S(=O)(=O)NC[C@@H]2C[C@@H]3O[C@H](CO)[C@@H](OCc4ccccc4)[C@@H]3O2)c1,CHEMBL3880441,=,=,Activity,%,10.0,Activity,%,10.0,C=Cc1cccc(S(=O)(=O)NC[C@@H]2C[C@@H]3O[C@H](CO)[C@@H](OCc4ccccc4)[C@@H]3O2)c1,2014
Binding affinity to His-tagged KRAS (1 to 169 residues) G12C mutant (unknown origin) at 10 to 100 uM after 24 hrs by mass spectrometric method,C=CS(=O)(=O)NCCOc1ccc2ccccc2c1,CHEMBL3880441,=,=,Activity,%,10.0,Activity,%,10.0,C=CS(=O)(=O)NCCOc1ccc2ccccc2c1,2014
Binding affinity to His-tagged KRAS (1 to 169 residues) G12C mutant (unknown origin) at 10 to 100 uM after 24 hrs by mass spectrometric method,C=CS(=O)(=O)NCCOc1cccc2ccccc12,CHEMBL3880441,=,=,Activity,%,10.0,Activity,%,10.0,C=CS(=O)(=O)NCCOc1cccc2ccccc12,2014
Binding affinity to His-tagged KRAS (1 to 169 residues) G12C mutant (unknown origin) at 10 to 100 uM after 24 hrs by mass spectrometric method,C=CS(=O)(=O)NCCNc1cccc2ccccc12,CHEMBL3880441,=,=,Activity,%,10.0,Activity,%,10.0,C=CS(=O)(=O)NCCNc1cccc2ccccc12,2014
Binding affinity to His-tagged KRAS (1 to 169 residues) G12C mutant (unknown origin) at 10 to 100 uM after 24 hrs by mass spectrometric method,C=CS(=O)(=O)NCCNc1ccc2ccccc2c1,CHEMBL3880441,=,=,Activity,%,5.0,Activity,%,5.0,C=CS(=O)(=O)NCCNc1ccc2ccccc2c1,2014
Binding affinity to His-tagged KRAS (1 to 169 residues) G12C mutant (unknown origin) at 10 to 100 uM after 24 hrs by mass spectrometric method,C=Cc1ccc(S(=O)(=O)NCCNc2ccc3ccccc3c2)cc1,CHEMBL3880441,=,=,Activity,%,5.0,Activity,%,5.0,C=Cc1ccc(S(=O)(=O)NCCNc2ccc3ccccc3c2)cc1,2014
Binding affinity to His-tagged KRAS (1 to 169 residues) G12C mutant (unknown origin) at 10 to 100 uM after 24 hrs by mass spectrometric method,C=Cc1ccc(S(=O)(=O)NCCOc2ccc3ccccc3c2)cc1,CHEMBL3880441,=,=,Activity,%,10.0,Activity,%,10.0,C=Cc1ccc(S(=O)(=O)NCCOc2ccc3ccccc3c2)cc1,2014
Binding affinity to His-tagged KRAS (1 to 169 residues) G12C mutant (unknown origin) at 10 to 100 uM after 24 hrs by mass spectrometric method,C=Cc1cccc(S(=O)(=O)NCCOc2cccc3ccccc23)c1,CHEMBL3880441,=,=,Activity,%,5.0,Activity,%,5.0,C=Cc1cccc(S(=O)(=O)NCCOc2cccc3ccccc23)c1,2014
Binding affinity to His-tagged KRAS (1 to 169 residues) G12C mutant (unknown origin) at 10 to 100 uM after 24 hrs by mass spectrometric method,C=Cc1cccc(S(=O)(=O)NCCOc2ccc3ccccc3c2)c1,CHEMBL3880441,=,=,Activity,%,10.0,Activity,%,10.0,C=Cc1cccc(S(=O)(=O)NCCOc2ccc3ccccc3c2)c1,2014
Binding affinity to His-tagged KRAS (1 to 169 residues) G12C mutant (unknown origin) at 10 to 100 uM after 24 hrs by mass spectrometric method,C=Cc1ccccc1S(=O)(=O)NCCOc1ccc2ccccc2c1,CHEMBL3880441,=,=,Activity,%,5.0,Activity,%,5.0,C=Cc1ccccc1S(=O)(=O)NCCOc1ccc2ccccc2c1,2014
Binding affinity to His-tagged KRAS (1 to 169 residues) G12C mutant (unknown origin) at 10 to 100 uM after 24 hrs by mass spectrometric method,C=Cc1ccc(S(=O)(=O)NCCNc2cccc3ccccc23)cc1,CHEMBL3880441,=,=,Activity,%,10.0,Activity,%,10.0,C=Cc1ccc(S(=O)(=O)NCCNc2cccc3ccccc23)cc1,2014
Binding affinity to His-tagged KRAS (1 to 169 residues) G12C mutant (unknown origin) at 10 to 100 uM after 24 hrs by mass spectrometric method,C=Cc1ccccc1S(=O)(=O)NCCNc1cccc2ccccc12,CHEMBL3880441,>,>,Activity,%,15.0,Activity,%,15.0,C=Cc1ccccc1S(=O)(=O)NCCNc1cccc2ccccc12,2014
Binding affinity to His-tagged KRAS (1 to 169 residues) G12C mutant (unknown origin) at 10 to 100 uM after 24 hrs by mass spectrometric method,C=Cc1ccccc1S(=O)(=O)NCCOc1cccc2ccccc12,CHEMBL3880441,=,=,Activity,%,10.0,Activity,%,10.0,C=Cc1ccccc1S(=O)(=O)NCCOc1cccc2ccccc12,2014
Binding affinity to His-tagged KRAS (1 to 169 residues) G12C mutant (unknown origin) at 10 to 100 uM after 24 hrs by mass spectrometric method,C=Cc1ccccc1S(=O)(=O)NCCNc1ccc2ccccc2c1,CHEMBL3880441,=,=,Activity,%,10.0,Activity,%,10.0,C=Cc1ccccc1S(=O)(=O)NCCNc1ccc2ccccc2c1,2014
Inhibition of biotinylated wild-type K-Ras (unknown origin) assessed as inhibition of human SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,42.0,IC50,nM,42.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated wild-type K-Ras (unknown origin) assessed as inhibition of human SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(C)=O)CSSC[C@@H](C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,142.0,IC50,nM,142.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(C)=O)CSSC[C@@H](C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated wild-type K-Ras (unknown origin) assessed as inhibition of human SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,82.0,IC50,nM,82.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated wild-type K-Ras (unknown origin) assessed as inhibition of human SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,763.0,IC50,nM,763.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated wild-type K-Ras (unknown origin) assessed as inhibition of human SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,>,>,IC50,nM,100000.0,IC50,nM,100000.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated wild-type K-Ras (unknown origin) assessed as inhibition of human SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,1730.0,IC50,nM,1730.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated wild-type K-Ras (unknown origin) assessed as inhibition of human SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C1=O,CHEMBL4020739,=,=,IC50,nM,39300.0,IC50,nM,39300.0,CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C1=O,2017
Inhibition of biotinylated wild-type K-Ras (unknown origin) assessed as inhibition of human SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](C)NC1=O,CHEMBL4020739,=,=,IC50,nM,764.0,IC50,nM,764.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](C)NC1=O,2017
Inhibition of biotinylated wild-type K-Ras (unknown origin) assessed as inhibition of human SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,4190.0,IC50,nM,4190.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated wild-type K-Ras (unknown origin) assessed as inhibition of human SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,65000.0,IC50,nM,65000.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated wild-type K-Ras (unknown origin) assessed as inhibition of human SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,216.0,IC50,nM,216.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated wild-type K-Ras (unknown origin) assessed as inhibition of human SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,105.0,IC50,nM,105.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated wild-type K-Ras (unknown origin) assessed as inhibition of human SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSCSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,439.0,IC50,nM,439.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSCSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated wild-type K-Ras (unknown origin) assessed as inhibition of human SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSCCSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,655.0,IC50,nM,655.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSCCSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated wild-type K-Ras (unknown origin) assessed as inhibition of human SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSCCCSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,2010.0,IC50,nM,2010.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSCCCSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated wild-type K-Ras (unknown origin) assessed as inhibition of human SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSC2=C(SC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CO)NC1=O)C(=O)NC2=O,CHEMBL4020739,=,=,IC50,nM,3920.0,IC50,nM,3920.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSC2=C(SC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CO)NC1=O)C(=O)NC2=O,2017
Inhibition of biotinylated wild-type K-Ras (unknown origin) assessed as inhibition of human SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSCc2ccccc2CSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,31000.0,IC50,nM,31000.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSCc2ccccc2CSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated K-Ras G12C mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,18.0,IC50,nM,18.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated K-Ras G12C mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(C)=O)CSSC[C@@H](C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,82.0,IC50,nM,82.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(C)=O)CSSC[C@@H](C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated K-Ras G12C mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,35.0,IC50,nM,35.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated K-Ras G12C mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,113.0,IC50,nM,113.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated K-Ras G12C mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,1630.0,IC50,nM,1630.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated K-Ras G12C mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,53.0,IC50,nM,53.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated K-Ras G12C mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C1=O,CHEMBL4020739,=,=,IC50,nM,5190.0,IC50,nM,5190.0,CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C1=O,2017
Inhibition of biotinylated K-Ras G12C mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](C)NC1=O,CHEMBL4020739,=,=,IC50,nM,36.0,IC50,nM,36.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](C)NC1=O,2017
Inhibition of biotinylated K-Ras G12C mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,358.0,IC50,nM,358.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated K-Ras G12C mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,975.0,IC50,nM,975.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated K-Ras G12C mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,12.0,IC50,nM,12.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated K-Ras G12C mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,44.0,IC50,nM,44.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated K-Ras G12C mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSCSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,243.0,IC50,nM,243.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSCSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated K-Ras G12C mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSCCSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,426.0,IC50,nM,426.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSCCSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated K-Ras G12C mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSCCCSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,848.0,IC50,nM,848.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSCCCSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated K-Ras G12C mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSC2=C(SC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CO)NC1=O)C(=O)NC2=O,CHEMBL4020739,=,=,IC50,nM,197.0,IC50,nM,197.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSC2=C(SC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CO)NC1=O)C(=O)NC2=O,2017
Inhibition of biotinylated K-Ras G12C mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSCc2ccccc2CSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,24600.0,IC50,nM,24600.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSCc2ccccc2CSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated K-Ras G12D mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,1.6,IC50,nM,1.6,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated K-Ras G12D mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(C)=O)CSSC[C@@H](C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,11.0,IC50,nM,11.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(C)=O)CSSC[C@@H](C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated K-Ras G12D mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,6.1,IC50,nM,6.1,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated K-Ras G12D mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,19.0,IC50,nM,19.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated K-Ras G12D mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,1790.0,IC50,nM,1790.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated K-Ras G12D mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,50.0,IC50,nM,50.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated K-Ras G12D mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C1=O,CHEMBL4020739,=,=,IC50,nM,20600.0,IC50,nM,20600.0,CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C1=O,2017
Inhibition of biotinylated K-Ras G12D mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](C)NC1=O,CHEMBL4020739,=,=,IC50,nM,6.3,IC50,nM,6.3,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](C)NC1=O,2017
Inhibition of biotinylated K-Ras G12D mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,64.0,IC50,nM,64.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated K-Ras G12D mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,15400.0,IC50,nM,15400.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated K-Ras G12D mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,2.7,IC50,nM,2.7,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated K-Ras G12D mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,7.5,IC50,nM,7.5,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated K-Ras G12D mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSCSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,18.0,IC50,nM,18.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSCSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated K-Ras G12D mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSCCSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,61.0,IC50,nM,61.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSCCSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated K-Ras G12D mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSCCCSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,83.0,IC50,nM,83.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSCCCSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated K-Ras G12D mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSC2=C(SC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CO)NC1=O)C(=O)NC2=O,CHEMBL4020739,=,=,IC50,nM,90.0,IC50,nM,90.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSC2=C(SC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CO)NC1=O)C(=O)NC2=O,2017
Inhibition of biotinylated K-Ras G12D mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSCc2ccccc2CSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,2580.0,IC50,nM,2580.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSCc2ccccc2CSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated K-Ras G12D mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr in presence of DTT by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,87.0,IC50,nM,87.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated K-Ras G12D mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr in presence of DTT by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(C)=O)CSSC[C@@H](C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,9770.0,IC50,nM,9770.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(C)=O)CSSC[C@@H](C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated K-Ras G12D mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr in presence of DTT by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,35.0,IC50,nM,35.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated K-Ras G12D mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr in presence of DTT by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,172.0,IC50,nM,172.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated K-Ras G12D mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr in presence of DTT by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,>,>,IC50,nM,100000.0,IC50,nM,100000.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated K-Ras G12D mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr in presence of DTT by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,192.0,IC50,nM,192.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated K-Ras G12D mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr in presence of DTT by TR-FRET assay,CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C1=O,CHEMBL4020739,=,=,IC50,nM,73500.0,IC50,nM,73500.0,CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C1=O,2017
Inhibition of biotinylated K-Ras G12D mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr in presence of DTT by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](C)NC1=O,CHEMBL4020739,=,=,IC50,nM,22.0,IC50,nM,22.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](C)NC1=O,2017
Inhibition of biotinylated K-Ras G12D mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr in presence of DTT by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,244.0,IC50,nM,244.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated K-Ras G12D mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr in presence of DTT by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,>,>,IC50,nM,100000.0,IC50,nM,100000.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated K-Ras G12D mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr in presence of DTT by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,7.4,IC50,nM,7.4,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated K-Ras G12D mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr in presence of DTT by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,35.8,IC50,nM,35.8,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated K-Ras G12D mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr in presence of DTT by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSCSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,12.0,IC50,nM,12.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSCSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated K-Ras G12D mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr in presence of DTT by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSCCSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,63.0,IC50,nM,63.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSCCSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated K-Ras G12D mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr in presence of DTT by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSCCCSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,110.0,IC50,nM,110.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSCCCSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of biotinylated K-Ras G12D mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr in presence of DTT by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSC2=C(SC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CO)NC1=O)C(=O)NC2=O,CHEMBL4020739,=,=,IC50,nM,59.0,IC50,nM,59.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSC2=C(SC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CO)NC1=O)C(=O)NC2=O,2017
Inhibition of biotinylated K-Ras G12D mutant (unknown origin) assessed as reduction in SOS1 (564 to 1049 residues)-mediated BODIPY-GDP-GTP exchange after 1 hr in presence of DTT by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSCc2ccccc2CSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4020739,=,=,IC50,nM,1190.0,IC50,nM,1190.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSCc2ccccc2CSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Binding affinity to human N-terminal His/AVi-tagged biotinylated GTPase KRas G12C mutant expressed in Escherichia coli BL21 (DE3) in presence of GDP by SPR assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4033768,,,Activity,,,Activity,,,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Binding affinity to human N-terminal His/AVi-tagged biotinylated GTPase KRas G12C mutant expressed in Escherichia coli BL21 (DE3) in presence of GDP by SPR assay,CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C1=O,CHEMBL4033768,,,Activity,,,Activity,,,CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C1=O,2017
Binding affinity to human N-terminal His/AVi-tagged biotinylated GTPase KRas G12C mutant expressed in Escherichia coli BL21 (DE3) in presence of GDP by SPR assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4033768,,,Activity,,,Activity,,,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Binding affinity to human N-terminal His/AVi-tagged biotinylated GTPase KRas G12D mutant (1 to 169 residues) expressed in Escherichia coli BL21 (DE3) in presence of GDP by SPR assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4033768,,,Activity,,,Activity,,,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Binding affinity to human N-terminal His/AVi-tagged biotinylated GTPase KRas G12D mutant (1 to 169 residues) expressed in Escherichia coli BL21 (DE3) in presence of GDP by SPR assay,CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C1=O,CHEMBL4033768,,,Activity,,,Activity,,,CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C1=O,2017
Binding affinity to human N-terminal His/AVi-tagged biotinylated GTPase KRas G12D mutant (1 to 169 residues) expressed in Escherichia coli BL21 (DE3) in presence of GDP by SPR assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4033768,,,Activity,,,Activity,,,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Binding affinity to human N-terminal His/AVi-tagged biotinylated GTPase KRas G12D mutant (1 to 169 residues) expressed in Escherichia coli BL21 (DE3) assessed as dissociation half life in presence of GTP by SRP assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4033768,=,=,T1/2,hr,0.006389,t1/2,s,23.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Binding affinity to human wild type N-terminal His/AVi-tagged biotinylated KRas expressed in Escherichia coli BL21 (DE3) assessed as dissociation half life in presence of GDP by SPR assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4033768,=,=,T1/2,hr,0.002083,t1/2,s,7.5,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Binding affinity to human N-terminal His/AVi-tagged biotinylated GTPase KRas G12C mutant expressed in Escherichia coli BL21 (DE3) assessed as dissociation half life in presence of GDP by SPR assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4033768,=,=,T1/2,hr,0.005556,t1/2,s,20.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Binding affinity to human N-terminal His/AVi-tagged biotinylated GTPase KRas G12D mutant (1 to 169 residues) expressed in Escherichia coli BL21 (DE3) assessed as dissociation half life in presence of GDP by SPR assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4033768,=,=,T1/2,hr,0.01694,t1/2,s,61.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Binding affinity to human wild type N-terminal His/AVi-tagged biotinylated KRas expressed in Escherichia coli BL21 (DE3) assessed as dissociation rate constant in presence of GTP by SPR assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4033768,=,=,K,10'-1/s,1.2,K,10'-1/s,1.2,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Binding affinity to human N-terminal His/AVi-tagged biotinylated GTPase KRas G12C mutant expressed in Escherichia coli BL21 (DE3) assessed as dissociation rate constant in presence of GTP by SPR assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4033768,=,=,K,10'-2/s,9.2,K,10'-2/s,9.2,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Binding affinity to human N-terminal His/AVi-tagged biotinylated GTPase KRas G12D mutant (1 to 169 residues) expressed in Escherichia coli BL21 (DE3) assessed as dissociation rate constant in presence of GTP by SRP assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4033768,=,=,K,10'-2/s,3.0,K,10'-2/s,3.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Binding affinity to human wild type N-terminal His/AVi-tagged biotinylated KRas expressed in Escherichia coli BL21 (DE3) assessed as dissociation rate constant in presence of GDP by SPR assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4033768,=,=,K,10'-2/s,9.3,K,10'-2/s,9.3,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Binding affinity to human N-terminal His/AVi-tagged biotinylated GTPase KRas G12C mutant expressed in Escherichia coli BL21 (DE3) assessed as dissociation rate constant in presence of GDP by SPR assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4033768,=,=,K,10'-2/s,3.5,K,10'-2/s,3.5,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Binding affinity to human N-terminal His/AVi-tagged biotinylated GTPase KRas G12D mutant (1 to 169 residues) expressed in Escherichia coli BL21 (DE3) assessed as dissociation rate constant in presence of GDP by SPR assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4033768,=,=,K,10'-2/s,1.1,K,10'-2/s,1.1,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Binding affinity to human wild type N-terminal His/AVi-tagged biotinylated KRas expressed in Escherichia coli BL21 (DE3) assessed as association rate constant in presence of GTP by SPR assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4033768,=,=,K,10'5/M/s,6.1,K,10'5/M/s,6.1,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Binding affinity to human N-terminal His/AVi-tagged biotinylated GTPase KRas G12C mutant expressed in Escherichia coli BL21 (DE3) assessed as association rate constant in presence of GTP by SPR assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4033768,=,=,K,10'5/M/s,3.7,K,10'5/M/s,3.7,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Binding affinity to human N-terminal His/AVi-tagged biotinylated GTPase KRas G12D mutant (1 to 169 residues) expressed in Escherichia coli BL21 (DE3) assessed as association rate constant in presence of GTP by SRP assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4033768,=,=,K,10'6/M/s,2.8,K,10'6/M/s,2.8,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Binding affinity to human wild type N-terminal His/AVi-tagged biotinylated KRas expressed in Escherichia coli BL21 (DE3) assessed as association rate constant in presence of GDP by SPR assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4033768,=,=,K,10'6/M/s,1.6,K,10'6/M/s,1.6,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Binding affinity to human N-terminal His/AVi-tagged biotinylated GTPase KRas G12C mutant expressed in Escherichia coli BL21 (DE3) assessed as association rate constant in presence of GDP by SPR assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4033768,=,=,K,10'6/M/s,1.0,K,10'6/M/s,1.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Binding affinity to human N-terminal His/AVi-tagged biotinylated GTPase KRas G12D mutant (1 to 169 residues) expressed in Escherichia coli BL21 (DE3) assessed as association rate constant in presence of GDP by SPR assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4033768,=,=,K,10'6/M/s,1.3,K,10'6/M/s,1.3,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Binding affinity to human wild type N-terminal His/AVi-tagged biotinylated KRas expressed in Escherichia coli BL21 (DE3) in presence of GTP by SPR assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4033768,=,=,Kd,nM,200.0,Kd,nM,200.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Binding affinity to human N-terminal His/AVi-tagged biotinylated GTPase KRas G12C mutant expressed in Escherichia coli BL21 (DE3) in presence of GTP by SPR assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4033768,=,=,Kd,nM,250.0,Kd,nM,250.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Binding affinity to human N-terminal His/AVi-tagged biotinylated GTPase KRas G12D mutant (1 to 169 residues) expressed in Escherichia coli BL21 (DE3) in presence of GTP by SPR assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4033768,=,=,Kd,nM,11.0,Kd,nM,11.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Binding affinity to human wild type N-terminal His/AVi-tagged biotinylated KRas expressed in Escherichia coli BL21 (DE3) in presence of GDP by SPR assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4033768,=,=,Kd,nM,58.0,Kd,nM,58.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Binding affinity to human N-terminal His/AVi-tagged biotinylated GTPase KRas G12C mutant expressed in Escherichia coli BL21 (DE3) in presence of GDP by SPR assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4033768,=,=,Kd,nM,35.0,Kd,nM,35.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Binding affinity to human N-terminal His/AVi-tagged biotinylated GTPase KRas G12D mutant (1 to 169 residues) expressed in Escherichia coli BL21 (DE3) in presence of GDP by SPR assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4033768,=,=,Kd,nM,8.9,Kd,nM,8.9,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Binding affinity to human N-terminal His/AVi-tagged biotinylated GTPase KRas G12C mutant expressed in Escherichia coli BL21 (DE3) assessed as dissociation half life in presence of GTP by SPR assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4033768,=,=,T1/2,hr,0.002083,t1/2,s,7.5,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Binding affinity to human wild type N-terminal His/AVi-tagged biotinylated KRas expressed in Escherichia coli BL21 (DE3) assessed as dissociation half life in presence of GTP by SPR assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4033768,=,=,T1/2,hr,0.001611,t1/2,s,5.8,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Binding affinity to human wild type N-terminal His/AVi-tagged biotinylated KRas expressed in Escherichia coli BL21 (DE3) in presence of GDP by SPR assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4033768,,,Activity,,,Activity,,,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Binding affinity to human wild type N-terminal His/AVi-tagged biotinylated KRas expressed in Escherichia coli BL21 (DE3) in presence of GDP by SPR assay,CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C1=O,CHEMBL4033768,,,Activity,,,Activity,,,CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C1=O,2017
Binding affinity to human wild type N-terminal His/AVi-tagged biotinylated KRas expressed in Escherichia coli BL21 (DE3) in presence of GDP by SPR assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4033768,,,Activity,,,Activity,,,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Binding affinity to human N-terminal His/AVi-tagged biotinylated GTPase KRas G12D mutant (1 to 169 residues) expressed in Escherichia coli BL21 (DE3) in presence of GTP by SPR assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4033768,,,Activity,,,Activity,,,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Binding affinity to human N-terminal His/AVi-tagged biotinylated GTPase KRas G12D mutant (1 to 169 residues) expressed in Escherichia coli BL21 (DE3) in presence of GTP by SPR assay,CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C1=O,CHEMBL4033768,,,Activity,,,Activity,,,CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C1=O,2017
Binding affinity to human N-terminal His/AVi-tagged biotinylated GTPase KRas G12D mutant (1 to 169 residues) expressed in Escherichia coli BL21 (DE3) in presence of GTP by SPR assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4033768,,,Activity,,,Activity,,,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Binding affinity to human N-terminal His/AVi-tagged biotinylated GTPase KRas G12C mutant expressed in Escherichia coli BL21 (DE3) in presence of GTP by SPR assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4033768,,,Activity,,,Activity,,,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Binding affinity to human N-terminal His/AVi-tagged biotinylated GTPase KRas G12C mutant expressed in Escherichia coli BL21 (DE3) in presence of GTP by SPR assay,CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C1=O,CHEMBL4033768,,,Activity,,,Activity,,,CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C1=O,2017
Binding affinity to human N-terminal His/AVi-tagged biotinylated GTPase KRas G12C mutant expressed in Escherichia coli BL21 (DE3) in presence of GTP by SPR assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4033768,,,Activity,,,Activity,,,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Binding affinity to human wild type N-terminal His/AVi-tagged biotinylated KRas expressed in Escherichia coli BL21 (DE3) in presence of GTP by SPR assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4033768,,,Activity,,,Activity,,,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Binding affinity to human wild type N-terminal His/AVi-tagged biotinylated KRas expressed in Escherichia coli BL21 (DE3) in presence of GTP by SPR assay,CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C1=O,CHEMBL4033768,,,Activity,,,Activity,,,CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C1=O,2017
Binding affinity to human wild type N-terminal His/AVi-tagged biotinylated KRas expressed in Escherichia coli BL21 (DE3) in presence of GTP by SPR assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4033768,,,Activity,,,Activity,,,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2017
Inhibition of KRas in human RKO cells at 0.2 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2CCN)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,0.0,INH,%,0.0,COc1cc(C2c3cc4c(cc3CCN2CCN)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human RKO cells at 0.2 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2CC#N)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,0.0,INH,%,0.0,COc1cc(C2c3cc4c(cc3CCN2CC#N)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human RKO cells at 0.2 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2CCO)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,0.0,INH,%,0.0,COc1cc(C2c3cc4c(cc3CCN2CCO)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human HCT cells at 20 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2c2ccc(C#N)cc2)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,45.2,INH,%,45.2,COc1cc(C2c3cc4c(cc3CCN2c2ccc(C#N)cc2)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human HCT cells at 20 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2c2ccc([N+](=O)[O-])cc2)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,55.9,INH,%,55.9,COc1cc(C2c3cc4c(cc3CCN2c2ccc([N+](=O)[O-])cc2)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human HCT cells at 20 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2CCN)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,56.9,INH,%,56.9,COc1cc(C2c3cc4c(cc3CCN2CCN)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human HCT cells at 20 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2CC#N)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,49.1,INH,%,49.1,COc1cc(C2c3cc4c(cc3CCN2CC#N)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human HCT cells at 20 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2CCO)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,46.5,INH,%,46.5,COc1cc(C2c3cc4c(cc3CCN2CCO)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human HCT cells at 2 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2c2ccc(C#N)cc2)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,16.0,INH,%,16.0,COc1cc(C2c3cc4c(cc3CCN2c2ccc(C#N)cc2)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human HCT cells at 2 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2c2ccc([N+](=O)[O-])cc2)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,19.3,INH,%,19.3,COc1cc(C2c3cc4c(cc3CCN2c2ccc([N+](=O)[O-])cc2)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human HCT cells at 2 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2CCN)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,16.2,INH,%,16.2,COc1cc(C2c3cc4c(cc3CCN2CCN)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human HCT cells at 2 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2CC#N)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,17.0,INH,%,17.0,COc1cc(C2c3cc4c(cc3CCN2CC#N)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human HCT cells at 2 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2CCO)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,12.1,INH,%,12.1,COc1cc(C2c3cc4c(cc3CCN2CCO)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human HCT cells at 0.2 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2c2ccc(C#N)cc2)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,35.9,INH,%,35.9,COc1cc(C2c3cc4c(cc3CCN2c2ccc(C#N)cc2)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human HCT cells at 0.2 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2c2ccc([N+](=O)[O-])cc2)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,0.0,INH,%,0.0,COc1cc(C2c3cc4c(cc3CCN2c2ccc([N+](=O)[O-])cc2)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human HCT cells at 0.2 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2CCN)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,0.0,INH,%,0.0,COc1cc(C2c3cc4c(cc3CCN2CCN)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human HCT cells at 0.2 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2CC#N)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,12.1,INH,%,12.1,COc1cc(C2c3cc4c(cc3CCN2CC#N)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human HCT cells at 0.2 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2CCO)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,18.0,INH,%,18.0,COc1cc(C2c3cc4c(cc3CCN2CCO)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human RKO cells at 2 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2CC#N)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,16.3,INH,%,16.3,COc1cc(C2c3cc4c(cc3CCN2CC#N)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human RKO cells at 2 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2CCO)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,6.3,INH,%,6.3,COc1cc(C2c3cc4c(cc3CCN2CCO)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human RKO cells at 0.2 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2c2ccc(C#N)cc2)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,95.8,INH,%,95.8,COc1cc(C2c3cc4c(cc3CCN2c2ccc(C#N)cc2)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human RKO cells at 0.2 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2c2ccc([N+](=O)[O-])cc2)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,17.9,INH,%,17.9,COc1cc(C2c3cc4c(cc3CCN2c2ccc([N+](=O)[O-])cc2)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human RKO cells at 2 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2CCN)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,10.1,INH,%,10.1,COc1cc(C2c3cc4c(cc3CCN2CCN)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human RKO cells at 2 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2c2ccc([N+](=O)[O-])cc2)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,32.9,INH,%,32.9,COc1cc(C2c3cc4c(cc3CCN2c2ccc([N+](=O)[O-])cc2)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human RKO cells at 2 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2c2ccc(C#N)cc2)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,7.7,INH,%,7.7,COc1cc(C2c3cc4c(cc3CCN2c2ccc(C#N)cc2)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human RKO cells at 20 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2CCO)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,76.7,INH,%,76.7,COc1cc(C2c3cc4c(cc3CCN2CCO)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human RKO cells at 20 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2CC#N)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,79.2,INH,%,79.2,COc1cc(C2c3cc4c(cc3CCN2CC#N)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human RKO cells at 20 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2CCN)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,92.7,INH,%,92.7,COc1cc(C2c3cc4c(cc3CCN2CCN)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human RKO cells at 20 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2c2ccc([N+](=O)[O-])cc2)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,70.5,INH,%,70.5,COc1cc(C2c3cc4c(cc3CCN2c2ccc([N+](=O)[O-])cc2)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human RKO cells at 20 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2c2ccc(C#N)cc2)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,66.5,INH,%,66.5,COc1cc(C2c3cc4c(cc3CCN2c2ccc(C#N)cc2)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human Colon 320 cells at 0.2 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2CCO)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,12.2,INH,%,12.2,COc1cc(C2c3cc4c(cc3CCN2CCO)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human Colon 320 cells at 0.2 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2CC#N)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,0.0,INH,%,0.0,COc1cc(C2c3cc4c(cc3CCN2CC#N)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human Colon 320 cells at 0.2 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2CCN)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,0.0,INH,%,0.0,COc1cc(C2c3cc4c(cc3CCN2CCN)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human Colon 320 cells at 0.2 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2c2ccc([N+](=O)[O-])cc2)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,0.0,INH,%,0.0,COc1cc(C2c3cc4c(cc3CCN2c2ccc([N+](=O)[O-])cc2)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human Colon 320 cells at 0.2 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2c2ccc(C#N)cc2)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,0.0,INH,%,0.0,COc1cc(C2c3cc4c(cc3CCN2c2ccc(C#N)cc2)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human Colon 320 cells at 2 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2CCO)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,0.0,INH,%,0.0,COc1cc(C2c3cc4c(cc3CCN2CCO)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human Colon 320 cells at 2 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2CC#N)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,8.2,INH,%,8.2,COc1cc(C2c3cc4c(cc3CCN2CC#N)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human Colon 320 cells at 2 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2CCN)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,20.1,INH,%,20.1,COc1cc(C2c3cc4c(cc3CCN2CCN)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human Colon 320 cells at 2 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2c2ccc([N+](=O)[O-])cc2)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,4.0,INH,%,4.0,COc1cc(C2c3cc4c(cc3CCN2c2ccc([N+](=O)[O-])cc2)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human Colon 320 cells at 2 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2c2ccc(C#N)cc2)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,22.5,INH,%,22.5,COc1cc(C2c3cc4c(cc3CCN2c2ccc(C#N)cc2)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human Colon 320 cells at 20 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2CCO)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,78.2,INH,%,78.2,COc1cc(C2c3cc4c(cc3CCN2CCO)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human Colon 320 cells at 20 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2CC#N)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,74.7,INH,%,74.7,COc1cc(C2c3cc4c(cc3CCN2CC#N)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human Colon 320 cells at 20 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2CCN)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,85.3,INH,%,85.3,COc1cc(C2c3cc4c(cc3CCN2CCN)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human Colon 320 cells at 20 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2c2ccc([N+](=O)[O-])cc2)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,92.5,INH,%,92.5,COc1cc(C2c3cc4c(cc3CCN2c2ccc([N+](=O)[O-])cc2)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human Colon 320 cells at 20 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2c2ccc(C#N)cc2)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,89.9,INH,%,89.9,COc1cc(C2c3cc4c(cc3CCN2c2ccc(C#N)cc2)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human SNU-C1 cells at 0.2 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2CCO)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,12.3,INH,%,12.3,COc1cc(C2c3cc4c(cc3CCN2CCO)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human SNU-C1 cells at 0.2 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2CC#N)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,10.0,INH,%,10.0,COc1cc(C2c3cc4c(cc3CCN2CC#N)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human SNU-C1 cells at 0.2 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2CCN)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,12.2,INH,%,12.2,COc1cc(C2c3cc4c(cc3CCN2CCN)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human SNU-C1 cells at 0.2 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2c2ccc([N+](=O)[O-])cc2)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,17.7,INH,%,17.7,COc1cc(C2c3cc4c(cc3CCN2c2ccc([N+](=O)[O-])cc2)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human SNU-C1 cells at 0.2 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2c2ccc(C#N)cc2)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,6.6,INH,%,6.6,COc1cc(C2c3cc4c(cc3CCN2c2ccc(C#N)cc2)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human SNU-C1 cells at 2 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2CCO)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,11.5,INH,%,11.5,COc1cc(C2c3cc4c(cc3CCN2CCO)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human SNU-C1 cells at 2 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2CC#N)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,6.0,INH,%,6.0,COc1cc(C2c3cc4c(cc3CCN2CC#N)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human SNU-C1 cells at 2 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2CCN)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,2.4,INH,%,2.4,COc1cc(C2c3cc4c(cc3CCN2CCN)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human SNU-C1 cells at 2 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2c2ccc([N+](=O)[O-])cc2)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,35.0,INH,%,35.0,COc1cc(C2c3cc4c(cc3CCN2c2ccc([N+](=O)[O-])cc2)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human SNU-C1 cells at 2 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2c2ccc(C#N)cc2)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,32.5,INH,%,32.5,COc1cc(C2c3cc4c(cc3CCN2c2ccc(C#N)cc2)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human SNU-C1 cells at 20 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2CCO)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,19.7,INH,%,19.7,COc1cc(C2c3cc4c(cc3CCN2CCO)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human SNU-C1 cells at 20 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2CC#N)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,59.8,INH,%,59.8,COc1cc(C2c3cc4c(cc3CCN2CC#N)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human SNU-C1 cells at 20 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2CCN)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,57.1,INH,%,57.1,COc1cc(C2c3cc4c(cc3CCN2CCN)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human SNU-C1 cells at 20 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2c2ccc([N+](=O)[O-])cc2)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,42.7,INH,%,42.7,COc1cc(C2c3cc4c(cc3CCN2c2ccc([N+](=O)[O-])cc2)OCCO4)cc(OC)c1OC,2018
Inhibition of KRas in human SNU-C1 cells at 20 uM relative to control,COc1cc(C2c3cc4c(cc3CCN2c2ccc(C#N)cc2)OCCO4)cc(OC)c1OC,CHEMBL4145473,=,=,Inhibition,%,43.5,INH,%,43.5,COc1cc(C2c3cc4c(cc3CCN2c2ccc(C#N)cc2)OCCO4)cc(OC)c1OC,2018
Ratio of Kinact to Ki for hexahistidine-tagged recombinant human KRas G12C mutant expressed in Escherichia coli BL21 (DE3),C=CC(=O)N1CCN(c2ncnc3c(F)c(-c4c(O)cccc4F)c(Cl)cc23)CC1,CHEMBL4196225,=,=,Ratio,/M/s,1100.0,Ratio,/M/s,1100.0,C=CC(=O)N1CCN(c2ncnc3c(F)c(-c4c(O)cccc4F)c(Cl)cc23)CC1,2018
Binding affinity to hexahistidine-tagged recombinant human KRas G12C mutant expressed in Escherichia coli BL21 (DE3) assessed as first-order rate constant in presence of GDP,C=CC(=O)N1CCN(c2ncnc3c(F)c(-c4c(O)cccc4F)c(Cl)cc23)CC1,CHEMBL4196225,>,>,Kinact,/s,0.066,Kinact,/s,0.066,C=CC(=O)N1CCN(c2ncnc3c(F)c(-c4c(O)cccc4F)c(Cl)cc23)CC1,2018
Binding affinity to hexahistidine-tagged recombinant human KRas G12C mutant expressed in Escherichia coli BL21 (DE3) in presence of GDP,C=CC(=O)N1CCN(c2ncnc3c(F)c(-c4c(O)cccc4F)c(Cl)cc23)CC1,CHEMBL4196225,>,>,Ki,nM,64000.0,Ki,uM,64.0,C=CC(=O)N1CCN(c2ncnc3c(F)c(-c4c(O)cccc4F)c(Cl)cc23)CC1,2018
Binding affinity to hexa-histidine-tagged recombinant human K-Ras isoform 2 G12C mutant (1 to 169 residues) expressed in Escherichia coli BL21 (DE3) at 10 uM after 24 hrs,C=CC(=O)N1CCN(C(=O)CNc2cc(I)c(Cl)cc2O)CC1,CHEMBL4270507,=,=,Activity,%,100.0,Activity,%,100.0,C=CC(=O)N1CCN(C(=O)CNc2cc(I)c(Cl)cc2O)CC1,2017
Binding affinity to hexa-histidine-tagged recombinant human K-Ras isoform 2 G12C mutant (1 to 169 residues) expressed in Escherichia coli BL21 (DE3) at 10 uM after 24 hrs,C=CC(=O)N1CCN(C(=O)CNc2cc(Cl)c(Cl)cc2OC)CC1,CHEMBL4270507,=,=,Activity,%,28.0,Activity,%,28.0,C=CC(=O)N1CCN(C(=O)CNc2cc(Cl)c(Cl)cc2OC)CC1,2017
Binding affinity to hexa-histidine-tagged recombinant human K-Ras isoform 2 G12C mutant (1 to 169 residues) expressed in Escherichia coli BL21 (DE3) at 10 uM after 24 hrs,C=CC(=O)N1CCN(C(=O)CNc2cc(C(F)(F)F)c(Cl)cc2OC)CC1,CHEMBL4270507,=,=,Activity,%,14.0,Activity,%,14.0,C=CC(=O)N1CCN(C(=O)CNc2cc(C(F)(F)F)c(Cl)cc2OC)CC1,2017
Binding affinity to hexa-histidine-tagged recombinant human K-Ras isoform 2 G12C mutant (1 to 169 residues) expressed in Escherichia coli BL21 (DE3) at 10 uM after 24 hrs,C=CS(=O)(=O)NC1CCN(C(=O)CNc2cc(I)c(Cl)cc2OC)CC1,CHEMBL4270507,=,=,Activity,%,100.0,Activity,%,100.0,C=CS(=O)(=O)NC1CCN(C(=O)CNc2cc(I)c(Cl)cc2OC)CC1,2017
Binding affinity to hexa-histidine-tagged recombinant human K-Ras isoform 2 G12C mutant (1 to 169 residues) expressed in Escherichia coli BL21 (DE3) at 10 uM after 24 hrs,C=CS(=O)(=O)NC1CCN(C(=O)CNc2cc(Cl)c(Cl)cc2O)CC1,CHEMBL4270507,=,=,Activity,%,87.0,Activity,%,87.0,C=CS(=O)(=O)NC1CCN(C(=O)CNc2cc(Cl)c(Cl)cc2O)CC1,2017
Binding affinity to hexa-histidine-tagged recombinant human K-Ras isoform 2 G12C mutant (1 to 169 residues) expressed in Escherichia coli BL21 (DE3) at 10 uM after 24 hrs,C=CS(=O)(=O)NC1CCN(C(=O)CNc2c(Cl)cc(Cl)c3c2OC(C)(C)O3)CC1,CHEMBL4270507,=,=,Activity,%,50.0,Activity,%,50.0,C=CS(=O)(=O)NC1CCN(C(=O)CNc2c(Cl)cc(Cl)c3c2OC(C)(C)O3)CC1,2017
Inhibition of KRAS G12C mutant (unknown origin),C=CC(=O)N1CC(N2CCN(C(=O)CNc3cc(C4(C)CC4)c(Cl)cc3O)CC2)C1,CHEMBL4308878,=,=,Ki,nM,200000.0,Ki,uM,200.0,C=CC(=O)N1CC(N2CCN(C(=O)CNc3cc(C4(C)CC4)c(Cl)cc3O)CC2)C1,2019
Inhibition of KRAS G12C mutant (unknown origin),C=CC(=O)N1CC(N2CCN(C(=O)CNc3cc(C4(C)CC4)c(Cl)cc3O)CC2)C1,CHEMBL4308878,=,=,Kinact,/s,0.05,Kinact,/s,0.05,C=CC(=O)N1CC(N2CCN(C(=O)CNc3cc(C4(C)CC4)c(Cl)cc3O)CC2)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) assessed as ratio of Kinact to Ki,C=CC(=O)N1CC(N2CCN(C(=O)CNc3cc(C4(C)CC4)c(Cl)cc3O)CC2)C1,CHEMBL4308878,=,=,Ratio,/M/s,250.0,Ratio,/M/s,250.0,C=CC(=O)N1CC(N2CCN(C(=O)CNc3cc(C4(C)CC4)c(Cl)cc3O)CC2)C1,2019
Ratio of Kinact to Ki for GDP-loaded His6-tagged KRAS G12C mutant (unknown origin) expressed in RAS-deficient MEF assessed as reduction in SOS-mediated mant-GDP-GTP exchange,C=CC(=O)N1CCN(c2ncnc3c(F)c(-c4c(O)cccc4F)c(Cl)cc23)CC1,CHEMBL4308878,=,=,Ratio,/M/s,1100.0,Ratio,/M/s,1100.0,C=CC(=O)N1CCN(c2ncnc3c(F)c(-c4c(O)cccc4F)c(Cl)cc23)CC1,2019
Inhibition of KRas mutant in human HCT116 cells pretreated with GSK3-beta assessed as cell viability by measuring ATP at 20 uM relative to control,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,66.0,INH,%,66.0,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human HCT116 cells pretreated with GSK3-beta assessed as cell viability by measuring ATP at 20 uM relative to control,CCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,31.0,INH,%,31.0,CCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human HCT116 cells pretreated with GSK3-beta assessed as cell viability by measuring ATP at 20 uM relative to control,CCCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,62.0,INH,%,62.0,CCCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human HCT116 cells pretreated with GSK3-beta assessed as cell viability by measuring ATP at 20 uM relative to control,CCCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,2.0,INH,%,2.0,CCCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human HCT116 cells pretreated with GSK3-beta assessed as cell viability by measuring ATP at 20 uM relative to control,Cc1c2c(c(CCCCBr)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,53.0,INH,%,53.0,Cc1c2c(c(CCCCBr)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human HCT116 cells pretreated with GSK3-beta assessed as cell viability by measuring ATP at 20 uM relative to control,Cc1c2c(c(CCCCBr)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,28.0,INH,%,28.0,Cc1c2c(c(CCCCBr)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human HCT116 cells pretreated with GSK3-beta assessed as cell viability by measuring ATP at 20 uM relative to control,CCCCCCc1c2c(c(C)c3c1C(=O)SC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,18.0,INH,%,18.0,CCCCCCc1c2c(c(C)c3c1C(=O)SC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human HCT116 cells pretreated with GSK3-beta assessed as cell viability by measuring ATP at 20 uM relative to control,CCCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)SC2,CHEMBL4312009,=,=,Inhibition,%,3.4,INH,%,3.4,CCCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)SC2,2020
Inhibition of KRas mutant in human HCT116 cells pretreated with GSK3-beta assessed as cell viability by measuring ATP at 20 uM relative to control,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccc(OC)cc1O2,CHEMBL4312009,=,=,Inhibition,%,6.0,INH,%,6.0,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccc(OC)cc1O2,2020
Inhibition of KRas mutant in human SW480 cells assessed as cell viability by measuring ATP,CCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,,,Inhibition,%,,INH,,,CCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human SW480 cells assessed as cell viability by measuring ATP,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,,,Inhibition,%,,INH,,,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human SW480 cells assessed as cell viability by measuring ATP,CCCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,,,Inhibition,%,,INH,,,CCCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human SW480 cells assessed as cell viability by measuring ATP,Cc1c2c(c(CCCCBr)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,,,Inhibition,%,,INH,,,Cc1c2c(c(CCCCBr)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human DLD1 cells assessed as cell viability by measuring ATP,CCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,,,Inhibition,%,,INH,,,CCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human DLD1 cells assessed as cell viability by measuring ATP,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,,,Inhibition,%,,INH,,,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human DLD1 cells assessed as cell viability by measuring ATP,CCCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,,,Inhibition,%,,INH,,,CCCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human DLD1 cells assessed as cell viability by measuring ATP,Cc1c2c(c(CCCCBr)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,,,Inhibition,%,,INH,,,Cc1c2c(c(CCCCBr)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human HCT116 cells assessed as cell viability by measuring ATP,CCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,,,Inhibition,%,,INH,,,CCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human HCT116 cells assessed as cell viability by measuring ATP,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,,,Inhibition,%,,INH,,,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human HCT116 cells assessed as cell viability by measuring ATP,CCCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,,,Inhibition,%,,INH,,,CCCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human HCT116 cells assessed as cell viability by measuring ATP,Cc1c2c(c(CCCCBr)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,,,Inhibition,%,,INH,,,Cc1c2c(c(CCCCBr)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human HCT116 cells pretreated with GSK3-beta assessed as cell viability by measuring ATP,CCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,,,Inhibition,%,,INH,,,CCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human HCT116 cells pretreated with GSK3-beta assessed as cell viability by measuring ATP,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,,,Inhibition,%,,INH,,,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human HCT116 cells pretreated with GSK3-beta assessed as cell viability by measuring ATP,CCCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,,,Inhibition,%,,INH,,,CCCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human HCT116 cells pretreated with GSK3-beta assessed as cell viability by measuring ATP,Cc1c2c(c(CCCCBr)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,,,Inhibition,%,,INH,,,Cc1c2c(c(CCCCBr)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human HCT116 cells assessed as cell viability by measuring ATP at 20 uM relative to control,CCCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,15.0,INH,%,15.0,CCCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human HCT116 cells assessed as cell viability by measuring ATP at 20 uM relative to control,Cc1c2c(c(CCCCBr)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,76.0,INH,%,76.0,Cc1c2c(c(CCCCBr)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human HCT116 cells assessed as cell viability by measuring ATP at 20 uM relative to control,Cc1c2c(c(CCCCBr)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,108.0,INH,%,108.0,Cc1c2c(c(CCCCBr)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human HCT116 cells assessed as cell viability by measuring ATP at 20 uM relative to control,CCCCCCc1c2c(c(C)c3c1C(=O)SC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,40.0,INH,%,40.0,CCCCCCc1c2c(c(C)c3c1C(=O)SC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human HCT116 cells assessed as cell viability by measuring ATP at 20 uM relative to control,CCCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)SC2,CHEMBL4312009,=,=,Inhibition,%,13.0,INH,%,13.0,CCCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)SC2,2020
Inhibition of KRas mutant in human HCT116 cells assessed as cell viability by measuring ATP at 20 uM relative to control,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccc(OC)cc1O2,CHEMBL4312009,=,=,Inhibition,%,40.0,INH,%,40.0,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccc(OC)cc1O2,2020
Inhibition of KRas mutant in human HCT116 cells assessed as cell viability by measuring ATP at 20 uM relative to control,CCCCCc1c2c(c(C)c3c1Oc1cc(OC)ccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,26.0,INH,%,26.0,CCCCCc1c2c(c(C)c3c1Oc1cc(OC)ccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human HCT116 cells pretreated with GSK3-beta assessed as cell viability by measuring ATP at 0.2 uM relative to control,CCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,67.0,INH,%,67.0,CCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human HCT116 cells pretreated with GSK3-beta assessed as cell viability by measuring ATP at 0.2 uM relative to control,CCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,-58.0,INH,%,-58.0,CCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human HCT116 cells pretreated with GSK3-beta assessed as cell viability by measuring ATP at 0.2 uM relative to control,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,5.0,INH,%,5.0,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human HCT116 cells pretreated with GSK3-beta assessed as cell viability by measuring ATP at 0.2 uM relative to control,CCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,44.0,INH,%,44.0,CCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human HCT116 cells pretreated with GSK3-beta assessed as cell viability by measuring ATP at 0.2 uM relative to control,CCCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,52.0,INH,%,52.0,CCCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human HCT116 cells pretreated with GSK3-beta assessed as cell viability by measuring ATP at 0.2 uM relative to control,CCCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,26.0,INH,%,26.0,CCCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human HCT116 cells pretreated with GSK3-beta assessed as cell viability by measuring ATP at 0.2 uM relative to control,Cc1c2c(c(CCCCBr)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,15.0,INH,%,15.0,Cc1c2c(c(CCCCBr)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human HCT116 cells pretreated with GSK3-beta assessed as cell viability by measuring ATP at 0.2 uM relative to control,Cc1c2c(c(CCCCBr)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,12.0,INH,%,12.0,Cc1c2c(c(CCCCBr)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human HCT116 cells pretreated with GSK3-beta assessed as cell viability by measuring ATP at 0.2 uM relative to control,CCCCCCc1c2c(c(C)c3c1C(=O)SC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,-29.0,INH,%,-29.0,CCCCCCc1c2c(c(C)c3c1C(=O)SC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human HCT116 cells pretreated with GSK3-beta assessed as cell viability by measuring ATP at 0.2 uM relative to control,CCCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)SC2,CHEMBL4312009,=,=,Inhibition,%,-106.0,INH,%,-106.0,CCCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)SC2,2020
Inhibition of KRas mutant in human HCT116 cells pretreated with GSK3-beta assessed as cell viability by measuring ATP at 0.2 uM relative to control,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccc(OC)cc1O2,CHEMBL4312009,=,=,Inhibition,%,52.0,INH,%,52.0,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccc(OC)cc1O2,2020
Inhibition of KRas mutant in human HCT116 cells pretreated with GSK3-beta assessed as cell viability by measuring ATP at 2 uM relative to control,CCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,63.0,INH,%,63.0,CCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human HCT116 cells pretreated with GSK3-beta assessed as cell viability by measuring ATP at 2 uM relative to control,CCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,0.4,INH,%,0.4,CCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human HCT116 cells pretreated with GSK3-beta assessed as cell viability by measuring ATP at 2 uM relative to control,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,59.0,INH,%,59.0,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human HCT116 cells pretreated with GSK3-beta assessed as cell viability by measuring ATP at 2 uM relative to control,CCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,28.0,INH,%,28.0,CCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human HCT116 cells pretreated with GSK3-beta assessed as cell viability by measuring ATP at 2 uM relative to control,CCCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,69.0,INH,%,69.0,CCCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human HCT116 cells pretreated with GSK3-beta assessed as cell viability by measuring ATP at 2 uM relative to control,CCCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,10.0,INH,%,10.0,CCCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human HCT116 cells pretreated with GSK3-beta assessed as cell viability by measuring ATP at 2 uM relative to control,Cc1c2c(c(CCCCBr)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,58.0,INH,%,58.0,Cc1c2c(c(CCCCBr)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human HCT116 cells pretreated with GSK3-beta assessed as cell viability by measuring ATP at 2 uM relative to control,Cc1c2c(c(CCCCBr)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,20.0,INH,%,20.0,Cc1c2c(c(CCCCBr)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human HCT116 cells pretreated with GSK3-beta assessed as cell viability by measuring ATP at 2 uM relative to control,CCCCCCc1c2c(c(C)c3c1C(=O)SC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,-4.0,INH,%,-4.0,CCCCCCc1c2c(c(C)c3c1C(=O)SC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human HCT116 cells pretreated with GSK3-beta assessed as cell viability by measuring ATP at 2 uM relative to control,CCCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)SC2,CHEMBL4312009,=,=,Inhibition,%,-5.6,INH,%,-5.6,CCCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)SC2,2020
Inhibition of KRas mutant in human HCT116 cells pretreated with GSK3-beta assessed as cell viability by measuring ATP at 2 uM relative to control,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccc(OC)cc1O2,CHEMBL4312009,=,=,Inhibition,%,8.0,INH,%,8.0,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccc(OC)cc1O2,2020
Inhibition of KRas mutant in human HCT116 cells pretreated with GSK3-beta assessed as cell viability by measuring ATP at 20 uM relative to control,CCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,80.0,INH,%,80.0,CCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human HCT116 cells pretreated with GSK3-beta assessed as cell viability by measuring ATP at 20 uM relative to control,CCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,2.0,INH,%,2.0,CCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human HCT116 cells assessed as cell viability by measuring ATP at 20 uM relative to control,CCCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,91.0,INH,%,91.0,CCCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human HCT116 cells assessed as cell viability by measuring ATP at 2 uM relative to control,CCCCCCc1c2c(c(C)c3c1C(=O)SC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,10.0,INH,%,10.0,CCCCCCc1c2c(c(C)c3c1C(=O)SC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human HCT116 cells assessed as cell viability by measuring ATP at 2 uM relative to control,CCCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)SC2,CHEMBL4312009,=,=,Inhibition,%,2.9,INH,%,2.9,CCCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)SC2,2020
Inhibition of KRas mutant in human HCT116 cells assessed as cell viability by measuring ATP at 2 uM relative to control,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccc(OC)cc1O2,CHEMBL4312009,=,=,Inhibition,%,7.9,INH,%,7.9,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccc(OC)cc1O2,2020
Inhibition of KRas mutant in human HCT116 cells assessed as cell viability by measuring ATP at 20 uM relative to control,CCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,78.0,INH,%,78.0,CCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human HCT116 cells assessed as cell viability by measuring ATP at 20 uM relative to control,CCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,38.0,INH,%,38.0,CCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human HCT116 cells assessed as cell viability by measuring ATP at 20 uM relative to control,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,89.0,INH,%,89.0,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human HCT116 cells assessed as cell viability by measuring ATP at 20 uM relative to control,CCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,35.0,INH,%,35.0,CCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human HCT116 cells assessed as cell viability by measuring ATP at 2 uM relative to control,Cc1c2c(c(CCCCBr)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,9.5,INH,%,9.5,Cc1c2c(c(CCCCBr)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human HCT116 cells assessed as cell viability by measuring ATP at 2 uM relative to control,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,62.0,INH,%,62.0,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human HCT116 cells assessed as cell viability by measuring ATP at 2 uM relative to control,CCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,12.0,INH,%,12.0,CCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human HCT116 cells assessed as cell viability by measuring ATP at 2 uM relative to control,CCCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,60.0,INH,%,60.0,CCCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human HCT116 cells assessed as cell viability by measuring ATP at 2 uM relative to control,CCCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,7.0,INH,%,7.0,CCCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human HCT116 cells assessed as cell viability by measuring ATP at 2 uM relative to control,Cc1c2c(c(CCCCBr)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,56.0,INH,%,56.0,Cc1c2c(c(CCCCBr)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human HCT116 cells assessed as cell viability by measuring ATP at 2 uM relative to control,CCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,7.0,INH,%,7.0,CCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human HCT116 cells assessed as cell viability by measuring ATP at 2 uM relative to control,CCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,66.0,INH,%,66.0,CCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human HCT116 cells assessed as cell viability by measuring ATP at 0.2 uM relative to control,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccc(OC)cc1O2,CHEMBL4312009,=,=,Inhibition,%,-14.0,INH,%,-14.0,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccc(OC)cc1O2,2020
Inhibition of KRas mutant in human HCT116 cells assessed as cell viability by measuring ATP at 0.2 uM relative to control,CCCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)SC2,CHEMBL4312009,=,=,Inhibition,%,-10.0,INH,%,-10.0,CCCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)SC2,2020
Inhibition of KRas mutant in human HCT116 cells assessed as cell viability by measuring ATP at 0.2 uM relative to control,CCCCCCc1c2c(c(C)c3c1C(=O)SC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,-17.0,INH,%,-17.0,CCCCCCc1c2c(c(C)c3c1C(=O)SC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human HCT116 cells assessed as cell viability by measuring ATP at 0.2 uM relative to control,Cc1c2c(c(CCCCBr)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,2.0,INH,%,2.0,Cc1c2c(c(CCCCBr)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human HCT116 cells assessed as cell viability by measuring ATP at 0.2 uM relative to control,Cc1c2c(c(CCCCBr)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,33.0,INH,%,33.0,Cc1c2c(c(CCCCBr)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human HCT116 cells assessed as cell viability by measuring ATP at 0.2 uM relative to control,CCCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,-3.0,INH,%,-3.0,CCCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human HCT116 cells assessed as cell viability by measuring ATP at 0.2 uM relative to control,CCCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,12.0,INH,%,12.0,CCCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human HCT116 cells assessed as cell viability by measuring ATP at 0.2 uM relative to control,CCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,-9.0,INH,%,-9.0,CCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human HCT116 cells assessed as cell viability by measuring ATP at 0.2 uM relative to control,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,20.0,INH,%,20.0,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human HCT116 cells assessed as cell viability by measuring ATP at 0.2 uM relative to control,CCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,39.0,INH,%,39.0,CCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human HCT116 cells assessed as cell viability by measuring ATP at 0.2 uM relative to control,CCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,5.0,INH,%,5.0,CCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human DLD1 cells assessed as cell viability by measuring ATP at 20 uM relative to control,CCCCCc1c2c(c(C)c3c1Oc1cc(OC)ccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,-3.9,INH,%,-3.9,CCCCCc1c2c(c(C)c3c1Oc1cc(OC)ccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human DLD1 cells assessed as cell viability by measuring ATP at 20 uM relative to control,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccc(OC)cc1O2,CHEMBL4312009,=,=,Inhibition,%,73.0,INH,%,73.0,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccc(OC)cc1O2,2020
Inhibition of KRas mutant in human DLD1 cells assessed as cell viability by measuring ATP at 20 uM relative to control,CCCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)SC2,CHEMBL4312009,=,=,Inhibition,%,14.0,INH,%,14.0,CCCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)SC2,2020
Inhibition of KRas mutant in human DLD1 cells assessed as cell viability by measuring ATP at 20 uM relative to control,CCCCCCc1c2c(c(C)c3c1C(=O)SC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,90.0,INH,%,90.0,CCCCCCc1c2c(c(C)c3c1C(=O)SC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human DLD1 cells assessed as cell viability by measuring ATP at 20 uM relative to control,Cc1c2c(c(CCCCBr)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,20.0,INH,%,20.0,Cc1c2c(c(CCCCBr)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human DLD1 cells assessed as cell viability by measuring ATP at 20 uM relative to control,Cc1c2c(c(CCCCBr)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,76.0,INH,%,76.0,Cc1c2c(c(CCCCBr)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human DLD1 cells assessed as cell viability by measuring ATP at 20 uM relative to control,CCCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,-15.0,INH,%,-15.0,CCCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human DLD1 cells assessed as cell viability by measuring ATP at 20 uM relative to control,CCCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,112.0,INH,%,112.0,CCCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human DLD1 cells assessed as cell viability by measuring ATP at 20 uM relative to control,CCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,40.0,INH,%,40.0,CCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human DLD1 cells assessed as cell viability by measuring ATP at 20 uM relative to control,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,120.0,INH,%,120.0,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human DLD1 cells assessed as cell viability by measuring ATP at 20 uM relative to control,CCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,41.0,INH,%,41.0,CCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human DLD1 cells assessed as cell viability by measuring ATP at 20 uM relative to control,CCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,91.0,INH,%,91.0,CCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human DLD1 cells assessed as cell viability by measuring ATP at 2 uM relative to control,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccc(OC)cc1O2,CHEMBL4312009,=,=,Inhibition,%,16.0,INH,%,16.0,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccc(OC)cc1O2,2020
Inhibition of KRas mutant in human DLD1 cells assessed as cell viability by measuring ATP at 2 uM relative to control,CCCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)SC2,CHEMBL4312009,=,=,Inhibition,%,6.0,INH,%,6.0,CCCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)SC2,2020
Inhibition of KRas mutant in human DLD1 cells assessed as cell viability by measuring ATP at 2 uM relative to control,CCCCCCc1c2c(c(C)c3c1C(=O)SC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,7.0,INH,%,7.0,CCCCCCc1c2c(c(C)c3c1C(=O)SC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human DLD1 cells assessed as cell viability by measuring ATP at 2 uM relative to control,Cc1c2c(c(CCCCBr)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,0.4,INH,%,0.4,Cc1c2c(c(CCCCBr)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human DLD1 cells assessed as cell viability by measuring ATP at 2 uM relative to control,Cc1c2c(c(CCCCBr)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,45.0,INH,%,45.0,Cc1c2c(c(CCCCBr)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human DLD1 cells assessed as cell viability by measuring ATP at 2 uM relative to control,CCCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,49.0,INH,%,49.0,CCCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human DLD1 cells assessed as cell viability by measuring ATP at 2 uM relative to control,CCCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,50.0,INH,%,50.0,CCCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human DLD1 cells assessed as cell viability by measuring ATP at 2 uM relative to control,CCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,17.0,INH,%,17.0,CCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human DLD1 cells assessed as cell viability by measuring ATP at 2 uM relative to control,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,63.0,INH,%,63.0,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human DLD1 cells assessed as cell viability by measuring ATP at 2 uM relative to control,CCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,6.0,INH,%,6.0,CCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human DLD1 cells assessed as cell viability by measuring ATP at 2 uM relative to control,CCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,65.0,INH,%,65.0,CCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human DLD1 cells assessed as cell viability by measuring ATP at 0.2 uM relative to control,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccc(OC)cc1O2,CHEMBL4312009,=,=,Inhibition,%,-17.0,INH,%,-17.0,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccc(OC)cc1O2,2020
Inhibition of KRas mutant in human DLD1 cells assessed as cell viability by measuring ATP at 0.2 uM relative to control,CCCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)SC2,CHEMBL4312009,=,=,Inhibition,%,-10.0,INH,%,-10.0,CCCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)SC2,2020
Inhibition of KRas mutant in human DLD1 cells assessed as cell viability by measuring ATP at 0.2 uM relative to control,CCCCCCc1c2c(c(C)c3c1C(=O)SC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,-9.0,INH,%,-9.0,CCCCCCc1c2c(c(C)c3c1C(=O)SC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human DLD1 cells assessed as cell viability by measuring ATP at 0.2 uM relative to control,Cc1c2c(c(CCCCBr)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,0.4,INH,%,0.4,Cc1c2c(c(CCCCBr)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human DLD1 cells assessed as cell viability by measuring ATP at 0.2 uM relative to control,Cc1c2c(c(CCCCBr)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,30.0,INH,%,30.0,Cc1c2c(c(CCCCBr)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human DLD1 cells assessed as cell viability by measuring ATP at 0.2 uM relative to control,CCCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,29.0,INH,%,29.0,CCCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human DLD1 cells assessed as cell viability by measuring ATP at 0.2 uM relative to control,CCCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,14.0,INH,%,14.0,CCCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human DLD1 cells assessed as cell viability by measuring ATP at 0.2 uM relative to control,CCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,-11.0,INH,%,-11.0,CCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human DLD1 cells assessed as cell viability by measuring ATP at 0.2 uM relative to control,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,60.0,INH,%,60.0,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human DLD1 cells assessed as cell viability by measuring ATP at 0.2 uM relative to control,CCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,-29.0,INH,%,-29.0,CCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human DLD1 cells assessed as cell viability by measuring ATP at 0.2 uM relative to control,CCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,17.0,INH,%,17.0,CCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human SW480 cells assessed as cell viability by measuring ATP at 20 uM relative to control,CCCCCc1c2c(c(C)c3c1Oc1cc(OC)ccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,-10.7,INH,%,-10.7,CCCCCc1c2c(c(C)c3c1Oc1cc(OC)ccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human SW480 cells assessed as cell viability by measuring ATP at 20 uM relative to control,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccc(OC)cc1O2,CHEMBL4312009,=,=,Inhibition,%,19.0,INH,%,19.0,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccc(OC)cc1O2,2020
Inhibition of KRas mutant in human SW480 cells assessed as cell viability by measuring ATP at 20 uM relative to control,CCCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)SC2,CHEMBL4312009,=,=,Inhibition,%,21.0,INH,%,21.0,CCCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)SC2,2020
Inhibition of KRas mutant in human SW480 cells assessed as cell viability by measuring ATP at 20 uM relative to control,CCCCCCc1c2c(c(C)c3c1C(=O)SC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,22.0,INH,%,22.0,CCCCCCc1c2c(c(C)c3c1C(=O)SC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human SW480 cells assessed as cell viability by measuring ATP at 20 uM relative to control,Cc1c2c(c(CCCCBr)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,55.0,INH,%,55.0,Cc1c2c(c(CCCCBr)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human SW480 cells assessed as cell viability by measuring ATP at 20 uM relative to control,Cc1c2c(c(CCCCBr)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,63.0,INH,%,63.0,Cc1c2c(c(CCCCBr)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human SW480 cells assessed as cell viability by measuring ATP at 20 uM relative to control,CCCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,12.0,INH,%,12.0,CCCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human SW480 cells assessed as cell viability by measuring ATP at 20 uM relative to control,CCCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,86.0,INH,%,86.0,CCCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human SW480 cells assessed as cell viability by measuring ATP at 20 uM relative to control,CCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,40.0,INH,%,40.0,CCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human SW480 cells assessed as cell viability by measuring ATP at 20 uM relative to control,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,86.0,INH,%,86.0,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human SW480 cells assessed as cell viability by measuring ATP at 20 uM relative to control,CCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,14.0,INH,%,14.0,CCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human SW480 cells assessed as cell viability by measuring ATP at 20 uM relative to control,CCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,138.0,INH,%,138.0,CCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human SW480 cells assessed as cell viability by measuring ATP at 2 uM relative to control,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccc(OC)cc1O2,CHEMBL4312009,=,=,Inhibition,%,16.0,INH,%,16.0,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccc(OC)cc1O2,2020
Inhibition of KRas mutant in human SW480 cells assessed as cell viability by measuring ATP at 2 uM relative to control,CCCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)SC2,CHEMBL4312009,=,=,Inhibition,%,10.0,INH,%,10.0,CCCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)SC2,2020
Inhibition of KRas mutant in human SW480 cells assessed as cell viability by measuring ATP at 2 uM relative to control,CCCCCCc1c2c(c(C)c3c1C(=O)SC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,9.0,INH,%,9.0,CCCCCCc1c2c(c(C)c3c1C(=O)SC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human SW480 cells assessed as cell viability by measuring ATP at 2 uM relative to control,Cc1c2c(c(CCCCBr)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,4.4,INH,%,4.4,Cc1c2c(c(CCCCBr)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human SW480 cells assessed as cell viability by measuring ATP at 2 uM relative to control,Cc1c2c(c(CCCCBr)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,62.0,INH,%,62.0,Cc1c2c(c(CCCCBr)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human SW480 cells assessed as cell viability by measuring ATP at 2 uM relative to control,CCCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,18.0,INH,%,18.0,CCCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human SW480 cells assessed as cell viability by measuring ATP at 2 uM relative to control,CCCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,58.0,INH,%,58.0,CCCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human SW480 cells assessed as cell viability by measuring ATP at 2 uM relative to control,CCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,21.0,INH,%,21.0,CCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human SW480 cells assessed as cell viability by measuring ATP at 2 uM relative to control,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,64.0,INH,%,64.0,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human SW480 cells assessed as cell viability by measuring ATP at 2 uM relative to control,CCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,14.0,INH,%,14.0,CCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human SW480 cells assessed as cell viability by measuring ATP at 2 uM relative to control,CCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,73.0,INH,%,73.0,CCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human SW480 cells assessed as cell viability by measuring ATP at 0.2 uM relative to control,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccc(OC)cc1O2,CHEMBL4312009,=,=,Inhibition,%,15.0,INH,%,15.0,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccc(OC)cc1O2,2020
Inhibition of KRas mutant in human SW480 cells assessed as cell viability by measuring ATP at 0.2 uM relative to control,CCCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)SC2,CHEMBL4312009,=,=,Inhibition,%,10.0,INH,%,10.0,CCCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)SC2,2020
Inhibition of KRas mutant in human SW480 cells assessed as cell viability by measuring ATP at 0.2 uM relative to control,CCCCCCc1c2c(c(C)c3c1C(=O)SC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,13.0,INH,%,13.0,CCCCCCc1c2c(c(C)c3c1C(=O)SC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human SW480 cells assessed as cell viability by measuring ATP at 0.2 uM relative to control,Cc1c2c(c(CCCCBr)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,-40.0,INH,%,-40.0,Cc1c2c(c(CCCCBr)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human SW480 cells assessed as cell viability by measuring ATP at 0.2 uM relative to control,Cc1c2c(c(CCCCBr)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,7.0,INH,%,7.0,Cc1c2c(c(CCCCBr)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human SW480 cells assessed as cell viability by measuring ATP at 0.2 uM relative to control,CCCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,16.0,INH,%,16.0,CCCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human SW480 cells assessed as cell viability by measuring ATP at 0.2 uM relative to control,CCCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,21.0,INH,%,21.0,CCCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human SW480 cells assessed as cell viability by measuring ATP at 0.2 uM relative to control,CCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,11.0,INH,%,11.0,CCCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human SW480 cells assessed as cell viability by measuring ATP at 0.2 uM relative to control,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,20.0,INH,%,20.0,CCCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Inhibition of KRas mutant in human SW480 cells assessed as cell viability by measuring ATP at 0.2 uM relative to control,CCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,CHEMBL4312009,=,=,Inhibition,%,12.0,INH,%,12.0,CCCCc1c2c(c(C)c3c1Oc1ccccc1O3)C(=O)OC2,2020
Inhibition of KRas mutant in human SW480 cells assessed as cell viability by measuring ATP at 0.2 uM relative to control,CCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,CHEMBL4312009,=,=,Inhibition,%,17.0,INH,%,17.0,CCCCc1c2c(c(C)c3c1C(=O)OC3)Oc1ccccc1O2,2020
Binding affinity to KRAS G12C mutant (unknown origin) assessed as covalent modification at 5 uM after 3 hrs by LC-MS analysis relative to control,C=CC(=O)N1CCN(c2ncnc3c2CCN(c2cccc4ccccc24)C3)CC1,CHEMBL4325929,=,=,Activity,%,13.0,Activity,%,13.0,C=CC(=O)N1CCN(c2ncnc3c2CCN(c2cccc4ccccc24)C3)CC1,2018
Binding affinity to KRAS G12C mutant (unknown origin) assessed as covalent modification at 5 uM after 3 hrs by LC-MS analysis relative to control,C=CC(=O)N1CCN(c2ncnc3c2CCN(c2c(C)ccc4[nH]ncc24)C3)CC1,CHEMBL4325929,=,=,Activity,%,22.0,Activity,%,22.0,C=CC(=O)N1CCN(c2ncnc3c2CCN(c2c(C)ccc4[nH]ncc24)C3)CC1,2018
Binding affinity to KRAS G12C mutant (unknown origin) assessed as covalent modification at 5 uM after 3 hrs by LC-MS analysis relative to control,C=CC(=O)N1CCN(c2ncnc3c2CCN(c2c(O)cccc2F)C3)CC1,CHEMBL4325929,=,=,Activity,%,2.0,Activity,%,2.0,C=CC(=O)N1CCN(c2ncnc3c2CCN(c2c(O)cccc2F)C3)CC1,2018
Binding affinity to KRAS G12C mutant (unknown origin) assessed as covalent modification at 5 uM after 3 hrs by LC-MS analysis relative to control,C=CC(=O)N1CCN(c2ncnc3c2CCN(c2cc(O)ccc2F)C3)CC1,CHEMBL4325929,=,=,Activity,%,2.0,Activity,%,2.0,C=CC(=O)N1CCN(c2ncnc3c2CCN(c2cc(O)ccc2F)C3)CC1,2018
Binding affinity to KRAS G12C mutant (unknown origin) assessed as covalent modification at 5 uM after 3 hrs by LC-MS analysis relative to control,C=CC(=O)N1CCN(c2ncnc3c2CCN(c2cc(O)cc4ccccc24)C3)CC1,CHEMBL4325929,=,=,Activity,%,99.0,Activity,%,99.0,C=CC(=O)N1CCN(c2ncnc3c2CCN(c2cc(O)cc4ccccc24)C3)CC1,2018
Binding affinity to KRAS G12C mutant (unknown origin) assessed as covalent modification at 5 uM after 3 hrs by LC-MS analysis relative to control,C=CC(=O)N1CCN(c2ncnc3c2CCN(c2cccc4ccc(O)cc24)C3)CC1,CHEMBL4325929,=,=,Activity,%,0.0,Activity,%,0.0,C=CC(=O)N1CCN(c2ncnc3c2CCN(c2cccc4ccc(O)cc24)C3)CC1,2018
Binding affinity to KRAS G12C mutant (unknown origin) assessed as covalent modification at 3 uM after 15 mins by LC-MS analysis relative to control,C=CC(=O)N1CCN(c2ncnc3c2CCN(c2cc(O)cc4ccccc24)C3)CC1,CHEMBL4325929,=,=,Activity,%,8.0,Activity,%,8.0,C=CC(=O)N1CCN(c2ncnc3c2CCN(c2cc(O)cc4ccccc24)C3)CC1,2018
Binding affinity to KRAS G12C mutant (unknown origin) assessed as covalent modification at 3 uM after 15 mins by LC-MS analysis relative to control,C=CC(=O)N1CCN(c2nc(OCCN(C)C)nc3c2CCN(c2cc(O)cc4ccccc24)C3)CC1,CHEMBL4325929,=,=,Activity,%,52.0,Activity,%,52.0,C=CC(=O)N1CCN(c2nc(OCCN(C)C)nc3c2CCN(c2cc(O)cc4ccccc24)C3)CC1,2018
Binding affinity to KRAS G12C mutant (unknown origin) assessed as covalent modification at 3 uM after 15 mins by LC-MS analysis relative to control,C=CC(=O)N1CCN(c2nc(OCCCN(C)C)nc3c2CCN(c2cc(O)cc4ccccc24)C3)CC1,CHEMBL4325929,=,=,Activity,%,22.0,Activity,%,22.0,C=CC(=O)N1CCN(c2nc(OCCCN(C)C)nc3c2CCN(c2cc(O)cc4ccccc24)C3)CC1,2018
Binding affinity to KRAS G12C mutant (unknown origin) assessed as covalent modification at 3 uM after 15 mins by LC-MS analysis relative to control,C=CC(=O)N1CCN(c2nc(O[C@@H](C)CN(C)C)nc3c2CCN(c2cc(O)cc4ccccc24)C3)CC1,CHEMBL4325929,=,=,Activity,%,21.0,Activity,%,21.0,C=CC(=O)N1CCN(c2nc(O[C@@H](C)CN(C)C)nc3c2CCN(c2cc(O)cc4ccccc24)C3)CC1,2018
Binding affinity to KRAS G12C mutant (unknown origin) assessed as covalent modification at 3 uM after 15 mins by LC-MS analysis relative to control,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cc(O)cc4ccccc24)C3)CC1,CHEMBL4325929,=,=,Activity,%,84.0,Activity,%,84.0,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cc(O)cc4ccccc24)C3)CC1,2018
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation measured after 3 hrs by Western blot analysis,C=CC(=O)N1CCN(c2ncnc3c2CCN(c2cccc4ccccc24)C3)CC1,CHEMBL4325929,>,>,IC50,nM,16000.0,IC50,uM,16.0,C=CC(=O)N1CCN(c2ncnc3c2CCN(c2cccc4ccccc24)C3)CC1,2018
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation measured after 3 hrs by Western blot analysis,C=CC(=O)N1CCN(c2ncnc3c2CCN(c2c(C)ccc4[nH]ncc24)C3)CC1,CHEMBL4325929,>,>,IC50,nM,16000.0,IC50,uM,16.0,C=CC(=O)N1CCN(c2ncnc3c2CCN(c2c(C)ccc4[nH]ncc24)C3)CC1,2018
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation measured after 3 hrs by Western blot analysis,C=CC(=O)N1CCN(c2ncnc3c2CCN(c2c(O)cccc2F)C3)CC1,CHEMBL4325929,>,>,IC50,nM,16000.0,IC50,uM,16.0,C=CC(=O)N1CCN(c2ncnc3c2CCN(c2c(O)cccc2F)C3)CC1,2018
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation measured after 3 hrs by Western blot analysis,C=CC(=O)N1CCN(c2ncnc3c2CCN(c2cc(O)ccc2F)C3)CC1,CHEMBL4325929,>,>,IC50,nM,16000.0,IC50,uM,16.0,C=CC(=O)N1CCN(c2ncnc3c2CCN(c2cc(O)ccc2F)C3)CC1,2018
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation measured after 3 hrs by Western blot analysis,C=CC(=O)N1CCN(c2ncnc3c2CCN(c2cc(O)cc4ccccc24)C3)CC1,CHEMBL4325929,=,=,IC50,nM,7600.0,IC50,uM,7.6,C=CC(=O)N1CCN(c2ncnc3c2CCN(c2cc(O)cc4ccccc24)C3)CC1,2018
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation measured after 3 hrs by Western blot analysis,C=CC(=O)N1CCN(c2ncnc3c2CCN(c2cccc4ccc(O)cc24)C3)CC1,CHEMBL4325929,>,>,IC50,nM,16000.0,IC50,uM,16.0,C=CC(=O)N1CCN(c2ncnc3c2CCN(c2cccc4ccc(O)cc24)C3)CC1,2018
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation measured after 3 hrs by Western blot analysis,C=CC(=O)N1CCN(c2nc(OCCN(C)C)nc3c2CCN(c2cc(O)cc4ccccc24)C3)CC1,CHEMBL4325929,=,=,IC50,nM,1900.0,IC50,uM,1.9,C=CC(=O)N1CCN(c2nc(OCCN(C)C)nc3c2CCN(c2cc(O)cc4ccccc24)C3)CC1,2018
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation measured after 3 hrs by Western blot analysis,C=CC(=O)N1CCN(c2nc(OCCCN(C)C)nc3c2CCN(c2cc(O)cc4ccccc24)C3)CC1,CHEMBL4325929,=,=,IC50,nM,1500.0,IC50,uM,1.5,C=CC(=O)N1CCN(c2nc(OCCCN(C)C)nc3c2CCN(c2cc(O)cc4ccccc24)C3)CC1,2018
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation measured after 3 hrs by Western blot analysis,C=CC(=O)N1CCN(c2nc(O[C@@H](C)CN(C)C)nc3c2CCN(c2cc(O)cc4ccccc24)C3)CC1,CHEMBL4325929,=,=,IC50,nM,540.0,IC50,uM,0.54,C=CC(=O)N1CCN(c2nc(O[C@@H](C)CN(C)C)nc3c2CCN(c2cc(O)cc4ccccc24)C3)CC1,2018
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation measured after 3 hrs by Western blot analysis,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cc(O)cc4ccccc24)C3)CC1,CHEMBL4325929,=,=,IC50,nM,70.0,IC50,uM,0.07,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cc(O)cc4ccccc24)C3)CC1,2018
Inhibition of wild type KRAS in human RKO cells assessed as reduction in ERK phosphorylation measured after 3 hrs by Western blot analysis,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cc(O)cc4ccccc24)C3)CC1,CHEMBL4325929,>,>,IC50,nM,16000.0,IC50,uM,16.0,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cc(O)cc4ccccc24)C3)CC1,2018
Inhibition of wild type KRAS in human SNUC5 cells assessed as reduction in ERK phosphorylation measured after 3 hrs by Western blot analysis,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cc(O)cc4ccccc24)C3)CC1,CHEMBL4325929,>,>,IC50,nM,16000.0,IC50,uM,16.0,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cc(O)cc4ccccc24)C3)CC1,2018
Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by Western blot analysis,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cc(O)cc4ccccc24)C3)CC1,CHEMBL4325929,>,>,IC50,nM,16000.0,IC50,uM,16.0,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cc(O)cc4ccccc24)C3)CC1,2018
Inhibition of KRAS G12C mutant in human MIAPaCa2 cells assessed as reduction in ERK phosphorylation measured after 3 hrs by Western blot analysis,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cc(O)cc4ccccc24)C3)CC1,CHEMBL4325929,=,=,IC50,nM,48.0,IC50,nM,48.0,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cc(O)cc4ccccc24)C3)CC1,2018
Inhibition of GDP bound recombinant human His-tagged KRAS G12C/C118A mutant (1 to 169 residues) assessed as reduction in SOS1-mediated GDP/GTP nucleotide exchange by measuring the disruption between GDP-bound recombinant His-tagged KRAS G12C/C118A (1 to 169 residues) and Ras binding domain of GST-tagged c-RAF (1 to 149 residues) preincubated for 5 mins followed by SOS1 and GTP addition and further incubated for 30 mins by AlphaLISA assay,C=CC(=O)N1CCN(c2ncnc3c(F)c(-c4c(O)cccc4F)c(Cl)cc23)CC1,CHEMBL4354832,=,=,IC50,nM,939.0,IC50,uM,0.939,C=CC(=O)N1CCN(c2ncnc3c(F)c(-c4c(O)cccc4F)c(Cl)cc23)CC1,2020
Inhibition of GDP bound recombinant human His-tagged KRAS G12C/C118A mutant (1 to 169 residues) assessed as reduction in SOS1-mediated GDP/GTP nucleotide exchange by measuring the disruption between GDP-bound recombinant His-tagged KRAS G12C/C118A (1 to 169 residues) and Ras binding domain of GST-tagged c-RAF (1 to 149 residues) preincubated for 5 mins followed by SOS1 and GTP addition and further incubated for 30 mins by AlphaLISA assay,C=CC(=O)N1CCN(c2nnc(-c3ccccc3)c3cc(-c4c(O)cccc4F)c(Cl)cc23)CC1,CHEMBL4354832,=,=,IC50,nM,20100.0,IC50,uM,20.1,C=CC(=O)N1CCN(c2nnc(-c3ccccc3)c3cc(-c4c(O)cccc4F)c(Cl)cc23)CC1,2020
Inhibition of GDP bound recombinant human His-tagged KRAS G12C/C118A mutant (1 to 169 residues) assessed as reduction in SOS1-mediated GDP/GTP nucleotide exchange by measuring the disruption between GDP-bound recombinant His-tagged KRAS G12C/C118A (1 to 169 residues) and Ras binding domain of GST-tagged c-RAF (1 to 149 residues) preincubated for 5 mins followed by SOS1 and GTP addition and further incubated for 30 mins by AlphaLISA assay,C=CC(=O)N1CCN(c2nnc(-c3ccccc3C)c3cc(-c4c(O)cccc4F)c(Cl)cc23)CC1,CHEMBL4354832,=,=,IC50,nM,5710.0,IC50,uM,5.71,C=CC(=O)N1CCN(c2nnc(-c3ccccc3C)c3cc(-c4c(O)cccc4F)c(Cl)cc23)CC1,2020
Inhibition of GDP bound recombinant human His-tagged KRAS G12C/C118A mutant (1 to 169 residues) assessed as reduction in SOS1-mediated GDP/GTP nucleotide exchange by measuring the disruption between GDP-bound recombinant His-tagged KRAS G12C/C118A (1 to 169 residues) and Ras binding domain of GST-tagged c-RAF (1 to 149 residues) preincubated for 5 mins followed by SOS1 and GTP addition and further incubated for 30 mins by AlphaLISA assay,C=CC(=O)N1CCN(c2nnc(-c3ccccc3Cl)c3cc(-c4c(O)cccc4F)c(Cl)cc23)CC1,CHEMBL4354832,=,=,IC50,nM,3520.0,IC50,uM,3.52,C=CC(=O)N1CCN(c2nnc(-c3ccccc3Cl)c3cc(-c4c(O)cccc4F)c(Cl)cc23)CC1,2020
Inhibition of GDP bound recombinant human His-tagged KRAS G12C/C118A mutant (1 to 169 residues) assessed as reduction in SOS1-mediated GDP/GTP nucleotide exchange by measuring the disruption between GDP-bound recombinant His-tagged KRAS G12C/C118A (1 to 169 residues) and Ras binding domain of GST-tagged c-RAF (1 to 149 residues) preincubated for 5 mins followed by SOS1 and GTP addition and further incubated for 30 mins by AlphaLISA assay,C=CC(=O)N1CCN(c2nnc(-c3ccccc3CC)c3cc(-c4c(O)cccc4F)c(Cl)cc23)CC1,CHEMBL4354832,=,=,IC50,nM,903.0,IC50,uM,0.903,C=CC(=O)N1CCN(c2nnc(-c3ccccc3CC)c3cc(-c4c(O)cccc4F)c(Cl)cc23)CC1,2020
Inhibition of GDP bound recombinant human His-tagged KRAS G12C/C118A mutant (1 to 169 residues) assessed as reduction in SOS1-mediated GDP/GTP nucleotide exchange by measuring the disruption between GDP-bound recombinant His-tagged KRAS G12C/C118A (1 to 169 residues) and Ras binding domain of GST-tagged c-RAF (1 to 149 residues) preincubated for 5 mins followed by SOS1 and GTP addition and further incubated for 30 mins by AlphaLISA assay,C=CC(=O)N1CCN(c2nnc(-c3ccccc3OC)c3cc(-c4c(O)cccc4F)c(Cl)cc23)CC1,CHEMBL4354832,=,=,IC50,nM,9150.0,IC50,uM,9.15,C=CC(=O)N1CCN(c2nnc(-c3ccccc3OC)c3cc(-c4c(O)cccc4F)c(Cl)cc23)CC1,2020
Inhibition of GDP bound recombinant human His-tagged KRAS G12C/C118A mutant (1 to 169 residues) assessed as reduction in SOS1-mediated GDP/GTP nucleotide exchange by measuring the disruption between GDP-bound recombinant His-tagged KRAS G12C/C118A (1 to 169 residues) and Ras binding domain of GST-tagged c-RAF (1 to 149 residues) preincubated for 5 mins followed by SOS1 and GTP addition and further incubated for 30 mins by AlphaLISA assay,C=CC(=O)N1CCN(c2nnc(-c3ccccc3C3CC3)c3cc(-c4c(O)cccc4F)c(Cl)cc23)CC1,CHEMBL4354832,=,=,IC50,nM,1550.0,IC50,uM,1.55,C=CC(=O)N1CCN(c2nnc(-c3ccccc3C3CC3)c3cc(-c4c(O)cccc4F)c(Cl)cc23)CC1,2020
Inhibition of GDP bound recombinant human His-tagged KRAS G12C/C118A mutant (1 to 169 residues) assessed as reduction in SOS1-mediated GDP/GTP nucleotide exchange by measuring the disruption between GDP-bound recombinant His-tagged KRAS G12C/C118A (1 to 169 residues) and Ras binding domain of GST-tagged c-RAF (1 to 149 residues) preincubated for 5 mins followed by SOS1 and GTP addition and further incubated for 30 mins by AlphaLISA assay,C=CC(=O)N1CCN(c2nnc(-c3ccccc3C(C)C)c3cc(-c4c(O)cccc4F)c(Cl)cc23)CC1,CHEMBL4354832,=,=,IC50,nM,683.0,IC50,uM,0.683,C=CC(=O)N1CCN(c2nnc(-c3ccccc3C(C)C)c3cc(-c4c(O)cccc4F)c(Cl)cc23)CC1,2020
Inhibition of GDP bound recombinant human His-tagged KRAS G12C/C118A mutant (1 to 169 residues) assessed as reduction in SOS1-mediated GDP/GTP nucleotide exchange by measuring the disruption between GDP-bound recombinant His-tagged KRAS G12C/C118A (1 to 169 residues) and Ras binding domain of GST-tagged c-RAF (1 to 149 residues) preincubated for 5 mins followed by SOS1 and GTP addition and further incubated for 30 mins by AlphaLISA assay,C=CC(=O)N1CCN(c2nc(=O)n(-c3ccccc3C(C)C)c3cc(-c4c(O)cccc4F)c(Cl)cc23)CC1,CHEMBL4354832,=,=,IC50,nM,101.0,IC50,uM,0.101,C=CC(=O)N1CCN(c2nc(=O)n(-c3ccccc3C(C)C)c3cc(-c4c(O)cccc4F)c(Cl)cc23)CC1,2020
Inhibition of GDP bound recombinant human His-tagged KRAS G12C/C118A mutant (1 to 169 residues) assessed as reduction in SOS1-mediated GDP/GTP nucleotide exchange by measuring the disruption between GDP-bound recombinant His-tagged KRAS G12C/C118A (1 to 169 residues) and Ras binding domain of GST-tagged c-RAF (1 to 149 residues) preincubated for 5 mins followed by SOS1 and GTP addition and further incubated for 30 mins by AlphaLISA assay,C=CC(=O)N1CCN(c2nc(=O)n(-c3ccccc3C(C)C)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,CHEMBL4354832,=,=,IC50,nM,51.0,IC50,uM,0.051,C=CC(=O)N1CCN(c2nc(=O)n(-c3ccccc3C(C)C)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,2020
Inhibition of GDP bound recombinant human His-tagged KRAS G12C/C118A mutant (1 to 169 residues) assessed as reduction in SOS1-mediated GDP/GTP nucleotide exchange by measuring the disruption between GDP-bound recombinant His-tagged KRAS G12C/C118A (1 to 169 residues) and Ras binding domain of GST-tagged c-RAF (1 to 149 residues) preincubated for 5 mins followed by SOS1 and GTP addition and further incubated for 30 mins by AlphaLISA assay,C=CC(=O)N1CCN(c2nc(=O)n(-c3ccccc3C3CC3)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,CHEMBL4354832,=,=,IC50,nM,225.0,IC50,uM,0.225,C=CC(=O)N1CCN(c2nc(=O)n(-c3ccccc3C3CC3)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,2020
Inhibition of GDP bound recombinant human His-tagged KRAS G12C/C118A mutant (1 to 169 residues) assessed as reduction in SOS1-mediated GDP/GTP nucleotide exchange by measuring the disruption between GDP-bound recombinant His-tagged KRAS G12C/C118A (1 to 169 residues) and Ras binding domain of GST-tagged c-RAF (1 to 149 residues) preincubated for 5 mins followed by SOS1 and GTP addition and further incubated for 30 mins by AlphaLISA assay,C=CC(=O)N1CCN(c2nc(=O)n(-c3ccccc3C(C)(C)C)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,CHEMBL4354832,=,=,IC50,nM,117.0,IC50,uM,0.117,C=CC(=O)N1CCN(c2nc(=O)n(-c3ccccc3C(C)(C)C)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,2020
Inhibition of GDP bound recombinant human His-tagged KRAS G12C/C118A mutant (1 to 169 residues) assessed as reduction in SOS1-mediated GDP/GTP nucleotide exchange by measuring the disruption between GDP-bound recombinant His-tagged KRAS G12C/C118A (1 to 169 residues) and Ras binding domain of GST-tagged c-RAF (1 to 149 residues) preincubated for 5 mins followed by SOS1 and GTP addition and further incubated for 30 mins by AlphaLISA assay,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)cccc3C(C)C)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,CHEMBL4354832,=,=,IC50,nM,25.0,IC50,uM,0.025,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)cccc3C(C)C)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,2020
Inhibition of GDP bound recombinant human His-tagged KRAS G12C/C118A mutant (1 to 169 residues) assessed as reduction in SOS1-mediated GDP/GTP nucleotide exchange by measuring the disruption between GDP-bound recombinant His-tagged KRAS G12C/C118A (1 to 169 residues) and Ras binding domain of GST-tagged c-RAF (1 to 149 residues) preincubated for 5 mins followed by SOS1 and GTP addition and further incubated for 30 mins by AlphaLISA assay,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)cccc3CC)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,CHEMBL4354832,=,=,IC50,nM,127.0,IC50,uM,0.127,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)cccc3CC)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,2020
Inhibition of GDP bound recombinant human His-tagged KRAS G12C/C118A mutant (1 to 169 residues) assessed as reduction in SOS1-mediated GDP/GTP nucleotide exchange by measuring the disruption between GDP-bound recombinant His-tagged KRAS G12C/C118A (1 to 169 residues) and Ras binding domain of GST-tagged c-RAF (1 to 149 residues) preincubated for 5 mins followed by SOS1 and GTP addition and further incubated for 30 mins by AlphaLISA assay,C=CC(=O)N1CCN(c2nc(=O)n(-c3ncccc3C(C)C)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,CHEMBL4354832,=,=,IC50,nM,83.0,IC50,uM,0.083,C=CC(=O)N1CCN(c2nc(=O)n(-c3ncccc3C(C)C)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,2020
Inhibition of GDP bound recombinant human His-tagged KRAS G12C/C118A mutant (1 to 169 residues) assessed as reduction in SOS1-mediated GDP/GTP nucleotide exchange by measuring the disruption between GDP-bound recombinant His-tagged KRAS G12C/C118A (1 to 169 residues) and Ras binding domain of GST-tagged c-RAF (1 to 149 residues) preincubated for 5 mins followed by SOS1 and GTP addition and further incubated for 30 mins by AlphaLISA assay,C=CC(=O)N1CCN(c2nc(=O)n(-c3ccnn3C(C)C)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,CHEMBL4354832,=,=,IC50,nM,164.0,IC50,uM,0.164,C=CC(=O)N1CCN(c2nc(=O)n(-c3ccnn3C(C)C)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,2020
Inhibition of GDP bound recombinant human His-tagged KRAS G12C/C118A mutant (1 to 169 residues) assessed as reduction in SOS1-mediated GDP/GTP nucleotide exchange by measuring the disruption between GDP-bound recombinant His-tagged KRAS G12C/C118A (1 to 169 residues) and Ras binding domain of GST-tagged c-RAF (1 to 149 residues) preincubated for 5 mins followed by SOS1 and GTP addition and further incubated for 30 mins by AlphaLISA assay,C=CC(=O)N1CCN(c2nc(=O)n(-c3scnc3C(C)C)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,CHEMBL4354832,=,=,IC50,nM,81.0,IC50,uM,0.081,C=CC(=O)N1CCN(c2nc(=O)n(-c3scnc3C(C)C)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,2020
Inhibition of GDP bound recombinant human His-tagged KRAS G12C/C118A mutant (1 to 169 residues) assessed as reduction in SOS1-mediated GDP/GTP nucleotide exchange by measuring the disruption between GDP-bound recombinant His-tagged KRAS G12C/C118A (1 to 169 residues) and Ras binding domain of GST-tagged c-RAF (1 to 149 residues) preincubated for 5 mins followed by SOS1 and GTP addition and further incubated for 30 mins by AlphaLISA assay,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)cnn3C(C)C)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,CHEMBL4354832,=,=,IC50,nM,53.0,IC50,uM,0.053,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)cnn3C(C)C)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,2020
Inhibition of GDP bound recombinant human His-tagged KRAS G12C/C118A mutant (1 to 169 residues) assessed as reduction in SOS1-mediated GDP/GTP nucleotide exchange by measuring the disruption between GDP-bound recombinant His-tagged KRAS G12C/C118A (1 to 169 residues) and Ras binding domain of GST-tagged c-RAF (1 to 149 residues) preincubated for 5 mins followed by SOS1 and GTP addition and further incubated for 30 mins by AlphaLISA assay,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)cccc3C)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,CHEMBL4354832,=,=,IC50,nM,306.0,IC50,uM,0.306,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)cccc3C)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,2020
Inhibition of GDP bound recombinant human His-tagged KRAS G12C/C118A mutant (1 to 169 residues) assessed as reduction in SOS1-mediated GDP/GTP nucleotide exchange by measuring the disruption between GDP-bound recombinant His-tagged KRAS G12C/C118A (1 to 169 residues) and Ras binding domain of GST-tagged c-RAF (1 to 149 residues) preincubated for 5 mins followed by SOS1 and GTP addition and further incubated for 30 mins by AlphaLISA assay,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(CC)cccc3CC)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,CHEMBL4354832,=,=,IC50,nM,68.0,IC50,uM,0.068,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(CC)cccc3CC)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,2020
Inhibition of GDP bound recombinant human His-tagged KRAS G12C/C118A mutant (1 to 169 residues) assessed as reduction in SOS1-mediated GDP/GTP nucleotide exchange by measuring the disruption between GDP-bound recombinant His-tagged KRAS G12C/C118A (1 to 169 residues) and Ras binding domain of GST-tagged c-RAF (1 to 149 residues) preincubated for 5 mins followed by SOS1 and GTP addition and further incubated for 30 mins by AlphaLISA assay,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C4CC4)ncnc3C3CC3)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,CHEMBL4354832,=,=,IC50,nM,34.0,IC50,uM,0.034,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C4CC4)ncnc3C3CC3)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,2020
Inhibition of GDP bound recombinant human His-tagged KRAS G12C/C118A mutant (1 to 169 residues) assessed as reduction in SOS1-mediated GDP/GTP nucleotide exchange by measuring the disruption between GDP-bound recombinant His-tagged KRAS G12C/C118A (1 to 169 residues) and Ras binding domain of GST-tagged c-RAF (1 to 149 residues) preincubated for 5 mins followed by SOS1 and GTP addition and further incubated for 30 mins by AlphaLISA assay,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C(C)C)ncnc3C(C)C)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,CHEMBL4354832,=,=,IC50,nM,21.0,IC50,uM,0.021,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C(C)C)ncnc3C(C)C)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,2020
Inhibition of KRAS in human MIAPaca2 cells assessed as decrease in EGF-stimulated ERK1/2 phosphorylation preincubated for 2 hrs followed by EGF stimulation,C=CC(=O)N1CCN(c2ncnc3c(F)c(-c4c(O)cccc4F)c(Cl)cc23)CC1,CHEMBL4354832,=,=,IC50,nM,831.0,IC50,uM,0.831,C=CC(=O)N1CCN(c2ncnc3c(F)c(-c4c(O)cccc4F)c(Cl)cc23)CC1,2020
Inhibition of KRAS in human MIAPaca2 cells assessed as decrease in EGF-stimulated ERK1/2 phosphorylation preincubated for 2 hrs followed by EGF stimulation,C=CC(=O)N1CCN(c2nnc(-c3ccccc3)c3cc(-c4c(O)cccc4F)c(Cl)cc23)CC1,CHEMBL4354832,=,=,IC50,nM,58000.0,IC50,uM,58.0,C=CC(=O)N1CCN(c2nnc(-c3ccccc3)c3cc(-c4c(O)cccc4F)c(Cl)cc23)CC1,2020
Inhibition of KRAS in human MIAPaca2 cells assessed as decrease in EGF-stimulated ERK1/2 phosphorylation preincubated for 2 hrs followed by EGF stimulation,C=CC(=O)N1CCN(c2nnc(-c3ccccc3C)c3cc(-c4c(O)cccc4F)c(Cl)cc23)CC1,CHEMBL4354832,=,=,IC50,nM,3330.0,IC50,uM,3.33,C=CC(=O)N1CCN(c2nnc(-c3ccccc3C)c3cc(-c4c(O)cccc4F)c(Cl)cc23)CC1,2020
Inhibition of KRAS in human MIAPaca2 cells assessed as decrease in EGF-stimulated ERK1/2 phosphorylation preincubated for 2 hrs followed by EGF stimulation,C=CC(=O)N1CCN(c2nnc(-c3ccccc3Cl)c3cc(-c4c(O)cccc4F)c(Cl)cc23)CC1,CHEMBL4354832,=,=,IC50,nM,3530.0,IC50,uM,3.53,C=CC(=O)N1CCN(c2nnc(-c3ccccc3Cl)c3cc(-c4c(O)cccc4F)c(Cl)cc23)CC1,2020
Inhibition of KRAS in human MIAPaca2 cells assessed as decrease in EGF-stimulated ERK1/2 phosphorylation preincubated for 2 hrs followed by EGF stimulation,C=CC(=O)N1CCN(c2nnc(-c3ccccc3CC)c3cc(-c4c(O)cccc4F)c(Cl)cc23)CC1,CHEMBL4354832,=,=,IC50,nM,2580.0,IC50,uM,2.58,C=CC(=O)N1CCN(c2nnc(-c3ccccc3CC)c3cc(-c4c(O)cccc4F)c(Cl)cc23)CC1,2020
Inhibition of KRAS in human MIAPaca2 cells assessed as decrease in EGF-stimulated ERK1/2 phosphorylation preincubated for 2 hrs followed by EGF stimulation,C=CC(=O)N1CCN(c2nnc(-c3ccccc3OC)c3cc(-c4c(O)cccc4F)c(Cl)cc23)CC1,CHEMBL4354832,=,=,IC50,nM,8050.0,IC50,uM,8.05,C=CC(=O)N1CCN(c2nnc(-c3ccccc3OC)c3cc(-c4c(O)cccc4F)c(Cl)cc23)CC1,2020
Inhibition of KRAS in human MIAPaca2 cells assessed as decrease in EGF-stimulated ERK1/2 phosphorylation preincubated for 2 hrs followed by EGF stimulation,C=CC(=O)N1CCN(c2nnc(-c3ccccc3C3CC3)c3cc(-c4c(O)cccc4F)c(Cl)cc23)CC1,CHEMBL4354832,=,=,IC50,nM,7150.0,IC50,uM,7.15,C=CC(=O)N1CCN(c2nnc(-c3ccccc3C3CC3)c3cc(-c4c(O)cccc4F)c(Cl)cc23)CC1,2020
Inhibition of KRAS in human MIAPaca2 cells assessed as decrease in EGF-stimulated ERK1/2 phosphorylation preincubated for 2 hrs followed by EGF stimulation,C=CC(=O)N1CCN(c2nnc(-c3ccccc3C(C)C)c3cc(-c4c(O)cccc4F)c(Cl)cc23)CC1,CHEMBL4354832,=,=,IC50,nM,1800.0,IC50,uM,1.8,C=CC(=O)N1CCN(c2nnc(-c3ccccc3C(C)C)c3cc(-c4c(O)cccc4F)c(Cl)cc23)CC1,2020
Inhibition of KRAS in human MIAPaca2 cells assessed as decrease in EGF-stimulated ERK1/2 phosphorylation preincubated for 2 hrs followed by EGF stimulation,C=CC(=O)N1CCN(c2nc(=O)n(-c3ccccc3C(C)C)c3cc(-c4c(O)cccc4F)c(Cl)cc23)CC1,CHEMBL4354832,=,=,IC50,nM,335.0,IC50,uM,0.335,C=CC(=O)N1CCN(c2nc(=O)n(-c3ccccc3C(C)C)c3cc(-c4c(O)cccc4F)c(Cl)cc23)CC1,2020
Inhibition of KRAS in human MIAPaca2 cells assessed as decrease in EGF-stimulated ERK1/2 phosphorylation preincubated for 2 hrs followed by EGF stimulation,C=CC(=O)N1CCN(c2nc(=O)n(-c3ccccc3C(C)C)c3cc(-c4c(O)cccc4F)c(Cl)cc23)CC1,CHEMBL4354832,=,=,IC50,nM,130.0,IC50,uM,0.13,C=CC(=O)N1CCN(c2nc(=O)n(-c3ccccc3C(C)C)c3cc(-c4c(O)cccc4F)c(Cl)cc23)CC1,2020
Inhibition of KRAS in human MIAPaca2 cells assessed as decrease in EGF-stimulated ERK1/2 phosphorylation preincubated for 2 hrs followed by EGF stimulation,C=CC(=O)N1CCN(c2nc(=O)n(-c3ccccc3C(C)C)c3cc(-c4c(C)ccc5[nH]ncc45)c(Cl)cc23)CC1,CHEMBL4354832,=,=,IC50,nM,8.0,IC50,uM,0.008,C=CC(=O)N1CCN(c2nc(=O)n(-c3ccccc3C(C)C)c3cc(-c4c(C)ccc5[nH]ncc45)c(Cl)cc23)CC1,2020
Inhibition of KRAS in human MIAPaca2 cells assessed as decrease in EGF-stimulated ERK1/2 phosphorylation preincubated for 2 hrs followed by EGF stimulation,C=CC(=O)N1CCN(c2nc(=O)n(-c3ccccc3C(C)C)c3cc(-c4ccccc4F)c(Cl)cc23)CC1,CHEMBL4354832,=,=,IC50,nM,80.0,IC50,uM,0.08,C=CC(=O)N1CCN(c2nc(=O)n(-c3ccccc3C(C)C)c3cc(-c4ccccc4F)c(Cl)cc23)CC1,2020
Inhibition of KRAS in human MIAPaca2 cells assessed as decrease in EGF-stimulated ERK1/2 phosphorylation preincubated for 2 hrs followed by EGF stimulation,C=CC(=O)N1CCN(c2nc(=O)n(-c3ccccc3C(C)C)c3cc(-c4ccccc4F)c(Cl)cc23)[C@@H](C)C1,CHEMBL4354832,=,=,IC50,nM,47.0,IC50,uM,0.047,C=CC(=O)N1CCN(c2nc(=O)n(-c3ccccc3C(C)C)c3cc(-c4ccccc4F)c(Cl)cc23)[C@@H](C)C1,2020
Inhibition of KRAS in human MIAPaca2 cells assessed as decrease in EGF-stimulated ERK1/2 phosphorylation preincubated for 2 hrs followed by EGF stimulation,C=CC(=O)N1CCN(c2nc(=O)n(-c3ccccc3C(C)C)c3cc(-c4ccccc4Cl)c(Cl)cc23)[C@@H](C)C1,CHEMBL4354832,=,=,IC50,nM,220.0,IC50,uM,0.22,C=CC(=O)N1CCN(c2nc(=O)n(-c3ccccc3C(C)C)c3cc(-c4ccccc4Cl)c(Cl)cc23)[C@@H](C)C1,2020
Inhibition of KRAS in human MIAPaca2 cells assessed as decrease in EGF-stimulated ERK1/2 phosphorylation preincubated for 2 hrs followed by EGF stimulation,C=CC(=O)N1CCN(c2nc(=O)n(-c3ccccc3C(C)C)c3cc(-c4ccccc4C(F)(F)F)c(Cl)cc23)[C@@H](C)C1,CHEMBL4354832,=,=,IC50,nM,442.0,IC50,uM,0.442,C=CC(=O)N1CCN(c2nc(=O)n(-c3ccccc3C(C)C)c3cc(-c4ccccc4C(F)(F)F)c(Cl)cc23)[C@@H](C)C1,2020
Inhibition of KRAS in human MIAPaca2 cells assessed as decrease in EGF-stimulated ERK1/2 phosphorylation preincubated for 2 hrs followed by EGF stimulation,C=CC(=O)N1CCN(c2nc(=O)n(-c3ccccc3C(C)C)c3cc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,CHEMBL4354832,=,=,IC50,nM,28.0,IC50,uM,0.028,C=CC(=O)N1CCN(c2nc(=O)n(-c3ccccc3C(C)C)c3cc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,2020
Inhibition of KRAS in human MIAPaca2 cells assessed as decrease in EGF-stimulated ERK1/2 phosphorylation preincubated for 2 hrs followed by EGF stimulation,C=CC(=O)N1CCN(c2nc(=O)n(-c3ccccc3C(C)C)c3nc(-c4c(O)cccc4F)c(Cl)cc23)CC1,CHEMBL4354832,=,=,IC50,nM,69.0,IC50,uM,0.069,C=CC(=O)N1CCN(c2nc(=O)n(-c3ccccc3C(C)C)c3nc(-c4c(O)cccc4F)c(Cl)cc23)CC1,2020
Inhibition of KRAS in human MIAPaca2 cells assessed as decrease in EGF-stimulated ERK1/2 phosphorylation preincubated for 2 hrs followed by EGF stimulation,C=CC(=O)N1CCN(c2nc(=O)n(-c3ccccc3C(C)C)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,CHEMBL4354832,=,=,IC50,nM,44.0,IC50,uM,0.044,C=CC(=O)N1CCN(c2nc(=O)n(-c3ccccc3C(C)C)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,2020
Inhibition of KRAS in human MIAPaca2 cells assessed as decrease in EGF-stimulated ERK1/2 phosphorylation preincubated for 2 hrs followed by EGF stimulation,C=CC(=O)N1CCN(c2nc(=O)n(-c3ccccc3C(C)C)c3nc(-c4ccccc4F)c(Cl)cc23)[C@@H](C)C1,CHEMBL4354832,=,=,IC50,nM,66.0,IC50,uM,0.066,C=CC(=O)N1CCN(c2nc(=O)n(-c3ccccc3C(C)C)c3nc(-c4ccccc4F)c(Cl)cc23)[C@@H](C)C1,2020
Inhibition of KRAS in human MIAPaca2 cells assessed as decrease in EGF-stimulated ERK1/2 phosphorylation preincubated for 2 hrs followed by EGF stimulation,C=CC(=O)N1CCN(c2nc(=O)n(-c3ccccc3C(C)C)c3nc(-c4ccccc4Cl)c(Cl)cc23)[C@@H](C)C1,CHEMBL4354832,=,=,IC50,nM,56.0,IC50,uM,0.056,C=CC(=O)N1CCN(c2nc(=O)n(-c3ccccc3C(C)C)c3nc(-c4ccccc4Cl)c(Cl)cc23)[C@@H](C)C1,2020
Inhibition of KRAS in human MIAPaca2 cells assessed as decrease in EGF-stimulated ERK1/2 phosphorylation preincubated for 2 hrs followed by EGF stimulation,C=CC(=O)N1CCN(c2nc(=O)n(-c3ccccc3C(C)C)c3nc(-c4ccccc4O)c(Cl)cc23)[C@@H](C)C1,CHEMBL4354832,=,=,IC50,nM,146.0,IC50,uM,0.146,C=CC(=O)N1CCN(c2nc(=O)n(-c3ccccc3C(C)C)c3nc(-c4ccccc4O)c(Cl)cc23)[C@@H](C)C1,2020
Inhibition of KRAS in human MIAPaca2 cells assessed as decrease in EGF-stimulated ERK1/2 phosphorylation preincubated for 2 hrs followed by EGF stimulation,C=CC(=O)N1CCN(c2nc(=O)n(-c3ccccc3C3CC3)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,CHEMBL4354832,=,=,IC50,nM,109.0,IC50,uM,0.109,C=CC(=O)N1CCN(c2nc(=O)n(-c3ccccc3C3CC3)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,2020
Inhibition of KRAS in human MIAPaca2 cells assessed as decrease in EGF-stimulated ERK1/2 phosphorylation preincubated for 2 hrs followed by EGF stimulation,C=CC(=O)N1CCN(c2nc(=O)n(-c3ccccc3C(C)(C)C)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,CHEMBL4354832,=,=,IC50,nM,51.0,IC50,uM,0.051,C=CC(=O)N1CCN(c2nc(=O)n(-c3ccccc3C(C)(C)C)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,2020
Inhibition of KRAS in human MIAPaca2 cells assessed as decrease in EGF-stimulated ERK1/2 phosphorylation preincubated for 2 hrs followed by EGF stimulation,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)cccc3C(C)C)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,CHEMBL4354832,=,=,IC50,nM,28.0,IC50,uM,0.028,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)cccc3C(C)C)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,2020
Inhibition of KRAS in human MIAPaca2 cells assessed as decrease in EGF-stimulated ERK1/2 phosphorylation preincubated for 2 hrs followed by EGF stimulation,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)cccc3CC)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,CHEMBL4354832,=,=,IC50,nM,25.0,IC50,uM,0.025,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)cccc3CC)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,2020
Inhibition of KRAS in human MIAPaca2 cells assessed as decrease in EGF-stimulated ERK1/2 phosphorylation preincubated for 2 hrs followed by EGF stimulation,C=CC(=O)N1CCN(c2nc(=O)n(-c3ncccc3C(C)C)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,CHEMBL4354832,=,=,IC50,nM,53.0,IC50,uM,0.053,C=CC(=O)N1CCN(c2nc(=O)n(-c3ncccc3C(C)C)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,2020
Inhibition of KRAS in human MIAPaca2 cells assessed as decrease in EGF-stimulated ERK1/2 phosphorylation preincubated for 2 hrs followed by EGF stimulation,C=CC(=O)N1CCN(c2nc(=O)n(-c3ccnn3C(C)C)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,CHEMBL4354832,=,=,IC50,nM,218.0,IC50,uM,0.218,C=CC(=O)N1CCN(c2nc(=O)n(-c3ccnn3C(C)C)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,2020
Inhibition of KRAS in human MIAPaca2 cells assessed as decrease in EGF-stimulated ERK1/2 phosphorylation preincubated for 2 hrs followed by EGF stimulation,C=CC(=O)N1CCN(c2nc(=O)n(-c3scnc3C(C)C)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,CHEMBL4354832,=,=,IC50,nM,63.0,IC50,uM,0.063,C=CC(=O)N1CCN(c2nc(=O)n(-c3scnc3C(C)C)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,2020
Inhibition of KRAS in human MIAPaca2 cells assessed as decrease in EGF-stimulated ERK1/2 phosphorylation preincubated for 2 hrs followed by EGF stimulation,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)cnn3C(C)C)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,CHEMBL4354832,=,=,IC50,nM,127.0,IC50,uM,0.127,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)cnn3C(C)C)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,2020
Inhibition of KRAS in human MIAPaca2 cells assessed as decrease in EGF-stimulated ERK1/2 phosphorylation preincubated for 2 hrs followed by EGF stimulation,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)cccc3C)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,CHEMBL4354832,=,=,IC50,nM,199.0,IC50,uM,0.199,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)cccc3C)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,2020
Inhibition of KRAS in human MIAPaca2 cells assessed as decrease in EGF-stimulated ERK1/2 phosphorylation preincubated for 2 hrs followed by EGF stimulation,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(CC)cccc3CC)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,CHEMBL4354832,=,=,IC50,nM,36.0,IC50,uM,0.036,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(CC)cccc3CC)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,2020
Inhibition of KRAS in human MIAPaca2 cells assessed as decrease in EGF-stimulated ERK1/2 phosphorylation preincubated for 2 hrs followed by EGF stimulation,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C4CC4)ncnc3C3CC3)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,CHEMBL4354832,=,=,IC50,nM,36.0,IC50,uM,0.036,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C4CC4)ncnc3C3CC3)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,2020
Inhibition of KRAS in human MIAPaca2 cells assessed as decrease in EGF-stimulated ERK1/2 phosphorylation preincubated for 2 hrs followed by EGF stimulation,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C(C)C)ncnc3C(C)C)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,CHEMBL4354832,=,=,IC50,nM,25.0,IC50,uM,0.025,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C(C)C)ncnc3C(C)C)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,2020
Inhibition of KRAS in human MIAPaca2 cells assessed as decrease in EGF-stimulated ERK1/2 phosphorylation preincubated for 2 hrs followed by EGF stimulation,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,CHEMBL4354832,=,=,IC50,nM,11.0,IC50,uM,0.011,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,2020
Inhibition of KRAS in human MIAPaca2 cells assessed as decrease in EGF-stimulated ERK1/2 phosphorylation preincubated for 2 hrs followed by EGF stimulation,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C(C)C)ccnc3C)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,CHEMBL4354832,=,=,IC50,nM,65.0,IC50,uM,0.065,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C(C)C)ccnc3C)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,2020
Inhibition of KRAS in human MIAPaca2 cells assessed as decrease in EGF-stimulated ERK1/2 phosphorylation preincubated for 2 hrs followed by EGF stimulation,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ncnc3C(C)C)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,CHEMBL4354832,=,=,IC50,nM,38.0,IC50,uM,0.038,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ncnc3C(C)C)c3nc(-c4c(O)cccc4F)c(Cl)cc23)[C@@H](C)C1,2020
Inhibition of KRAS in human MIAPaca2 cells assessed as decrease in EGF-stimulated ERK1/2 phosphorylation preincubated for 2 hrs followed by EGF stimulation,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)cccc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1,CHEMBL4354832,=,=,IC50,nM,90.0,IC50,uM,0.09,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)cccc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1,2020
Inhibition of KRAS in human MIAPaca2 cells assessed as decrease in EGF-stimulated ERK1/2 phosphorylation preincubated for 2 hrs followed by EGF stimulation,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1,CHEMBL4354832,=,=,IC50,nM,68.0,IC50,uM,0.068,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1,2020
Inhibition of KRAS in human MIAPaca2 cells assessed as decrease in EGF-stimulated ERK1/2 phosphorylation preincubated for 2 hrs followed by EGF stimulation,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C(C)C)ccnc3C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1,CHEMBL4354832,=,=,IC50,nM,142.0,IC50,uM,0.142,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C(C)C)ccnc3C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1,2020
Inhibition of KRAS in human MIAPaca2 cells assessed as decrease in EGF-stimulated ERK1/2 phosphorylation preincubated for 2 hrs followed by EGF stimulation,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ncnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1,CHEMBL4354832,=,=,IC50,nM,128.0,IC50,uM,0.128,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ncnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1,2020
Covalent inhibition of recombinant human His-tagged KRAS G12C/C51S/C80L/C118S mutant (1 to 169 residues) expressed in Escherichia coli assessed as enzyme-compound adduct formation by measuring ratio of Kinact/Ki after 16 to 20 hrs of overnight incubation by mass spectrometry analysis,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1,CHEMBL4354832,=,=,Ratio,/M/s,9900.0,Ratio,/M/s,9900.0,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1,2020
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 0.02 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2ccc3cc(Br)ccc32)C1,CHEMBL4364340,,,Inhibition,%,,INH,,,C=CC(=O)N1CC(NC(=O)Cn2ccc3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) assessed as pseudo first order rate constant incubated for 0.02 to 20 hrs in presence of GDP by rapidfire mass spectrometry analysis,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)NCc3ccccc3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,K,/M/s,5.0,K,/M/s,5.0,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)NCc3ccccc3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 0.02 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,Inhibition,%,13.0,INH,%,13.0,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 0.02 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)NCc3ccccc3)c3cc(Br)ccc32)C1,CHEMBL4364340,,,Inhibition,%,,INH,,,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)NCc3ccccc3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 0.02 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)NCCc3ccccc3)c3cc(Br)ccc32)C1,CHEMBL4364340,,,Inhibition,%,,INH,,,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)NCCc3ccccc3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 0.02 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N(C)Cc3ccccc3)c3cc(Br)ccc32)C1,CHEMBL4364340,,,Inhibition,%,,INH,,,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N(C)Cc3ccccc3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 0.02 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4ccccc4C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,Inhibition,%,0.0,INH,%,0.0,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4ccccc4C3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 0.02 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4cc(F)ccc4C3)c3cc(Br)ccc32)C1,CHEMBL4364340,,,Inhibition,%,,INH,,,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4cc(F)ccc4C3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 0.02 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(F)cccc4C3)c3cc(Br)ccc32)C1,CHEMBL4364340,,,Inhibition,%,,INH,,,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(F)cccc4C3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 0.02 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4cc(Cl)ccc4C3)c3cc(Br)ccc32)C1,CHEMBL4364340,,,Inhibition,%,,INH,,,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4cc(Cl)ccc4C3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 0.02 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(Cl)cccc4C3)c3cc(Br)ccc32)C1,CHEMBL4364340,,,Inhibition,%,,INH,,,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(Cl)cccc4C3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 0.02 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,Inhibition,%,14.0,INH,%,14.0,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 0.02 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2c(C3CC3)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,Inhibition,%,35.0,INH,%,35.0,C=CC(=O)N1CC(NC(=O)Cn2c(C3CC3)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 0.02 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)cc(C)c32)C1,CHEMBL4364340,,,Inhibition,%,,INH,,,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)cc(C)c32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 0.02 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)cc(C)c32)C1,CHEMBL4364340,,,Inhibition,%,,INH,,,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)cc(C)c32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 0.02 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Cl)ccc32)C1,CHEMBL4364340,,,Inhibition,%,,INH,,,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Cl)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 0.02 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Cl)cc(C)c32)C1,CHEMBL4364340,=,=,Inhibition,%,40.0,INH,%,40.0,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Cl)cc(C)c32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 0.02 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2c(C3CC3)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Cl)cc(C)c32)C1,CHEMBL4364340,=,=,Inhibition,%,69.0,INH,%,69.0,C=CC(=O)N1CC(NC(=O)Cn2c(C3CC3)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Cl)cc(C)c32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 0.2 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2ccc3cc(Br)ccc32)C1,CHEMBL4364340,,,Inhibition,%,,INH,,,C=CC(=O)N1CC(NC(=O)Cn2ccc3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 0.2 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,Inhibition,%,92.0,INH,%,92.0,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 0.2 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)NCc3ccccc3)c3cc(Br)ccc32)C1,CHEMBL4364340,,,Inhibition,%,,INH,,,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)NCc3ccccc3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 0.2 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)NCCc3ccccc3)c3cc(Br)ccc32)C1,CHEMBL4364340,,,Inhibition,%,,INH,,,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)NCCc3ccccc3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 0.2 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N(C)Cc3ccccc3)c3cc(Br)ccc32)C1,CHEMBL4364340,,,Inhibition,%,,INH,,,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N(C)Cc3ccccc3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 0.2 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4ccccc4C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,Inhibition,%,100.0,INH,%,100.0,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4ccccc4C3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 0.2 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4cc(F)ccc4C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,Inhibition,%,86.0,INH,%,86.0,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4cc(F)ccc4C3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 0.2 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(F)cccc4C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,Inhibition,%,77.0,INH,%,77.0,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(F)cccc4C3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 0.2 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4cc(Cl)ccc4C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,Inhibition,%,55.0,INH,%,55.0,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4cc(Cl)ccc4C3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 0.2 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(Cl)cccc4C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,Inhibition,%,67.0,INH,%,67.0,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(Cl)cccc4C3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 0.2 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,Inhibition,%,91.0,INH,%,91.0,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 0.2 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2c(C3CC3)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,Inhibition,%,90.0,INH,%,90.0,C=CC(=O)N1CC(NC(=O)Cn2c(C3CC3)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 0.2 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)cc(C)c32)C1,CHEMBL4364340,=,=,Inhibition,%,100.0,INH,%,100.0,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)cc(C)c32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 0.2 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)cc(C)c32)C1,CHEMBL4364340,=,=,Inhibition,%,39.0,INH,%,39.0,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)cc(C)c32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 0.2 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Cl)ccc32)C1,CHEMBL4364340,=,=,Inhibition,%,34.0,INH,%,34.0,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Cl)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 0.2 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Cl)cc(C)c32)C1,CHEMBL4364340,=,=,Inhibition,%,85.0,INH,%,85.0,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Cl)cc(C)c32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 0.2 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2c(C3CC3)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Cl)cc(C)c32)C1,CHEMBL4364340,=,=,Inhibition,%,94.0,INH,%,94.0,C=CC(=O)N1CC(NC(=O)Cn2c(C3CC3)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Cl)cc(C)c32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 2 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2ccc3cc(Br)ccc32)C1,CHEMBL4364340,=,=,Inhibition,%,14.0,INH,%,14.0,C=CC(=O)N1CC(NC(=O)Cn2ccc3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 2 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,Inhibition,%,100.0,INH,%,100.0,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 2 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)NCc3ccccc3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,Inhibition,%,29.0,INH,%,29.0,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)NCc3ccccc3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 2 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)NCCc3ccccc3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,Inhibition,%,59.0,INH,%,59.0,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)NCCc3ccccc3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 2 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N(C)Cc3ccccc3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,Inhibition,%,35.0,INH,%,35.0,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N(C)Cc3ccccc3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 2 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4ccccc4C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,Inhibition,%,100.0,INH,%,100.0,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4ccccc4C3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 2 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4cc(F)ccc4C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,Inhibition,%,100.0,INH,%,100.0,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4cc(F)ccc4C3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 2 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(F)cccc4C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,Inhibition,%,100.0,INH,%,100.0,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(F)cccc4C3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 2 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4cc(Cl)ccc4C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,Inhibition,%,100.0,INH,%,100.0,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4cc(Cl)ccc4C3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 2 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(Cl)cccc4C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,Inhibition,%,100.0,INH,%,100.0,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(Cl)cccc4C3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 2 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,Inhibition,%,100.0,INH,%,100.0,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 2 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2c(C3CC3)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,Inhibition,%,100.0,INH,%,100.0,C=CC(=O)N1CC(NC(=O)Cn2c(C3CC3)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 2 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)cc(C)c32)C1,CHEMBL4364340,=,=,Inhibition,%,100.0,INH,%,100.0,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)cc(C)c32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 2 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)cc(C)c32)C1,CHEMBL4364340,=,=,Inhibition,%,100.0,INH,%,100.0,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)cc(C)c32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 2 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Cl)ccc32)C1,CHEMBL4364340,=,=,Inhibition,%,100.0,INH,%,100.0,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Cl)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 2 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Cl)cc(C)c32)C1,CHEMBL4364340,=,=,Inhibition,%,100.0,INH,%,100.0,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Cl)cc(C)c32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 2 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2c(C3CC3)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Cl)cc(C)c32)C1,CHEMBL4364340,=,=,Inhibition,%,100.0,INH,%,100.0,C=CC(=O)N1CC(NC(=O)Cn2c(C3CC3)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Cl)cc(C)c32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 2 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)COc2ccc(Br)cc2NC(=O)c2cc(C)no2)C1,CHEMBL4364340,=,=,Inhibition,%,11.0,INH,%,11.0,C=CC(=O)N1CC(NC(=O)COc2ccc(Br)cc2NC(=O)c2cc(C)no2)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 20 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2ccc3cc(Br)ccc32)C1,CHEMBL4364340,=,=,Inhibition,%,67.0,INH,%,67.0,C=CC(=O)N1CC(NC(=O)Cn2ccc3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 20 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,Inhibition,%,100.0,INH,%,100.0,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 20 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)NCc3ccccc3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,Inhibition,%,93.0,INH,%,93.0,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)NCc3ccccc3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 20 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)NCCc3ccccc3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,Inhibition,%,100.0,INH,%,100.0,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)NCCc3ccccc3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 20 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N(C)Cc3ccccc3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,Inhibition,%,100.0,INH,%,100.0,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N(C)Cc3ccccc3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 20 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4ccccc4C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,Inhibition,%,100.0,INH,%,100.0,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4ccccc4C3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 20 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4cc(F)ccc4C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,Inhibition,%,100.0,INH,%,100.0,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4cc(F)ccc4C3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 20 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(F)cccc4C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,Inhibition,%,100.0,INH,%,100.0,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(F)cccc4C3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 20 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4cc(Cl)ccc4C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,Inhibition,%,100.0,INH,%,100.0,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4cc(Cl)ccc4C3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 20 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(Cl)cccc4C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,Inhibition,%,100.0,INH,%,100.0,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(Cl)cccc4C3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 20 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,Inhibition,%,100.0,INH,%,100.0,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 20 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2c(C3CC3)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)ccc32)C1,CHEMBL4364340,,,Inhibition,%,,INH,,,C=CC(=O)N1CC(NC(=O)Cn2c(C3CC3)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 20 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)cc(C)c32)C1,CHEMBL4364340,=,=,Inhibition,%,100.0,INH,%,100.0,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)cc(C)c32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 20 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)cc(C)c32)C1,CHEMBL4364340,,,Inhibition,%,,INH,,,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)cc(C)c32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 20 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Cl)ccc32)C1,CHEMBL4364340,=,=,Inhibition,%,100.0,INH,%,100.0,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Cl)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 20 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Cl)cc(C)c32)C1,CHEMBL4364340,=,=,Inhibition,%,100.0,INH,%,100.0,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Cl)cc(C)c32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 20 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)Cn2c(C3CC3)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Cl)cc(C)c32)C1,CHEMBL4364340,=,=,Inhibition,%,100.0,INH,%,100.0,C=CC(=O)N1CC(NC(=O)Cn2c(C3CC3)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Cl)cc(C)c32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) at 10 uM incubated for 20 hrs in presence of GDP by rapidfire mass spectrometry analysis relative to control,C=CC(=O)N1CC(NC(=O)COc2ccc(Br)cc2NC(=O)c2cc(C)no2)C1,CHEMBL4364340,=,=,Inhibition,%,63.0,INH,%,63.0,C=CC(=O)N1CC(NC(=O)COc2ccc(Br)cc2NC(=O)c2cc(C)no2)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) assessed as pseudo first order rate constant incubated for 0.02 to 20 hrs in presence of GDP by rapidfire mass spectrometry analysis,C=CC(=O)N1CC(NC(=O)Cn2ccc3cc(Br)ccc32)C1,CHEMBL4364340,=,=,K,/M/s,2.0,K,/M/s,2.0,C=CC(=O)N1CC(NC(=O)Cn2ccc3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) assessed as pseudo first order rate constant incubated for 0.02 to 20 hrs in presence of GDP by rapidfire mass spectrometry analysis,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,K,/M/s,230.0,K,/M/s,230.0,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) assessed as pseudo first order rate constant incubated for 0.02 to 20 hrs in presence of GDP by rapidfire mass spectrometry analysis,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)NCCc3ccccc3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,K,/M/s,12.0,K,/M/s,12.0,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)NCCc3ccccc3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) assessed as pseudo first order rate constant incubated for 0.02 to 20 hrs in presence of GDP by rapidfire mass spectrometry analysis,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N(C)Cc3ccccc3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,K,/M/s,6.0,K,/M/s,6.0,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N(C)Cc3ccccc3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) assessed as pseudo first order rate constant incubated for 0.02 to 20 hrs in presence of GDP by rapidfire mass spectrometry analysis,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4ccccc4C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,K,/M/s,308.0,K,/M/s,308.0,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4ccccc4C3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) assessed as pseudo first order rate constant incubated for 0.02 to 20 hrs in presence of GDP by rapidfire mass spectrometry analysis,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4cc(F)ccc4C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,K,/M/s,326.0,K,/M/s,326.0,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4cc(F)ccc4C3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) assessed as pseudo first order rate constant incubated for 0.02 to 20 hrs in presence of GDP by rapidfire mass spectrometry analysis,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(F)cccc4C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,K,/M/s,247.0,K,/M/s,247.0,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(F)cccc4C3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) assessed as pseudo first order rate constant incubated for 0.02 to 20 hrs in presence of GDP by rapidfire mass spectrometry analysis,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4cc(Cl)ccc4C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,K,/M/s,132.0,K,/M/s,132.0,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4cc(Cl)ccc4C3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) assessed as pseudo first order rate constant incubated for 0.02 to 20 hrs in presence of GDP by rapidfire mass spectrometry analysis,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(Cl)cccc4C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,K,/M/s,188.0,K,/M/s,188.0,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(Cl)cccc4C3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) assessed as pseudo first order rate constant incubated for 0.02 to 20 hrs in presence of GDP by rapidfire mass spectrometry analysis,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,K,/M/s,256.0,K,/M/s,256.0,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) assessed as pseudo first order rate constant incubated for 0.02 to 20 hrs in presence of GDP by rapidfire mass spectrometry analysis,C=CC(=O)N1CC(NC(=O)Cn2c(C3CC3)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,K,/M/s,549.0,K,/M/s,549.0,C=CC(=O)N1CC(NC(=O)Cn2c(C3CC3)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) assessed as pseudo first order rate constant incubated for 0.02 to 20 hrs in presence of GDP by rapidfire mass spectrometry analysis,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)cc(C)c32)C1,CHEMBL4364340,>,>,K,/M/s,400.0,K,/M/s,400.0,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)cc(C)c32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) assessed as pseudo first order rate constant incubated for 0.02 to 20 hrs in presence of GDP by rapidfire mass spectrometry analysis,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)cc(C)c32)C1,CHEMBL4364340,=,=,K,/M/s,83.0,K,/M/s,83.0,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)cc(C)c32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) assessed as pseudo first order rate constant incubated for 0.02 to 20 hrs in presence of GDP by rapidfire mass spectrometry analysis,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Cl)ccc32)C1,CHEMBL4364340,=,=,K,/M/s,69.0,K,/M/s,69.0,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Cl)ccc32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) assessed as pseudo first order rate constant incubated for 0.02 to 20 hrs in presence of GDP by rapidfire mass spectrometry analysis,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Cl)cc(C)c32)C1,CHEMBL4364340,=,=,K,/M/s,583.0,K,/M/s,583.0,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Cl)cc(C)c32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) assessed as pseudo first order rate constant incubated for 0.02 to 20 hrs in presence of GDP by rapidfire mass spectrometry analysis,C=CC(=O)N1CC(NC(=O)Cn2c(C3CC3)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Cl)cc(C)c32)C1,CHEMBL4364340,=,=,K,/M/s,2640.0,K,/M/s,2640.0,C=CC(=O)N1CC(NC(=O)Cn2c(C3CC3)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Cl)cc(C)c32)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) assessed as pseudo first order rate constant incubated for 0.02 to 20 hrs in presence of GDP by rapidfire mass spectrometry analysis,C=CC(=O)N1CC(NC(=O)COc2ccc(Br)cc2C(=O)N2CC=C(c3ccccc3)C2)C1,CHEMBL4364340,=,=,K,/M/s,26.0,K,/M/s,26.0,C=CC(=O)N1CC(NC(=O)COc2ccc(Br)cc2C(=O)N2CC=C(c3ccccc3)C2)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) assessed as pseudo first order rate constant incubated for 0.02 to 20 hrs in presence of GDP by rapidfire mass spectrometry analysis,C=CC(=O)N1CC(NC(=O)COc2ccc(Br)cc2NC(=O)c2cc(C)no2)C1,CHEMBL4364340,=,=,K,/M/s,2.0,K,/M/s,2.0,C=CC(=O)N1CC(NC(=O)COc2ccc(Br)cc2NC(=O)c2cc(C)no2)C1,2019
Inhibition of KRAS G12C mutant (unknown origin) assessed as pseudo first order rate constant incubated for 0.02 to 20 hrs in presence of GDP by rapidfire mass spectrometry analysis,C=CC(=O)N1CC(NC(=O)COc2ccc(Br)cc2)C1,CHEMBL4364340,=,=,K,/M/s,0.3,K,/M/s,0.3,C=CC(=O)N1CC(NC(=O)COc2ccc(Br)cc2)C1,2019
Inhibition of GDP bound N terminal His-tagged KRAS G12C/C118A mutant (unknown origin) (1 to 169 residues) assessed as reduction in SOS-mediated guanine nucleotide exchange preincubated for 2 hrs followed by addition of SOS and GTP and measured after 1 hr by alphascreen assay,C=CC(=O)N1CC(NC(=O)Cn2ccc3cc(Br)ccc32)C1,CHEMBL4364340,>,>,IC50,nM,250000.0,IC50,uM,250.0,C=CC(=O)N1CC(NC(=O)Cn2ccc3cc(Br)ccc32)C1,2019
Inhibition of GDP bound N terminal His-tagged KRAS G12C/C118A mutant (unknown origin) (1 to 169 residues) assessed as reduction in SOS-mediated guanine nucleotide exchange preincubated for 2 hrs followed by addition of SOS and GTP and measured after 1 hr by alphascreen assay,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,IC50,nM,638.0,IC50,uM,0.638,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)ccc32)C1,2019
Inhibition of GDP bound N terminal His-tagged KRAS G12C/C118A mutant (unknown origin) (1 to 169 residues) assessed as reduction in SOS-mediated guanine nucleotide exchange preincubated for 2 hrs followed by addition of SOS and GTP and measured after 1 hr by alphascreen assay,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)NCc3ccccc3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,IC50,nM,14200.0,IC50,uM,14.2,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)NCc3ccccc3)c3cc(Br)ccc32)C1,2019
Inhibition of GDP bound N terminal His-tagged KRAS G12C/C118A mutant (unknown origin) (1 to 169 residues) assessed as reduction in SOS-mediated guanine nucleotide exchange preincubated for 2 hrs followed by addition of SOS and GTP and measured after 1 hr by alphascreen assay,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)NCCc3ccccc3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,IC50,nM,4260.0,IC50,uM,4.26,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)NCCc3ccccc3)c3cc(Br)ccc32)C1,2019
Inhibition of GDP bound N terminal His-tagged KRAS G12C/C118A mutant (unknown origin) (1 to 169 residues) assessed as reduction in SOS-mediated guanine nucleotide exchange preincubated for 2 hrs followed by addition of SOS and GTP and measured after 1 hr by alphascreen assay,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N(C)Cc3ccccc3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,IC50,nM,6630.0,IC50,uM,6.63,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N(C)Cc3ccccc3)c3cc(Br)ccc32)C1,2019
Inhibition of GDP bound N terminal His-tagged KRAS G12C/C118A mutant (unknown origin) (1 to 169 residues) assessed as reduction in SOS-mediated guanine nucleotide exchange preincubated for 2 hrs followed by addition of SOS and GTP and measured after 1 hr by alphascreen assay,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4ccccc4C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,IC50,nM,1270.0,IC50,uM,1.27,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4ccccc4C3)c3cc(Br)ccc32)C1,2019
Inhibition of GDP bound N terminal His-tagged KRAS G12C/C118A mutant (unknown origin) (1 to 169 residues) assessed as reduction in SOS-mediated guanine nucleotide exchange preincubated for 2 hrs followed by addition of SOS and GTP and measured after 1 hr by alphascreen assay,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4cc(F)ccc4C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,IC50,nM,1370.0,IC50,uM,1.37,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4cc(F)ccc4C3)c3cc(Br)ccc32)C1,2019
Inhibition of GDP bound N terminal His-tagged KRAS G12C/C118A mutant (unknown origin) (1 to 169 residues) assessed as reduction in SOS-mediated guanine nucleotide exchange preincubated for 2 hrs followed by addition of SOS and GTP and measured after 1 hr by alphascreen assay,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(F)cccc4C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,IC50,nM,2120.0,IC50,uM,2.12,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(F)cccc4C3)c3cc(Br)ccc32)C1,2019
Inhibition of GDP bound N terminal His-tagged KRAS G12C/C118A mutant (unknown origin) (1 to 169 residues) assessed as reduction in SOS-mediated guanine nucleotide exchange preincubated for 2 hrs followed by addition of SOS and GTP and measured after 1 hr by alphascreen assay,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4cc(Cl)ccc4C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,IC50,nM,2000.0,IC50,uM,2.0,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4cc(Cl)ccc4C3)c3cc(Br)ccc32)C1,2019
Inhibition of GDP bound N terminal His-tagged KRAS G12C/C118A mutant (unknown origin) (1 to 169 residues) assessed as reduction in SOS-mediated guanine nucleotide exchange preincubated for 2 hrs followed by addition of SOS and GTP and measured after 1 hr by alphascreen assay,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(Cl)cccc4C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,IC50,nM,1290.0,IC50,uM,1.29,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(Cl)cccc4C3)c3cc(Br)ccc32)C1,2019
Inhibition of GDP bound N terminal His-tagged KRAS G12C/C118A mutant (unknown origin) (1 to 169 residues) assessed as reduction in SOS-mediated guanine nucleotide exchange preincubated for 2 hrs followed by addition of SOS and GTP and measured after 1 hr by alphascreen assay,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,IC50,nM,299.0,IC50,uM,0.299,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)ccc32)C1,2019
Inhibition of GDP bound N terminal His-tagged KRAS G12C/C118A mutant (unknown origin) (1 to 169 residues) assessed as reduction in SOS-mediated guanine nucleotide exchange preincubated for 2 hrs followed by addition of SOS and GTP and measured after 1 hr by alphascreen assay,C=CC(=O)N1CC(NC(=O)Cn2c(C3CC3)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,IC50,nM,139.0,IC50,uM,0.139,C=CC(=O)N1CC(NC(=O)Cn2c(C3CC3)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)ccc32)C1,2019
Inhibition of GDP bound N terminal His-tagged KRAS G12C/C118A mutant (unknown origin) (1 to 169 residues) assessed as reduction in SOS-mediated guanine nucleotide exchange preincubated for 2 hrs followed by addition of SOS and GTP and measured after 1 hr by alphascreen assay,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)cc(C)c32)C1,CHEMBL4364340,=,=,IC50,nM,174.0,IC50,uM,0.174,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)cc(C)c32)C1,2019
Inhibition of GDP bound N terminal His-tagged KRAS G12C/C118A mutant (unknown origin) (1 to 169 residues) assessed as reduction in SOS-mediated guanine nucleotide exchange preincubated for 2 hrs followed by addition of SOS and GTP and measured after 1 hr by alphascreen assay,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)cc(C)c32)C1,CHEMBL4364340,=,=,IC50,nM,109.0,IC50,uM,0.109,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)cc(C)c32)C1,2019
Inhibition of GDP bound N terminal His-tagged KRAS G12C/C118A mutant (unknown origin) (1 to 169 residues) assessed as reduction in SOS-mediated guanine nucleotide exchange preincubated for 2 hrs followed by addition of SOS and GTP and measured after 1 hr by alphascreen assay,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Cl)ccc32)C1,CHEMBL4364340,=,=,IC50,nM,369.0,IC50,uM,0.369,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Cl)ccc32)C1,2019
Inhibition of GDP bound N terminal His-tagged KRAS G12C/C118A mutant (unknown origin) (1 to 169 residues) assessed as reduction in SOS-mediated guanine nucleotide exchange preincubated for 2 hrs followed by addition of SOS and GTP and measured after 1 hr by alphascreen assay,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Cl)cc(C)c32)C1,CHEMBL4364340,=,=,IC50,nM,150.0,IC50,uM,0.15,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Cl)cc(C)c32)C1,2019
Inhibition of GDP bound N terminal His-tagged KRAS G12C/C118A mutant (unknown origin) (1 to 169 residues) assessed as reduction in SOS-mediated guanine nucleotide exchange preincubated for 2 hrs followed by addition of SOS and GTP and measured after 1 hr by alphascreen assay,C=CC(=O)N1CC(NC(=O)Cn2c(C3CC3)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Cl)cc(C)c32)C1,CHEMBL4364340,=,=,IC50,nM,115.0,IC50,uM,0.115,C=CC(=O)N1CC(NC(=O)Cn2c(C3CC3)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Cl)cc(C)c32)C1,2019
Inhibition of GDP bound N terminal His-tagged KRAS G12C/C118A mutant (unknown origin) (1 to 169 residues) assessed as reduction in SOS-mediated guanine nucleotide exchange preincubated for 2 hrs followed by addition of SOS and GTP and measured after 1 hr by alphascreen assay,C=CC(=O)N1CC(NC(=O)COc2ccc(Br)cc2C(=O)N2CC=C(c3ccccc3)C2)C1,CHEMBL4364340,=,=,IC50,nM,2780.0,IC50,uM,2.78,C=CC(=O)N1CC(NC(=O)COc2ccc(Br)cc2C(=O)N2CC=C(c3ccccc3)C2)C1,2019
Inhibition of KRAS G12C mutant in human MIAPaCa2 cells assessed as reduction in EGF-induced ERK1/2 phosphorylation incubated for 4 hrs followed by EGF addition by luminescence based assay,C=CC(=O)N1CC(NC(=O)Cn2ccc3cc(Br)ccc32)C1,CHEMBL4364340,,,IC50,,,IC50,,,C=CC(=O)N1CC(NC(=O)Cn2ccc3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant in human MIAPaCa2 cells assessed as reduction in EGF-induced ERK1/2 phosphorylation incubated for 4 hrs followed by EGF addition by luminescence based assay,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,IC50,nM,11400.0,IC50,uM,11.4,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant in human MIAPaCa2 cells assessed as reduction in EGF-induced ERK1/2 phosphorylation incubated for 4 hrs followed by EGF addition by luminescence based assay,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)NCc3ccccc3)c3cc(Br)ccc32)C1,CHEMBL4364340,>,>,IC50,nM,100000.0,IC50,uM,100.0,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)NCc3ccccc3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant in human MIAPaCa2 cells assessed as reduction in EGF-induced ERK1/2 phosphorylation incubated for 4 hrs followed by EGF addition by luminescence based assay,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)NCCc3ccccc3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,IC50,nM,41200.0,IC50,uM,41.2,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)NCCc3ccccc3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant in human MIAPaCa2 cells assessed as reduction in EGF-induced ERK1/2 phosphorylation incubated for 4 hrs followed by EGF addition by luminescence based assay,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N(C)Cc3ccccc3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,IC50,nM,52700.0,IC50,uM,52.7,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N(C)Cc3ccccc3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant in human MIAPaCa2 cells assessed as reduction in EGF-induced ERK1/2 phosphorylation incubated for 4 hrs followed by EGF addition by luminescence based assay,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4ccccc4C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,IC50,nM,36500.0,IC50,uM,36.5,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4ccccc4C3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant in human MIAPaCa2 cells assessed as reduction in EGF-induced ERK1/2 phosphorylation incubated for 4 hrs followed by EGF addition by luminescence based assay,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4cc(F)ccc4C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,IC50,nM,28000.0,IC50,uM,28.0,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4cc(F)ccc4C3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant in human MIAPaCa2 cells assessed as reduction in EGF-induced ERK1/2 phosphorylation incubated for 4 hrs followed by EGF addition by luminescence based assay,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(F)cccc4C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,IC50,nM,30000.0,IC50,uM,30.0,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(F)cccc4C3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant in human MIAPaCa2 cells assessed as reduction in EGF-induced ERK1/2 phosphorylation incubated for 4 hrs followed by EGF addition by luminescence based assay,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4cc(Cl)ccc4C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,IC50,nM,17900.0,IC50,uM,17.9,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4cc(Cl)ccc4C3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant in human MIAPaCa2 cells assessed as reduction in EGF-induced ERK1/2 phosphorylation incubated for 4 hrs followed by EGF addition by luminescence based assay,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(Cl)cccc4C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,IC50,nM,23900.0,IC50,uM,23.9,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(Cl)cccc4C3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant in human MIAPaCa2 cells assessed as reduction in EGF-induced ERK1/2 phosphorylation incubated for 4 hrs followed by EGF addition by luminescence based assay,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,IC50,nM,1680.0,IC50,uM,1.68,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant in human MIAPaCa2 cells assessed as reduction in EGF-induced ERK1/2 phosphorylation incubated for 4 hrs followed by EGF addition by luminescence based assay,C=CC(=O)N1CC(NC(=O)Cn2c(C3CC3)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)ccc32)C1,CHEMBL4364340,=,=,IC50,nM,604.0,IC50,uM,0.604,C=CC(=O)N1CC(NC(=O)Cn2c(C3CC3)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)ccc32)C1,2019
Inhibition of KRAS G12C mutant in human MIAPaCa2 cells assessed as reduction in EGF-induced ERK1/2 phosphorylation incubated for 4 hrs followed by EGF addition by luminescence based assay,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)cc(C)c32)C1,CHEMBL4364340,=,=,IC50,nM,12800.0,IC50,uM,12.8,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)cc(C)c32)C1,2019
Inhibition of KRAS G12C mutant in human MIAPaCa2 cells assessed as reduction in EGF-induced ERK1/2 phosphorylation incubated for 4 hrs followed by EGF addition by luminescence based assay,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)cc(C)c32)C1,CHEMBL4364340,=,=,IC50,nM,299.0,IC50,uM,0.299,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)cc(C)c32)C1,2019
Inhibition of KRAS G12C mutant in human MIAPaCa2 cells assessed as reduction in EGF-induced ERK1/2 phosphorylation incubated for 4 hrs followed by EGF addition by luminescence based assay,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Cl)ccc32)C1,CHEMBL4364340,=,=,IC50,nM,3550.0,IC50,uM,3.55,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Cl)ccc32)C1,2019
Inhibition of KRAS G12C mutant in human MIAPaCa2 cells assessed as reduction in EGF-induced ERK1/2 phosphorylation incubated for 4 hrs followed by EGF addition by luminescence based assay,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Cl)cc(C)c32)C1,CHEMBL4364340,=,=,IC50,nM,683.0,IC50,uM,0.683,C=CC(=O)N1CC(NC(=O)Cn2c(C)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Cl)cc(C)c32)C1,2019
Inhibition of KRAS G12C mutant in human MIAPaCa2 cells assessed as reduction in EGF-induced ERK1/2 phosphorylation incubated for 4 hrs followed by EGF addition by luminescence based assay,C=CC(=O)N1CC(NC(=O)Cn2c(C3CC3)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Cl)cc(C)c32)C1,CHEMBL4364340,=,=,IC50,nM,219.0,IC50,uM,0.219,C=CC(=O)N1CC(NC(=O)Cn2c(C3CC3)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Cl)cc(C)c32)C1,2019
Inhibition of KRAS G12C mutant in human MIAPaCa2 cells assessed as reduction in EGF-induced ERK1/2 phosphorylation incubated for 4 hrs followed by EGF addition by luminescence based assay,C=CC(=O)N1CC(NC(=O)COc2ccc(Br)cc2C(=O)N2CC=C(c3ccccc3)C2)C1,CHEMBL4364340,=,=,IC50,nM,11300.0,IC50,uM,11.3,C=CC(=O)N1CC(NC(=O)COc2ccc(Br)cc2C(=O)N2CC=C(c3ccccc3)C2)C1,2019
Binding affinity to KRAS (unknown origin) by H-ddNMR analysis,C=CC(=O)N1CC(NC(=O)Cn2c(C3CC3)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Cl)cc(C)c32)C1,CHEMBL4364340,=,=,Kd,nM,20000.0,Kd,uM,20.0,C=CC(=O)N1CC(NC(=O)Cn2c(C3CC3)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Cl)cc(C)c32)C1,2019
Inhibition of KRAS G12C mutant in human A549 cells assessed as reduction in EGF-induced ERK1/2 phosphorylation incubated for 4 hrs followed by EGF addition by luminescence based assay,C=CC(=O)N1CC(NC(=O)Cn2c(C3CC3)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Cl)cc(C)c32)C1,CHEMBL4364340,>,>,IC50,nM,10000.0,IC50,uM,10.0,C=CC(=O)N1CC(NC(=O)Cn2c(C3CC3)c(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Cl)cc(C)c32)C1,2019
Inhibition of KRAS G12C mutant in human MIAPaCa2 cells assessed as increase in accumulation of GDP bound KRAS G12C mutant protein incubated for 6 hrs,C=CC(=O)N1CCN(c2nc(N3CC(N(C)C)C3)nc3c2C[C@@H](C)[C@H](c2c(Cl)c(C)cc4[nH]ncc24)C3)CC1,CHEMBL4364352,=,=,IC50,nM,126.0,IC50,uM,0.126,C=CC(=O)N1CCN(c2nc(N3CC(N(C)C)C3)nc3c2C[C@@H](C)[C@H](c2c(Cl)c(C)cc4[nH]ncc24)C3)CC1,2019
Inhibition of KRAS G12C mutant in human MIAPaCa2 cells assessed as increase in accumulation of GDP bound KRAS G12C mutant protein incubated for 6 hrs,C=CC(=O)N1CCN(c2nc(OC[C@H]3CCCN3C)nc3c2C[C@@H](C)[C@H](c2c(C)ccc4[nH]ncc24)C3)CC1,CHEMBL4364352,=,=,IC50,nM,236.0,IC50,uM,0.236,C=CC(=O)N1CCN(c2nc(OC[C@H]3CCCN3C)nc3c2C[C@@H](C)[C@H](c2c(C)ccc4[nH]ncc24)C3)CC1,2019
Inhibition of KRAS G12C mutant in human MIAPaCa2 cells assessed as increase in accumulation of GDP bound KRAS G12C mutant protein incubated for 6 hrs,C=CC(=O)N1CCN(c2nc(OCCCN(C)C)nc3c2C[C@@H](C)[C@H](c2c(C)ccc4[nH]ncc24)C3)CC1,CHEMBL4364352,=,=,IC50,nM,214.0,IC50,uM,0.214,C=CC(=O)N1CCN(c2nc(OCCCN(C)C)nc3c2C[C@@H](C)[C@H](c2c(C)ccc4[nH]ncc24)C3)CC1,2019
Inhibition of KRAS G12C mutant in human MIAPaCa2 cells assessed as increase in accumulation of GDP bound KRAS G12C mutant protein incubated for 6 hrs,C=CC(=O)N1CCN(c2ncnc3c2CCC(c2c(C)ccc4[nH]ncc24)C3)[C@@H](C)C1,CHEMBL4364352,=,=,IC50,nM,4860.0,IC50,uM,4.86,C=CC(=O)N1CCN(c2ncnc3c2CCC(c2c(C)ccc4[nH]ncc24)C3)[C@@H](C)C1,2019
Inhibition of KRAS G12C mutant in human MIAPaCa2 cells assessed as increase in accumulation of GDP bound KRAS G12C mutant protein incubated for 6 hrs,C=CC(=O)N1CCN(c2ncnc3c2C[C@@H](C)[C@H](c2c(C)ccc4[nH]ncc24)C3)CC1,CHEMBL4364352,=,=,IC50,nM,640.0,IC50,uM,0.64,C=CC(=O)N1CCN(c2ncnc3c2C[C@@H](C)[C@H](c2c(C)ccc4[nH]ncc24)C3)CC1,2019
Binding affinity to GDP-loaded KRAS G12C mutant (1 to 169 residues) (unknown origin) assessed as covalent adduct formation by measuring protein modification measured at 10 mM measured after 0.5 hrs by mass spectrometry reactivity assay relative to control,C=CC(=O)N1CCN(c2nc(N3CC(N(C)C)C3)nc3c2C[C@@H](C)[C@H](c2c(Cl)ccc4[nH]ncc24)C3)CC1,CHEMBL4364352,=,=,Activity,%,85.0,Activity,%,85.0,C=CC(=O)N1CCN(c2nc(N3CC(N(C)C)C3)nc3c2C[C@@H](C)[C@H](c2c(Cl)ccc4[nH]ncc24)C3)CC1,2019
Binding affinity to GDP-loaded KRAS G12C mutant (1 to 169 residues) (unknown origin) assessed as covalent adduct formation by measuring protein modification measured at 10 mM measured after 0.5 hrs by mass spectrometry reactivity assay relative to control,C=CC(=O)N1CCN(c2nc(N3CC(N(C)C)C3)nc3c2C[C@@H](C)[C@H](c2c(Cl)c(C)cc4[nH]ncc24)C3)CC1,CHEMBL4364352,=,=,Activity,%,83.0,Activity,%,83.0,C=CC(=O)N1CCN(c2nc(N3CC(N(C)C)C3)nc3c2C[C@@H](C)[C@H](c2c(Cl)c(C)cc4[nH]ncc24)C3)CC1,2019
Binding affinity to GDP-loaded KRAS G12C mutant (1 to 169 residues) (unknown origin) assessed as covalent adduct formation by measuring protein modification measured at 10 mM measured after 0.5 hrs by mass spectrometry reactivity assay relative to control,C=CC(=O)N1CCN(c2nc(OC[C@H]3CCCN3C)nc3c2C[C@@H](C)[C@H](c2c(C)ccc4[nH]ncc24)C3)CC1,CHEMBL4364352,=,=,Activity,%,80.0,Activity,%,80.0,C=CC(=O)N1CCN(c2nc(OC[C@H]3CCCN3C)nc3c2C[C@@H](C)[C@H](c2c(C)ccc4[nH]ncc24)C3)CC1,2019
Binding affinity to GDP-loaded KRAS G12C mutant (1 to 169 residues) (unknown origin) assessed as covalent adduct formation by measuring protein modification measured at 10 mM measured after 0.5 hrs by mass spectrometry reactivity assay relative to control,C=CC(=O)N1CCN(c2nc(OCCCN(C)C)nc3c2C[C@@H](C)[C@H](c2c(C)ccc4[nH]ncc24)C3)CC1,CHEMBL4364352,=,=,Activity,%,74.0,Activity,%,74.0,C=CC(=O)N1CCN(c2nc(OCCCN(C)C)nc3c2C[C@@H](C)[C@H](c2c(C)ccc4[nH]ncc24)C3)CC1,2019
Binding affinity to GDP-loaded KRAS G12C mutant (1 to 169 residues) (unknown origin) assessed as covalent adduct formation by measuring protein modification measured at 10 mM measured after 0.5 hrs by mass spectrometry reactivity assay relative to control,C=CC(=O)N1CCN(c2ncnc3c2CCC(c2c(C)ccc4[nH]ncc24)C3)[C@@H](C)C1,CHEMBL4364352,=,=,Activity,%,13.0,Activity,%,13.0,C=CC(=O)N1CCN(c2ncnc3c2CCC(c2c(C)ccc4[nH]ncc24)C3)[C@@H](C)C1,2019
Binding affinity to GDP-loaded KRAS G12C mutant (1 to 169 residues) (unknown origin) assessed as covalent adduct formation by measuring protein modification measured at 10 mM measured after 0.5 hrs by mass spectrometry reactivity assay relative to control,C=CC(=O)N1CCN(c2ncnc3c2C[C@@H](C)[C@H](c2c(C)ccc4[nH]ncc24)C3)CC1,CHEMBL4364352,=,=,Activity,%,77.0,Activity,%,77.0,C=CC(=O)N1CCN(c2ncnc3c2C[C@@H](C)[C@H](c2c(C)ccc4[nH]ncc24)C3)CC1,2019
Inhibition of KRAS G12C mutant in human MIAPaCa2 cells assessed as increase in accumulation of GDP bound KRAS G12C mutant protein incubated for 6 hrs,C=CC(=O)N1CCN(c2nc(N3CC(N(C)C)C3)nc3c2C[C@@H](C)[C@H](c2c(Cl)ccc4[nH]ncc24)C3)CC1,CHEMBL4364352,=,=,IC50,nM,169.0,IC50,uM,0.169,C=CC(=O)N1CCN(c2nc(N3CC(N(C)C)C3)nc3c2C[C@@H](C)[C@H](c2c(Cl)ccc4[nH]ncc24)C3)CC1,2019
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as increase in accumulation of GDP bound KRAS G12C mutant protein incubated for 6 hrs,C=CC(=O)N1CCN(c2ncnc3c2C[C@@H](C)[C@H](c2c(C)ccc4[nH]ncc24)C3)CC1,CHEMBL4364352,=,=,IC50,nM,780.0,IC50,uM,0.78,C=CC(=O)N1CCN(c2ncnc3c2C[C@@H](C)[C@H](c2c(C)ccc4[nH]ncc24)C3)CC1,2019
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as increase in accumulation of GDP bound KRAS G12C mutant protein incubated for 6 hrs,C=CC(=O)N1CCN(c2nc(OCCCN(C)C)nc3c2C[C@@H](C)[C@H](c2c(C)ccc4[nH]ncc24)C3)CC1,CHEMBL4364352,=,=,IC50,nM,468.0,IC50,uM,0.468,C=CC(=O)N1CCN(c2nc(OCCCN(C)C)nc3c2C[C@@H](C)[C@H](c2c(C)ccc4[nH]ncc24)C3)CC1,2019
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as increase in accumulation of GDP bound KRAS G12C mutant protein incubated for 6 hrs,C=CC(=O)N1CCN(c2nc(OC[C@H]3CCCN3C)nc3c2C[C@@H](C)[C@H](c2c(C)ccc4[nH]ncc24)C3)CC1,CHEMBL4364352,=,=,IC50,nM,129.0,IC50,uM,0.129,C=CC(=O)N1CCN(c2nc(OC[C@H]3CCCN3C)nc3c2C[C@@H](C)[C@H](c2c(C)ccc4[nH]ncc24)C3)CC1,2019
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as increase in accumulation of GDP bound KRAS G12C mutant protein incubated for 6 hrs,C=CC(=O)N1CCN(c2nc(N3CC(N(C)C)C3)nc3c2C[C@@H](C)[C@H](c2c(Cl)c(C)cc4[nH]ncc24)C3)CC1,CHEMBL4364352,=,=,IC50,nM,116.0,IC50,uM,0.116,C=CC(=O)N1CCN(c2nc(N3CC(N(C)C)C3)nc3c2C[C@@H](C)[C@H](c2c(Cl)c(C)cc4[nH]ncc24)C3)CC1,2019
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as increase in accumulation of GDP bound KRAS G12C mutant protein incubated for 6 hrs,C=CC(=O)N1CCN(c2nc(N3CC(N(C)C)C3)nc3c2C[C@@H](C)[C@H](c2c(Cl)ccc4[nH]ncc24)C3)CC1,CHEMBL4364352,=,=,IC50,nM,395.0,IC50,uM,0.395,C=CC(=O)N1CCN(c2nc(N3CC(N(C)C)C3)nc3c2C[C@@H](C)[C@H](c2c(Cl)ccc4[nH]ncc24)C3)CC1,2019
Binding affinity to biotinylated N-terminal His6-tagged recombinant KRAS G12C mutant (unknown origin) assessed as association constant by BLI method,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C\CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC1=O,CHEMBL4373743,=,=,Ka,10'3/M.s,6.65,Ka,10'3/M.s,6.65,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C\CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC1=O,2020
Inhibition of mant-GDP bound N-terminal His6-tagged recombinant KRAS G12C mutant (unknown origin) by fluorescence based assay,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C\CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC1=O,CHEMBL4373743,,,Inhibition,%,,INH,,,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C\CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC1=O,2020
Inhibition of mant-GDP bound N-terminal His6-tagged recombinant KRAS G12C mutant (unknown origin) by fluorescence based assay,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C\CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC1=O,CHEMBL4373743,,,Inhibition,%,,INH,,,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C\CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC1=O,2020
Binding affinity to biotinylated N-terminal His6-tagged recombinant KRAS G12C mutant (unknown origin) assessed as dissociation constant by BLI method,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C\CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC1=O,CHEMBL4373743,=,=,Kdiss,10'-3/s,6.37,Kdiss,10'-3/s,6.37,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C\CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC1=O,2020
Binding affinity to biotinylated N-terminal His6-tagged recombinant KRAS G12C mutant (unknown origin) assessed as dissociation constant by BLI method,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C\CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC1=O,CHEMBL4373743,=,=,Kdiss,10'-2/s,4.07,Kdiss,10'-2/s,4.07,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C\CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC1=O,2020
Binding affinity to biotinylated N-terminal His6-tagged recombinant KRAS G12C mutant (unknown origin) assessed as dissociation constant by BLI method,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C\CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC1=O,CHEMBL4373743,=,=,Kdiss,10'-2/s,1.19,Kdiss,10'-2/s,1.19,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C\CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC1=O,2020
Binding affinity to biotinylated N-terminal His6-tagged recombinant KRAS G12C mutant (unknown origin) assessed as dissociation constant by BLI method,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C\CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC1=O,CHEMBL4373743,=,=,Kdiss,10'-1/s,1.73,Kdiss,10'-1/s,1.73,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C\CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC1=O,2020
Binding affinity to biotinylated N-terminal His6-tagged recombinant KRAS G12C mutant (unknown origin) assessed as dissociation constant by BLI method,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C\CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC1=O,CHEMBL4373743,=,=,Kdiss,10'-1/s,1.17,Kdiss,10'-1/s,1.17,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C\CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC1=O,2020
Binding affinity to biotinylated N-terminal His6-tagged recombinant KRAS G12C mutant (unknown origin) assessed as association constant by BLI method,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C\CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC1=O,CHEMBL4373743,=,=,Ka,10'3/M.s,7.3,Ka,10'3/M.s,7.3,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C\CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC1=O,2020
Binding affinity to biotinylated N-terminal His6-tagged recombinant KRAS G12C mutant (unknown origin) assessed as association constant by BLI method,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C\CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC1=O,CHEMBL4373743,=,=,Ka,10'3/M.s,4.62,Ka,10'3/M.s,4.62,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C\CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC1=O,2020
Binding affinity to biotinylated N-terminal His6-tagged recombinant KRAS G12C mutant (unknown origin) assessed as association constant by BLI method,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C\CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC1=O,CHEMBL4373743,=,=,Ka,10'3/M.s,3.73,Ka,10'3/M.s,3.73,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C\CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC1=O,2020
Binding affinity to biotinylated N-terminal His6-tagged recombinant KRAS G12C mutant (unknown origin) assessed as association constant by BLI method,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C\CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC1=O,CHEMBL4373743,=,=,Ka,10'3/M.s,2.44,Ka,10'3/M.s,2.44,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C\CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC1=O,2020
Binding affinity to biotinylated N-terminal His6-tagged recombinant KRAS G12C mutant (unknown origin) by BLI method,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C\CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC1=O,CHEMBL4373743,=,=,Kd,nM,870.0,Kd,uM,0.87,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C\CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC1=O,2020
Binding affinity to biotinylated N-terminal His6-tagged recombinant KRAS G12C mutant (unknown origin) by BLI method,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C\CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC1=O,CHEMBL4373743,=,=,Kd,nM,8810.0,Kd,uM,8.81,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C\CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC1=O,2020
Binding affinity to biotinylated N-terminal His6-tagged recombinant KRAS G12C mutant (unknown origin) by BLI method,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C\CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC1=O,CHEMBL4373743,=,=,Kd,nM,3200.0,Kd,uM,3.2,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C\CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC1=O,2020
Binding affinity to biotinylated N-terminal His6-tagged recombinant KRAS G12C mutant (unknown origin) by BLI method,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C\CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC1=O,CHEMBL4373743,=,=,Kd,nM,26100.0,Kd,uM,26.1,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C\CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC1=O,2020
Binding affinity to biotinylated N-terminal His6-tagged recombinant KRAS G12C mutant (unknown origin) by BLI method,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C\CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC1=O,CHEMBL4373743,=,=,Kd,nM,47800.0,Kd,uM,47.8,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C\CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC1=O,2020
Inhibition of KRAS in human PANC1 cells assessed as decrease in KRAS mRNA level at 15 nM followed by 7.2 J/cm2 irradiation after 4 hrs by qRT-PCR analysis,CCCCCCCCCCCCCC[n+]1ccc(-c2c3nc(c(-c4cc[n+](C)cc4)c4ccc([nH]4)c(-c4cc[n+](C)cc4)c4nc(c(-c5cc[n+](C)cc5)c5ccc2[nH]5)C=C4)C=C3)cc1.[I-].[I-].[I-].[I-],CHEMBL4376882,,,Inhibition,%,,INH,,,CCCCCCCCCCCCCC[n+]1ccc(-c2c3nc(c(-c4cc[n+](C)cc4)c4ccc([nH]4)c(-c4cc[n+](C)cc4)c4nc(c(-c5cc[n+](C)cc5)c5ccc2[nH]5)C=C4)C=C3)cc1.[I-].[I-].[I-].[I-],2020
Inhibition of KRAS in human PANC1 cells assessed as decrease in KRAS mRNA level at 15 nM followed by 7.2 J/cm2 irradiation after 4 hrs by qRT-PCR analysis,CCCCCCCCCCCCCCCCCC[n+]1ccc(-c2c3nc(c(-c4cc[n+](C)cc4)c4ccc([nH]4)c(-c4cc[n+](C)cc4)c4nc(c(-c5cc[n+](C)cc5)c5ccc2[nH]5)C=C4)C=C3)cc1.[I-].[I-].[I-].[I-],CHEMBL4376882,,,Inhibition,%,,INH,,,CCCCCCCCCCCCCCCCCC[n+]1ccc(-c2c3nc(c(-c4cc[n+](C)cc4)c4ccc([nH]4)c(-c4cc[n+](C)cc4)c4nc(c(-c5cc[n+](C)cc5)c5ccc2[nH]5)C=C4)C=C3)cc1.[I-].[I-].[I-].[I-],2020
Inhibition of KRAS in human PANC1 cells assessed as downregulation of KRAS expression at 15 nM followed by 7.2 J/cm2 irradiation after 4 hrs by Western blot analysis (Rvb = 5 %),CCCCCCCCCCCCCC[n+]1ccc(-c2c3nc(c(-c4cc[n+](C)cc4)c4ccc([nH]4)c(-c4cc[n+](C)cc4)c4nc(c(-c5cc[n+](C)cc5)c5ccc2[nH]5)C=C4)C=C3)cc1.[I-].[I-].[I-].[I-],CHEMBL4376882,=,=,Inhibition,%,20.0,INH,%,20.0,CCCCCCCCCCCCCC[n+]1ccc(-c2c3nc(c(-c4cc[n+](C)cc4)c4ccc([nH]4)c(-c4cc[n+](C)cc4)c4nc(c(-c5cc[n+](C)cc5)c5ccc2[nH]5)C=C4)C=C3)cc1.[I-].[I-].[I-].[I-],2020
Inhibition of KRAS in human PANC1 cells assessed as downregulation of KRAS expression at 15 nM followed by 7.2 J/cm2 irradiation after 4 hrs by Western blot analysis (Rvb = 5 %),CCCCCCCCCCCCCCCCCC[n+]1ccc(-c2c3nc(c(-c4cc[n+](C)cc4)c4ccc([nH]4)c(-c4cc[n+](C)cc4)c4nc(c(-c5cc[n+](C)cc5)c5ccc2[nH]5)C=C4)C=C3)cc1.[I-].[I-].[I-].[I-],CHEMBL4376882,=,=,Inhibition,%,20.0,INH,%,20.0,CCCCCCCCCCCCCCCCCC[n+]1ccc(-c2c3nc(c(-c4cc[n+](C)cc4)c4ccc([nH]4)c(-c4cc[n+](C)cc4)c4nc(c(-c5cc[n+](C)cc5)c5ccc2[nH]5)C=C4)C=C3)cc1.[I-].[I-].[I-].[I-],2020
Inhibition of KRAS in human PANC1 cells assessed as downregulation of KRAS expression at 15 nM after 4 hrs by Western blot analysis,CCCCCCCCCCCCCC[n+]1ccc(-c2c3nc(c(-c4cc[n+](C)cc4)c4ccc([nH]4)c(-c4cc[n+](C)cc4)c4nc(c(-c5cc[n+](C)cc5)c5ccc2[nH]5)C=C4)C=C3)cc1.[I-].[I-].[I-].[I-],CHEMBL4376882,,,Inhibition,%,,INH,,,CCCCCCCCCCCCCC[n+]1ccc(-c2c3nc(c(-c4cc[n+](C)cc4)c4ccc([nH]4)c(-c4cc[n+](C)cc4)c4nc(c(-c5cc[n+](C)cc5)c5ccc2[nH]5)C=C4)C=C3)cc1.[I-].[I-].[I-].[I-],2020
Inhibition of KRAS in human PANC1 cells assessed as downregulation of KRAS expression at 15 nM after 4 hrs by Western blot analysis,CCCCCCCCCCCCCCCCCC[n+]1ccc(-c2c3nc(c(-c4cc[n+](C)cc4)c4ccc([nH]4)c(-c4cc[n+](C)cc4)c4nc(c(-c5cc[n+](C)cc5)c5ccc2[nH]5)C=C4)C=C3)cc1.[I-].[I-].[I-].[I-],CHEMBL4376882,,,Inhibition,%,,INH,,,CCCCCCCCCCCCCCCCCC[n+]1ccc(-c2c3nc(c(-c4cc[n+](C)cc4)c4ccc([nH]4)c(-c4cc[n+](C)cc4)c4nc(c(-c5cc[n+](C)cc5)c5ccc2[nH]5)C=C4)C=C3)cc1.[I-].[I-].[I-].[I-],2020
Binding affinity to GDP loaded biotin-labeled KRAS G12C mutant (unknown origin) assessed as compound-protein adduct formation at 10 uM after 4 hrs by mass spectrometry analysis,C=CC(=O)N1CCN2c3ncnc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)c(c34)OC[C@@H]2C1,CHEMBL4382280,=,=,Activity,%,95.0,Activity,%,95.0,C=CC(=O)N1CCN2c3ncnc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)c(c34)OC[C@@H]2C1,2019
Inhibition of GDP loaded biotin-labeled KRAS G12C mutant (unknown origin) assessed as reduction in guanine nucleotide exchange preincubated for 4 hrs followed by GST-RAF-RBD addition in presence of GTPgammaS by FRET assay,C=CC(=O)N1CCN2c3ncnc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)c(c34)OC[C@@H]2C1,CHEMBL4382280,=,=,IC50,nM,12.0,IC50,uM,0.012,C=CC(=O)N1CCN2c3ncnc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)c(c34)OC[C@@H]2C1,2019
Inhibition of GDP loaded biotin-labeled KRAS G12C mutant (unknown origin) assessed as reduction in guanine nucleotide exchange preincubated for 4 hrs followed by GST-RAF-RBD addition in presence of GTPgammaS by FRET assay,C=CC(=O)N1CCN2c3nc(NCCN(C)C)nc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)c(c34)OC[C@@H]2C1,CHEMBL4382280,=,=,IC50,nM,18.0,IC50,uM,0.018,C=CC(=O)N1CCN2c3nc(NCCN(C)C)nc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)c(c34)OC[C@@H]2C1,2019
Inhibition of GDP loaded biotin-labeled KRAS G12C mutant (unknown origin) assessed as reduction in guanine nucleotide exchange preincubated for 4 hrs followed by GST-RAF-RBD addition in presence of GTPgammaS by FRET assay,C=CC(=O)N1CCN2c3nc(N4CC(N(C)C)C4)nc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)c(c34)OC[C@@H]2C1,CHEMBL4382280,=,=,IC50,nM,21.0,IC50,uM,0.021,C=CC(=O)N1CCN2c3nc(N4CC(N(C)C)C4)nc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)c(c34)OC[C@@H]2C1,2019
Inhibition of GDP loaded biotin-labeled KRAS G12C mutant (unknown origin) assessed as reduction in guanine nucleotide exchange preincubated for 4 hrs followed by GST-RAF-RBD addition in presence of GTPgammaS by FRET assay,C=CC(=O)N1CCN2c3nc(N4CC(N(C)C)C4)nc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)c(c34)OC[C@@H]2C1,CHEMBL4382280,=,=,IC50,nM,19.0,IC50,uM,0.019,C=CC(=O)N1CCN2c3nc(N4CC(N(C)C)C4)nc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)c(c34)OC[C@@H]2C1,2019
Inhibition of GDP loaded biotin-labeled KRAS G12C mutant (unknown origin) assessed as reduction in guanine nucleotide exchange preincubated for 4 hrs followed by GST-RAF-RBD addition in presence of GTPgammaS by FRET assay,C=CC(=O)N1CCN2c3nc(NC4CCN(C5CC5)CC4)nc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)c(c34)OC[C@@H]2C1,CHEMBL4382280,=,=,IC50,nM,12.0,IC50,uM,0.012,C=CC(=O)N1CCN2c3nc(NC4CCN(C5CC5)CC4)nc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)c(c34)OC[C@@H]2C1,2019
Inhibition of GDP loaded biotin-labeled KRAS G12C mutant (unknown origin) assessed as reduction in guanine nucleotide exchange preincubated for 4 hrs followed by GST-RAF-RBD addition in presence of GTPgammaS by FRET assay,C=CC(=O)N1CCN2c3ncnc4c(F)c(-c5c(O)cccc5F)c(Cl)c(c34)OC[C@@H]2C1,CHEMBL4382280,=,=,IC50,nM,29.0,IC50,uM,0.029,C=CC(=O)N1CCN2c3ncnc4c(F)c(-c5c(O)cccc5F)c(Cl)c(c34)OC[C@@H]2C1,2019
Inhibition of GDP loaded biotin-labeled KRAS G12C mutant (unknown origin) assessed as reduction in guanine nucleotide exchange preincubated for 4 hrs followed by GST-RAF-RBD addition in presence of GTPgammaS by FRET assay,C=CC(=O)N1CCN2c3ncnc4cc(-c5c(O)cccc5Cl)c(Cl)c(c34)OC[C@@H]2C1,CHEMBL4382280,=,=,IC50,nM,32.0,IC50,uM,0.032,C=CC(=O)N1CCN2c3ncnc4cc(-c5c(O)cccc5Cl)c(Cl)c(c34)OC[C@@H]2C1,2019
Inhibition of GDP loaded biotin-labeled KRAS G12C mutant (unknown origin) assessed as reduction in guanine nucleotide exchange preincubated for 4 hrs followed by GST-RAF-RBD addition in presence of GTPgammaS by FRET assay,C=CC(=O)N1CCN2c3ncnc4cc(-c5c(O)cccc5F)c(Cl)c(c34)OC[C@@H]2C1,CHEMBL4382280,=,=,IC50,nM,97.0,IC50,uM,0.097,C=CC(=O)N1CCN2c3ncnc4cc(-c5c(O)cccc5F)c(Cl)c(c34)OC[C@@H]2C1,2019
Inhibition of GDP loaded biotin-labeled KRAS G12C mutant (unknown origin) assessed as reduction in guanine nucleotide exchange preincubated for 4 hrs followed by GST-RAF-RBD addition in presence of GTPgammaS by FRET assay,C=CC(=O)N1CCN2c3ncnc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)c(c34)OC[C@@H]2C1,CHEMBL4382280,=,=,IC50,nM,82.0,IC50,uM,0.082,C=CC(=O)N1CCN2c3ncnc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)c(c34)OC[C@@H]2C1,2019
Inhibition of GDP loaded biotin-labeled KRAS G12C mutant (unknown origin) assessed as reduction in guanine nucleotide exchange preincubated for 4 hrs followed by GST-RAF-RBD addition in presence of GTPgammaS by FRET assay,C=CC(=O)N1CCN2c3ncnc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)c(c34)OC[C@@H]2C1,CHEMBL4382280,=,=,IC50,nM,123.0,IC50,uM,0.123,C=CC(=O)N1CCN2c3ncnc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)c(c34)OC[C@@H]2C1,2019
Binding affinity to GDP loaded biotin-labeled KRAS G12C mutant (unknown origin) assessed as compound-protein adduct formation at 10 uM after 4 hrs by mass spectrometry analysis,C=CC(=O)N1CCN2c3ncnc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)c(c34)OC[C@@H]2C1,CHEMBL4382280,=,=,Activity,%,96.0,Activity,%,96.0,C=CC(=O)N1CCN2c3ncnc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)c(c34)OC[C@@H]2C1,2019
Binding affinity to GDP loaded biotin-labeled KRAS G12C mutant (unknown origin) assessed as compound-protein adduct formation at 10 uM after 4 hrs by mass spectrometry analysis,C=CC(=O)N1CCN2c3ncnc4cc(-c5c(O)cccc5F)c(Cl)c(c34)OC[C@@H]2C1,CHEMBL4382280,=,=,Activity,%,92.0,Activity,%,92.0,C=CC(=O)N1CCN2c3ncnc4cc(-c5c(O)cccc5F)c(Cl)c(c34)OC[C@@H]2C1,2019
Binding affinity to GDP loaded biotin-labeled KRAS G12C mutant (unknown origin) assessed as compound-protein adduct formation at 10 uM after 4 hrs by mass spectrometry analysis,C=CC(=O)N1CCN2c3ncnc4cc(-c5c(O)cccc5Cl)c(Cl)c(c34)OC[C@@H]2C1,CHEMBL4382280,=,=,Activity,%,100.0,Activity,%,100.0,C=CC(=O)N1CCN2c3ncnc4cc(-c5c(O)cccc5Cl)c(Cl)c(c34)OC[C@@H]2C1,2019
Binding affinity to GDP loaded biotin-labeled KRAS G12C mutant (unknown origin) assessed as compound-protein adduct formation at 10 uM after 4 hrs by mass spectrometry analysis,C=CC(=O)N1CCN2c3ncnc4c(F)c(-c5c(O)cccc5F)c(Cl)c(c34)OC[C@@H]2C1,CHEMBL4382280,=,=,Activity,%,100.0,Activity,%,100.0,C=CC(=O)N1CCN2c3ncnc4c(F)c(-c5c(O)cccc5F)c(Cl)c(c34)OC[C@@H]2C1,2019
Binding affinity to GDP loaded biotin-labeled KRAS G12C mutant (unknown origin) assessed as compound-protein adduct formation at 10 uM after 4 hrs by mass spectrometry analysis,C=CC(=O)N1CCN2c3nc(NC4CCN(C5CC5)CC4)nc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)c(c34)OC[C@@H]2C1,CHEMBL4382280,=,=,Activity,%,94.0,Activity,%,94.0,C=CC(=O)N1CCN2c3nc(NC4CCN(C5CC5)CC4)nc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)c(c34)OC[C@@H]2C1,2019
Binding affinity to GDP loaded biotin-labeled KRAS G12C mutant (unknown origin) assessed as compound-protein adduct formation at 10 uM after 4 hrs by mass spectrometry analysis,C=CC(=O)N1CCN2c3nc(N4CC(N(C)C)C4)nc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)c(c34)OC[C@@H]2C1,CHEMBL4382280,=,=,Activity,%,57.0,Activity,%,57.0,C=CC(=O)N1CCN2c3nc(N4CC(N(C)C)C4)nc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)c(c34)OC[C@@H]2C1,2019
Binding affinity to GDP loaded biotin-labeled KRAS G12C mutant (unknown origin) assessed as compound-protein adduct formation at 10 uM after 4 hrs by mass spectrometry analysis,C=CC(=O)N1CCN2c3nc(N4CC(N(C)C)C4)nc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)c(c34)OC[C@@H]2C1,CHEMBL4382280,=,=,Activity,%,100.0,Activity,%,100.0,C=CC(=O)N1CCN2c3nc(N4CC(N(C)C)C4)nc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)c(c34)OC[C@@H]2C1,2019
Binding affinity to GDP loaded biotin-labeled KRAS G12C mutant (unknown origin) assessed as compound-protein adduct formation at 10 uM after 4 hrs by mass spectrometry analysis,C=CC(=O)N1CCN2c3nc(NCCN(C)C)nc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)c(c34)OC[C@@H]2C1,CHEMBL4382280,=,=,Activity,%,90.0,Activity,%,90.0,C=CC(=O)N1CCN2c3nc(NCCN(C)C)nc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)c(c34)OC[C@@H]2C1,2019
Binding affinity to GDP loaded biotin-labeled KRAS G12C mutant (unknown origin) assessed as compound-protein adduct formation at 10 uM after 4 hrs by mass spectrometry analysis,C=CC(=O)N1CCN2c3ncnc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)c(c34)OC[C@@H]2C1,CHEMBL4382280,=,=,Activity,%,100.0,Activity,%,100.0,C=CC(=O)N1CCN2c3ncnc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)c(c34)OC[C@@H]2C1,2019
Inhibition of GDP bound biotinylated human C-terminal Avi/His6-tagged KRAS G12C mutant (1 to 166 residues) expressed in Escherichia coli BL21 (DE3) assessed as reduction in SOS1-mediated GDP/GTP nucleotide exchange by preventing recognition between KRAS G12C mutant and Ras binding domain of N-terminal Avi/GST-tagged Raf-1 (51 to 149 residues) preincubated for 4 hrs followed by SOS1 and GTPgammaS addition by FRET assay,C=CC(=O)N1CCN2c3c(cnc4c(F)c(-c5c(O)cccc5F)c(Cl)cc34)N(C)C(=O)[C@H]2C1,CHEMBL4402559,=,=,IC50,nM,18.0,IC50,uM,0.018,C=CC(=O)N1CCN2c3c(cnc4c(F)c(-c5c(O)cccc5F)c(Cl)cc34)N(C)C(=O)[C@H]2C1,2020
Inhibition of GDP bound biotinylated human C-terminal Avi/His6-tagged KRAS G12C mutant (1 to 166 residues) expressed in Escherichia coli BL21 (DE3) assessed as reduction in SOS1-mediated GDP/GTP nucleotide exchange by preventing recognition between KRAS G12C mutant and Ras binding domain of N-terminal Avi/GST-tagged Raf-1 (51 to 149 residues) preincubated for 4 hrs followed by SOS1 and GTPgammaS addition by FRET assay,C=CC(=O)N1CCN2c3c(cnc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)cc34)OCC[C@H]2C1,CHEMBL4402559,=,=,IC50,nM,627.0,IC50,uM,0.627,C=CC(=O)N1CCN2c3c(cnc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)cc34)OCC[C@H]2C1,2020
Inhibition of GDP bound biotinylated human C-terminal Avi/His6-tagged KRAS G12C mutant (1 to 166 residues) expressed in Escherichia coli BL21 (DE3) assessed as reduction in SOS1-mediated GDP/GTP nucleotide exchange by preventing recognition between KRAS G12C mutant and Ras binding domain of N-terminal Avi/GST-tagged Raf-1 (51 to 149 residues) preincubated for 4 hrs followed by SOS1 and GTPgammaS addition by FRET assay,C=CC(=O)N1CCN2c3c(cnc4c(OC)c(-c5c(O)cccc5F)c(Cl)cc34)OC[C@H]2C1,CHEMBL4402559,=,=,IC50,nM,70.0,IC50,uM,0.07,C=CC(=O)N1CCN2c3c(cnc4c(OC)c(-c5c(O)cccc5F)c(Cl)cc34)OC[C@H]2C1,2020
Inhibition of GDP bound biotinylated human C-terminal Avi/His6-tagged KRAS G12C mutant (1 to 166 residues) expressed in Escherichia coli BL21 (DE3) assessed as reduction in SOS1-mediated GDP/GTP nucleotide exchange by preventing recognition between KRAS G12C mutant and Ras binding domain of N-terminal Avi/GST-tagged Raf-1 (51 to 149 residues) preincubated for 4 hrs followed by SOS1 and GTPgammaS addition by FRET assay,C=CC(=O)N1C[C@@H]2COc3cnc4cc(-c5c(O)cccc5F)c(Cl)cc4c3N2C[C@@H]1C,CHEMBL4402559,=,=,IC50,nM,7653.0,IC50,uM,7.653,C=CC(=O)N1C[C@@H]2COc3cnc4cc(-c5c(O)cccc5F)c(Cl)cc4c3N2C[C@@H]1C,2020
Inhibition of GDP bound biotinylated human C-terminal Avi/His6-tagged KRAS G12C mutant (1 to 166 residues) expressed in Escherichia coli BL21 (DE3) assessed as reduction in SOS1-mediated GDP/GTP nucleotide exchange by preventing recognition between KRAS G12C mutant and Ras binding domain of N-terminal Avi/GST-tagged Raf-1 (51 to 149 residues) preincubated for 4 hrs followed by SOS1 and GTPgammaS addition by FRET assay,C=CC(=O)N1CCN2c3c(cnc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)cc34)OCC[C@@H]2C1,CHEMBL4402559,=,=,IC50,nM,4342.0,IC50,uM,4.342,C=CC(=O)N1CCN2c3c(cnc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)cc34)OCC[C@@H]2C1,2020
Inhibition of GDP bound biotinylated human C-terminal Avi/His6-tagged KRAS G12C mutant (1 to 166 residues) expressed in Escherichia coli BL21 (DE3) assessed as reduction in SOS1-mediated GDP/GTP nucleotide exchange by preventing recognition between KRAS G12C mutant and Ras binding domain of N-terminal Avi/GST-tagged Raf-1 (51 to 149 residues) preincubated for 4 hrs followed by SOS1 and GTPgammaS addition by FRET assay,C=CC(=O)N1CCN2c3c(cnc4c(C)c(-c5c(O)cccc5F)c(Cl)cc34)OC[C@H]2C1,CHEMBL4402559,=,=,IC50,nM,97.0,IC50,uM,0.097,C=CC(=O)N1CCN2c3c(cnc4c(C)c(-c5c(O)cccc5F)c(Cl)cc34)OC[C@H]2C1,2020
Inhibition of GDP bound biotinylated human C-terminal Avi/His6-tagged KRAS G12C mutant (1 to 166 residues) expressed in Escherichia coli BL21 (DE3) assessed as reduction in SOS1-mediated GDP/GTP nucleotide exchange by preventing recognition between KRAS G12C mutant and Ras binding domain of N-terminal Avi/GST-tagged Raf-1 (51 to 149 residues) preincubated for 4 hrs followed by SOS1 and GTPgammaS addition by FRET assay,C=CC(=O)N1CCN2c3c(cnc4c(F)c(-c5c(O)cccc5F)c(Cl)cc34)OC[C@H]2C1,CHEMBL4402559,=,=,IC50,nM,16.0,IC50,uM,0.016,C=CC(=O)N1CCN2c3c(cnc4c(F)c(-c5c(O)cccc5F)c(Cl)cc34)OC[C@H]2C1,2020
Inhibition of GDP bound biotinylated human C-terminal Avi/His6-tagged KRAS G12C mutant (1 to 166 residues) expressed in Escherichia coli BL21 (DE3) assessed as reduction in SOS1-mediated GDP/GTP nucleotide exchange by preventing recognition between KRAS G12C mutant and Ras binding domain of N-terminal Avi/GST-tagged Raf-1 (51 to 149 residues) preincubated for 4 hrs followed by SOS1 and GTPgammaS addition by FRET assay,C=CC(=O)N1CCN2c3c(cnc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)cc34)OC[C@H]2C1,CHEMBL4402559,=,=,IC50,nM,1381.0,IC50,uM,1.381,C=CC(=O)N1CCN2c3c(cnc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)cc34)OC[C@H]2C1,2020
Inhibition of GDP bound biotinylated human C-terminal Avi/His6-tagged KRAS G12C mutant (1 to 166 residues) expressed in Escherichia coli BL21 (DE3) assessed as reduction in SOS1-mediated GDP/GTP nucleotide exchange by preventing recognition between KRAS G12C mutant and Ras binding domain of N-terminal Avi/GST-tagged Raf-1 (51 to 149 residues) preincubated for 4 hrs followed by SOS1 and GTPgammaS addition by FRET assay,C=CC(=O)N1CCN2c3c(cnc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)cc34)OC[C@H]2C1,CHEMBL4402559,=,=,IC50,nM,81.0,IC50,uM,0.081,C=CC(=O)N1CCN2c3c(cnc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)cc34)OC[C@H]2C1,2020
Inhibition of GDP bound biotinylated human C-terminal Avi/His6-tagged KRAS G12C mutant (1 to 166 residues) expressed in Escherichia coli BL21 (DE3) assessed as reduction in SOS1-mediated GDP/GTP nucleotide exchange by preventing recognition between KRAS G12C mutant and Ras binding domain of N-terminal Avi/GST-tagged Raf-1 (51 to 149 residues) preincubated for 4 hrs followed by SOS1 and GTPgammaS addition by FRET assay,C=CC(=O)N1CCN2c3c(cnc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)cc34)OC[C@@H]2C1,CHEMBL4402559,=,=,IC50,nM,610.0,IC50,uM,0.61,C=CC(=O)N1CCN2c3c(cnc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)cc34)OC[C@@H]2C1,2020
Inhibition of GDP bound biotinylated human C-terminal Avi/His6-tagged KRAS G12C mutant (1 to 166 residues) expressed in Escherichia coli BL21 (DE3) assessed as reduction in SOS1-mediated GDP/GTP nucleotide exchange by preventing recognition between KRAS G12C mutant and Ras binding domain of N-terminal Avi/GST-tagged Raf-1 (51 to 149 residues) preincubated for 4 hrs followed by SOS1 and GTPgammaS addition by FRET assay,C=CC(=O)N1CCN2c3c(cnc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)cc34)OC[C@@H]2C1,CHEMBL4402559,=,=,IC50,nM,8857.0,IC50,uM,8.857,C=CC(=O)N1CCN2c3c(cnc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)cc34)OC[C@@H]2C1,2020
Inhibition of GDP bound biotinylated human C-terminal Avi/His6-tagged KRAS G12C mutant (1 to 166 residues) expressed in Escherichia coli BL21 (DE3) assessed as reduction in SOS1-mediated GDP/GTP nucleotide exchange by preventing recognition between KRAS G12C mutant and Ras binding domain of N-terminal Avi/GST-tagged Raf-1 (51 to 149 residues) preincubated for 4 hrs followed by SOS1 and GTPgammaS addition by FRET assay,C=CC(=O)N1CCN2c3c(cnc4cc(-c5c(O)cccc5F)c(Cl)cc34)NC(=O)[C@H]2C1,CHEMBL4402559,=,=,IC50,nM,73.0,IC50,uM,0.073,C=CC(=O)N1CCN2c3c(cnc4cc(-c5c(O)cccc5F)c(Cl)cc34)NC(=O)[C@H]2C1,2020
Inhibition of GDP bound biotinylated human C-terminal Avi/His6-tagged KRAS G12C mutant (1 to 166 residues) expressed in Escherichia coli BL21 (DE3) assessed as reduction in SOS1-mediated GDP/GTP nucleotide exchange by preventing recognition between KRAS G12C mutant and Ras binding domain of N-terminal Avi/GST-tagged Raf-1 (51 to 149 residues) preincubated for 4 hrs followed by SOS1 and GTPgammaS addition by FRET assay,C=CC(=O)N1CCN2c3c(cnc4cc(-c5c(O)cccc5F)c(Cl)cc34)N(C)C(=O)[C@H]2C1,CHEMBL4402559,=,=,IC50,nM,150.0,IC50,uM,0.15,C=CC(=O)N1CCN2c3c(cnc4cc(-c5c(O)cccc5F)c(Cl)cc34)N(C)C(=O)[C@H]2C1,2020
Inhibition of GDP bound biotinylated human C-terminal Avi/His6-tagged KRAS G12C mutant (1 to 166 residues) expressed in Escherichia coli BL21 (DE3) assessed as reduction in SOS1-mediated GDP/GTP nucleotide exchange by preventing recognition between KRAS G12C mutant and Ras binding domain of N-terminal Avi/GST-tagged Raf-1 (51 to 149 residues) preincubated for 4 hrs followed by SOS1 and GTPgammaS addition by FRET assay,C=CC(=O)N1C[C@@H]2COc3cnc4cc(-c5c(O)cccc5F)c(Cl)cc4c3N2C[C@H]1C,CHEMBL4402559,=,=,IC50,nM,52.0,IC50,uM,0.052,C=CC(=O)N1C[C@@H]2COc3cnc4cc(-c5c(O)cccc5F)c(Cl)cc4c3N2C[C@H]1C,2020
Inhibition of GDP bound biotinylated human C-terminal Avi/His6-tagged KRAS G12C mutant (1 to 166 residues) expressed in Escherichia coli BL21 (DE3) assessed as reduction in SOS1-mediated GDP/GTP nucleotide exchange by preventing recognition between KRAS G12C mutant and Ras binding domain of N-terminal Avi/GST-tagged Raf-1 (51 to 149 residues) preincubated for 4 hrs followed by SOS1 and GTPgammaS addition by FRET assay,C=CC(=O)N1CCN2c3c(cnc4cc(-c5c(O)cccc5F)c(Cl)cc34)OC[C@H]2C1,CHEMBL4402559,=,=,IC50,nM,211.0,IC50,uM,0.211,C=CC(=O)N1CCN2c3c(cnc4cc(-c5c(O)cccc5F)c(Cl)cc34)OC[C@H]2C1,2020
Inhibition of GDP bound biotinylated human C-terminal Avi/His6-tagged KRAS G12C mutant (1 to 166 residues) expressed in Escherichia coli BL21 (DE3) assessed as reduction in SOS1-mediated GDP/GTP nucleotide exchange by preventing recognition between KRAS G12C mutant and Ras binding domain of N-terminal Avi/GST-tagged Raf-1 (51 to 149 residues) preincubated for 4 hrs followed by SOS1 and GTPgammaS addition by FRET assay,C=CC(=O)N1CCN2c3c(cnc4cc(-c5c(O)cccc5F)c(Cl)cc34)NC[C@H]2C1,CHEMBL4402559,=,=,IC50,nM,387.0,IC50,uM,0.387,C=CC(=O)N1CCN2c3c(cnc4cc(-c5c(O)cccc5F)c(Cl)cc34)NC[C@H]2C1,2020
Inhibition of GDP bound biotinylated human C-terminal Avi/His6-tagged KRAS G12C mutant (1 to 166 residues) expressed in Escherichia coli BL21 (DE3) assessed as reduction in SOS1-mediated GDP/GTP nucleotide exchange by preventing recognition between KRAS G12C mutant and Ras binding domain of N-terminal Avi/GST-tagged Raf-1 (51 to 149 residues) preincubated for 4 hrs followed by SOS1 and GTPgammaS addition by FRET assay,C=CC(=O)N1CCN2c3c(cnc4cc(-c5c(O)cccc5F)c(Cl)cc34)N(C)C[C@H]2C1,CHEMBL4402559,=,=,IC50,nM,132.0,IC50,uM,0.132,C=CC(=O)N1CCN2c3c(cnc4cc(-c5c(O)cccc5F)c(Cl)cc34)N(C)C[C@H]2C1,2020
Inhibition of GDP bound biotinylated human C-terminal Avi/His6-tagged KRAS G12C mutant (1 to 166 residues) expressed in Escherichia coli BL21 (DE3) assessed as reduction in SOS1-mediated GDP/GTP nucleotide exchange by preventing recognition between KRAS G12C mutant and Ras binding domain of N-terminal Avi/GST-tagged Raf-1 (51 to 149 residues) preincubated for 4 hrs followed by SOS1 and GTPgammaS addition by FRET assay,C=CC(=O)N1CCN(c2ncnc3cc(-c4c(C)ccc5[nH]ncc45)c(Cl)cc23)CC1,CHEMBL4402559,=,=,IC50,nM,496.0,IC50,uM,0.496,C=CC(=O)N1CCN(c2ncnc3cc(-c4c(C)ccc5[nH]ncc45)c(Cl)cc23)CC1,2020
Inhibition of GDP bound biotinylated human C-terminal Avi/His6-tagged KRAS G12C mutant (1 to 166 residues) expressed in Escherichia coli BL21 (DE3) assessed as reduction in SOS1-mediated GDP/GTP nucleotide exchange by preventing recognition between KRAS G12C mutant and Ras binding domain of N-terminal Avi/GST-tagged Raf-1 (51 to 149 residues) preincubated for 4 hrs followed by SOS1 and GTPgammaS addition by FRET assay,C=CC(=O)N1C[C@@H]2C(=O)N(C)c3cnc4c(F)c(-c5c(O)cccc5F)c(Cl)cc4c3N2C[C@H]1C,CHEMBL4402559,<,<,IC50,nM,5.0,IC50,uM,0.005,C=CC(=O)N1C[C@@H]2C(=O)N(C)c3cnc4c(F)c(-c5c(O)cccc5F)c(Cl)cc4c3N2C[C@H]1C,2020
Binding affinity to KRAS G12C mutant in human NCI-H338 cell lysate assessed as trypsin-mediated biotinylated cysteine residues digestion by measuring reduction in protein level at 4 uM prelabeled with iodoacetamide desthiobiotin followed by compound treatment measured after 4 hrs by MS analysis relative to control,C=CC(=O)N1C[C@@H]2C(=O)N(C)c3cnc4c(F)c(-c5c(O)cccc5F)c(Cl)cc4c3N2C[C@H]1C,CHEMBL4402559,>,>,FC,,2.0,FC,,2.0,C=CC(=O)N1C[C@@H]2C(=O)N(C)c3cnc4c(F)c(-c5c(O)cccc5F)c(Cl)cc4c3N2C[C@H]1C,2020
Inhibition of KRAS G12C mutant in human H358 cells assessed as cell growth inhibition at 1 uM measured after 6 hrs by TQ-UPLC/MS analysis relative to control,C=CC(=O)N1C[C@@H]2C(=O)N(C)c3cnc4c(F)c(-c5c(O)cccc5F)c(Cl)cc4c3N2C[C@H]1C,CHEMBL4402559,=,=,Inhibition,%,82.0,INH,%,82.0,C=CC(=O)N1C[C@@H]2C(=O)N(C)c3cnc4c(F)c(-c5c(O)cccc5F)c(Cl)cc4c3N2C[C@H]1C,2020
Inhibition of KRAS G12C mutant expressed in human HCC44 cells assessed as cell growth inhibition at 1 uM measured after 6 hrs by TQ-UPLC/MS analysis relative to control,C=CC(=O)N1C[C@@H]2C(=O)N(C)c3cnc4c(F)c(-c5c(O)cccc5F)c(Cl)cc4c3N2C[C@H]1C,CHEMBL4402559,=,=,Inhibition,%,79.0,INH,%,79.0,C=CC(=O)N1C[C@@H]2C(=O)N(C)c3cnc4c(F)c(-c5c(O)cccc5F)c(Cl)cc4c3N2C[C@H]1C,2020
Inhibition of KRAS G12C mutant expressed in human MIAPaCa2 cells assessed as cell growth inhibition at 1 uM measured after 6 hrs by TQ-UPLC/MS analysis,C=CC(=O)N1C[C@@H]2C(=O)N(C)c3cnc4c(F)c(-c5c(O)cccc5F)c(Cl)cc4c3N2C[C@H]1C,CHEMBL4402559,,,Inhibition,%,,INH,,,C=CC(=O)N1C[C@@H]2C(=O)N(C)c3cnc4c(F)c(-c5c(O)cccc5F)c(Cl)cc4c3N2C[C@H]1C,2020
Inhibition of KRAS G12C mutant expressed in human H1792 cells assessed as cell growth inhibition at 1 uM measured after 6 hrs by TQ-UPLC/MS analysis relative to control,C=CC(=O)N1C[C@@H]2C(=O)N(C)c3cnc4c(F)c(-c5c(O)cccc5F)c(Cl)cc4c3N2C[C@H]1C,CHEMBL4402559,=,=,Inhibition,%,75.0,INH,%,75.0,C=CC(=O)N1C[C@@H]2C(=O)N(C)c3cnc4c(F)c(-c5c(O)cccc5F)c(Cl)cc4c3N2C[C@H]1C,2020
Inhibition of KRAS G12C mutant expressed in human H23 cells assessed as cell growth inhibition at 1 uM measured after 6 hrs by TQ-UPLC/MS analysis relative to control,C=CC(=O)N1C[C@@H]2C(=O)N(C)c3cnc4c(F)c(-c5c(O)cccc5F)c(Cl)cc4c3N2C[C@H]1C,CHEMBL4402559,=,=,Inhibition,%,80.0,INH,%,80.0,C=CC(=O)N1C[C@@H]2C(=O)N(C)c3cnc4c(F)c(-c5c(O)cccc5F)c(Cl)cc4c3N2C[C@H]1C,2020
Inhibition of KRAS G12C mutant expressed in human Calu1 cells assessed as cell growth inhibition at 1 uM measured after 6 hrs by TQ-UPLC/MS analysis relative to control,C=CC(=O)N1C[C@@H]2C(=O)N(C)c3cnc4c(F)c(-c5c(O)cccc5F)c(Cl)cc4c3N2C[C@H]1C,CHEMBL4402559,=,=,Inhibition,%,73.0,INH,%,73.0,C=CC(=O)N1C[C@@H]2C(=O)N(C)c3cnc4c(F)c(-c5c(O)cccc5F)c(Cl)cc4c3N2C[C@H]1C,2020
Inhibition of KRAS G12C mutant expressed in human HOP62 cells assessed as cell growth inhibition at 1 uM measured after 6 hrs by TQ-UPLC/MS analysis relative to control,C=CC(=O)N1C[C@@H]2C(=O)N(C)c3cnc4c(F)c(-c5c(O)cccc5F)c(Cl)cc4c3N2C[C@H]1C,CHEMBL4402559,=,=,Inhibition,%,89.0,INH,%,89.0,C=CC(=O)N1C[C@@H]2C(=O)N(C)c3cnc4c(F)c(-c5c(O)cccc5F)c(Cl)cc4c3N2C[C@H]1C,2020
Inhibition of KRAS G12C mutant expressed in human LU65 cells assessed as cell growth inhibition at 1 uM measured after 6 hrs by TQ-UPLC/MS analysis relative to control,C=CC(=O)N1C[C@@H]2C(=O)N(C)c3cnc4c(F)c(-c5c(O)cccc5F)c(Cl)cc4c3N2C[C@H]1C,CHEMBL4402559,=,=,Inhibition,%,84.0,INH,%,84.0,C=CC(=O)N1C[C@@H]2C(=O)N(C)c3cnc4c(F)c(-c5c(O)cccc5F)c(Cl)cc4c3N2C[C@H]1C,2020
Inhibition of KRAS G12C mutant expressed in human H2122 cells assessed as cell growth inhibition at 1 uM measured after 6 hrs by TQ-UPLC/MS analysis relative to control,C=CC(=O)N1C[C@@H]2C(=O)N(C)c3cnc4c(F)c(-c5c(O)cccc5F)c(Cl)cc4c3N2C[C@H]1C,CHEMBL4402559,=,=,Inhibition,%,74.0,INH,%,74.0,C=CC(=O)N1C[C@@H]2C(=O)N(C)c3cnc4c(F)c(-c5c(O)cccc5F)c(Cl)cc4c3N2C[C@H]1C,2020
Inhibition of KRAS G12C mutant expressed in human H1373 cells assessed as cell growth inhibition at 1 uM measured after 6 hrs by TQ-UPLC/MS analysis relative to control,C=CC(=O)N1C[C@@H]2C(=O)N(C)c3cnc4c(F)c(-c5c(O)cccc5F)c(Cl)cc4c3N2C[C@H]1C,CHEMBL4402559,=,=,Inhibition,%,86.0,INH,%,86.0,C=CC(=O)N1C[C@@H]2C(=O)N(C)c3cnc4c(F)c(-c5c(O)cccc5F)c(Cl)cc4c3N2C[C@H]1C,2020
Inhibition of KRAS G12C mutant expressed in human LU99 cells assessed as cell growth inhibition at 1 uM measured after 6 hrs by TQ-UPLC/MS analysis relative to control,C=CC(=O)N1C[C@@H]2C(=O)N(C)c3cnc4c(F)c(-c5c(O)cccc5F)c(Cl)cc4c3N2C[C@H]1C,CHEMBL4402559,=,=,Inhibition,%,100.0,INH,%,100.0,C=CC(=O)N1C[C@@H]2C(=O)N(C)c3cnc4c(F)c(-c5c(O)cccc5F)c(Cl)cc4c3N2C[C@H]1C,2020
Inhibition of KRAS G12C mutant expressed in human SW1573 cells assessed as cell growth inhibition at 1 uM measured after 6 hrs by TQ-UPLC/MS analysis relative to control,C=CC(=O)N1C[C@@H]2C(=O)N(C)c3cnc4c(F)c(-c5c(O)cccc5F)c(Cl)cc4c3N2C[C@H]1C,CHEMBL4402559,=,=,Inhibition,%,70.0,INH,%,70.0,C=CC(=O)N1C[C@@H]2C(=O)N(C)c3cnc4c(F)c(-c5c(O)cccc5F)c(Cl)cc4c3N2C[C@H]1C,2020
Inhibition of wild type KRAS expressed in human PC9 cells assessed as cell growth inhibition at 1 uM measured after 6 hrs by TQ-UPLC/MS analysis,C=CC(=O)N1C[C@@H]2C(=O)N(C)c3cnc4c(F)c(-c5c(O)cccc5F)c(Cl)cc4c3N2C[C@H]1C,CHEMBL4402559,,,Inhibition,%,,INH,,,C=CC(=O)N1C[C@@H]2C(=O)N(C)c3cnc4c(F)c(-c5c(O)cccc5F)c(Cl)cc4c3N2C[C@H]1C,2020
Inhibition of KRas mutant expressed in human A549 cells assessed as cell growth inhibition at 1 uM measured after 6 hrs by TQ-UPLC/MS analysis,C=CC(=O)N1C[C@@H]2C(=O)N(C)c3cnc4c(F)c(-c5c(O)cccc5F)c(Cl)cc4c3N2C[C@H]1C,CHEMBL4402559,,,Inhibition,%,,INH,,,C=CC(=O)N1C[C@@H]2C(=O)N(C)c3cnc4c(F)c(-c5c(O)cccc5F)c(Cl)cc4c3N2C[C@H]1C,2020
Inhibition of KRas mutant expressed in human H2291 cells assessed as cell growth inhibition at 1 uM measured after 6 hrs by TQ-UPLC/MS analysis,C=CC(=O)N1C[C@@H]2C(=O)N(C)c3cnc4c(F)c(-c5c(O)cccc5F)c(Cl)cc4c3N2C[C@H]1C,CHEMBL4402559,,,Inhibition,%,,INH,,,C=CC(=O)N1C[C@@H]2C(=O)N(C)c3cnc4c(F)c(-c5c(O)cccc5F)c(Cl)cc4c3N2C[C@H]1C,2020
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 3 hrs by in-cell western method,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cc(O)cc4ccccc24)C3)CC1,CHEMBL4610106,=,=,IC50,nM,142.0,IC50,nM,142.0,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cc(O)cc4ccccc24)C3)CC1,2020
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 3 hrs by in-cell western method,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2c(C)ccc4[nH]ncc24)C3)CC1,CHEMBL4610106,=,=,IC50,nM,1500.0,IC50,nM,1500.0,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2c(C)ccc4[nH]ncc24)C3)CC1,2020
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 3 hrs by in-cell western method,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2c(CC)ccc4[nH]ncc24)C3)CC1,CHEMBL4610106,=,=,IC50,nM,1080.0,IC50,nM,1080.0,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2c(CC)ccc4[nH]ncc24)C3)CC1,2020
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 3 hrs by in-cell western method,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2c(C(C)C)ccc4[nH]ncc24)C3)CC1,CHEMBL4610106,=,=,IC50,nM,1180.0,IC50,nM,1180.0,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2c(C(C)C)ccc4[nH]ncc24)C3)CC1,2020
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 3 hrs by in-cell western method,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2c(C(F)(F)F)ccc4[nH]ncc24)C3)CC1,CHEMBL4610106,=,=,IC50,nM,351.0,IC50,nM,351.0,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2c(C(F)(F)F)ccc4[nH]ncc24)C3)CC1,2020
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 3 hrs by in-cell western method,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2c(C)c(C)cc4[nH]ncc24)C3)CC1,CHEMBL4610106,=,=,IC50,nM,254.0,IC50,nM,254.0,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2c(C)c(C)cc4[nH]ncc24)C3)CC1,2020
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 3 hrs by in-cell western method,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4ccccc24)C3)CC1,CHEMBL4610106,=,=,IC50,nM,4400.0,IC50,nM,4400.0,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4ccccc24)C3)CC1,2020
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 3 hrs by in-cell western method,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4ccccc24)C3)CC1CO,CHEMBL4610106,=,=,IC50,nM,4630.0,IC50,nM,4630.0,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4ccccc24)C3)CC1CO,2020
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 3 hrs by in-cell western method,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4ccccc24)C3)C(CO)C1,CHEMBL4610106,=,=,IC50,nM,4530.0,IC50,nM,4530.0,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4ccccc24)C3)C(CO)C1,2020
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 3 hrs by in-cell western method,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4ccccc24)C3)CC1CCO,CHEMBL4610106,>,>,IC50,nM,5000.0,IC50,nM,5000.0,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4ccccc24)C3)CC1CCO,2020
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 3 hrs by in-cell western method,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4ccccc24)C3)C(CCO)C1,CHEMBL4610106,=,=,IC50,nM,4840.0,IC50,nM,4840.0,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4ccccc24)C3)C(CCO)C1,2020
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 3 hrs by in-cell western method,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4ccccc24)C3)CC1CC#N,CHEMBL4610106,=,=,IC50,nM,14.0,IC50,nM,14.0,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4ccccc24)C3)CC1CC#N,2020
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 3 hrs by in-cell western method,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4ccccc24)C3)C[C@@H]1CC#N,CHEMBL4610106,=,=,IC50,nM,10.0,IC50,nM,10.0,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4ccccc24)C3)C[C@@H]1CC#N,2020
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 3 hrs by in-cell western method,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4ccccc24)C3)C[C@H]1CC#N,CHEMBL4610106,=,=,IC50,nM,1020.0,IC50,nM,1020.0,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4ccccc24)C3)C[C@H]1CC#N,2020
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 3 hrs by in-cell western method,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4ccccc24)C3)C(CC#N)C1,CHEMBL4610106,=,=,IC50,nM,3320.0,IC50,nM,3320.0,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4ccccc24)C3)C(CC#N)C1,2020
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 3 hrs by in-cell western method,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(OC)c24)C3)C[C@@H]1CC#N,CHEMBL4610106,=,=,IC50,nM,22.0,IC50,nM,22.0,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(OC)c24)C3)C[C@@H]1CC#N,2020
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 3 hrs by in-cell western method,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(C#N)c24)C3)C[C@@H]1CC#N,CHEMBL4610106,=,=,IC50,nM,64.0,IC50,nM,64.0,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(C#N)c24)C3)C[C@@H]1CC#N,2020
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 3 hrs by in-cell western method,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(CC)c24)C3)C[C@@H]1CC#N,CHEMBL4610106,=,=,IC50,nM,6.0,IC50,nM,6.0,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(CC)c24)C3)C[C@@H]1CC#N,2020
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 3 hrs by in-cell western method,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(C(F)(F)F)c24)C3)C[C@@H]1CC#N,CHEMBL4610106,=,=,IC50,nM,4.0,IC50,nM,4.0,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(C(F)(F)F)c24)C3)C[C@@H]1CC#N,2020
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 3 hrs by in-cell western method,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,CHEMBL4610106,=,=,IC50,nM,1.0,IC50,nM,1.0,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,2020
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 3 hrs by in-cell western method,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(C)c24)C3)C[C@@H]1CC#N,CHEMBL4610106,=,=,IC50,nM,1.0,IC50,nM,1.0,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(C)c24)C3)C[C@@H]1CC#N,2020
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 3 hrs by in-cell western method,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,CHEMBL4610106,=,=,IC50,nM,14.0,IC50,nM,14.0,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,2020
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 3 hrs by in-cell western method,C=C(OC)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,CHEMBL4610106,>,>,IC50,nM,5000.0,IC50,nM,5000.0,C=C(OC)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,2020
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 3 hrs by in-cell western method,CN1CCC[C@H]1COc1nc2c(c(N3CCN(C(=O)/C=C/CF)[C@@H](CC#N)C3)n1)CCN(c1cccc3cccc(Cl)c13)C2,CHEMBL4610106,=,=,IC50,nM,3.0,IC50,nM,3.0,CN1CCC[C@H]1COc1nc2c(c(N3CCN(C(=O)/C=C/CF)[C@@H](CC#N)C3)n1)CCN(c1cccc3cccc(Cl)c13)C2,2020
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 3 hrs by in-cell western method,COC/C=C/C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,CHEMBL4610106,=,=,IC50,nM,9.0,IC50,nM,9.0,COC/C=C/C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,2020
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 3 hrs by in-cell western method,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4ccccc24)C3)C[C@@H]1CC#N,CHEMBL4610106,=,=,fIC50,nM,200.0,fIC50,nM,200.0,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4ccccc24)C3)C[C@@H]1CC#N,2020
"In-vivo target engagement at KRAS G12C mutant in athymic nude-Foxn1nu mouse xenografted with human NCI-H358 cells assessed as KRAS G12C modification level in tumor lysate at 10 mg/kg, po dosed via gavage as single administration measured after 6 hrs by LC-MS analysis relative to control",C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,CHEMBL4610106,=,=,Activity,%,70.0,Activity,%,70.0,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,2020
"In-vivo target engagement at KRAS G12C mutant in athymic nude-Foxn1nu mouse xenografted with human NCI-H358 cells assessed as KRAS G12C modification level in tumor lysate at 10 mg/kg, po dosed via gavage as single administration measured after 6 hrs by LC-MS analysis relative to control",C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(C)c24)C3)C[C@@H]1CC#N,CHEMBL4610106,=,=,Activity,%,20.0,Activity,%,20.0,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(C)c24)C3)C[C@@H]1CC#N,2020
"In-vivo target engagement at KRAS G12C mutant in athymic nude-Foxn1nu mouse xenografted with human NCI-H358 cells assessed as KRAS G12C modification level in tumor lysate at 30 mg/kg, po dosed via gavage as single administration measured after 6 hrs by LC-MS analysis relative to control",C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,CHEMBL4610106,=,=,Activity,%,89.0,Activity,%,89.0,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,2020
"In-vivo target engagement at KRAS G12C mutant in athymic nude-Foxn1nu mouse xenografted with human NCI-H358 cells assessed as KRAS G12C modification level in tumor lysate at 30 mg/kg, po dosed via gavage as single administration measured after 6 hrs by LC-MS analysis relative to control",C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(C)c24)C3)C[C@@H]1CC#N,CHEMBL4610106,=,=,Activity,%,60.0,Activity,%,60.0,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(C)c24)C3)C[C@@H]1CC#N,2020
"In-vivo target engagement at KRAS G12C mutant in athymic nude-Foxn1nu mouse xenografted with human NCI-H358 cells assessed as KRAS G12C modification level in tumor lysate at 100 mg/kg, po dosed via gavage as single administration measured after 6 hrs by LC-MS analysis relative to contro",C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,CHEMBL4610106,>,>,Activity,%,90.0,Activity,%,90.0,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,2020
"In-vivo target engagement at KRAS G12C mutant in athymic nude-Foxn1nu mouse xenografted with human NCI-H358 cells assessed as KRAS G12C modification level in tumor lysate at 100 mg/kg, po dosed via gavage as single administration measured after 6 hrs by LC-MS analysis relative to contro",C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(C)c24)C3)C[C@@H]1CC#N,CHEMBL4610106,=,=,Activity,%,80.0,Activity,%,80.0,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(C)c24)C3)C[C@@H]1CC#N,2020
Inhibition of KRAS G12C mutant in human MIAPaCa2 cells assessed as reduction in ERK phosphorylation incubated for 24 hrs by in-cell western method,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,CHEMBL4610106,=,=,IC50,nM,5.0,IC50,nM,5.0,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,2020
Inhibition of recombinant KRAS G12C mutant (unknown origin) assessed as reversible affinity constant by LC-MS analysis,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,CHEMBL4610106,=,=,Kinact,/s,0.13,Kinact,/s,0.13,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,2020
Inhibition of recombinant KRAS G12C mutant (unknown origin) assessed as rate of inactivation by LC-MS analysis,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,CHEMBL4610106,=,=,Ki,nM,3700.0,Ki,uM,3.7,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,2020
Inhibition of recombinant KRAS G12C mutant (unknown origin) assessed as Kinact/Ki ratio by LC-MS analysis,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,CHEMBL4610106,=,=,Ratio,/mM/s,35.0,Ratio,/mM/s,35.0,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,2020
Inhibition of recombinant KRAS G12C mutant (unknown origin) assessed as Kinact/Ki ratio by LC-MS analysis,C=CC(=O)N1CCN(c2ncnc3c(F)c(-c4c(O)cccc4F)c(Cl)cc23)CC1,CHEMBL4610106,=,=,Ratio,/mM/s,1.1,Ratio,/mM/s,1.1,C=CC(=O)N1CCN(c2ncnc3c(F)c(-c4c(O)cccc4F)c(Cl)cc23)CC1,2020
Inhibition of recombinant KRAS G12C mutant (unknown origin) assessed as Kinact/Ki ratio by LC-MS analysis,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1,CHEMBL4610106,=,=,Ratio,/mM/s,9.9,Ratio,/mM/s,9.9,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1,2020
Binding affinity to KRAS G12C mutant in human NCI-H358 cells assessed as protein engagement ratio at 1 uM pre-incubated for 3 hrs by thiol-reactive probe based MS-based proteomic cysteine profiling relative to control,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,CHEMBL4610106,=,=,Ratio,,0.03,Ratio,,0.03,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,2020
"Binding affinity to KRAS G12C mutant in human NCI-H358 cells assessed as reduction in KRAS G12C mutant level at 1 uM incubated for 3 hrs in presence of 2-[(2S)-4-[7-(8-chloro-1-naphthyl)-2-[[(2S)-1-pent-4-ynylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile by LC-MS analysis based click chemistry target identification based assay",C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,CHEMBL4610106,,,Activity,,,Activity,,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,2020
"In-vivo target engagement at KRAS G12C mutant in athymic nude-Foxn1nu mouse xenografted with human NCI-H358 cells assessed as KRAS G12C modification level in tumor lysate at 10 to 30 mg/kg, po dosed via gavage as single administration measured after 6 hrs by LC-MS analysis relative to control",C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,CHEMBL4610106,,,Activity,,,Activity,,,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,2020
Inhibition of GFP-tagged KRAS G12V mutant (unknown origin) expressed in MDCK cells cotransfected with mCherry-CAXX assessed as increase in KRAS G12V-plasma membrane dissociation incubated for 48 hrs by quantitative confocal microscopic method,COc1cc(/C=C/C(=O)c2ccc(F)cc2)cc(OC)c1OC,CHEMBL4619740,=,=,IC50,nM,15900.0,IC50,uM,15.9,COc1cc(/C=C/C(=O)c2ccc(F)cc2)cc(OC)c1OC,2020
Inhibition of GFP-tagged KRAS G12V mutant (unknown origin) expressed in MDCK cells cotransfected with mCherry-CAXX assessed as increase in KRAS G12V-plasma membrane dissociation incubated for 48 hrs by quantitative confocal microscopic method,COc1cc(/C=C/C(=O)c2ccc(N)cc2)cc(OC)c1OC,CHEMBL4619740,=,=,IC50,nM,9170.0,IC50,uM,9.17,COc1cc(/C=C/C(=O)c2ccc(N)cc2)cc(OC)c1OC,2020
Inhibition of GFP-tagged KRAS G12V mutant (unknown origin) expressed in MDCK cells cotransfected with mCherry-CAXX assessed as increase in KRAS G12V-plasma membrane dissociation incubated for 48 hrs by quantitative confocal microscopic method,COc1cc(/C=C/C(=O)c2ccc(Br)cc2)cc(OC)c1OC,CHEMBL4619740,=,=,IC50,nM,24640.0,IC50,uM,24.64,COc1cc(/C=C/C(=O)c2ccc(Br)cc2)cc(OC)c1OC,2020
Inhibition of GFP-tagged KRAS G12V mutant (unknown origin) expressed in MDCK cells cotransfected with mCherry-CAXX assessed as increase in KRAS G12V-plasma membrane dissociation incubated for 48 hrs by quantitative confocal microscopic method,COc1cc(/C=C/C(=O)c2ccccn2)cc(OC)c1OC,CHEMBL4619740,=,=,IC50,nM,52970.0,IC50,uM,52.97,COc1cc(/C=C/C(=O)c2ccccn2)cc(OC)c1OC,2020
Inhibition of GFP-tagged KRAS G12V mutant (unknown origin) expressed in MDCK cells cotransfected with mCherry-CAXX assessed as increase in KRAS G12V-plasma membrane dissociation incubated for 48 hrs by quantitative confocal microscopic method,COc1cc(/C=C/C(=O)c2c(F)cccc2F)cc(OC)c1OC,CHEMBL4619740,=,=,IC50,nM,8200.0,IC50,uM,8.2,COc1cc(/C=C/C(=O)c2c(F)cccc2F)cc(OC)c1OC,2020
Inhibition of GFP-tagged KRAS G12V mutant (unknown origin) expressed in MDCK cells cotransfected with mCherry-CAXX assessed as increase in KRAS G12V-plasma membrane dissociation incubated for 48 hrs by quantitative confocal microscopic method,COc1cc(/C=C/C(=O)c2ccc([N+](=O)[O-])cc2)cc(OC)c1OC,CHEMBL4619740,=,=,IC50,nM,7010.0,IC50,uM,7.01,COc1cc(/C=C/C(=O)c2ccc([N+](=O)[O-])cc2)cc(OC)c1OC,2020
Inhibition of GFP-tagged KRAS G12V mutant (unknown origin) expressed in MDCK cells cotransfected with mCherry-CAXX assessed as increase in KRAS G12V-plasma membrane dissociation incubated for 48 hrs by quantitative confocal microscopic method,COc1ccc(C(=O)/C=C/c2cc(OC)c(OC)c(OC)c2)cc1,CHEMBL4619740,=,=,IC50,nM,8290.0,IC50,uM,8.29,COc1ccc(C(=O)/C=C/c2cc(OC)c(OC)c(OC)c2)cc1,2020
Inhibition of GFP-tagged KRAS G12V mutant (unknown origin) expressed in MDCK cells cotransfected with mCherry-CAXX assessed as increase in KRAS G12V-plasma membrane dissociation incubated for 48 hrs by quantitative confocal microscopic method,COc1cc(/C=C/C(=O)c2ccc(N(C)C)cc2)cc(OC)c1OC,CHEMBL4619740,=,=,IC50,nM,7420.0,IC50,uM,7.42,COc1cc(/C=C/C(=O)c2ccc(N(C)C)cc2)cc(OC)c1OC,2020
Inhibition of GFP-tagged KRAS G12V mutant (unknown origin) expressed in MDCK cells cotransfected with mCherry-CAXX assessed as increase in KRAS G12V-plasma membrane dissociation incubated for 48 hrs by quantitative confocal microscopic method,COc1cc(C(=O)/C=C/c2ccc([N+](=O)[O-])cc2)cc(OC)c1OC,CHEMBL4619740,=,=,IC50,nM,8200.0,IC50,uM,8.2,COc1cc(C(=O)/C=C/c2ccc([N+](=O)[O-])cc2)cc(OC)c1OC,2020
Inhibition of GFP-tagged KRAS G12V mutant (unknown origin) expressed in MDCK cells cotransfected with mCherry-CAXX assessed as increase in KRAS G12V-plasma membrane dissociation incubated for 48 hrs by quantitative confocal microscopic method,COc1cc(C(=O)/C=C/c2c(F)cccc2F)cc(OC)c1OC,CHEMBL4619740,=,=,IC50,nM,7490.0,IC50,uM,7.49,COc1cc(C(=O)/C=C/c2c(F)cccc2F)cc(OC)c1OC,2020
Inhibition of GFP-tagged KRAS G12V mutant (unknown origin) expressed in MDCK cells cotransfected with mCherry-CAXX assessed as increase in KRAS G12V-plasma membrane dissociation incubated for 48 hrs by quantitative confocal microscopic method relative to control,COc1cc(/C=C/C(=O)c2ccc([N+](=O)[O-])cc2)cc(OC)c1OC,CHEMBL4619740,=,=,Emax,%,0.57,Emax,%,0.57,COc1cc(/C=C/C(=O)c2ccc([N+](=O)[O-])cc2)cc(OC)c1OC,2020
Inhibition of GFP-tagged KRAS G12V mutant (unknown origin) expressed in MDCK cells cotransfected with mCherry-CAXX assessed as increase in KRAS G12V-plasma membrane dissociation incubated for 48 hrs by quantitative confocal microscopic method relative to control,COc1cc(/C=C/C(=O)c2ccc(N)cc2)cc(OC)c1OC,CHEMBL4619740,=,=,Emax,%,0.54,Emax,%,0.54,COc1cc(/C=C/C(=O)c2ccc(N)cc2)cc(OC)c1OC,2020
Inhibition of GFP-tagged KRAS G12V mutant (unknown origin) expressed in MDCK cells cotransfected with mCherry-CAXX assessed as increase in KRAS G12V-plasma membrane dissociation incubated for 48 hrs by quantitative confocal microscopic method relative to control,COc1cc(/C=C/C(=O)c2ccccn2)cc(OC)c1OC,CHEMBL4619740,=,=,Emax,%,0.45,Emax,%,0.45,COc1cc(/C=C/C(=O)c2ccccn2)cc(OC)c1OC,2020
Inhibition of GFP-tagged KRAS G12V mutant (unknown origin) expressed in MDCK cells cotransfected with mCherry-CAXX assessed as increase in KRAS G12V-plasma membrane dissociation incubated for 48 hrs by quantitative confocal microscopic method relative to control,COc1cc(/C=C/C(=O)c2c(F)cccc2F)cc(OC)c1OC,CHEMBL4619740,=,=,Emax,%,0.45,Emax,%,0.45,COc1cc(/C=C/C(=O)c2c(F)cccc2F)cc(OC)c1OC,2020
Inhibition of GFP-tagged KRAS G12V mutant (unknown origin) expressed in MDCK cells cotransfected with mCherry-CAXX assessed as increase in KRAS G12V-plasma membrane dissociation incubated for 48 hrs by quantitative confocal microscopic method relative to control,COc1cc(/C=C/C(=O)c2ccc(F)cc2)cc(OC)c1OC,CHEMBL4619740,=,=,Emax,%,0.39,Emax,%,0.39,COc1cc(/C=C/C(=O)c2ccc(F)cc2)cc(OC)c1OC,2020
Inhibition of GFP-tagged KRAS G12V mutant (unknown origin) expressed in MDCK cells cotransfected with mCherry-CAXX assessed as increase in KRAS G12V-plasma membrane dissociation incubated for 48 hrs by quantitative confocal microscopic method relative to control,COc1cc(/C=C/C(=O)c2ccc(Br)cc2)cc(OC)c1OC,CHEMBL4619740,=,=,Emax,%,0.47,Emax,%,0.47,COc1cc(/C=C/C(=O)c2ccc(Br)cc2)cc(OC)c1OC,2020
Inhibition of GFP-tagged KRAS G12V mutant (unknown origin) expressed in MDCK cells cotransfected with mCherry-CAXX assessed as increase in KRAS G12V-plasma membrane dissociation incubated for 48 hrs by quantitative confocal microscopic method relative to control,COc1ccc(C(=O)/C=C/c2cc(OC)c(OC)c(OC)c2)cc1,CHEMBL4619740,=,=,Emax,%,0.45,Emax,%,0.45,COc1ccc(C(=O)/C=C/c2cc(OC)c(OC)c(OC)c2)cc1,2020
Inhibition of GFP-tagged KRAS G12V mutant (unknown origin) expressed in MDCK cells cotransfected with mCherry-CAXX assessed as increase in KRAS G12V-plasma membrane dissociation incubated for 48 hrs by quantitative confocal microscopic method relative to control,COc1cc(/C=C/C(=O)c2ccc(N(C)C)cc2)cc(OC)c1OC,CHEMBL4619740,=,=,Emax,%,0.58,Emax,%,0.58,COc1cc(/C=C/C(=O)c2ccc(N(C)C)cc2)cc(OC)c1OC,2020
Inhibition of GFP-tagged KRAS G12V mutant (unknown origin) expressed in MDCK cells cotransfected with mCherry-CAXX assessed as increase in KRAS G12V-plasma membrane dissociation incubated for 48 hrs by quantitative confocal microscopic method relative to control,COc1cc(C(=O)/C=C/c2ccc([N+](=O)[O-])cc2)cc(OC)c1OC,CHEMBL4619740,=,=,Emax,%,0.46,Emax,%,0.46,COc1cc(C(=O)/C=C/c2ccc([N+](=O)[O-])cc2)cc(OC)c1OC,2020
Inhibition of GFP-tagged KRAS G12V mutant (unknown origin) expressed in MDCK cells cotransfected with mCherry-CAXX assessed as increase in KRAS G12V-plasma membrane dissociation incubated for 48 hrs by quantitative confocal microscopic method relative to control,COc1cc(C(=O)/C=C/c2c(F)cccc2F)cc(OC)c1OC,CHEMBL4619740,=,=,Emax,%,0.45,Emax,%,0.45,COc1cc(C(=O)/C=C/c2c(F)cccc2F)cc(OC)c1OC,2020
Inhibition of GFP-tagged KRAS G12V mutant (unknown origin) expressed in MDCK cells assessed as reduction in Akt phosphorylation level incubated for 48 hrs by Western blot analysis,COc1cc(/C=C/C(=O)c2ccc([N+](=O)[O-])cc2)cc(OC)c1OC,CHEMBL4619740,,,Inhibition,%,,INH,,,COc1cc(/C=C/C(=O)c2ccc([N+](=O)[O-])cc2)cc(OC)c1OC,2020
Inhibition of GFP-tagged KRAS G12V mutant (unknown origin) expressed in MDCK cells assessed as reduction in ERK phosphorylation level incubated for 48 hrs by Western blot analysis,COc1cc(/C=C/C(=O)c2ccc([N+](=O)[O-])cc2)cc(OC)c1OC,CHEMBL4619740,,,Inhibition,%,,INH,,,COc1cc(/C=C/C(=O)c2ccc([N+](=O)[O-])cc2)cc(OC)c1OC,2020
Inhibition of KRAS in human NCI-H358 cells assessed as MARCK phosphorylation level at 1 uM incubated for 48 hrs by Western blot analysis (Rvb = 1.00 +/- 0.39 No_unit),COc1cc(/C=C/C(=O)c2ccc([N+](=O)[O-])cc2)cc(OC)c1OC,CHEMBL4619740,=,=,FC,,1.89,FC,,1.89,COc1cc(/C=C/C(=O)c2ccc([N+](=O)[O-])cc2)cc(OC)c1OC,2020
Inhibition of KRAS in human NCI-H358 cells assessed as MARCK phosphorylation level at 5 uM incubated for 48 hrs by Western blot analysis (Rvb = 1.00 +/- 0.39 No_unit),COc1cc(/C=C/C(=O)c2ccc([N+](=O)[O-])cc2)cc(OC)c1OC,CHEMBL4619740,=,=,FC,,1.92,FC,,1.92,COc1cc(/C=C/C(=O)c2ccc([N+](=O)[O-])cc2)cc(OC)c1OC,2020
Inhibition of KRAS in human NCI-H358 cells assessed as MARCK phosphorylation level at 10 uM incubated for 48 hrs by Western blot analysis (Rvb = 1.00 +/- 0.39 No_unit),COc1cc(/C=C/C(=O)c2ccc([N+](=O)[O-])cc2)cc(OC)c1OC,CHEMBL4619740,=,=,FC,,2.57,FC,,2.57,COc1cc(/C=C/C(=O)c2ccc([N+](=O)[O-])cc2)cc(OC)c1OC,2020
Inhibition of KRAS in human NCI-H358 cells assessed as MARCK phosphorylation level at 25 uM incubated for 48 hrs by Western blot analysis (Rvb = 1.00 +/- 0.39 No_unit),COc1cc(/C=C/C(=O)c2ccc([N+](=O)[O-])cc2)cc(OC)c1OC,CHEMBL4619740,=,=,FC,,2.65,FC,,2.65,COc1cc(/C=C/C(=O)c2ccc([N+](=O)[O-])cc2)cc(OC)c1OC,2020
Inhibition of GFP-tagged KRAS G12V mutant (unknown origin) expressed in MDCK cells assessed as MARCK phosphorylation level at 1 uM incubated for 48 hrs by Western blot analysis (Rvb = 1.00 +/- 0.13 No_unit),COc1cc(/C=C/C(=O)c2ccc([N+](=O)[O-])cc2)cc(OC)c1OC,CHEMBL4619740,=,=,FC,,1.31,FC,,1.31,COc1cc(/C=C/C(=O)c2ccc([N+](=O)[O-])cc2)cc(OC)c1OC,2020
Inhibition of GFP-tagged KRAS G12V mutant (unknown origin) expressed in MDCK cells assessed as MARCK phosphorylation level at 5 uM incubated for 48 hrs by Western blot analysis (Rvb = 1.00 +/- 0.13 No_unit),COc1cc(/C=C/C(=O)c2ccc([N+](=O)[O-])cc2)cc(OC)c1OC,CHEMBL4619740,=,=,FC,,1.76,FC,,1.76,COc1cc(/C=C/C(=O)c2ccc([N+](=O)[O-])cc2)cc(OC)c1OC,2020
Inhibition of GFP-tagged KRAS G12V mutant (unknown origin) expressed in MDCK cells assessed as MARCK phosphorylation level at 10 uM incubated for 48 hrs by Western blot analysis (Rvb = 1.00 +/- 0.13 No_unit),COc1cc(/C=C/C(=O)c2ccc([N+](=O)[O-])cc2)cc(OC)c1OC,CHEMBL4619740,=,=,FC,,2.85,FC,,2.85,COc1cc(/C=C/C(=O)c2ccc([N+](=O)[O-])cc2)cc(OC)c1OC,2020
Inhibition of GFP-tagged KRAS G12V mutant (unknown origin) expressed in MDCK cells assessed as MARCK phosphorylation level at 25 uM incubated for 48 hrs by Western blot analysis (Rvb = 1.00 +/- 0.13 No_unit),COc1cc(/C=C/C(=O)c2ccc([N+](=O)[O-])cc2)cc(OC)c1OC,CHEMBL4619740,=,=,FC,,2.8,FC,,2.8,COc1cc(/C=C/C(=O)c2ccc([N+](=O)[O-])cc2)cc(OC)c1OC,2020
Inhibition of KRAS in human NCI-H358 cells assessed as reduction in MARCK phosphorylation level incubated for 48 hrs by Western blot analysis,COc1cc(/C=C/C(=O)c2ccc([N+](=O)[O-])cc2)cc(OC)c1OC,CHEMBL4619740,,,Inhibition,%,,INH,,,COc1cc(/C=C/C(=O)c2ccc([N+](=O)[O-])cc2)cc(OC)c1OC,2020
Inhibition of GFP-tagged KRAS G12V mutant (unknown origin) expressed in MDCK cells assessed as reduction in MARCK phosphorylation level incubated for 48 hrs by Western blot analysis,COc1cc(/C=C/C(=O)c2ccc([N+](=O)[O-])cc2)cc(OC)c1OC,CHEMBL4619740,,,Inhibition,%,,INH,,,COc1cc(/C=C/C(=O)c2ccc([N+](=O)[O-])cc2)cc(OC)c1OC,2020
Inhibition of GFP-tagged KRAS G12V/S181A mutant (unknown origin) expressed in MDCK cells cotransfected with mCherry-CAXX assessed as reduction in KRAS G12V-plasma membrane dissociation incubated for 48 hrs by quantitative confocal microscopic method,COc1cc(/C=C/C(=O)c2ccc([N+](=O)[O-])cc2)cc(OC)c1OC,CHEMBL4619740,,,Inhibition,%,,INH,,,COc1cc(/C=C/C(=O)c2ccc([N+](=O)[O-])cc2)cc(OC)c1OC,2020
Inhibition of KRAS in human MDA-MB-231 cells assessed as reduction in Pan RAS protein level at 15 uM measured after 24 hrs by Western blot analysis relative to control,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,CHEMBL4622932,=,=,FC,,1.16,FC,,1.16,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,2020
Inhibition of KRAS in human MDA-MB-231 cells assessed as reduction in phosphorylated RAF-1 E1 protein level at 15 uM measured after 24 hrs by Western blot analysis relative to control,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,CHEMBL4622932,=,=,FC,,0.85,FC,,0.85,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,2020
Inhibition of KRAS in human MDA-MB-231 cells assessed as reduction in MEK1/2 9G3 protein level at 15 uM measured after 24 hrs by Western blot analysis relative to control,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,CHEMBL4622932,=,=,FC,,0.91,FC,,0.91,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,2020
Inhibition of KRAS in human MDA-MB-231 cells assessed as reduction in phosphorylated MEK1/2 at Ser217/221 residues protein level at 15 uM measured after 24 hrs by Western blot analysis relative to control,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,CHEMBL4622932,=,=,FC,,1.24,FC,,1.24,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,2020
Inhibition of KRAS in human MDA-MB-231 cells assessed as reduction in ERK1/2 137F5 protein level at 15 uM measured after 24 hrs by Western blot analysis relative to control,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,CHEMBL4622932,=,=,FC,,0.99,FC,,0.99,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,2020
Inhibition of KRAS in human MDA-MB-231 cells assessed as reduction in phosphorylated ERK1/2 at Thr185/Tyr187 residues protein level at 15 uM measured after 24 hrs by Western blot analysis relative to control,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,CHEMBL4622932,=,=,FC,,1.15,FC,,1.15,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,2020
Inhibition of KRAS in human MDA-MB-231 cells assessed as reduction in Pan RAS protein level at 25 uM measured after 24 hrs by Western blot analysis relative to control,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,CHEMBL4622932,=,=,FC,,1.18,FC,,1.18,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,2020
Inhibition of KRAS in human MDA-MB-231 cells assessed as reduction in phosphorylated RAF-1 E1 protein level at 25 uM measured after 24 hrs by Western blot analysis relative to control,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,CHEMBL4622932,=,=,FC,,0.14,FC,,0.14,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,2020
Inhibition of KRAS in human MDA-MB-231 cells assessed as reduction in MEK1/2 9G3 protein level at 25 uM measured after 24 hrs by Western blot analysis relative to control,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,CHEMBL4622932,=,=,FC,,0.61,FC,,0.61,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,2020
Inhibition of KRAS in human MDA-MB-231 cells assessed as reduction in phosphorylated MEK1/2 at Ser217/221 residues protein level at 25 uM measured after 24 hrs by Western blot analysis relative to control,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,CHEMBL4622932,=,=,FC,,0.97,FC,,0.97,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,2020
Inhibition of KRAS in human MDA-MB-231 cells assessed as reduction in ERK1/2 137F5 protein level at 25 uM measured after 24 hrs by Western blot analysis relative to control,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,CHEMBL4622932,=,=,FC,,0.91,FC,,0.91,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,2020
Inhibition of KRAS in human MDA-MB-231 cells assessed as reduction in phosphorylated ERK1/2 at Thr185/Tyr187 residues protein level at 25 uM measured after 24 hrs by Western blot analysis relative to control,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,CHEMBL4622932,=,=,FC,,1.0,FC,,1.0,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,2020
Inhibition of KRAS in human MDA-MB-231 cells assessed as reduction in Pan RAS protein level at 35 uM measured after 24 hrs by Western blot analysis relative to control,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,CHEMBL4622932,=,=,FC,,0.46,FC,,0.46,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,2020
Inhibition of KRAS in human MDA-MB-231 cells assessed as reduction in phosphorylated RAF-1 E1 protein level at 35 uM measured after 24 hrs by Western blot analysis relative to control,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,CHEMBL4622932,=,=,FC,,0.17,FC,,0.17,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,2020
Inhibition of KRAS in human MDA-MB-231 cells assessed as reduction in MEK1/2 9G3 protein level at 35 uM measured after 24 hrs by Western blot analysis relative to control,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,CHEMBL4622932,=,=,FC,,0.46,FC,,0.46,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,2020
Inhibition of KRAS in human MDA-MB-231 cells assessed as reduction in phosphorylated MEK1/2 at Ser217/221 residues protein level at 35 uM measured after 24 hrs by Western blot analysis relative to control,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,CHEMBL4622932,=,=,FC,,0.53,FC,,0.53,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,2020
Inhibition of KRAS in human MDA-MB-231 cells assessed as reduction in ERK1/2 137F5 protein level at 35 uM measured after 24 hrs by Western blot analysis relative to control,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,CHEMBL4622932,=,=,FC,,0.93,FC,,0.93,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,2020
Inhibition of KRAS in human MDA-MB-231 cells assessed as reduction in phosphorylated ERK1/2 at Thr185/Tyr187 residues protein level at 35 uM measured after 24 hrs by Western blot analysis relative to control,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,CHEMBL4622932,=,=,FC,,0.42,FC,,0.42,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,2020
Inhibition of KRAS in human MCF7 cells assessed as reduction in Pan RAS protein level at 15 uM measured after 24 hrs by Western blot analysis relative to control,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,CHEMBL4622932,=,=,FC,,0.99,FC,,0.99,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,2020
Inhibition of KRAS in human MCF7 cells assessed as reduction in phosphorylated RAF-1 E1 protein level at 15 uM measured after 24 hrs by Western blot analysis relative to control,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,CHEMBL4622932,=,=,FC,,1.06,FC,,1.06,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,2020
Inhibition of KRAS in human MCF7 cells assessed as reduction in MEK1/2 9G3 protein level at 15 uM measured after 24 hrs by Western blot analysis relative to control,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,CHEMBL4622932,=,=,FC,,0.97,FC,,0.97,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,2020
Inhibition of KRAS in human MCF7 cells assessed as reduction in phosphorylated MEK1/2 at Ser217/221 residues protein level at 15 uM measured after 24 hrs by Western blot analysis relative to control,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,CHEMBL4622932,=,=,FC,,0.91,FC,,0.91,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,2020
Inhibition of KRAS in human MCF7 cells assessed as reduction in ERK1/2 137F5 protein level at 15 uM measured after 24 hrs by Western blot analysis relative to control,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,CHEMBL4622932,=,=,FC,,1.25,FC,,1.25,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,2020
Inhibition of KRAS in human MCF7 cells assessed as reduction in phosphorylated ERK1/2 at Thr185/Tyr187 residues protein level at 15 uM measured after 24 hrs by Western blot analysis relative to control,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,CHEMBL4622932,=,=,FC,,1.02,FC,,1.02,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,2020
Inhibition of KRAS in human MCF7 cells assessed as reduction in Pan RAS protein level at 25 uM measured after 24 hrs by Western blot analysis relative to control,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,CHEMBL4622932,=,=,FC,,1.16,FC,,1.16,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,2020
Inhibition of KRAS in human MCF7 cells assessed as reduction in phosphorylated RAF-1 E1 protein level at 25 uM measured after 24 hrs by Western blot analysis relative to control,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,CHEMBL4622932,=,=,FC,,0.99,FC,,0.99,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,2020
Inhibition of KRAS in human MCF7 cells assessed as reduction in MEK1/2 9G3 protein level at 25 uM measured after 24 hrs by Western blot analysis relative to control,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,CHEMBL4622932,=,=,FC,,1.06,FC,,1.06,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,2020
Inhibition of KRAS in human MCF7 cells assessed as reduction in phosphorylated MEK1/2 at Ser217/221 residues protein level at 25 uM measured after 24 hrs by Western blot analysis relative to control,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,CHEMBL4622932,=,=,FC,,1.12,FC,,1.12,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,2020
Inhibition of KRAS in human MCF7 cells assessed as reduction in ERK1/2 137F5 protein level at 25 uM measured after 24 hrs by Western blot analysis relative to control,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,CHEMBL4622932,=,=,FC,,1.14,FC,,1.14,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,2020
Inhibition of KRAS in human MCF7 cells assessed as reduction in phosphorylated ERK1/2 at Thr185/Tyr187 residues protein level at 25 uM measured after 24 hrs by Western blot analysis relative to control,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,CHEMBL4622932,=,=,FC,,0.91,FC,,0.91,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,2020
Inhibition of KRAS in human MCF7 cells assessed as reduction in Pan RAS protein level at 35 uM measured after 24 hrs by Western blot analysis relative to control,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,CHEMBL4622932,=,=,FC,,1.11,FC,,1.11,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,2020
Inhibition of KRAS in human MCF7 cells assessed as reduction in phosphorylated RAF-1 E1 protein level at 35 uM measured after 24 hrs by Western blot analysis relative to control,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,CHEMBL4622932,=,=,FC,,1.05,FC,,1.05,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,2020
Inhibition of KRAS in human MCF7 cells assessed as reduction in MEK1/2 9G3 protein level at 35 uM measured after 24 hrs by Western blot analysis relative to control,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,CHEMBL4622932,=,=,FC,,0.87,FC,,0.87,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,2020
Inhibition of KRAS in human MCF7 cells assessed as reduction in phosphorylated MEK1/2 at Ser217/221 residues protein level at 35 uM measured after 24 hrs by Western blot analysis relative to control,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,CHEMBL4622932,=,=,FC,,0.86,FC,,0.86,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,2020
Inhibition of KRAS in human MCF7 cells assessed as reduction in ERK1/2 137F5 protein level at 35 uM measured after 24 hrs by Western blot analysis relative to control,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,CHEMBL4622932,=,=,FC,,1.11,FC,,1.11,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,2020
Inhibition of KRAS in human MCF7 cells assessed as reduction in phosphorylated ERK1/2 at Thr185/Tyr187 residues protein level at 35 uM measured after 24 hrs by Western blot analysis relative to control,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,CHEMBL4622932,=,=,FC,,0.35,FC,,0.35,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,2020
Inhibition of KRAS in human MDA-MB-231 cells assessed as reduction in phosphorylation of RAF measured after 24 hrs by Western blot analysis,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,CHEMBL4622932,,,Inhibition,%,,INH,,,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,2020
Inhibition of KRAS in human MDA-MB-231 cells assessed as reduction in phosphorylation of MEK measured after 24 hrs by Western blot analysis,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,CHEMBL4622932,,,Inhibition,%,,INH,,,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,2020
Inhibition of KRAS in human MDA-MB-231 cells assessed as reduction in phosphorylation of ERK measured after 24 hrs by Western blot analysis,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,CHEMBL4622932,,,Inhibition,%,,INH,,,O=P(Oc1ccccc1)(Oc1ccccc1)OC1C2OC3(c4ccccc4)OC(C2O)C(O)C1O3,2020
Inhibition of KRas G12C mutant in human H358 cells assessed as antiproliferative activity incubated for 3 days by CellTiter-Glo assay,CCCC(CCC)COC(=O)[C@@H](C)NP(=O)(OCCNC(=O)CCl)OP(=O)(O)OC[C@H]1O[C@@H](N2C=NC3C(=O)NC(N)=NC32)[C@H](O)[C@@H]1O,CHEMBL4673313,=,=,EC50,nM,26600.0,EC50,uM,26.6,CCCC(CCC)COC(=O)[C@@H](C)NP(=O)(OCCNC(=O)CCl)OP(=O)(O)OC[C@H]1O[C@@H](N2C=NC3C(=O)NC(N)=NC32)[C@H](O)[C@@H]1O,2020
Inhibition of KRas G12C mutant in human NCI-H1792 cells assessed as antiproliferative activity incubated for 3 days by CellTiter-Glo assay,C=CC(=O)N1CCN(C(=O)CNc2cc(I)c(Cl)cc2O)CC1,CHEMBL4673313,=,=,EC50,nM,320.0,EC50,uM,0.32,C=CC(=O)N1CCN(C(=O)CNc2cc(I)c(Cl)cc2O)CC1,2020
Covalent binding affinity to GDP-loaded hexahistidine-tagged KRas G12C mutant (1 to 169 residues) (unknown origin) expressed in Escherichia coli assessed as rate constant by liquid chromatography-electrospray mass spectrometry analysis,C=CC(=O)N1CC(N2CCN(C(=O)CNc3cc(C4(C)CC4)c(Cl)cc3O)CC2)C1,CHEMBL4673313,=,=,K,/M/s,76.0,K,/M/s,76.0,C=CC(=O)N1CC(N2CCN(C(=O)CNc3cc(C4(C)CC4)c(Cl)cc3O)CC2)C1,2020
Inhibition of KRas G12C mutant in human H358 cells assessed as reduction in ERK phosphorylation at T202/Y204 residue incubated for 24 hrs by immunoblot analysis,C=CC(=O)N1CC(N2CCN(C(=O)CNc3cc(C4(C)CC4)c(Cl)cc3O)CC2)C1,CHEMBL4673313,=,=,IC50,nM,1700.0,IC50,uM,1.7,C=CC(=O)N1CC(N2CCN(C(=O)CNc3cc(C4(C)CC4)c(Cl)cc3O)CC2)C1,2020
Inhibition of KRas G12C mutant in human H358 cells assessed as reduction in ERK phosphorylation at T202/Y204 residue incubated for 24 hrs by immunoblot analysis,C=CC(=O)N1CCN(c2ncnc3c(F)c(-c4c(O)cccc4F)c(Cl)cc23)CC1,CHEMBL4673313,=,=,IC50,nM,120.0,IC50,uM,0.12,C=CC(=O)N1CCN(c2ncnc3c(F)c(-c4c(O)cccc4F)c(Cl)cc23)CC1,2020
Binding affinity to human hexahistidine-tagged KRas G12C mutant (1 to 169 residues) expressed in Escherichia coli(BL21 (DE3)) assessed as rate constant for covalent modification by measuring Kobs/[I] at 10 uM by liquid chromatography-electrospray mass spectrometry analysis,C=CC(=O)N1CC(N2CCN(C(=O)CNc3cc(C4(C)CC4)c(Cl)cc3O)CC2)C1,CHEMBL4673313,=,=,K,/M/s,140.0,K,/M/s,140.0,C=CC(=O)N1CC(N2CCN(C(=O)CNc3cc(C4(C)CC4)c(Cl)cc3O)CC2)C1,2020
Binding affinity to human hexahistidine-tagged KRas G12C mutant (1 to 169 residues) expressed in Escherichia coli(BL21 (DE3)) assessed as rate constant for covalent modification by measuring Kobs/[I] at 10 uM by liquid chromatography-electrospray mass spectrometry analysis,C=CC(=O)N1CCN(c2ncnc3cc(-c4ccccc4O)c(Cl)cc23)CC1,CHEMBL4673313,=,=,K,/M/s,12.0,K,/M/s,12.0,C=CC(=O)N1CCN(c2ncnc3cc(-c4ccccc4O)c(Cl)cc23)CC1,2020
Binding affinity to human hexahistidine-tagged KRas G12C mutant (1 to 169 residues) expressed in Escherichia coli(BL21 (DE3)) assessed as rate constant for covalent modification by measuring Kobs/[I] at 10 uM by liquid chromatography-electrospray mass spectrometry analysis,C=CC(=O)N1CCN(c2ncnc3c(F)c(-c4c(O)cccc4F)c(Cl)cc23)CC1,CHEMBL4673313,=,=,K,/M/s,1100.0,K,/M/s,1100.0,C=CC(=O)N1CCN(c2ncnc3c(F)c(-c4c(O)cccc4F)c(Cl)cc23)CC1,2020
Inhibition of KRas activation in HEK 293T-REx Flp-In cells harboring Venus-RBD-CRD/mCherry-CAAX assessed as reduction in Venus-RBD-CRD recruitment to plasma membrane by inverted confocal microscopy,Cc1[nH]c2cc(Cl)cc(Cl)c2c1CCN,CHEMBL4673313,=,=,EC50,nM,15800.0,EC50,uM,15.8,Cc1[nH]c2cc(Cl)cc(Cl)c2c1CCN,2020
Binding affinity to 15N-labelled GDP bound KRas G12D mutant ( 1 to 169 residues) (unknown origin) expressed in Escherichia coli Rosetta 2 (DE3) cells by 1H/15N- HSQC spectroscopy,c1ccc2c(Cc3nc4ccncc4[nH]3)c[nH]c2c1,CHEMBL4673313,=,=,Kd,nM,1300000.0,Kd,uM,1300.0,c1ccc2c(Cc3nc4ccncc4[nH]3)c[nH]c2c1,2020
Binding affinity to 15N-labelled GDP bound KRas G12D mutant ( 1 to 169 residues) (unknown origin) expressed in Escherichia coli Rosetta 2 (DE3) cells by 1H/15N- HSQC spectroscopy,CC[C@H](C)[C@H](N)C(=O)Nc1ccc2nc(Cc3c[nH]c4ccccc34)[nH]c2c1,CHEMBL4673313,=,=,Kd,nM,190000.0,Kd,uM,190.0,CC[C@H](C)[C@H](N)C(=O)Nc1ccc2nc(Cc3c[nH]c4ccccc34)[nH]c2c1,2020
Binding affinity to 15N-labelled GDP bound KRas G12D mutant ( 1 to 169 residues) (unknown origin) expressed in Escherichia coli Rosetta 2 (DE3) cells by 1H/15N- HSQC spectroscopy,O=C(Nc1ccc2nc(Cc3c[nH]c4ccccc34)[nH]c2c1)[C@@H]1CCCN1,CHEMBL4673313,=,=,Kd,nM,340000.0,Kd,uM,340.0,O=C(Nc1ccc2nc(Cc3c[nH]c4ccccc34)[nH]c2c1)[C@@H]1CCCN1,2020
Inhibition of GDP-bound KRas activation (unknown origin) expressed in Escherichia coli Rosetta2 (DE3) cells assessed as reduction in SOS-catalyzed nucleotide exchange at 1 mM in presence of BODIPY-GTP by fluorescence method relative to control,CC[C@H](C)[C@H](N)C(=O)Nc1ccc2nc(Cc3c[nH]c4ccccc34)[nH]c2c1,CHEMBL4673313,=,=,Inhibition,%,78.0,INH,%,78.0,CC[C@H](C)[C@H](N)C(=O)Nc1ccc2nc(Cc3c[nH]c4ccccc34)[nH]c2c1,2020
Binding affinity to GCP-KRAS G12D (unknown origin) by isothermal titration calorimetry,CN(C)Cc1[nH]c2ccccc2c1[C@H]1NC(=O)c2ccc(O)cc21,CHEMBL4673313,=,=,Kd,nM,20000.0,Kd,uM,20.0,CN(C)Cc1[nH]c2ccccc2c1[C@H]1NC(=O)c2ccc(O)cc21,2020
Inhibition of C-terminal Avi-tagged biotinylated KRas G12D mutant (1 to 169 residues) (unknown origin) expressed in Escherichia coli assessed as reduction in KRas G12D mutant-SOS1 (564 to 1049 residues) protein-protein interaction incubated for 60 mins by TR-FRET LANCE assay,CN(C)Cc1[nH]c2ccccc2c1[C@H]1NC(=O)c2ccc(O)cc21,CHEMBL4673313,=,=,IC50,nM,33000.0,IC50,uM,33.0,CN(C)Cc1[nH]c2ccccc2c1[C@H]1NC(=O)c2ccc(O)cc21,2020
Inhibition of C-terminal Avi-tagged biotinylated KRas G12D mutant (1 to 169 residues) (unknown origin) expressed in Escherichia coli assessed as reduction in KRas G12D mutant-SOS1 (564 to 1049 residues) protein-protein interaction incubated for 60 mins by TR-FRET LANCE assay,O=C1N[C@H](c2c(CNCc3ccc4ccn(Cc5ccccc5)c4c3)[nH]c3ccccc23)c2cc(O)ccc21,CHEMBL4673313,=,=,IC50,nM,870.0,IC50,uM,0.87,O=C1N[C@H](c2c(CNCc3ccc4ccn(Cc5ccccc5)c4c3)[nH]c3ccccc23)c2cc(O)ccc21,2020
Binding affinity to GTP-KRAS G12D (unknown origin) by isothermal titration calorimetry,Cn1cnc(Cn2ccc3ccc(CNCc4[nH]c5ccccc5c4[C@H]4NC(=O)c5ccc(O)cc54)cc32)c1,CHEMBL4673313,=,=,Kd,nM,750.0,Kd,uM,0.75,Cn1cnc(Cn2ccc3ccc(CNCc4[nH]c5ccccc5c4[C@H]4NC(=O)c5ccc(O)cc54)cc32)c1,2020
Inhibition of N-terminal 6His-tagged/C-terminal Avi-tagged biotinylated GDP-bound human KRas G12D mutant (1 to 169 residues) assessed as reduction in KRas G12D mutant-SOS1 (564 to 1049 residues) protein-protein interaction by alpha screen assay,Cn1cnc(Cn2ccc3ccc(CNCc4[nH]c5ccccc5c4[C@H]4NC(=O)c5ccc(O)cc54)cc32)c1,CHEMBL4673313,=,=,IC50,nM,450.0,IC50,uM,0.45,Cn1cnc(Cn2ccc3ccc(CNCc4[nH]c5ccccc5c4[C@H]4NC(=O)c5ccc(O)cc54)cc32)c1,2020
Binding affinity to GST-tagged GppNHp bound KRas G12V mutant (unknown origin) expressed in Escherichia coli C41(DE3) by 1H-CPMG NMR spectroscopy,COc1nc(-c2cccc3c2OCCO3)ccc1Nc1ccc(CN(C)C)cc1,CHEMBL4673313,=,=,Kd,nM,51.0,Kd,nM,51.0,COc1nc(-c2cccc3c2OCCO3)ccc1Nc1ccc(CN(C)C)cc1,2020
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in p-ERK levels,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1,CHEMBL4699491,=,=,IC50,nM,30.0,IC50,uM,0.03,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1,2020
Inhibition of KRAS G12C mutant in human MIA PaCa-2 cells assessed as reduction in p-ERK levels,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,CHEMBL4699491,=,=,IC50,nM,10.0,IC50,uM,0.01,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,2020
Binding affinity to human KRAS G12D mutant (1 to 169 residues) expressed in Escherichia coli BL21(DE3) by HSQC NMR spectroscopy,c1ccc2c(Cc3nc4ccncc4[nH]3)c[nH]c2c1,CHEMBL4699657,=,=,Kd,nM,1200000.0,Kd,uM,1200.0,c1ccc2c(Cc3nc4ccncc4[nH]3)c[nH]c2c1,2020
Binding affinity to human GCP-KRAS G12D mutant (1 to 169 residues) expressed in Escherichia coli BL21(DE3) by isothermal titration calorimetry assay,Cn1cnc(Cn2ccc3ccc(CNCc4[nH]c5ccccc5c4[C@H]4NC(=O)c5ccc(O)cc54)cc32)c1,CHEMBL4699657,=,=,Kd,nM,750.0,Kd,uM,0.75,Cn1cnc(Cn2ccc3ccc(CNCc4[nH]c5ccccc5c4[C@H]4NC(=O)c5ccc(O)cc54)cc32)c1,2020
"Covalent binding affinity to KRAS G12C mutant at Cys12 residue in human NCI-H358 cells assessed as reduction of log2 H/L ratio for tryptic peptide LVVVGACGVGK at 2 uM incubated for 4 hrs followed by cell lysis and subsequently labelled with light thiol probe N-((S)-18-iodo-11-isopropyl-10,13,17-trioxo-3,6-dioxa-9,12,16-triazaoctadecyl)-6-((4R,5S)-5-methyl-2-oxoimidazolidin-4-yl)hexanamide and heavy thiol probe 4 for 1 hr under dark conditions followed by tryptic digestion for overnight and measured by discovery ABPP based nano LC-MS/MS analysis",C=CC(=O)N1CCN(c2ncnc3c(F)c(-c4c(O)cccc4F)c(Cl)cc23)CC1,CHEMBL4715824,,,Activity,,,Activity,,,C=CC(=O)N1CCN(c2ncnc3c(F)c(-c4c(O)cccc4F)c(Cl)cc23)CC1,2018
"Covalent binding affinity to KRAS G12C mutant at Cys12 residue in human NCI-H358 cells assessed as log2 H/L ratio at 10 uM pretreated for 3 hrs followed by N-(((6S,7R)-7-(4-chloro-3-fluorophenyl)-1,4-oxazepan-6-yl)methyl)-2-hydroxyacetamide treatment for 3 hrs by competitive TMT click chemistry pull-down experiment based LC-MS/MS analysis",C=CC(=O)N1CCN(c2ncnc3c(F)c(-c4c(O)cccc4F)c(Cl)cc23)CC1,CHEMBL4715824,=,=,Ratio,,-1.8,Ratio,,-1.8,C=CC(=O)N1CCN(c2ncnc3c(F)c(-c4c(O)cccc4F)c(Cl)cc23)CC1,2018
"Covalent binding affinity to KRAS G12C mutant at Cys12 residue in human NCI-H358 cells assessed as reduction of log2 H/L ratio for tryptic peptide LVVVGACGVGK incubated for 4 hrs followed by cell lysis and subsequently labelled with light thiol probe N-((S)-18-iodo-11-isopropyl-10,13,17-trioxo-3,6-dioxa-9,12,16-triazaoctadecyl)-6-((4R,5S)-5-methyl-2-oxoimidazolidin-4-yl)hexanamide and heavy thiol probe 4 for 1 hr under dark conditions followed by tryptic digestion for overnight and measured by discovery ABPP based nano LC-MS/MS analysis",C=CC(=O)N1CCN(c2ncnc3c(F)c(-c4c(O)cccc4F)c(Cl)cc23)CC1,CHEMBL4715824,,,Inhibition,%,,INH,,,C=CC(=O)N1CCN(c2ncnc3c(F)c(-c4c(O)cccc4F)c(Cl)cc23)CC1,2018
"Covalent binding affinity to KRAS G12C mutant at Cys12 residue in human NCI-H358 cells assessed as reduction of log2 H/L ratio for tryptic peptide LVVVGACGVGK incubated for 4 hrs followed by cell lysis and subsequently labelled with light thiol probe N-((S)-18-iodo-11-isopropyl-10,13,17-trioxo-3,6-dioxa-9,12,16-triazaoctadecyl)-6-((4R,5S)-5-methyl-2-oxoimidazolidin-4-yl)hexanamide and heavy thiol probe 4 for 1 hr under dark conditions followed by tryptic digestion for overnight and measured by discovery ABPP based nano LC-MS/MS analysis",C=CC(=O)N1CCN(c2ncnc3c(F)c(-c4c(O)cccc4F)c(Cl)cc23)CC1,CHEMBL4715824,=,=,IC50,nM,1590.0,IC50,uM,1.59,C=CC(=O)N1CCN(c2ncnc3c(F)c(-c4c(O)cccc4F)c(Cl)cc23)CC1,2018
"Covalent binding affinity to KRAS G12C mutant at Cys12 residue in human NCI-H358 cells assessed as reduction of log2 H/L ratio for tryptic peptide LVVVGACGVGK incubated for 4 hrs followed by cell lysis and subsequently labelled with light thiol probe N-((S)-18-iodo-11-isopropyl-10,13,17-trioxo-3,6-dioxa-9,12,16-triazaoctadecyl)-6-((4R,5S)-5-methyl-2-oxoimidazolidin-4-yl)hexanamide and heavy thiol probe 4 for 1 hr under dark conditions followed by tryptic digestion for overnight and measured by ABPP target occupancy based UHPLC Q-SIM MS analysis",C=CC(=O)N1CCN(c2ncnc3c(F)c(-c4c(O)cccc4F)c(Cl)cc23)CC1,CHEMBL4715824,=,=,IC50,nM,1800.0,IC50,uM,1.8,C=CC(=O)N1CCN(c2ncnc3c(F)c(-c4c(O)cccc4F)c(Cl)cc23)CC1,2018
Covalent inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as loss of C12 tryptic peptide of KRAS G12C mutant measured after 6 hrs by LC-MS/MS analysis,C=CC(=O)N1CC(N2CCN(C(=O)CNc3cc(C4(C)CC4)c(Cl)cc3O)CC2)C1,CHEMBL4715824,=,=,IC50,nM,1600.0,IC50,uM,1.6,C=CC(=O)N1CC(N2CCN(C(=O)CNc3cc(C4(C)CC4)c(Cl)cc3O)CC2)C1,2018
Covalent inhibition of GDP bound HexaHis-TEV-tagged KRAS G12C mutant (1 to 169 residues) (unknown origin) expressed in Escherichia coli assessed as enzyme-compound adduct formation by measuring ratio of Kinact/Ki by LC-MS analysis,C=CC(=O)N1CC(N2CCN(C(=O)CNc3cc(C4(C)CC4)c(Cl)cc3O)CC2)C1,CHEMBL4715824,=,=,Ratio,/M/s,76.0,Ratio,/M/s,76.0,C=CC(=O)N1CC(N2CCN(C(=O)CNc3cc(C4(C)CC4)c(Cl)cc3O)CC2)C1,2018
Inhibition of KRAS in human U2OS cells assessed as inhibition in phosphorylation of ERK at 20 uM incubated for 15 mins by Western blot analysis,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C/CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(N)=O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC1=O,CHEMBL4725447,,,Inhibition,%,,INH,,,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C/CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(N)=O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC1=O,2020
Inhibition of KRAS in human U2OS cells assessed as inhibition in phosphorylation of ERK at 20 uM incubated for 15 mins by Western blot analysis,CCCC[C@H]1NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](CCC(N)=O)NC1=O,CHEMBL4725447,,,Activity,,,Activity,,,CCCC[C@H]1NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](CCC(N)=O)NC1=O,2020
Binding affinity to wild type KRAS (unknown origin) using FAM-labelled peptide as substrate in absence of Tween20 by fluorescence polarization assay,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C/CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(N)=O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC1=O,CHEMBL4725447,=,=,Kd,nM,430.0,Kd,nM,430.0,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C/CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(N)=O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC1=O,2020
Binding affinity to KRAS G12V mutant (unknown origin) by isothermal titration calorimetry,CCCC[C@H]1NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](CCC(N)=O)NC1=O,CHEMBL4725447,,,Activity,,,Activity,,,CCCC[C@H]1NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](CCC(N)=O)NC1=O,2020
Binding affinity to KRAS G12D mutant (unknown origin) using FAM-labelled peptide as substrate in absence of Tween20 by fluorescence polarization assay,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C/CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(N)=O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC1=O,CHEMBL4725447,=,=,Kd,nM,430.0,Kd,nM,430.0,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C/CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(N)=O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC1=O,2020
Binding affinity to KRAS G12D mutant (unknown origin) using FAM-labelled peptide as substrate in absence of Tween20 by fluorescence polarization assay,CC[C@H](C)[C@H](NC(=O)[C@]1(C)CCC/C=C/CCC[C@](C)(NC(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(N)=O)[C@@H](C)O,CHEMBL4725447,,,Activity,,,Activity,,,CC[C@H](C)[C@H](NC(=O)[C@]1(C)CCC/C=C/CCC[C@](C)(NC(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(N)=O)[C@@H](C)O,2020
Binding affinity to KRAS G12D mutant (unknown origin) upto 1 uM by surface plasmon resonance analysis,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C/CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(N)=O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC1=O,CHEMBL4725447,,,Activity,,,Activity,,,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C/CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(N)=O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC1=O,2020
Binding affinity to KRAS G12D mutant (unknown origin) upto 1 uM by surface plasmon resonance analysis,CCCC[C@H]1NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](CCC(N)=O)NC1=O,CHEMBL4725447,,,Activity,,,Activity,,,CCCC[C@H]1NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](CCC(N)=O)NC1=O,2020
Binding affinity to KRAS G12D mutant (unknown origin) upto 1 uM by surface plasmon resonance analysis,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4725447,,,Activity,,,Activity,,,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2020
Binding affinity to KRAS G12D mutant (unknown origin) by isothermal titration calorimetry,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C/CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(N)=O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC1=O,CHEMBL4725447,,,Activity,,,Activity,,,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C/CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(N)=O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC1=O,2020
Binding affinity to KRAS G12D mutant (unknown origin) by isothermal titration calorimetry,CCCC[C@H]1NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](CCC(N)=O)NC1=O,CHEMBL4725447,,,Activity,,,Activity,,,CCCC[C@H]1NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](CCC(N)=O)NC1=O,2020
Binding affinity to KRAS G12D mutant (unknown origin) assessed as dissociation constant by isothermal titration calorimetry,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4725447,=,=,Kd,nM,21.0,Kd,nM,21.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2020
Binding affinity to KRAS G12D mutant (unknown origin) assessed as change in melting temperature by SYPRO orange dye based thermal shift assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4725447,=,=,Delta Tm,degrees C,11.5,deltaTm,degrees C,11.5,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2020
Binding affinity to KRAS G12D mutant (unknown origin) assessed as change in melting temperature by SYPRO orange dye based thermal shift assay,CCCC[C@H]1NC(=O)[C@@H](Cc2ccc(F)cc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](C)NC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCC(N)=O)NC1=O,CHEMBL4725447,=,=,Delta Tm,degrees C,-5.9,deltaTm,degrees C,-5.9,CCCC[C@H]1NC(=O)[C@@H](Cc2ccc(F)cc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](C)NC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCC(N)=O)NC1=O,2020
Binding affinity to KRAS G12D mutant (unknown origin) assessed as absence in deuterium uptake by hydrogen/deuterium exchange/mass spectrometry,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C/CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(N)=O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC1=O,CHEMBL4725447,,,Activity,,,Activity,,,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C/CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(N)=O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC1=O,2020
Binding affinity to KRAS G12D mutant (unknown origin) assessed as absence in deuterium uptake by hydrogen/deuterium exchange/mass spectrometry,CCCC[C@H]1NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](CCC(N)=O)NC1=O,CHEMBL4725447,,,Activity,,,Activity,,,CCCC[C@H]1NC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](CCC(N)=O)NC1=O,2020
Binding affinity to KRAS G12D mutant (unknown origin) assessed as absence in deuterium uptake by hydrogen/deuterium exchange/mass spectrometry,CCCC[C@H]1NC(=O)[C@@H](Cc2ccc(F)cc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](C)NC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCC(N)=O)NC1=O,CHEMBL4725447,,,Activity,,,Activity,,,CCCC[C@H]1NC(=O)[C@@H](Cc2ccc(F)cc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](C)NC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCC(N)=O)NC1=O,2020
Binding affinity to KRAS G12D mutant (unknown origin) using FAM-labelled peptide as substrate in presence of Tween20 by fluorescence polarization assay,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C/CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(N)=O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC1=O,CHEMBL4725447,,,Activity,,,Activity,,,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C/CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(N)=O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC1=O,2020
Binding affinity to KRAS G12D mutant (unknown origin) using FAM-labelled peptide as substrate in presence of Tween20 by fluorescence polarization assay,CC[C@H](C)[C@H](NC(=O)[C@]1(C)CCC/C=C/CCC[C@](C)(NC(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(N)=O)[C@@H](C)O,CHEMBL4725447,,,Activity,,,Activity,,,CC[C@H](C)[C@H](NC(=O)[C@]1(C)CCC/C=C/CCC[C@](C)(NC(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(N)=O)[C@@H](C)O,2020
Binding affinity to KRAS G12D mutant (unknown origin) using FAM-labelled peptide as substrate in presence of Tween20 by fluorescence polarization assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4725447,=,=,Kd,nM,16.0,Kd,nM,16.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2020
Binding affinity to wild type KRAS (unknown origin) using FAM-labelled peptide as substrate in presence of Tween20 by fluorescence polarization assay,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C/CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(N)=O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC1=O,CHEMBL4725447,,,Activity,,,Activity,,,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C/CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(N)=O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC1=O,2020
Binding affinity to KRAS G12D mutant (unknown origin) in presence of FAM-labelled peptide at 1 uM by surface plasmon resonance analysis,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C/CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(N)=O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC1=O,CHEMBL4725447,,,Activity,,,Activity,,,CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)C(=O)N[C@@]1(C)CCC/C=C/CCC[C@@](C)(C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(N)=O)[C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC1=O,2020
Binding affinity to KRAS G12D mutant (unknown origin) in presence of FAM-labelled peptide at 1 uM by surface plasmon resonance analysis,CC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@]1(C)CCCCCC/C=C/CCC[C@@](C)(C(=O)N[C@H](CO)C(=O)N[C@H](C)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@@H](CC2CCC2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CCC(=O)O)NC1=O)[C@@H](C)O,CHEMBL4725447,,,Activity,,,Activity,,,CC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@]1(C)CCCCCC/C=C/CCC[C@@](C)(C(=O)N[C@H](CO)C(=O)N[C@H](C)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@@H](CC2CCC2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CCC(=O)O)NC1=O)[C@@H](C)O,2020
Binding affinity to KRAS G12D mutant (unknown origin) in presence of FAM-labelled peptide at 1 uM by surface plasmon resonance analysis,CC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NC(C)(C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NC(C)(C)C(=O)N[C@@H](CC(C)C)C(N)=O,CHEMBL4725447,,,Activity,,,Activity,,,CC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NC(C)(C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NC(C)(C)C(=O)N[C@@H](CC(C)C)C(N)=O,2020
Inhibition of KRAS G12C mutant (unknown origin),C=CC(=O)N1CCN2c3c(cnc4cc(-c5c(O)cccc5F)c(Cl)cc34)N(C)C(=O)[C@H]2C1,CHEMBL4732037,=,=,IC50,nM,150.0,IC50,nM,150.0,C=CC(=O)N1CCN2c3c(cnc4cc(-c5c(O)cccc5F)c(Cl)cc34)N(C)C(=O)[C@H]2C1,2021
Inhibition of KRAS G12C mutant (unknown origin),C=CC(=O)N1CCN2c3c(cnc4cc(-c5c(O)cccc5F)c(Cl)cc34)NC(=O)[C@H]2C1,CHEMBL4732037,=,=,IC50,nM,73.0,IC50,nM,73.0,C=CC(=O)N1CCN2c3c(cnc4cc(-c5c(O)cccc5F)c(Cl)cc34)NC(=O)[C@H]2C1,2021
Inhibition of KRAS G12C mutant (unknown origin),C=CC(=O)N1CCN2c3c(cnc4cc(-c5c(O)cccc5F)c(Cl)cc34)N(C)C[C@H]2C1,CHEMBL4732037,=,=,IC50,nM,132.0,IC50,nM,132.0,C=CC(=O)N1CCN2c3c(cnc4cc(-c5c(O)cccc5F)c(Cl)cc34)N(C)C[C@H]2C1,2021
Inhibition of KRAS G12C mutant (unknown origin),C=CC(=O)N1CCN2c3c(cnc4cc(-c5c(O)cccc5F)c(Cl)cc34)NC[C@H]2C1,CHEMBL4732037,=,=,IC50,nM,387.0,IC50,nM,387.0,C=CC(=O)N1CCN2c3c(cnc4cc(-c5c(O)cccc5F)c(Cl)cc34)NC[C@H]2C1,2021
Inhibition of recombinant human N-terminal His-tagged KRAS (2 to 185 residues) expressed in baculovirus infected Sf9 insect cells using GTP as substrate measured after 2 hrs by GTPase-glo assay,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1,CHEMBL4732119,>,>,IC50,nM,10000.0,IC50,uM,10.0,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1,2021
Inhibition of recombinant human N-terminal His-tagged KRAS (2 to 185 residues) expressed in baculovirus infected Sf9 insect cells using GTP as substrate measured after 2 hrs by GTPase-glo assay,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3c(F)c(-c4c(O)cccc4F)ncc23)[C@@H](C)C1,CHEMBL4732119,>,>,IC50,nM,10000.0,IC50,uM,10.0,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3c(F)c(-c4c(O)cccc4F)ncc23)[C@@H](C)C1,2021
Inhibition of recombinant human N-terminal His-tagged KRAS (2 to 185 residues) expressed in baculovirus infected Sf9 insect cells using GTP as substrate measured after 2 hrs by GTPase-glo assay,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3c(Cl)c(-c4c(O)cccc4F)ncc23)[C@@H](C)C1,CHEMBL4732119,>,>,IC50,nM,10000.0,IC50,uM,10.0,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3c(Cl)c(-c4c(O)cccc4F)ncc23)[C@@H](C)C1,2021
Inhibition of recombinant human N-terminal His-tagged KRAS (2 to 185 residues) expressed in baculovirus infected Sf9 insect cells using GTP as substrate measured after 2 hrs by GTPase-glo assay,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C(C)C)ncnc3C(C)C)c3c(Cl)c(-c4c(O)cccc4F)ncc23)[C@@H](C)C1,CHEMBL4732119,>,>,IC50,nM,10000.0,IC50,uM,10.0,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C(C)C)ncnc3C(C)C)c3c(Cl)c(-c4c(O)cccc4F)ncc23)[C@@H](C)C1,2021
Inhibition of recombinant human N-terminal His-tagged KRAS (2 to 185 residues) expressed in baculovirus infected Sf9 insect cells using GTP as substrate measured after 2 hrs by GTPase-glo assay,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C(C)C)ncnc3C(C)C)c3c(F)c(-c4c(O)cccc4F)ncc23)[C@@H](C)C1,CHEMBL4732119,>,>,IC50,nM,10000.0,IC50,uM,10.0,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C(C)C)ncnc3C(C)C)c3c(F)c(-c4c(O)cccc4F)ncc23)[C@@H](C)C1,2021
Inhibition of recombinant human N-terminal His-tagged KRAS (2 to 185 residues) expressed in baculovirus infected Sf9 insect cells using GTP as substrate measured after 2 hrs by GTPase-glo assay,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C(C)C)cccc3C(C)C)c3c(F)c(-c4c(O)cccc4F)ncc23)[C@@H](C)C1,CHEMBL4732119,>,>,IC50,nM,10000.0,IC50,uM,10.0,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C(C)C)cccc3C(C)C)c3c(F)c(-c4c(O)cccc4F)ncc23)[C@@H](C)C1,2021
Inhibition of recombinant human N-terminal His-tagged KRAS (2 to 185 residues) expressed in baculovirus infected Sf9 insect cells using GTP as substrate measured after 2 hrs by GTPase-glo assay,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3c(F)c(-c4c(O)cccc4F)ncc23)[C@@H](C)C1,CHEMBL4732119,>,>,IC50,nM,10000.0,IC50,uM,10.0,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3c(F)c(-c4c(O)cccc4F)ncc23)[C@@H](C)C1,2021
Inhibition of recombinant human N-terminal His-tagged KRAS (2 to 185 residues) expressed in baculovirus infected Sf9 insect cells using GTP as substrate measured after 2 hrs by GTPase-glo assay,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3c(F)c(-c4c(O)cccc4F)ncc23)[C@@H](C)C1,CHEMBL4732119,>,>,IC50,nM,10000.0,IC50,uM,10.0,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3c(F)c(-c4c(O)cccc4F)ncc23)[C@@H](C)C1,2021
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as down regulation of KRAS-GTP at 1 uM measured after 24 hrs by pull down assay,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1,CHEMBL4732119,,,Inhibition,%,,INH,,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1,2021
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as down regulation of KRAS-GTP at 1 uM measured after 24 hrs by pull down assay,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3c(F)c(-c4c(O)cccc4F)ncc23)[C@@H](C)C1,CHEMBL4732119,,,Inhibition,%,,INH,,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3c(F)c(-c4c(O)cccc4F)ncc23)[C@@H](C)C1,2021
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as upward shift of protein band migration measured after 6 hrs by Western blot analysis,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1,CHEMBL4732119,,,Inhibition,%,,INH,,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1,2021
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as upward shift of protein band migration measured after 6 hrs by Western blot analysis,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3c(F)c(-c4c(O)cccc4F)ncc23)[C@@H](C)C1,CHEMBL4732119,,,Inhibition,%,,INH,,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3c(F)c(-c4c(O)cccc4F)ncc23)[C@@H](C)C1,2021
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation measured after 6 hrs by Western blot analysis,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3c(F)c(-c4c(O)cccc4F)ncc23)[C@@H](C)C1,CHEMBL4732119,,,Inhibition,%,,INH,,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3c(F)c(-c4c(O)cccc4F)ncc23)[C@@H](C)C1,2021
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in AKT phosphorylation measured after 6 hrs by Western blot analysis,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3c(F)c(-c4c(O)cccc4F)ncc23)[C@@H](C)C1,CHEMBL4732119,,,Inhibition,%,,INH,,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3c(F)c(-c4c(O)cccc4F)ncc23)[C@@H](C)C1,2021
Inhibition of MEK1 (unknown origin) assessed as residual activity measured at 1 uM,Cc1nc(Nc2ncc(C(=O)Nc3c(C)csc3Cl)s2)cc(N2CCN(CCO)CC2)n1,CHEMBL4806967,>,>,Activity,%,75.0,Activity,%,75.0,Cc1nc(Nc2ncc(C(=O)Nc3c(C)csc3Cl)s2)cc(N2CCN(CCO)CC2)n1,2020
Inhibition of MEK1 (unknown origin) assessed as residual activity measured at 1 uM,Cc1nc(Nc2ncc(C(=O)Nc3c(Cl)ccnc3C)s2)cc(NN2CCN(CCO)CC2)n1,CHEMBL4806967,>,>,Activity,%,75.0,Activity,%,75.0,Cc1nc(Nc2ncc(C(=O)Nc3c(Cl)ccnc3C)s2)cc(NN2CCN(CCO)CC2)n1,2020
Inhibition of MEK1 (unknown origin) assessed as residual activity measured at 1 uM,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,CHEMBL4806967,>,>,Activity,%,75.0,Activity,%,75.0,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,2020
Inhibition of biotinylated KRAS G12C mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human recombinant SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,C=CC(=O)N1CCN(c2cc(C(=O)N[C@@H]3CCC[C@H]3N(C)C)nc3c2CCN(c2cccc4cccc(C)c24)C3)C[C@@H]1CC#N,CHEMBL4808238,=,=,IC50,nM,1.0,IC50,nM,1.0,C=CC(=O)N1CCN(c2cc(C(=O)N[C@@H]3CCC[C@H]3N(C)C)nc3c2CCN(c2cccc4cccc(C)c24)C3)C[C@@H]1CC#N,2021
Inhibition of biotinylated KRAS G12C mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human recombinant SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,C=CC(=O)N1CCN(c2cc(C(=O)N[C@H](C)CN3CC(C)(O)C3)nc3c2CCN(c2cccc4cccc(C)c24)C3)C[C@@H]1CC#N,CHEMBL4808238,=,=,IC50,nM,2.2,IC50,nM,2.2,C=CC(=O)N1CCN(c2cc(C(=O)N[C@H](C)CN3CC(C)(O)C3)nc3c2CCN(c2cccc4cccc(C)c24)C3)C[C@@H]1CC#N,2021
Inhibition of biotinylated KRAS G12C mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human recombinant SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,C=CC(=O)N1CCN(c2cc(C(=O)NC(C)CN3CCC(C)(O)C3)nc3c2CCN(c2cccc4cccc(C)c24)C3)C[C@@H]1CC#N,CHEMBL4808238,=,=,IC50,nM,6.2,IC50,nM,6.2,C=CC(=O)N1CCN(c2cc(C(=O)NC(C)CN3CCC(C)(O)C3)nc3c2CCN(c2cccc4cccc(C)c24)C3)C[C@@H]1CC#N,2021
Inhibition of biotinylated KRAS G12C mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human recombinant SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,C=CC(=O)N1CCN(c2cc(C(=O)NC(C)CN3CCC(C)(O)C3)nc3c2CCN(c2cccc4cccc(C)c24)C3)C[C@@H]1CC#N,CHEMBL4808238,=,=,IC50,nM,7.2,IC50,nM,7.2,C=CC(=O)N1CCN(c2cc(C(=O)NC(C)CN3CCC(C)(O)C3)nc3c2CCN(c2cccc4cccc(C)c24)C3)C[C@@H]1CC#N,2021
Inhibition of biotinylated KRAS G12C mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human recombinant SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,C=C(F)C(=O)N1CCN(c2cc(C(=O)NC(C)CN3CCC(C)(O)C3)nc3c2CCN(c2cccc4cccc(C)c24)C3)C[C@@H]1CC#N,CHEMBL4808238,=,=,IC50,nM,5.0,IC50,nM,5.0,C=C(F)C(=O)N1CCN(c2cc(C(=O)NC(C)CN3CCC(C)(O)C3)nc3c2CCN(c2cccc4cccc(C)c24)C3)C[C@@H]1CC#N,2021
Inhibition of biotinylated KRAS G12C mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human recombinant SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,C=C(F)C(=O)N1CCN(c2cc(C(=O)N[C@H](C)CN(C)C)nc3c2CCN(c2cccc4cccc(C)c24)C3)C[C@@H]1CC#N,CHEMBL4808238,=,=,IC50,nM,8.3,IC50,nM,8.3,C=C(F)C(=O)N1CCN(c2cc(C(=O)N[C@H](C)CN(C)C)nc3c2CCN(c2cccc4cccc(C)c24)C3)C[C@@H]1CC#N,2021
Inhibition of biotinylated KRAS G12C mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human recombinant SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,C=CC(=O)N1CCN(c2cc(C(=O)NCC3CCCN3C)nc3c2CCN(c2cccc4cccc(C)c24)C3)C[C@@H]1CC#N,CHEMBL4808238,=,=,IC50,nM,4.8,IC50,nM,4.8,C=CC(=O)N1CCN(c2cc(C(=O)NCC3CCCN3C)nc3c2CCN(c2cccc4cccc(C)c24)C3)C[C@@H]1CC#N,2021
Inhibition of biotinylated KRAS G12C mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human recombinant SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,C=CC(=O)N1CCN(c2cc(C(=O)N[C@H](C)CN(C)C)nc3c2CCN(c2c(Cl)c(C)cc4[nH]ncc24)C3)C[C@@H]1CC#N,CHEMBL4808238,=,=,IC50,nM,0.9,IC50,nM,0.9,C=CC(=O)N1CCN(c2cc(C(=O)N[C@H](C)CN(C)C)nc3c2CCN(c2c(Cl)c(C)cc4[nH]ncc24)C3)C[C@@H]1CC#N,2021
Inhibition of biotinylated KRAS G12C mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human recombinant SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,C=CC(=O)N1CCN(c2cc(C(=O)NC[C@H]3CCCN3)nc3c2CCN(c2cccc4cccc(C)c24)C3)C[C@@H]1CC#N,CHEMBL4808238,=,=,IC50,nM,6.2,IC50,nM,6.2,C=CC(=O)N1CCN(c2cc(C(=O)NC[C@H]3CCCN3)nc3c2CCN(c2cccc4cccc(C)c24)C3)C[C@@H]1CC#N,2021
Inhibition of biotinylated KRAS G12C mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human recombinant SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,C=CC(=O)N1CCN(c2cc(C(=O)NCC3CCCCN3)nc3c2CCN(c2cccc4cccc(C)c24)C3)C[C@@H]1CC#N,CHEMBL4808238,=,=,IC50,nM,8.3,IC50,nM,8.3,C=CC(=O)N1CCN(c2cc(C(=O)NCC3CCCCN3)nc3c2CCN(c2cccc4cccc(C)c24)C3)C[C@@H]1CC#N,2021
Inhibition of biotinylated KRAS G12C mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human recombinant SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,C=CC(=O)N1CCN(c2cc(C(=O)NC3(CC)CCNC3)nc3c2CCN(c2cccc4cccc(C)c24)C3)C[C@@H]1CC#N,CHEMBL4808238,=,=,IC50,nM,4.5,IC50,nM,4.5,C=CC(=O)N1CCN(c2cc(C(=O)NC3(CC)CCNC3)nc3c2CCN(c2cccc4cccc(C)c24)C3)C[C@@H]1CC#N,2021
Inhibition of biotinylated KRAS G12C mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human recombinant SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,C=CC(=O)N1CCN(c2cc(C(=O)NC3(C)CCCNC3)nc3c2CCN(c2cccc4cccc(C)c24)C3)C[C@@H]1CC#N,CHEMBL4808238,=,=,IC50,nM,5.4,IC50,nM,5.4,C=CC(=O)N1CCN(c2cc(C(=O)NC3(C)CCCNC3)nc3c2CCN(c2cccc4cccc(C)c24)C3)C[C@@H]1CC#N,2021
Inhibition of biotinylated KRAS G12C/C51S/C80L/C118S mutant (unknown origin) pretreated for 60 mins followed by recombinant SOS addition by SOS-catalyzed nucleotide exchange-based TR-FRET analysis,C=CC(=O)N1CCN(c2nc(=O)n3c4nc(c(F)cc24)-c2c(F)cccc2OCCCCc2ccnc(C(C)C)c2-3)[C@@H](C)C1,CHEMBL4823310,=,=,IC50,nM,2.4,IC50,nM,2.4,C=CC(=O)N1CCN(c2nc(=O)n3c4nc(c(F)cc24)-c2c(F)cccc2OCCCCc2ccnc(C(C)C)c2-3)[C@@H](C)C1,2021
Inhibition of biotinylated KRAS G12C/C51S/C80L/C118S mutant (unknown origin) pretreated for 60 mins followed by recombinant SOS addition by SOS-catalyzed nucleotide exchange-based TR-FRET analysis,C=CC(=O)N1C[C@H](C)N(c2nc(=O)n3c4nc(c(F)cc24)-c2c(F)cccc2OCCCCc2ccnc(C(C)C)c2-3)C[C@H]1C,CHEMBL4823310,=,=,IC50,nM,3.5,IC50,nM,3.5,C=CC(=O)N1C[C@H](C)N(c2nc(=O)n3c4nc(c(F)cc24)-c2c(F)cccc2OCCCCc2ccnc(C(C)C)c2-3)C[C@H]1C,2021
Inhibition of biotinylated KRAS G12C/C51S/C80L/C118S mutant (unknown origin) pretreated for 60 mins followed by recombinant SOS addition by SOS-catalyzed nucleotide exchange-based TR-FRET analysis,C=CC(=O)N1CCN(c2nc(=O)n3c4nc(c(F)cc24)-c2c(F)cccc2OCCCc2ccnc(C(C)C)c2-3)[C@@H](C)C1,CHEMBL4823310,=,=,IC50,nM,4.3,IC50,nM,4.3,C=CC(=O)N1CCN(c2nc(=O)n3c4nc(c(F)cc24)-c2c(F)cccc2OCCCc2ccnc(C(C)C)c2-3)[C@@H](C)C1,2021
Inhibition of biotinylated KRAS G12C/C51S/C80L/C118S mutant (unknown origin) pretreated for 60 mins followed by recombinant SOS addition by SOS-catalyzed nucleotide exchange-based TR-FRET analysis,C=CC(=O)N1C[C@H](C)N(c2nc(=O)n3c4nc(c(Cl)cc24)-c2c(F)ccc(F)c2OCCOc2ccnc(C(C)C)c2-3)C[C@H]1C,CHEMBL4823310,=,=,IC50,nM,1.1,IC50,nM,1.1,C=CC(=O)N1C[C@H](C)N(c2nc(=O)n3c4nc(c(Cl)cc24)-c2c(F)ccc(F)c2OCCOc2ccnc(C(C)C)c2-3)C[C@H]1C,2021
Inhibition of biotinylated KRAS G12C/C51S/C80L/C118S mutant (unknown origin) pretreated for 60 mins followed by recombinant SOS addition by SOS-catalyzed nucleotide exchange-based TR-FRET analysis,[2H]C1([2H])Oc2ccc(F)c(F)c2-c2nc3c(cc2Cl)c(N2C[C@@H](C)N(C(=O)C=C)C[C@@H]2C)nc(=O)n3-c2c(ccnc2C(C)C)OC1([2H])[2H],CHEMBL4823310,=,=,IC50,nM,0.51,IC50,nM,0.51,[2H]C1([2H])Oc2ccc(F)c(F)c2-c2nc3c(cc2Cl)c(N2C[C@@H](C)N(C(=O)C=C)C[C@@H]2C)nc(=O)n3-c2c(ccnc2C(C)C)OC1([2H])[2H],2021
Inhibition of biotinylated KRAS G12C/C51S/C80L/C118S mutant (unknown origin) pretreated for 60 mins followed by recombinant SOS addition by SOS-catalyzed nucleotide exchange-based TR-FRET analysis,C=CC(=O)N1C[C@H](C)N(c2nc(=O)n3c4nc(c(Cl)cc24)-c2c(F)cccc2OCC(F)(F)COc2ccnc(C(C)C)c2-3)C[C@H]1C,CHEMBL4823310,=,=,IC50,nM,0.91,IC50,nM,0.91,C=CC(=O)N1C[C@H](C)N(c2nc(=O)n3c4nc(c(Cl)cc24)-c2c(F)cccc2OCC(F)(F)COc2ccnc(C(C)C)c2-3)C[C@H]1C,2021
Inhibition of biotinylated KRAS G12C/C51S/C80L/C118S mutant (unknown origin) pretreated for 60 mins followed by recombinant SOS addition by SOS-catalyzed nucleotide exchange-based TR-FRET analysis,C=CC(=O)N1C[C@H](C)N(c2nc(=O)n3c4nc(c(Cl)cc24)-c2c(ccc(F)c2F)OCCCc2ncnc(C(C)C)c2-3)C[C@H]1C,CHEMBL4823310,=,=,IC50,nM,0.51,IC50,nM,0.51,C=CC(=O)N1C[C@H](C)N(c2nc(=O)n3c4nc(c(Cl)cc24)-c2c(ccc(F)c2F)OCCCc2ncnc(C(C)C)c2-3)C[C@H]1C,2021
Inhibition of biotinylated KRAS G12C/C51S/C80L/C118S mutant (unknown origin) pretreated for 60 mins followed by recombinant SOS addition by SOS-catalyzed nucleotide exchange-based TR-FRET analysis,C=CC(=O)N1C[C@H](C)N(c2nc(=O)n3c4nc(c(F)cc24)-c2c(F)cccc2OCCCc2ccnc(C(C)C)c2-3)C[C@H]1C,CHEMBL4823310,=,=,IC50,nM,1.7,IC50,nM,1.7,C=CC(=O)N1C[C@H](C)N(c2nc(=O)n3c4nc(c(F)cc24)-c2c(F)cccc2OCCCc2ccnc(C(C)C)c2-3)C[C@H]1C,2021
Inhibition of biotinylated KRAS G12C/C51S/C80L/C118S mutant (unknown origin) pretreated for 60 mins followed by recombinant SOS addition by SOS-catalyzed nucleotide exchange-based TR-FRET analysis,C=CC(=O)N1C[C@H](C)N(c2nc(=O)n3c4nc(c(F)cc24)-c2c(Cl)cccc2OCCCc2ccnc(C(C)C)c2-3)C[C@H]1C,CHEMBL4823310,=,=,IC50,nM,2.3,IC50,nM,2.3,C=CC(=O)N1C[C@H](C)N(c2nc(=O)n3c4nc(c(F)cc24)-c2c(Cl)cccc2OCCCc2ccnc(C(C)C)c2-3)C[C@H]1C,2021
Inhibition of biotinylated KRAS G12C/C51S/C80L/C118S mutant (unknown origin) pretreated for 60 mins followed by recombinant SOS addition by SOS-catalyzed nucleotide exchange-based TR-FRET analysis,C=CC(=O)N1C[C@H](C)N(c2nc(=O)n3c4nc(c(F)cc24)-c2c(ccc(F)c2F)OCCC(C)c2ccnc(C(C)C)c2-3)C[C@H]1C,CHEMBL4823310,=,=,IC50,nM,1.4,IC50,nM,1.4,C=CC(=O)N1C[C@H](C)N(c2nc(=O)n3c4nc(c(F)cc24)-c2c(ccc(F)c2F)OCCC(C)c2ccnc(C(C)C)c2-3)C[C@H]1C,2021
Inhibition of biotinylated KRAS G12C/C51S/C80L/C118S mutant (unknown origin) pretreated for 60 mins followed by recombinant SOS addition by SOS-catalyzed nucleotide exchange-based TR-FRET analysis,C=CC(=O)N1CCN(c2nc(=O)n3c4nc(c(Cl)cc24)-c2c(F)cccc2OCC(F)(F)CCc2ccnc(C(C)C)c2-3)[C@@H](C)C1,CHEMBL4823310,=,=,IC50,nM,0.56,IC50,nM,0.56,C=CC(=O)N1CCN(c2nc(=O)n3c4nc(c(Cl)cc24)-c2c(F)cccc2OCC(F)(F)CCc2ccnc(C(C)C)c2-3)[C@@H](C)C1,2021
Inhibition of biotinylated KRAS G12C/C51S/C80L/C118S mutant (unknown origin) pretreated for 60 mins followed by recombinant SOS addition by SOS-catalyzed nucleotide exchange-based TR-FRET analysis,C=CC(=O)N1C[C@H](C)N(c2nc(=O)n3c4nc(c(Cl)cc24)-c2c(F)cccc2OCCc2ccnc(C(C)C)c2-3)C[C@H]1C,CHEMBL4823310,=,=,IC50,nM,2.6,IC50,nM,2.6,C=CC(=O)N1C[C@H](C)N(c2nc(=O)n3c4nc(c(Cl)cc24)-c2c(F)cccc2OCCc2ccnc(C(C)C)c2-3)C[C@H]1C,2021
Binding affinity to KRAS G12C mutant (unknown origin) by traditional Western blot CETSA analysis,C=CC(=O)N1CCN(c2ncnc3c(F)c(-c4c(O)cccc4F)c(Cl)cc23)CC1,CHEMBL4825748,,,Activity,,,Activity,,,C=CC(=O)N1CCN(c2ncnc3c(F)c(-c4c(O)cccc4F)c(Cl)cc23)CC1,2021
Binding affinity to HiBiT-tagged KRAS G12C mutant in human NCI-H358 cells assessed as stabilization by measuring luminescence signal by BiTSA assay,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(F)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1,CHEMBL4825748,,,Activity,,,Activity,,,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(F)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1,2021
Binding affinity to HiBiT-tagged KRAS G12C mutant in human NCI-H358 cells assessed as stabilization by measuring remaining luminescence signal at 75 degC at 1 to 10 uM by BiTSA assay,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(F)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1,CHEMBL4825748,>,>,Activity,%,50.0,Activity,%,50.0,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(F)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1,2021
Binding affinity to HiBiT-tagged KRAS G12C mutant in human NCI-H358 cells assessed as stabilization by measuring luminescence signal by BiTSA-ITDR assay,C=CC(=O)N1CCN(c2ncnc3c(F)c(-c4c(O)cccc4F)c(Cl)cc23)CC1,CHEMBL4825748,,,Activity,,,Activity,,,C=CC(=O)N1CCN(c2ncnc3c(F)c(-c4c(O)cccc4F)c(Cl)cc23)CC1,2021
Inhibition of GDP-bound KRAS G12C mutant (1 to 169 residues) (unknown origin) assessed as inhibition of SOS-mediated nucleotide exchange pretreated with KRAS for 5 mins followed by incubation with SOS (564 to 1049 residues) and GTP for 30 mins and later incubated with GST-tagged cRAF (1 to 149 residues) for 10 mins by AlphaLISA assay,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2CCN(C(=O)C=O)C[C@@H]2C)c2cc(Cl)c(-c3ccccc3F)nc21,CHEMBL4825768,=,=,IC50,nM,610.0,IC50,uM,0.61,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2CCN(C(=O)C=O)C[C@@H]2C)c2cc(Cl)c(-c3ccccc3F)nc21,2021
Inhibition of GDP-bound KRAS G12C mutant (1 to 169 residues) (unknown origin) assessed as inhibition of SOS-mediated nucleotide exchange pretreated with KRAS for 5 mins followed by incubation with SOS (564 to 1049 residues) and GTP for 30 mins and later incubated with GST-tagged cRAF (1 to 149 residues) for 10 mins by AlphaLISA assay,COC(=O)/C=C/C(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4ccccc4F)c(Cl)cc23)[C@@H](C)C1,CHEMBL4825768,=,=,IC50,nM,95.0,IC50,uM,0.095,COC(=O)/C=C/C(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4ccccc4F)c(Cl)cc23)[C@@H](C)C1,2021
Inhibition of GDP-bound KRAS G12C mutant (1 to 169 residues) (unknown origin) assessed as inhibition of SOS-mediated nucleotide exchange pretreated with KRAS for 5 mins followed by incubation with SOS (564 to 1049 residues) and GTP for 30 mins and later incubated with GST-tagged cRAF (1 to 149 residues) for 10 mins by AlphaLISA assay,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2CCN(C(=O)[C@H]3CO3)C[C@@H]2C)c2cc(Cl)c(-c3ccccc3F)nc21,CHEMBL4825768,=,=,IC50,nM,3780.0,IC50,uM,3.78,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2CCN(C(=O)[C@H]3CO3)C[C@@H]2C)c2cc(Cl)c(-c3ccccc3F)nc21,2021
Inhibition of GDP-bound KRAS G12C mutant (1 to 169 residues) (unknown origin) assessed as inhibition of SOS-mediated nucleotide exchange pretreated with KRAS for 5 mins followed by incubation with SOS (564 to 1049 residues) and GTP for 30 mins and later incubated with GST-tagged cRAF (1 to 149 residues) for 10 mins by AlphaLISA assay,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2CCN(C(=O)C3OC3C)C[C@@H]2C)c2cc(Cl)c(-c3ccccc3F)nc21,CHEMBL4825768,=,=,IC50,nM,17800.0,IC50,uM,17.8,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2CCN(C(=O)C3OC3C)C[C@@H]2C)c2cc(Cl)c(-c3ccccc3F)nc21,2021
Inhibition of GDP-bound KRAS G12C mutant (1 to 169 residues) (unknown origin) assessed as inhibition of SOS-mediated nucleotide exchange pretreated with KRAS for 5 mins followed by incubation with SOS (564 to 1049 residues) and GTP for 30 mins and later incubated with GST-tagged cRAF (1 to 149 residues) for 10 mins by AlphaLISA assay,CCOC(=O)[C@@H]1O[C@H]1C(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4ccccc4F)c(Cl)cc23)[C@@H](C)C1,CHEMBL4825768,=,=,IC50,nM,216.0,IC50,uM,0.21600000000000003,CCOC(=O)[C@@H]1O[C@H]1C(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4ccccc4F)c(Cl)cc23)[C@@H](C)C1,2021
Inhibition of GDP-bound KRAS G12C mutant (1 to 169 residues) (unknown origin) assessed as inhibition of SOS-mediated nucleotide exchange pretreated with KRAS for 5 mins followed by incubation with SOS (564 to 1049 residues) and GTP for 30 mins and later incubated with GST-tagged cRAF (1 to 149 residues) for 10 mins by AlphaLISA assay,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2CCN(C(=O)[C@@H]3O[C@H]3CN3CCCCC3)C[C@@H]2C)c2cc(Cl)c(-c3ccccc3F)nc21,CHEMBL4825768,=,=,IC50,nM,1120.0,IC50,uM,1.12,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2CCN(C(=O)[C@@H]3O[C@H]3CN3CCCCC3)C[C@@H]2C)c2cc(Cl)c(-c3ccccc3F)nc21,2021
Inhibition of GDP-bound KRAS G12C mutant (1 to 169 residues) (unknown origin) assessed as inhibition of SOS-mediated nucleotide exchange pretreated with KRAS for 5 mins followed by incubation with SOS (564 to 1049 residues) and GTP for 30 mins and later incubated with GST-tagged cRAF (1 to 149 residues) for 10 mins by AlphaLISA assay,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2CCN(C(=O)[C@@H]3O[C@H]3CO)C[C@@H]2C)c2cc(Cl)c(-c3ccccc3F)nc21,CHEMBL4825768,=,=,IC50,nM,6260.0,IC50,uM,6.26,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2CCN(C(=O)[C@@H]3O[C@H]3CO)C[C@@H]2C)c2cc(Cl)c(-c3ccccc3F)nc21,2021
Inhibition of GDP-bound KRAS G12C mutant (1 to 169 residues) (unknown origin) assessed as inhibition of SOS-mediated nucleotide exchange pretreated with KRAS for 5 mins followed by incubation with SOS (564 to 1049 residues) and GTP for 30 mins and later incubated with GST-tagged cRAF (1 to 149 residues) for 10 mins by AlphaLISA assay,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2CC(NC(=O)C3CO3)C2)c2cc(Cl)c(-c3ccccc3F)nc21,CHEMBL4825768,=,=,IC50,nM,4410.0,IC50,uM,4.41,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2CC(NC(=O)C3CO3)C2)c2cc(Cl)c(-c3ccccc3F)nc21,2021
Inhibition of GDP-bound KRAS G12C mutant (1 to 169 residues) (unknown origin) assessed as inhibition of SOS-mediated nucleotide exchange pretreated with KRAS for 5 mins followed by incubation with SOS (564 to 1049 residues) and GTP for 30 mins and later incubated with GST-tagged cRAF (1 to 149 residues) for 10 mins by AlphaLISA assay,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N(C)C2CN(C(=O)C3CO3)C2)c2cc(Cl)c(-c3ccccc3F)nc21,CHEMBL4825768,=,=,IC50,nM,13800.0,IC50,uM,13.8,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N(C)C2CN(C(=O)C3CO3)C2)c2cc(Cl)c(-c3ccccc3F)nc21,2021
Inhibition of GDP-bound KRAS G12C mutant (1 to 169 residues) (unknown origin) assessed as inhibition of SOS-mediated nucleotide exchange pretreated with KRAS for 5 mins followed by incubation with SOS (564 to 1049 residues) and GTP for 30 mins and later incubated with GST-tagged cRAF (1 to 149 residues) for 10 mins by AlphaLISA assay,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2C[C@@H](C)N(C(=O)[C@H]3CO3)C[C@@H]2C)c2cc(Cl)c(-c3c(O)cccc3F)nc21,CHEMBL4825768,=,=,IC50,nM,653.0,IC50,uM,0.653,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2C[C@@H](C)N(C(=O)[C@H]3CO3)C[C@@H]2C)c2cc(Cl)c(-c3c(O)cccc3F)nc21,2021
Inhibition of GDP-bound KRAS G12C mutant (1 to 169 residues) (unknown origin) assessed as inhibition of SOS-mediated nucleotide exchange pretreated with KRAS for 5 mins followed by incubation with SOS (564 to 1049 residues) and GTP for 30 mins and later incubated with GST-tagged cRAF (1 to 149 residues) for 10 mins by AlphaLISA assay,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2C[C@@H](C)N(C(=O)[C@H]3CO3)C[C@@H]2C)c2cc(Cl)c(-c3c(N)cccc3F)nc21,CHEMBL4825768,=,=,IC50,nM,560.0,IC50,uM,0.56,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2C[C@@H](C)N(C(=O)[C@H]3CO3)C[C@@H]2C)c2cc(Cl)c(-c3c(N)cccc3F)nc21,2021
Inhibition of GDP-bound KRAS G12C mutant (1 to 169 residues) (unknown origin) assessed as inhibition of SOS-mediated nucleotide exchange pretreated with KRAS for 20 hrs followed by incubation with SOS (564 to 1049 residues) and GTP for 30 mins and later incubated with GST-tagged cRAF (1 to 149 residues) for 10 mins by AlphaLISA assay,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2CCN(C(=O)C=O)C[C@@H]2C)c2cc(Cl)c(-c3ccccc3F)nc21,CHEMBL4825768,=,=,IC50,nM,39.0,IC50,uM,0.039,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2CCN(C(=O)C=O)C[C@@H]2C)c2cc(Cl)c(-c3ccccc3F)nc21,2021
Inhibition of GDP-bound KRAS G12C mutant (1 to 169 residues) (unknown origin) assessed as inhibition of SOS-mediated nucleotide exchange pretreated with KRAS for 20 hrs followed by incubation with SOS (564 to 1049 residues) and GTP for 30 mins and later incubated with GST-tagged cRAF (1 to 149 residues) for 10 mins by AlphaLISA assay,COC(=O)/C=C/C(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4ccccc4F)c(Cl)cc23)[C@@H](C)C1,CHEMBL4825768,=,=,IC50,nM,26.0,IC50,uM,0.026000000000000002,COC(=O)/C=C/C(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4ccccc4F)c(Cl)cc23)[C@@H](C)C1,2021
Inhibition of GDP-bound KRAS G12C mutant (1 to 169 residues) (unknown origin) assessed as inhibition of SOS-mediated nucleotide exchange pretreated with KRAS for 20 hrs followed by incubation with SOS (564 to 1049 residues) and GTP for 30 mins and later incubated with GST-tagged cRAF (1 to 149 residues) for 10 mins by AlphaLISA assay,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2CCN(C(=O)[C@H]3CO3)C[C@@H]2C)c2cc(Cl)c(-c3ccccc3F)nc21,CHEMBL4825768,=,=,IC50,nM,27.0,IC50,uM,0.027000000000000003,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2CCN(C(=O)[C@H]3CO3)C[C@@H]2C)c2cc(Cl)c(-c3ccccc3F)nc21,2021
Inhibition of GDP-bound KRAS G12C mutant (1 to 169 residues) (unknown origin) assessed as inhibition of SOS-mediated nucleotide exchange pretreated with KRAS for 20 hrs followed by incubation with SOS (564 to 1049 residues) and GTP for 30 mins and later incubated with GST-tagged cRAF (1 to 149 residues) for 10 mins by AlphaLISA assay,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2CCN(C(=O)C3OC3C)C[C@@H]2C)c2cc(Cl)c(-c3ccccc3F)nc21,CHEMBL4825768,=,=,IC50,nM,96.0,IC50,uM,0.096,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2CCN(C(=O)C3OC3C)C[C@@H]2C)c2cc(Cl)c(-c3ccccc3F)nc21,2021
Inhibition of GDP-bound KRAS G12C mutant (1 to 169 residues) (unknown origin) assessed as inhibition of SOS-mediated nucleotide exchange pretreated with KRAS for 20 hrs followed by incubation with SOS (564 to 1049 residues) and GTP for 30 mins and later incubated with GST-tagged cRAF (1 to 149 residues) for 10 mins by AlphaLISA assay,CCOC(=O)[C@@H]1O[C@H]1C(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4ccccc4F)c(Cl)cc23)[C@@H](C)C1,CHEMBL4825768,=,=,IC50,nM,5.0,IC50,uM,0.005,CCOC(=O)[C@@H]1O[C@H]1C(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4ccccc4F)c(Cl)cc23)[C@@H](C)C1,2021
Inhibition of GDP-bound KRAS G12C mutant (1 to 169 residues) (unknown origin) assessed as inhibition of SOS-mediated nucleotide exchange pretreated with KRAS for 20 hrs followed by incubation with SOS (564 to 1049 residues) and GTP for 30 mins and later incubated with GST-tagged cRAF (1 to 149 residues) for 10 mins by AlphaLISA assay,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2CCN(C(=O)[C@@H]3O[C@H]3CN3CCCCC3)C[C@@H]2C)c2cc(Cl)c(-c3ccccc3F)nc21,CHEMBL4825768,=,=,IC50,nM,5.0,IC50,uM,0.005,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2CCN(C(=O)[C@@H]3O[C@H]3CN3CCCCC3)C[C@@H]2C)c2cc(Cl)c(-c3ccccc3F)nc21,2021
Inhibition of GDP-bound KRAS G12C mutant (1 to 169 residues) (unknown origin) assessed as inhibition of SOS-mediated nucleotide exchange pretreated with KRAS for 20 hrs followed by incubation with SOS (564 to 1049 residues) and GTP for 30 mins and later incubated with GST-tagged cRAF (1 to 149 residues) for 10 mins by AlphaLISA assay,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2CCN(C(=O)[C@@H]3O[C@H]3CO)C[C@@H]2C)c2cc(Cl)c(-c3ccccc3F)nc21,CHEMBL4825768,=,=,IC50,nM,64.0,IC50,uM,0.064,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2CCN(C(=O)[C@@H]3O[C@H]3CO)C[C@@H]2C)c2cc(Cl)c(-c3ccccc3F)nc21,2021
Inhibition of GDP-bound KRAS G12C mutant (1 to 169 residues) (unknown origin) assessed as inhibition of SOS-mediated nucleotide exchange pretreated with KRAS for 20 hrs followed by incubation with SOS (564 to 1049 residues) and GTP for 30 mins and later incubated with GST-tagged cRAF (1 to 149 residues) for 10 mins by AlphaLISA assay,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2CC(NC(=O)C3CO3)C2)c2cc(Cl)c(-c3ccccc3F)nc21,CHEMBL4825768,=,=,IC50,nM,18.0,IC50,uM,0.018000000000000002,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2CC(NC(=O)C3CO3)C2)c2cc(Cl)c(-c3ccccc3F)nc21,2021
Inhibition of GDP-bound KRAS G12C mutant (1 to 169 residues) (unknown origin) assessed as inhibition of SOS-mediated nucleotide exchange pretreated with KRAS for 20 hrs followed by incubation with SOS (564 to 1049 residues) and GTP for 30 mins and later incubated with GST-tagged cRAF (1 to 149 residues) for 10 mins by AlphaLISA assay,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N(C)C2CN(C(=O)C3CO3)C2)c2cc(Cl)c(-c3ccccc3F)nc21,CHEMBL4825768,=,=,IC50,nM,227.0,IC50,uM,0.22699999999999998,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N(C)C2CN(C(=O)C3CO3)C2)c2cc(Cl)c(-c3ccccc3F)nc21,2021
Inhibition of GDP-bound KRAS G12C mutant (1 to 169 residues) (unknown origin) assessed as inhibition of SOS-mediated nucleotide exchange pretreated with KRAS for 20 hrs followed by incubation with SOS (564 to 1049 residues) and GTP for 30 mins and later incubated with GST-tagged cRAF (1 to 149 residues) for 10 mins by AlphaLISA assay,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2C[C@@H](C)N(C(=O)[C@H]3CO3)C[C@@H]2C)c2cc(Cl)c(-c3c(O)cccc3F)nc21,CHEMBL4825768,=,=,IC50,nM,24.0,IC50,uM,0.024,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2C[C@@H](C)N(C(=O)[C@H]3CO3)C[C@@H]2C)c2cc(Cl)c(-c3c(O)cccc3F)nc21,2021
Inhibition of GDP-bound KRAS G12C mutant (1 to 169 residues) (unknown origin) assessed as inhibition of SOS-mediated nucleotide exchange pretreated with KRAS for 20 hrs followed by incubation with SOS (564 to 1049 residues) and GTP for 30 mins and later incubated with GST-tagged cRAF (1 to 149 residues) for 10 mins by AlphaLISA assay,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2C[C@@H](C)N(C(=O)[C@H]3CO3)C[C@@H]2C)c2cc(Cl)c(-c3c(N)cccc3F)nc21,CHEMBL4825768,=,=,IC50,nM,15.0,IC50,uM,0.015,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2C[C@@H](C)N(C(=O)[C@H]3CO3)C[C@@H]2C)c2cc(Cl)c(-c3c(N)cccc3F)nc21,2021
Inhibition of KRAS G12C mutant in human MIA PaCa-2 cells assessed as reduction in phosphorylated ERK1/2 level incubated for 2 hrs by MSD assay,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2CCN(C(=O)C=O)C[C@@H]2C)c2cc(Cl)c(-c3ccccc3F)nc21,CHEMBL4825768,=,=,IC50,nM,711.0,IC50,uM,0.711,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2CCN(C(=O)C=O)C[C@@H]2C)c2cc(Cl)c(-c3ccccc3F)nc21,2021
Inhibition of KRAS G12C mutant in human MIA PaCa-2 cells assessed as reduction in phosphorylated ERK1/2 level incubated for 2 hrs by MSD assay,COC(=O)/C=C/C(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4ccccc4F)c(Cl)cc23)[C@@H](C)C1,CHEMBL4825768,=,=,IC50,nM,61.0,IC50,uM,0.061,COC(=O)/C=C/C(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4ccccc4F)c(Cl)cc23)[C@@H](C)C1,2021
Inhibition of KRAS G12C mutant in human MIA PaCa-2 cells assessed as reduction in phosphorylated ERK1/2 level incubated for 2 hrs by MSD assay,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2CCN(C(=O)[C@H]3CO3)C[C@@H]2C)c2cc(Cl)c(-c3ccccc3F)nc21,CHEMBL4825768,,,IC50,,,IC50,,,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2CCN(C(=O)[C@H]3CO3)C[C@@H]2C)c2cc(Cl)c(-c3ccccc3F)nc21,2021
Inhibition of KRAS G12C mutant in human MIA PaCa-2 cells assessed as reduction in phosphorylated ERK1/2 level incubated for 2 hrs by MSD assay,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2CCN(C(=O)C3OC3C)C[C@@H]2C)c2cc(Cl)c(-c3ccccc3F)nc21,CHEMBL4825768,,,IC50,,,IC50,,,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2CCN(C(=O)C3OC3C)C[C@@H]2C)c2cc(Cl)c(-c3ccccc3F)nc21,2021
Inhibition of KRAS G12C mutant in human MIA PaCa-2 cells assessed as reduction in phosphorylated ERK1/2 level incubated for 2 hrs by MSD assay,CCOC(=O)[C@@H]1O[C@H]1C(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4ccccc4F)c(Cl)cc23)[C@@H](C)C1,CHEMBL4825768,=,=,IC50,nM,96.0,IC50,uM,0.096,CCOC(=O)[C@@H]1O[C@H]1C(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4ccccc4F)c(Cl)cc23)[C@@H](C)C1,2021
Inhibition of KRAS G12C mutant in human MIA PaCa-2 cells assessed as reduction in phosphorylated ERK1/2 level incubated for 2 hrs by MSD assay,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2CCN(C(=O)[C@@H]3O[C@H]3CN3CCCCC3)C[C@@H]2C)c2cc(Cl)c(-c3ccccc3F)nc21,CHEMBL4825768,,,IC50,,,IC50,,,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2CCN(C(=O)[C@@H]3O[C@H]3CN3CCCCC3)C[C@@H]2C)c2cc(Cl)c(-c3ccccc3F)nc21,2021
Inhibition of KRAS G12C mutant in human MIA PaCa-2 cells assessed as reduction in phosphorylated ERK1/2 level incubated for 2 hrs by MSD assay,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2CCN(C(=O)[C@@H]3O[C@H]3CO)C[C@@H]2C)c2cc(Cl)c(-c3ccccc3F)nc21,CHEMBL4825768,,,IC50,,,IC50,,,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2CCN(C(=O)[C@@H]3O[C@H]3CO)C[C@@H]2C)c2cc(Cl)c(-c3ccccc3F)nc21,2021
Inhibition of KRAS G12C mutant in human MIA PaCa-2 cells assessed as reduction in phosphorylated ERK1/2 level incubated for 2 hrs by MSD assay,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2CC(NC(=O)C3CO3)C2)c2cc(Cl)c(-c3ccccc3F)nc21,CHEMBL4825768,,,IC50,,,IC50,,,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2CC(NC(=O)C3CO3)C2)c2cc(Cl)c(-c3ccccc3F)nc21,2021
Inhibition of KRAS G12C mutant in human MIA PaCa-2 cells assessed as reduction in phosphorylated ERK1/2 level incubated for 2 hrs by MSD assay,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N(C)C2CN(C(=O)C3CO3)C2)c2cc(Cl)c(-c3ccccc3F)nc21,CHEMBL4825768,,,IC50,,,IC50,,,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N(C)C2CN(C(=O)C3CO3)C2)c2cc(Cl)c(-c3ccccc3F)nc21,2021
Inhibition of KRAS G12C mutant in human MIA PaCa-2 cells assessed as reduction in phosphorylated ERK1/2 level incubated for 2 hrs by MSD assay,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2C[C@@H](C)N(C(=O)[C@H]3CO3)C[C@@H]2C)c2cc(Cl)c(-c3c(O)cccc3F)nc21,CHEMBL4825768,,,IC50,,,IC50,,,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2C[C@@H](C)N(C(=O)[C@H]3CO3)C[C@@H]2C)c2cc(Cl)c(-c3c(O)cccc3F)nc21,2021
Inhibition of KRAS G12C mutant in human MIA PaCa-2 cells assessed as reduction in phosphorylated ERK1/2 level incubated for 2 hrs by MSD assay,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2C[C@@H](C)N(C(=O)[C@H]3CO3)C[C@@H]2C)c2cc(Cl)c(-c3c(N)cccc3F)nc21,CHEMBL4825768,,,IC50,,,IC50,,,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2C[C@@H](C)N(C(=O)[C@H]3CO3)C[C@@H]2C)c2cc(Cl)c(-c3c(N)cccc3F)nc21,2021
Binding affinity to GDP-bound KRAS G12D mutant (unknown origin) assessed as bound fraction at 100 uM incubated for 20 hrs by RF-MS analysis relative to control,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2CCN(C(=O)C=O)C[C@@H]2C)c2cc(Cl)c(-c3ccccc3F)nc21,CHEMBL4825768,,,Activity,,,Activity,,,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2CCN(C(=O)C=O)C[C@@H]2C)c2cc(Cl)c(-c3ccccc3F)nc21,2021
Binding affinity to GDP-bound KRAS G12D mutant (unknown origin) assessed as bound fraction at 100 uM incubated for 20 hrs by RF-MS analysis relative to control,COC(=O)/C=C/C(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4ccccc4F)c(Cl)cc23)[C@@H](C)C1,CHEMBL4825768,,,Activity,,,Activity,,,COC(=O)/C=C/C(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4ccccc4F)c(Cl)cc23)[C@@H](C)C1,2021
Binding affinity to GDP-bound KRAS G12D mutant (unknown origin) assessed as bound fraction at 100 uM incubated for 20 hrs by RF-MS analysis relative to control,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2CCN(C(=O)[C@H]3CO3)C[C@@H]2C)c2cc(Cl)c(-c3ccccc3F)nc21,CHEMBL4825768,=,=,Activity,%,3.4,Activity,%,3.4,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2CCN(C(=O)[C@H]3CO3)C[C@@H]2C)c2cc(Cl)c(-c3ccccc3F)nc21,2021
Binding affinity to GDP-bound KRAS G12D mutant (unknown origin) assessed as bound fraction at 100 uM incubated for 20 hrs by RF-MS analysis relative to control,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2CCN(C(=O)C3OC3C)C[C@@H]2C)c2cc(Cl)c(-c3ccccc3F)nc21,CHEMBL4825768,,,Activity,,,Activity,,,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2CCN(C(=O)C3OC3C)C[C@@H]2C)c2cc(Cl)c(-c3ccccc3F)nc21,2021
Binding affinity to GDP-bound KRAS G12D mutant (unknown origin) assessed as bound fraction at 100 uM incubated for 20 hrs by RF-MS analysis relative to control,CCOC(=O)[C@@H]1O[C@H]1C(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4ccccc4F)c(Cl)cc23)[C@@H](C)C1,CHEMBL4825768,=,=,Activity,%,3.4,Activity,%,3.4,CCOC(=O)[C@@H]1O[C@H]1C(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4ccccc4F)c(Cl)cc23)[C@@H](C)C1,2021
Binding affinity to GDP-bound KRAS G12D mutant (unknown origin) assessed as bound fraction at 100 uM incubated for 20 hrs by RF-MS analysis relative to control,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2CCN(C(=O)[C@@H]3O[C@H]3CN3CCCCC3)C[C@@H]2C)c2cc(Cl)c(-c3ccccc3F)nc21,CHEMBL4825768,,,Activity,,,Activity,,,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2CCN(C(=O)[C@@H]3O[C@H]3CN3CCCCC3)C[C@@H]2C)c2cc(Cl)c(-c3ccccc3F)nc21,2021
Binding affinity to GDP-bound KRAS G12D mutant (unknown origin) assessed as bound fraction at 100 uM incubated for 20 hrs by RF-MS analysis relative to control,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2CCN(C(=O)[C@@H]3O[C@H]3CO)C[C@@H]2C)c2cc(Cl)c(-c3ccccc3F)nc21,CHEMBL4825768,,,Activity,,,Activity,,,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2CCN(C(=O)[C@@H]3O[C@H]3CO)C[C@@H]2C)c2cc(Cl)c(-c3ccccc3F)nc21,2021
Binding affinity to GDP-bound KRAS G12D mutant (unknown origin) assessed as bound fraction at 100 uM incubated for 20 hrs by RF-MS analysis relative to control,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2CC(NC(=O)C3CO3)C2)c2cc(Cl)c(-c3ccccc3F)nc21,CHEMBL4825768,,,Activity,,,Activity,,,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2CC(NC(=O)C3CO3)C2)c2cc(Cl)c(-c3ccccc3F)nc21,2021
Binding affinity to GDP-bound KRAS G12D mutant (unknown origin) assessed as bound fraction at 100 uM incubated for 20 hrs by RF-MS analysis relative to control,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N(C)C2CN(C(=O)C3CO3)C2)c2cc(Cl)c(-c3ccccc3F)nc21,CHEMBL4825768,,,Activity,,,Activity,,,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N(C)C2CN(C(=O)C3CO3)C2)c2cc(Cl)c(-c3ccccc3F)nc21,2021
Binding affinity to GDP-bound KRAS G12D mutant (unknown origin) assessed as bound fraction at 100 uM incubated for 20 hrs by RF-MS analysis relative to control,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2C[C@@H](C)N(C(=O)[C@H]3CO3)C[C@@H]2C)c2cc(Cl)c(-c3c(O)cccc3F)nc21,CHEMBL4825768,=,=,Activity,%,8.1,Activity,%,8.1,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2C[C@@H](C)N(C(=O)[C@H]3CO3)C[C@@H]2C)c2cc(Cl)c(-c3c(O)cccc3F)nc21,2021
Binding affinity to GDP-bound KRAS G12D mutant (unknown origin) assessed as bound fraction at 100 uM incubated for 20 hrs by RF-MS analysis relative to control,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2C[C@@H](C)N(C(=O)[C@H]3CO3)C[C@@H]2C)c2cc(Cl)c(-c3c(N)cccc3F)nc21,CHEMBL4825768,=,=,Activity,%,15.8,Activity,%,15.8,Cc1ccnc(C(C)C)c1-n1c(=O)nc(N2C[C@@H](C)N(C(=O)[C@H]3CO3)C[C@@H]2C)c2cc(Cl)c(-c3c(N)cccc3F)nc21,2021
Inhibition of recombinant his-tagged KRAS G12D mutant (unknown origin) expressed in Escherichia coli BL21(DE3) assessed as inhibition of GDP-GTP exchange rate in presence of recombinant SOS1/GMPPNP incubated for 1 hr by BODIPY fluorescence assay,Oc1cc(N2CCc3c(nc(OCC4(CN5CC[C@@H](F)C5)CC4)nc3N3CC4CCC(C3)N4)C2)c2c(Br)cccc2c1,CHEMBL4834492,=,=,IC50,nM,1.5,IC50,nM,1.5,Oc1cc(N2CCc3c(nc(OCC4(CN5CC[C@@H](F)C5)CC4)nc3N3CC4CCC(C3)N4)C2)c2c(Br)cccc2c1,2021
Inhibition of recombinant his-tagged KRAS G12D mutant (unknown origin) expressed in Escherichia coli BL21(DE3) assessed as inhibition of GDP-GTP exchange rate in presence of recombinant SOS1/GMPPNP incubated for 1 hr by BODIPY fluorescence assay,Oc1cc(N2CCc3c(nc(OCC4(CN5CCOCC5)CC4)nc3N3CC4CCC(C3)N4)C2)c2c(Br)cccc2c1,CHEMBL4834492,=,=,IC50,nM,1.2,IC50,nM,1.2,Oc1cc(N2CCc3c(nc(OCC4(CN5CCOCC5)CC4)nc3N3CC4CCC(C3)N4)C2)c2c(Br)cccc2c1,2021
Inhibition of recombinant his-tagged KRAS G12D mutant (unknown origin) expressed in Escherichia coli BL21(DE3) assessed as inhibition of GDP-GTP exchange rate in presence of recombinant SOS1/GMPPNP incubated for 1 hr by BODIPY fluorescence assay,Cc1cccc2cc(O)cc(N3CCc4c(nc(OCC5(CN6CCOCC6)CC5)nc4N4CC5CCC(C4)N5)C3)c12,CHEMBL4834492,=,=,IC50,nM,3.2,IC50,nM,3.2,Cc1cccc2cc(O)cc(N3CCc4c(nc(OCC5(CN6CCOCC6)CC5)nc4N4CC5CCC(C4)N5)C3)c12,2021
Inhibition of recombinant his-tagged KRAS G12D mutant (unknown origin) expressed in Escherichia coli BL21(DE3) assessed as inhibition of GDP-GTP exchange rate in presence of recombinant SOS1/GMPPNP incubated for 1 hr by BODIPY fluorescence assay,CN(C)CC1(COc2nc3c(c(N4CC5CCC(C4)N5)n2)CCN(c2cc(O)cc4cccc(I)c24)C3)CC1,CHEMBL4834492,=,=,IC50,nM,0.7,IC50,nM,0.7,CN(C)CC1(COc2nc3c(c(N4CC5CCC(C4)N5)n2)CCN(c2cc(O)cc4cccc(I)c24)C3)CC1,2021
Inhibition of recombinant his-tagged KRAS G12D mutant (unknown origin) expressed in Escherichia coli BL21(DE3) assessed as inhibition of GDP-GTP exchange rate in presence of recombinant SOS1/GMPPNP incubated for 1 hr by BODIPY fluorescence assay,Oc1cc(N2CCc3c(nc(OCC4(CN5CC[C@@H](F)C5)CC4)nc3N3CC4CCC(C3)N4)C2)c2c(I)cccc2c1,CHEMBL4834492,=,=,IC50,nM,0.9,IC50,nM,0.9,Oc1cc(N2CCc3c(nc(OCC4(CN5CC[C@@H](F)C5)CC4)nc3N3CC4CCC(C3)N4)C2)c2c(I)cccc2c1,2021
Inhibition of recombinant his-tagged KRAS G12D mutant (unknown origin) expressed in Escherichia coli BL21(DE3) assessed as inhibition of GDP-GTP exchange rate in presence of recombinant SOS1/GMPPNP incubated for 1 hr by BODIPY fluorescence assay,Oc1cc(N2CCc3c(nc(OCC4(CN5CCOCC5)CC4)nc3N3CC4CCC(C3)N4)C2)c2c(I)cccc2c1,CHEMBL4834492,=,=,IC50,nM,0.7,IC50,nM,0.7,Oc1cc(N2CCc3c(nc(OCC4(CN5CCOCC5)CC4)nc3N3CC4CCC(C3)N4)C2)c2c(I)cccc2c1,2021
Inhibition of recombinant his-tagged KRAS G12D mutant (unknown origin) expressed in Escherichia coli BL21(DE3) assessed as inhibition of GDP-GTP exchange rate in presence of recombinant SOS1/GMPPNP incubated for 1 hr by BODIPY fluorescence assay,CN(C)CC1(COc2nc(N3CC4CCC(C3)N4)c3cc(F)c(-c4cc(O)cc5ccccc45)c(F)c3n2)CC1,CHEMBL4834492,=,=,IC50,nM,5.1,IC50,nM,5.1,CN(C)CC1(COc2nc(N3CC4CCC(C3)N4)c3cc(F)c(-c4cc(O)cc5ccccc45)c(F)c3n2)CC1,2021
Inhibition of recombinant his-tagged KRAS G12D mutant (unknown origin) expressed in Escherichia coli BL21(DE3) assessed as inhibition of GDP-GTP exchange rate in presence of recombinant SOS1/GMPPNP incubated for 1 hr by BODIPY fluorescence assay,CN(C)CC1(COc2nc3c(c(N4CC5CCC(C4)N5)n2)CCN(c2cc(O)cc4cccc(Br)c24)C3)CC1(F)F,CHEMBL4834492,=,=,IC50,nM,9.7,IC50,nM,9.7,CN(C)CC1(COc2nc3c(c(N4CC5CCC(C4)N5)n2)CCN(c2cc(O)cc4cccc(Br)c24)C3)CC1(F)F,2021
Inhibition of recombinant his-tagged KRAS G12D mutant (unknown origin) expressed in Escherichia coli BL21(DE3) assessed as inhibition of GDP-GTP exchange rate in presence of recombinant SOS1/GMPPNP incubated for 1 hr by BODIPY fluorescence assay,CN1C[C@H](F)C[C@H]1COc1nc2c(c(N3CC4CCC(C3)N4)n1)CCN(c1cc(O)cc3cccc(Br)c13)C2,CHEMBL4834492,=,=,IC50,nM,18.5,IC50,nM,18.5,CN1C[C@H](F)C[C@H]1COc1nc2c(c(N3CC4CCC(C3)N4)n1)CCN(c1cc(O)cc3cccc(Br)c13)C2,2021
Binding affinity to GTP-bound K-Ras G12V mutant (1 to 185 residues) (unknown origin) expressed in Escherichia coli BL21 cells incubated for 2.5 hrs by fluorescence anisotropy,CC(C)[C@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC1=O,CHEMBL4842360,=,=,Kd,nM,1200.0,Kd,uM,1.2,CC(C)[C@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC1=O,2021
Binding affinity to GppNHp-bound K-Ras G12V mutant (1 to 185 residues) (unknown origin) expressed in Escherichia coli BL21 cells incubated for 2.5 hrs by fluorescence anisotropy,CC(C)[C@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC1=O,CHEMBL4842360,=,=,Kd,nM,1600.0,Kd,uM,1.6,CC(C)[C@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC1=O,2021
Binding affinity to GDP-bound K-Ras G12V mutant (1 to 185 residues) (unknown origin) expressed in Escherichia coli BL21 cells incubated for 2.5 hrs by fluorescence anisotropy,CC(C)[C@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC1=O,CHEMBL4842360,=,=,Kd,nM,9300.0,Kd,uM,9.3,CC(C)[C@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC1=O,2021
Displacement of BODIPY-FL-GD from human KRAS G12D (Met1 to Lys169 residues) incubated for over 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4842360,=,=,Kd,nM,1.6,Kd,nM,1.6,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2021
Displacement of BODIPY-FL-GD from human KRAS G12C (Met1 to Lys169 residues) incubated for over 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4842360,=,=,Kd,nM,18.0,Kd,nM,18.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2021
Displacement of BODIPY-FL-GD from human wild type KRAS (Met1 to Lys169 residues) incubated for over 1 hr by TR-FRET assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL4842360,=,=,Kd,nM,42.0,Kd,nM,42.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2021
Inhibition of GPPNP bound KRAS G12V mutant (unknown origin) assessed as reduction in KRAS/GST-fused Raf RBD interaction incubated for 2 hrs by HTRF assay,CC[C@@H](C)[C@@H]1NC(=O)[C@H](Cc2cn(CCc3c(C)[nH]c4cc(Cl)cc(Cl)c34)nn2)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](C)NC(=O)c2cc3cc(c2)C(=O)NC[C@@H](C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccc4ccccc4c2)NC(=O)[C@H](Cc2ccccc2)NC(=O)C(CCCCNC3=O)NC(=O)[C@H](CC(=O)O)NC1=O,CHEMBL4842360,=,=,IC50,nM,3400.0,IC50,uM,3.4,CC[C@@H](C)[C@@H]1NC(=O)[C@H](Cc2cn(CCc3c(C)[nH]c4cc(Cl)cc(Cl)c34)nn2)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](C)NC(=O)c2cc3cc(c2)C(=O)NC[C@@H](C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc2ccc4ccccc4c2)NC(=O)[C@H](Cc2ccccc2)NC(=O)C(CCCCNC3=O)NC(=O)[C@H](CC(=O)O)NC1=O,2021
Binding affinity to recombinant human KRAS G12D mutant incubated for 0.5 hrs by ELISA,CCCCCCC[C@@H]1NC(=O)[C@@H]2CSCCCSC[C@H](NC(=O)[C@H](Cc3c[nH]c4ccccc34)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc3ccc(F)cc3)NC(=O)[C@H](CO)NC1=O)C(=O)NCCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCC)C(=O)N2,CHEMBL4842360,=,=,Kd,nM,22.0,Kd,nM,22.0,CCCCCCC[C@@H]1NC(=O)[C@@H]2CSCCCSC[C@H](NC(=O)[C@H](Cc3c[nH]c4ccccc34)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc3ccc(F)cc3)NC(=O)[C@H](CO)NC1=O)C(=O)NCCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCC)C(=O)N2,2021
Binding affinity to GppNHp bound His6-tagged KRas G12V mutant (1 to 186 residues) (unknown origin) expressed in Escherichia coli BL21(DE3) cells,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)NCCC(=O)NCCC(=O)NC(CCCCN)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,CHEMBL4842360,=,=,Kd,nM,140.0,Kd,uM,0.14,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)NCCC(=O)NCCC(=O)NC(CCCCN)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,CHEMBL4842360,=,=,IC50,nM,690.0,IC50,uM,0.69,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)NCCC(=O)NCCC(=O)NC(CCCCN)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,CHEMBL4842360,=,=,IC50,nM,4.4,IC50,nM,4.4,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)NCCC(=O)NCCC(=O)NC(CCCCN)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,CC(C)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](Cc1ccc(O)cc1)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](C)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(=O)N[C@@H](CCCCN)C(N)=O,CHEMBL4842360,,,IC50,,,IC50,,,CC(C)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](Cc1ccc(O)cc1)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](C)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(=O)N[C@@H](CCCCN)C(N)=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N2CCC[C@@H]2C(=O)N[C@H](Cc2ccc(O)cc2)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,CHEMBL4842360,=,=,IC50,nM,5800.0,IC50,uM,5.8,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N2CCC[C@@H]2C(=O)N[C@H](Cc2ccc(O)cc2)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](C(=O)N[C@@H](CO)C(=O)N2CCC[C@@H]2C(=O)N2CCCC[C@@H]2C(=O)N[C@@H](CCCCN)C(N)=O)[C@H](C)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,CHEMBL4842360,=,=,IC50,nM,8000.0,IC50,uM,8.0,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](C(=O)N[C@@H](CO)C(=O)N2CCC[C@@H]2C(=O)N2CCCC[C@@H]2C(=O)N[C@@H](CCCCN)C(N)=O)[C@H](C)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCN)CC(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccc(F)cc2)C(=O)N[C@H](C)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,CHEMBL4842360,=,=,IC50,nM,1700.0,IC50,uM,1.7,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCN)CC(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccc(F)cc2)C(=O)N[C@H](C)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](C(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(N)=O)[C@H](C)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,CHEMBL4842360,=,=,IC50,nM,6900.0,IC50,uM,6.9,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](C(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(N)=O)[C@H](C)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,CC[C@H](C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](C)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(N)=O,CHEMBL4842360,=,=,IC50,nM,9700.0,IC50,uM,9.7,CC[C@H](C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](C)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(N)=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,CC(C)C[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](C)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(N)=O,CHEMBL4842360,=,=,IC50,nM,1700.0,IC50,uM,1.7,CC(C)C[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](C)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(N)=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,CC(C)C[C@@H](NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](C)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(=O)N[C@@H](CO)C(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](CCCNC(=N)N)C(N)=O,CHEMBL4842360,=,=,IC50,nM,18000.0,IC50,uM,18.0,CC(C)C[C@@H](NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](C)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(=O)N[C@@H](CO)C(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](CCCNC(=N)N)C(N)=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,CC(C)[C@@H](NC(=O)C[C@@H](CC(N)=O)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](C)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(=O)N[C@H](C)CC(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)NCCC(N)=O,CHEMBL4842360,,,IC50,,,IC50,,,CC(C)[C@@H](NC(=O)C[C@@H](CC(N)=O)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](C)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(=O)N[C@H](C)CC(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)NCCC(N)=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N2CCC[C@@H]2C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@H](Cc2ccc(O)cc2)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,CHEMBL4842360,,,IC50,,,IC50,,,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N2CCC[C@@H]2C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@H](Cc2ccc(O)cc2)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,CCCC[C@H](NC(=O)CNC(=O)C[C@H](CCC)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](C)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(=O)N[C@H](CCCNC(=N)N)C(N)=O,CHEMBL4842360,=,=,IC50,nM,7200.0,IC50,uM,7.2,CCCC[C@H](NC(=O)CNC(=O)C[C@H](CCC)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](C)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(=O)N[C@H](CCCNC(=N)N)C(N)=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@H](NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](C)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(F)cc1)C(N)=O,CHEMBL4842360,=,=,IC50,nM,3100.0,IC50,uM,3.1,C[C@H](NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](C)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(F)cc1)C(N)=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@H](CC(=O)N[C@@H](Cc1ccc(F)cc1)C(N)=O)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)C[C@H](CCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](C)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1,CHEMBL4842360,=,=,IC50,nM,1700.0,IC50,uM,1.7,C[C@H](CC(=O)N[C@@H](Cc1ccc(F)cc1)C(N)=O)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)C[C@H](CCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](C)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@H](Cc2ccc(O)cc2)C(=O)N[C@H](CCC(=O)O)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,CHEMBL4842360,,,IC50,,,IC50,,,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@H](Cc2ccc(O)cc2)C(=O)N[C@H](CCC(=O)O)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,CC(C)[C@@H](NC(=O)C[C@H](CCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](C)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(=O)N[C@H](C)CC(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)NCCC(N)=O,CHEMBL4842360,=,=,IC50,nM,2900.0,IC50,uM,2.9,CC(C)[C@@H](NC(=O)C[C@H](CCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](C)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(=O)N[C@H](C)CC(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)NCCC(N)=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N2CCC[C@@H]2C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](Cc2ccc3ccccc3c2)C(=O)N[C@@H](CCC(=O)O)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,CHEMBL4842360,,,IC50,,,IC50,,,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N2CCC[C@@H]2C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](Cc2ccc3ccccc3c2)C(=O)N[C@@H](CCC(=O)O)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCN)CC(=O)N[C@H](CC(N)=O)C(=O)N[C@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(N)=O)[C@H](C)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,CHEMBL4842360,=,=,IC50,nM,5700.0,IC50,uM,5.7,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCN)CC(=O)N[C@H](CC(N)=O)C(=O)N[C@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(N)=O)[C@H](C)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccc(F)cc2)C(=O)N[C@H](C)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,CHEMBL4842360,=,=,IC50,nM,1700.0,IC50,uM,1.7,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccc(F)cc2)C(=O)N[C@H](C)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCN)CC(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccc(F)cc2)C(=O)N[C@H](C)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,CHEMBL4842360,=,=,IC50,nM,890.0,IC50,uM,0.89,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCN)CC(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccc(F)cc2)C(=O)N[C@H](C)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCN)CC(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccc(F)cc2)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,CHEMBL4842360,=,=,IC50,nM,700.0,IC50,uM,0.7,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCN)CC(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccc(F)cc2)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCN)CC(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccc(F)cc2)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,CHEMBL4842360,=,=,IC50,nM,550.0,IC50,uM,0.55,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCN)CC(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccc(F)cc2)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCN)CC(=O)N[C@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,CHEMBL4842360,=,=,IC50,nM,700.0,IC50,uM,0.7,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCN)CC(=O)N[C@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCCN)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,CHEMBL4842360,=,=,IC50,nM,1300.0,IC50,uM,1.3,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCCN)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCN)CC(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,CHEMBL4842360,=,=,IC50,nM,510.0,IC50,uM,0.51,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCN)CC(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCN)CC(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,CHEMBL4842360,=,=,IC50,nM,1100.0,IC50,uM,1.1,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCN)CC(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,CHEMBL4842360,=,=,IC50,nM,1000.0,IC50,uM,1.0,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,CHEMBL4842360,=,=,IC50,nM,700.0,IC50,uM,0.7,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCc2ccccc2)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,CHEMBL4842360,=,=,IC50,nM,770.0,IC50,uM,0.77,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCc2ccccc2)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,CHEMBL4842360,=,=,IC50,nM,2200.0,IC50,uM,2.2,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,CHEMBL4842360,=,=,IC50,nM,940.0,IC50,uM,0.94,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@H](C)C(N)=O)c2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,CHEMBL4842360,=,=,IC50,nM,760.0,IC50,uM,0.76,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@H](C)C(N)=O)c2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccc(F)c(F)c2)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,CHEMBL4842360,=,=,IC50,nM,500.0,IC50,uM,0.5,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccc(F)c(F)c2)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2cccc(Cl)c2)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,CHEMBL4842360,=,=,IC50,nM,330.0,IC50,uM,0.33,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2cccc(Cl)c2)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2cccnc2)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,CHEMBL4842360,=,=,IC50,nM,410.0,IC50,uM,0.41,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2cccnc2)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccc(F)cc2)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,CHEMBL4842360,=,=,IC50,nM,1100.0,IC50,uM,1.1,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccc(F)cc2)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CN)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccc(F)cc2)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,CHEMBL4842360,=,=,IC50,nM,1700.0,IC50,uM,1.7,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CN)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccc(F)cc2)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,CHEMBL4842360,=,=,IC50,nM,870.0,IC50,uM,0.87,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,CHEMBL4842360,=,=,IC50,nM,280.0,IC50,uM,0.28,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,CHEMBL4842360,=,=,IC50,nM,230.0,IC50,uM,0.23,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,CHEMBL4842360,=,=,IC50,nM,650.0,IC50,uM,0.65,C[C@@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](C)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,CHEMBL4842360,=,=,IC50,nM,520.0,IC50,uM,0.52,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](C)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,CC[C@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,CHEMBL4842360,=,=,IC50,nM,610.0,IC50,uM,0.61,CC[C@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,CC(C)C[C@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,CHEMBL4842360,=,=,IC50,nM,790.0,IC50,uM,0.79,CC(C)C[C@H]1NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC1=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@H](CO)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,CHEMBL4842360,=,=,IC50,nM,560.0,IC50,uM,0.56,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@H](CO)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@H](Cc2cnc[nH]2)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,CHEMBL4842360,=,=,IC50,nM,1000.0,IC50,uM,1.0,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@H](Cc2cnc[nH]2)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,CHEMBL4842360,=,=,IC50,nM,1200.0,IC50,uM,1.2,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@H](CCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,CHEMBL4842360,=,=,IC50,nM,830.0,IC50,uM,0.83,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@H](CCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2csc4ccccc24)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,CHEMBL4842360,=,=,IC50,nM,640.0,IC50,uM,0.64,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2csc4ccccc24)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@@H]1NC(=O)[C@H](CO)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)c2cc3cc(c2)C(=O)NC[C@@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CCCCNC3=O)NC(=O)[C@H](c2ccccc2)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC1=O,CHEMBL4842360,=,=,IC50,nM,710.0,IC50,uM,0.71,C[C@@H]1NC(=O)[C@H](CO)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(=O)c2cc3cc(c2)C(=O)NC[C@@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CCCCNC3=O)NC(=O)[C@H](c2ccccc2)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC1=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,CHEMBL4842360,=,=,IC50,nM,860.0,IC50,uM,0.86,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,CHEMBL4842360,=,=,IC50,nM,1300.0,IC50,uM,1.3,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](C[C@H](N)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,CHEMBL4842360,=,=,IC50,nM,1200.0,IC50,uM,1.2,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](C[C@H](N)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CCO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,CHEMBL4842360,=,=,IC50,nM,1000.0,IC50,uM,1.0,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CCO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2csc4ccccc24)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,CHEMBL4842360,=,=,IC50,nM,750.0,IC50,uM,0.75,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2csc4ccccc24)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccc(F)cc2)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,CHEMBL4842360,=,=,IC50,nM,550.0,IC50,uM,0.55,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccc(F)cc2)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2cccc(Cl)c2)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,CHEMBL4842360,=,=,IC50,nM,710.0,IC50,uM,0.71,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2cccc(Cl)c2)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,CHEMBL4842360,=,=,IC50,nM,560.0,IC50,uM,0.56,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@H](NC(=O)C[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,CHEMBL4842360,=,=,IC50,nM,710.0,IC50,uM,0.71,C[C@H](NC(=O)C[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,CC(C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,CHEMBL4842360,=,=,IC50,nM,610.0,IC50,uM,0.61,CC(C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,C[C@@H](O)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,CHEMBL4842360,=,=,IC50,nM,570.0,IC50,uM,0.57,C[C@@H](O)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,N=C(N)NCCC[C@@H]1NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](CO)C(N)=O)NC1=O,CHEMBL4842360,=,=,IC50,nM,750.0,IC50,uM,0.75,N=C(N)NCCC[C@@H]1NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](CO)C(N)=O)NC1=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,N=C(N)NCCC[C@@H]1NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](CC(N)=O)C(N)=O)NC1=O,CHEMBL4842360,=,=,IC50,nM,2200.0,IC50,uM,2.2,N=C(N)NCCC[C@@H]1NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](CC(N)=O)C(N)=O)NC1=O,2021
Inhibition of His6-tagged KRas G12V mutant (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as reduction in Ras/GST-fused Raf RBD interaction incubated for 1 hr by HTRF assay,N=C(N)NCCC[C@@H]1NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccccc2)C(=O)NCCC(N)=O)NC1=O,CHEMBL4842360,=,=,IC50,nM,1100.0,IC50,uM,1.1,N=C(N)NCCC[C@@H]1NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H]2CCCCNC(=O)c3cc(cc(c3)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc3ccc4ccccc4c3)C(=O)N[C@@H](c3ccccc3)C(=O)N2)C(=O)NC[C@@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccccc2)C(=O)NCCC(N)=O)NC1=O,2021
Binding affinity to GTPgammaS bound His6-tagged KRas G12V mutant (unknown origin) incubated for 1 hr by fluorescence polarization,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,CHEMBL4842360,=,=,Kd,nM,42.0,Kd,nM,42.0,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,2021
Binding affinity to GppNHp bound His6-tagged KRas G12V mutant (unknown origin) incubated for 1 hr by fluorescence polarization,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,CHEMBL4842360,=,=,Kd,nM,21.0,Kd,nM,21.0,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,2021
Binding affinity to GDP bound His6-tagged KRas G12V mutant (unknown origin) incubated for 1 hr by fluorescence polarization,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,CHEMBL4842360,=,=,Kd,nM,230.0,Kd,nM,230.0,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,2021
Binding affinity to GFP-fused KRas G12V mutant (unknown origin) expressed in MDCK assessed as colocalization with protein at interfaces of adjacent cells using tetramethylrhodamine labeled compound using at 5 uM incubated for 2 hrs by live-cell confocal microscopy,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,CHEMBL4842360,,,Activity,,,Activity,,,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,2021
Inhibition of KRas G12V mutant (unknown origin) expressed in HEK293T cells coexpressing GFP-fused CRAF RBD assessed as reduction in Ras-Raf interaction using coelenterazine 400a as substrate incubated for 20 hrs by BRET2 assay,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,CHEMBL4842360,,,Inhibition,%,,INH,,,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,2021
Inhibition of KRas G12D mutant (unknown origin) expressed in HEK293T cells coexpressing GFP-fused CRAF RBD assessed as reduction in Ras-Raf interaction using coelenterazine 400a as substrate incubated for 20 hrs by BRET2 assay,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,CHEMBL4842360,,,Inhibition,%,,INH,,,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,2021
Inhibition of KRas G12D mutant (unknown origin) expressed in HEK293T cells coexpressing GFP-fused CRAF RBD assessed as reduction in Ras-Raf interaction using coelenterazine 400a as substrate up to 15 uM incubated for 20 hrs by BRET2 assay,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,CHEMBL4842360,,,Inhibition,%,,INH,,,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,2021
Inhibition of KRas G12V mutant (unknown origin) expressed in HEK293T cells coexpressing GFP-fused CRAF RBD assessed as reduction in Ras-Raf interaction using coelenterazine 400a as substrate up to 15 uM incubated for 20 hrs by BRET2 assay,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,CHEMBL4842360,,,Inhibition,%,,INH,,,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,2021
Inhibition of KRas signaling in EGF-stimulated human NCI-H358 cells assessed as reduction in Akt phosphorylation at ser473 residue preincubated for 4 hrs followed by EGF stimulation and measured after 10 mins by Western blot analysis,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,CHEMBL4842360,=,=,IC50,nM,3000.0,IC50,uM,3.0,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,2021
Inhibition of KRas signaling in EGF-stimulated human NCI-H358 cells assessed as reduction in Akt phosphorylation at ser473 residue preincubated for 4 hrs followed by EGF stimulation and measured after 10 mins by Western blot analysis,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,CHEMBL4842360,,,Inhibition,%,,INH,,,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,2021
Inhibition of KRas signaling in EGF-stimulated human NCI-H358 cells assessed as reduction in Akt phosphorylation at thr308 residue preincubated for 4 hrs followed by EGF stimulation and measured after 10 mins by Western blot analysis,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,CHEMBL4842360,=,=,IC50,nM,3000.0,IC50,uM,3.0,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,2021
Inhibition of KRas signaling in EGF-stimulated human NCI-H358 cells assessed as reduction in Akt phosphorylation at thr308 residue preincubated for 4 hrs followed by EGF stimulation and measured after 10 mins by Western blot analysis,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,CHEMBL4842360,,,Inhibition,%,,INH,,,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,2021
Inhibition of KRas signaling in EGF-stimulated human NCI-H358 cells assessed as reduction in MEK phosphorylation preincubated for 4 hrs followed by EGF stimulation and measured after 10 mins by Western blot analysis,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,CHEMBL4842360,,,Inhibition,%,,INH,,,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,2021
Inhibition of KRas signaling in EGF-stimulated human NCI-H358 cells assessed as reduction in MEK phosphorylation preincubated for 4 hrs followed by EGF stimulation and measured after 10 mins by Western blot analysis,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,CHEMBL4842360,=,=,IC50,nM,3000.0,IC50,uM,3.0,C[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCN)NC(=O)[C@@H]1CNC(=O)c2cc3cc(c2)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](Cc2ccc4ccccc4c2)C(=O)N[C@@H](c2ccccc2)C(=O)N[C@@H](CCCCNC3=O)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1)C(N)=O,2021
Inhibition of GDP-loaded His-tagged KRAS G12C mutant (2 to 182 residues) (unknown origin) assessed as inhibition of SOS1-catalyzed nucleotide exchange preincubated for 1 hr followed by SOS1 addition measured after 1 hr by TR-FRET assay,C=CC(=O)N1CCN(c2c(C#N)c(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(N)c(Cl)cc(Cl)c4F)c(Cl)cc23)C[C@@H]1CC#N,CHEMBL4842392,=,=,IC50,nM,6.66,IC50,nM,6.66,C=CC(=O)N1CCN(c2c(C#N)c(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(N)c(Cl)cc(Cl)c4F)c(Cl)cc23)C[C@@H]1CC#N,2021
Inhibition of GDP-loaded His-tagged KRAS G12C mutant (2 to 182 residues) (unknown origin) assessed as inhibition of SOS1-catalyzed nucleotide exchange preincubated for 1 hr followed by SOS1 addition measured after 1 hr by TR-FRET assay,C=CC(=O)N1[C@H](C)CN(c2c(C#N)c(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(N)c(Cl)cc(Cl)c4F)c(Cl)cc23)C[C@@H]1C,CHEMBL4842392,=,=,IC50,nM,2.832,IC50,nM,2.832,C=CC(=O)N1[C@H](C)CN(c2c(C#N)c(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(N)c(Cl)cc(Cl)c4F)c(Cl)cc23)C[C@@H]1C,2021
Inhibition of GDP-loaded His-tagged KRAS G12C mutant (2 to 182 residues) (unknown origin) assessed as inhibition of SOS1-catalyzed nucleotide exchange preincubated for 1 hr followed by SOS1 addition measured after 1 hr by TR-FRET assay,C=CC(=O)N1CCN(c2c(C#N)c(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(N)c(Cl)cc(Cl)c4F)c(Cl)cc23)C[C@H]1C,CHEMBL4842392,=,=,IC50,nM,2.535,IC50,nM,2.535,C=CC(=O)N1CCN(c2c(C#N)c(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(N)c(Cl)cc(Cl)c4F)c(Cl)cc23)C[C@H]1C,2021
Inhibition of GDP-loaded His-tagged KRAS G12C mutant (2 to 182 residues) (unknown origin) assessed as inhibition of SOS1-catalyzed nucleotide exchange preincubated for 1 hr followed by SOS1 addition measured after 1 hr by TR-FRET assay,C=CC(=O)N1CCN(c2c(C#N)c(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(N)c(Cl)cc(Cl)c4F)c(Cl)cc23)CC1,CHEMBL4842392,=,=,IC50,nM,1.947,IC50,nM,1.9469999999999998,C=CC(=O)N1CCN(c2c(C#N)c(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(N)c(Cl)cc(Cl)c4F)c(Cl)cc23)CC1,2021
Inhibition of GDP-loaded His-tagged KRAS G12C mutant (2 to 182 residues) (unknown origin) assessed as inhibition of SOS1-catalyzed nucleotide exchange preincubated for 1 hr followed by SOS1 addition measured after 1 hr by TR-FRET assay,C=CC(=O)N1CCN(c2c(C#N)c(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(N)c(Cl)cc(Cl)c4F)c(Cl)cc23)CC1,CHEMBL4842392,=,=,IC50,nM,1.542,IC50,nM,1.5419999999999998,C=CC(=O)N1CCN(c2c(C#N)c(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(N)c(Cl)cc(Cl)c4F)c(Cl)cc23)CC1,2021
Inhibition of GDP-loaded His-tagged KRAS G12C mutant (2 to 182 residues) (unknown origin) assessed as inhibition of SOS1-catalyzed nucleotide exchange preincubated for 1 hr followed by SOS1 addition measured after 1 hr by TR-FRET assay,C=CC(=O)N1CCN(c2c(C#N)c(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(N)c(Cl)cc(Cl)c4F)c(Cl)cc23)CC1CC#N,CHEMBL4842392,=,=,IC50,nM,5.188,IC50,nM,5.188,C=CC(=O)N1CCN(c2c(C#N)c(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(N)c(Cl)cc(Cl)c4F)c(Cl)cc23)CC1CC#N,2021
Inhibition of GDP-loaded His-tagged KRAS G12C mutant (2 to 182 residues) (unknown origin) assessed as inhibition of SOS1-catalyzed nucleotide exchange preincubated for 1 hr followed by SOS1 addition measured after 1 hr by TR-FRET assay,C=CC(=O)N1CCN(c2c(C#N)c(=O)n(-c3c(C(C)C)ncnc3C(C)C)c3nc(-c4c(N)c(Cl)cc(Cl)c4F)c(Cl)cc23)CC1,CHEMBL4842392,=,=,IC50,nM,4.737,IC50,nM,4.737,C=CC(=O)N1CCN(c2c(C#N)c(=O)n(-c3c(C(C)C)ncnc3C(C)C)c3nc(-c4c(N)c(Cl)cc(Cl)c4F)c(Cl)cc23)CC1,2021
Inhibition of GDP-loaded His-tagged KRAS G12C mutant (2 to 182 residues) (unknown origin) assessed as inhibition of SOS1-catalyzed nucleotide exchange preincubated for 1 hr followed by SOS1 addition measured after 1 hr by TR-FRET assay,C=CC(=O)N1CCN(c2c(C#N)c(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4ccccc4F)c(Cl)cc23)CC1,CHEMBL4842392,=,=,IC50,nM,4.4,IC50,nM,4.4,C=CC(=O)N1CCN(c2c(C#N)c(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4ccccc4F)c(Cl)cc23)CC1,2021
Inhibition of GDP-loaded His-tagged KRAS G12C mutant (2 to 182 residues) (unknown origin) assessed as inhibition of SOS1-catalyzed nucleotide exchange preincubated for 1 hr followed by SOS1 addition measured after 1 hr by TR-FRET assay,C=CC(=O)N1CCN(c2c(C#N)c(=O)n(-c3c(C(C)C)ncnc3C(C)C)c3nc(-c4c(N)cccc4F)c(Cl)cc23)CC1,CHEMBL4842392,=,=,IC50,nM,2.77,IC50,nM,2.77,C=CC(=O)N1CCN(c2c(C#N)c(=O)n(-c3c(C(C)C)ncnc3C(C)C)c3nc(-c4c(N)cccc4F)c(Cl)cc23)CC1,2021
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 2 hrs by HTRF assay,C=CC(=O)N1CCN(c2c(C#N)c(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(N)c(Cl)cc(Cl)c4F)c(Cl)cc23)C[C@@H]1CC#N,CHEMBL4842392,=,=,IC50,nM,12.25,IC50,nM,12.25,C=CC(=O)N1CCN(c2c(C#N)c(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(N)c(Cl)cc(Cl)c4F)c(Cl)cc23)C[C@@H]1CC#N,2021
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 2 hrs by HTRF assay,C=CC(=O)N1[C@H](C)CN(c2c(C#N)c(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(N)c(Cl)cc(Cl)c4F)c(Cl)cc23)C[C@@H]1C,CHEMBL4842392,=,=,IC50,nM,38.11,IC50,nM,38.11,C=CC(=O)N1[C@H](C)CN(c2c(C#N)c(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(N)c(Cl)cc(Cl)c4F)c(Cl)cc23)C[C@@H]1C,2021
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 2 hrs by HTRF assay,C=CC(=O)N1CCN(c2c(C#N)c(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(N)c(Cl)cc(Cl)c4F)c(Cl)cc23)C[C@H]1C,CHEMBL4842392,=,=,IC50,nM,28.8,IC50,nM,28.8,C=CC(=O)N1CCN(c2c(C#N)c(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(N)c(Cl)cc(Cl)c4F)c(Cl)cc23)C[C@H]1C,2021
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 2 hrs by HTRF assay,C=CC(=O)N1CCN(c2c(C#N)c(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(N)c(Cl)cc(Cl)c4F)c(Cl)cc23)CC1,CHEMBL4842392,=,=,IC50,nM,10.36,IC50,nM,10.36,C=CC(=O)N1CCN(c2c(C#N)c(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(N)c(Cl)cc(Cl)c4F)c(Cl)cc23)CC1,2021
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 2 hrs by HTRF assay,C=CC(=O)N1CCN(c2c(C#N)c(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(N)c(Cl)cc(Cl)c4F)c(Cl)cc23)CC1,CHEMBL4842392,=,=,IC50,nM,11.69,IC50,nM,11.69,C=CC(=O)N1CCN(c2c(C#N)c(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(N)c(Cl)cc(Cl)c4F)c(Cl)cc23)CC1,2021
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 2 hrs by HTRF assay,C=CC(=O)N1CCN(c2c(C#N)c(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(N)c(Cl)cc(Cl)c4F)c(Cl)cc23)CC1CC#N,CHEMBL4842392,=,=,IC50,nM,14.92,IC50,nM,14.92,C=CC(=O)N1CCN(c2c(C#N)c(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(N)c(Cl)cc(Cl)c4F)c(Cl)cc23)CC1CC#N,2021
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 2 hrs by HTRF assay,C=CC(=O)N1CCN(c2c(C#N)c(=O)n(-c3c(C(C)C)ncnc3C(C)C)c3nc(-c4c(N)c(Cl)cc(Cl)c4F)c(Cl)cc23)CC1,CHEMBL4842392,=,=,IC50,nM,18.51,IC50,nM,18.51,C=CC(=O)N1CCN(c2c(C#N)c(=O)n(-c3c(C(C)C)ncnc3C(C)C)c3nc(-c4c(N)c(Cl)cc(Cl)c4F)c(Cl)cc23)CC1,2021
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 2 hrs by HTRF assay,C=CC(=O)N1CCN(c2c(C#N)c(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4ccccc4F)c(Cl)cc23)CC1,CHEMBL4842392,=,=,IC50,nM,29.9,IC50,nM,29.9,C=CC(=O)N1CCN(c2c(C#N)c(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4ccccc4F)c(Cl)cc23)CC1,2021
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 2 hrs by HTRF assay,C=CC(=O)N1CCN(c2c(C#N)c(=O)n(-c3c(C(C)C)ncnc3C(C)C)c3nc(-c4c(N)cccc4F)c(Cl)cc23)CC1,CHEMBL4842392,=,=,IC50,nM,20.1,IC50,nM,20.1,C=CC(=O)N1CCN(c2c(C#N)c(=O)n(-c3c(C(C)C)ncnc3C(C)C)c3nc(-c4c(N)cccc4F)c(Cl)cc23)CC1,2021
Displacement of Cy5-labelled tracer from biotinylated GDP-loaded human recombinant KRAS G12D mutant (1 to 169 residues) measured after 60 mins by TR-FRET assay,Oc1cc(-c2ncc3c(N4CC5CCC(C4)N5)nc(OCC45CCCN4CCC5)nc3c2F)c2c(Cl)cccc2c1,CHEMBL4842393,=,=,IC50,nM,0.4,IC50,nM,0.4,Oc1cc(-c2ncc3c(N4CC5CCC(C4)N5)nc(OCC45CCCN4CCC5)nc3c2F)c2c(Cl)cccc2c1,2021
Displacement of Cy5-labelled tracer from biotinylated GDP-loaded human recombinant KRAS G12D mutant (1 to 169 residues) measured after 60 mins by TR-FRET assay,C#Cc1cccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC56CCCN5CCC6)nc4c3F)c12,CHEMBL4842393,=,=,IC50,nM,0.3,IC50,nM,0.3,C#Cc1cccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC56CCCN5CCC6)nc4c3F)c12,2021
Displacement of Cy5-labelled tracer from biotinylated GDP-loaded human recombinant KRAS G12D mutant (1 to 169 residues) measured after 60 mins by TR-FRET assay,C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC56CCCN5CCC6)nc4c3F)c12,CHEMBL4842393,=,=,IC50,nM,0.6,IC50,nM,0.6,C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OCC56CCCN5CCC6)nc4c3F)c12,2021
Displacement of Cy5-labelled tracer from biotinylated GDP-loaded human recombinant KRAS G12D mutant (1 to 169 residues) measured after 60 mins by TR-FRET assay,C#Cc1cccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OC[C@@]56CCCN5C[C@H](F)C6)nc4c3F)c12,CHEMBL4842393,=,=,IC50,nM,0.4,IC50,nM,0.4,C#Cc1cccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OC[C@@]56CCCN5C[C@H](F)C6)nc4c3F)c12,2021
Displacement of Cy5-labelled tracer from biotinylated GDP-loaded human recombinant KRAS G12D mutant (1 to 169 residues) measured after 60 mins by TR-FRET assay,Oc1cc(-c2ncc3c(N4CC5CCC(C4)N5)nc(OCC45CCCN4CCC5)nc3c2F)c2c(Cl)c(F)ccc2c1,CHEMBL4842393,=,=,IC50,nM,0.5,IC50,nM,0.5,Oc1cc(-c2ncc3c(N4CC5CCC(C4)N5)nc(OCC45CCCN4CCC5)nc3c2F)c2c(Cl)c(F)ccc2c1,2021
Displacement of Cy5-labelled tracer from biotinylated GDP-loaded human recombinant KRAS G12D mutant (1 to 169 residues) measured after 60 mins by TR-FRET assay,Oc1cc(-c2ncc3c(N4CC5CCC(C4)N5)nc(OC[C@@]45CCCN4C[C@H](F)C5)nc3c2F)c2c(F)c(F)ccc2c1,CHEMBL4842393,=,=,IC50,nM,0.6,IC50,nM,0.6,Oc1cc(-c2ncc3c(N4CC5CCC(C4)N5)nc(OC[C@@]45CCCN4C[C@H](F)C5)nc3c2F)c2c(F)c(F)ccc2c1,2021
Displacement of Cy5-labelled tracer from biotinylated GDP-loaded human recombinant KRAS G12D mutant (1 to 169 residues) measured after 60 mins by TR-FRET assay,Oc1cc(-c2ncc3c(N4CC5CCC(C4)N5)nc(OC[C@@]45CCCN4C[C@H](F)C5)nc3c2F)c2c(Cl)cccc2c1,CHEMBL4842393,=,=,IC50,nM,0.2,IC50,nM,0.2,Oc1cc(-c2ncc3c(N4CC5CCC(C4)N5)nc(OC[C@@]45CCCN4C[C@H](F)C5)nc3c2F)c2c(Cl)cccc2c1,2021
Displacement of Cy5-labelled tracer from biotinylated GDP-loaded human recombinant KRAS G12D mutant (1 to 169 residues) measured after 60 mins by TR-FRET assay,C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OC[C@@]56CCCN5C[C@H](F)C6)nc4c3F)c12,CHEMBL4842393,=,=,IC50,nM,0.4,IC50,nM,0.4,C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OC[C@@]56CCCN5C[C@H](F)C6)nc4c3F)c12,2021
Displacement of Cy5-labelled tracer from biotinylated GDP-loaded human recombinant KRAS G12D mutant (1 to 169 residues) measured after 60 mins by TR-FRET assay,CCc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OC[C@@]56CCCN5C[C@H](F)C6)nc4c3F)c12,CHEMBL4842393,=,=,IC50,nM,0.8,IC50,nM,0.8,CCc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OC[C@@]56CCCN5C[C@H](F)C6)nc4c3F)c12,2021
Displacement of Cy5-labelled tracer from biotinylated GDP-loaded human recombinant KRAS G12D mutant (1 to 169 residues) measured after 60 mins by TR-FRET assay,Oc1cc(-c2ncc3c(N4CC5CCC(C4)N5)nc(OCC45CCCN4C(CF)CC5)nc3c2F)c2ccccc2c1,CHEMBL4842393,=,=,IC50,nM,0.1,IC50,nM,0.1,Oc1cc(-c2ncc3c(N4CC5CCC(C4)N5)nc(OCC45CCCN4C(CF)CC5)nc3c2F)c2ccccc2c1,2021
Displacement of Cy5-labelled tracer from biotinylated GDP-loaded human recombinant KRAS G12D mutant (1 to 169 residues) measured after 60 mins by TR-FRET assay,COC1CN2CCCC2(COc2nc(N3CC4CCC(C3)N4)c3cnc(-c4cc(O)cc5cccc(F)c45)c(F)c3n2)C1,CHEMBL4842393,=,=,IC50,nM,0.6,IC50,nM,0.6,COC1CN2CCCC2(COc2nc(N3CC4CCC(C3)N4)c3cnc(-c4cc(O)cc5cccc(F)c45)c(F)c3n2)C1,2021
Displacement of Cy5-labelled tracer from biotinylated GDP-loaded human recombinant KRAS G12D mutant (1 to 169 residues) measured after 60 mins by TR-FRET assay,Fc1c(-c2cccc3c2CC2CC32)ncc2c(N3CC4CCC(C3)N4)nc(OC[C@@]34CCCN3C[C@H](F)C4)nc12,CHEMBL4842393,=,=,IC50,nM,20.1,IC50,nM,20.1,Fc1c(-c2cccc3c2CC2CC32)ncc2c(N3CC4CCC(C3)N4)nc(OC[C@@]34CCCN3C[C@H](F)C4)nc12,2021
Inhibition of human KRAS G12C mutant incubated for 2 hrs by scintillation counter based covalent competition assay,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5C)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5029190,=,=,IC50,nM,17.0,IC50,uM,0.017,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5C)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
Inhibition of human KRAS G12C mutant incubated for 2 hrs by scintillation counter based covalent competition assay,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5C)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5029190,=,=,IC50,nM,444.0,IC50,uM,0.444,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5C)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
Inhibition of human KRAS G12C mutant incubated for 2 hrs by scintillation counter based covalent competition assay,C=CC(=O)N1CC2(CC(n3nc(-c4ccc(-n5cncn5)cc4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5029190,=,=,IC50,nM,93.0,IC50,uM,0.09300000000000001,C=CC(=O)N1CC2(CC(n3nc(-c4ccc(-n5cncn5)cc4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
Inhibition of human KRAS G12C mutant incubated for 2 hrs by scintillation counter based covalent competition assay,C=CC(=O)N1CC2(CC(n3nc(-c4ccc(-n5cncn5)cc4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5029190,>,>,IC50,nM,50000.0,IC50,uM,50.0,C=CC(=O)N1CC2(CC(n3nc(-c4ccc(-n5cncn5)cc4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
Inhibition of human KRAS G12C mutant incubated for 2 hrs by scintillation counter based covalent competition assay,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5CCN5CC[C@H](F)C5)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5029190,=,=,IC50,nM,14.0,IC50,uM,0.013999999999999999,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5CCN5CC[C@H](F)C5)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
Inhibition of human KRAS G12C mutant incubated for 2 hrs by scintillation counter based covalent competition assay,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5CCN5CC[C@H](F)C5)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5029190,>,>,IC50,nM,50000.0,IC50,uM,50.0,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5CCN5CC[C@H](F)C5)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
Inhibition of human KRAS G12C mutant incubated for 2 hrs by scintillation counter based covalent competition assay,C=CC(=O)N1CC2(CC(n3nc(-c4ccc(N5CCC5=O)cc4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5029190,=,=,IC50,nM,27.0,IC50,uM,0.027000000000000003,C=CC(=O)N1CC2(CC(n3nc(-c4ccc(N5CCC5=O)cc4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
Inhibition of human KRAS G12C mutant incubated for 2 hrs by scintillation counter based covalent competition assay,C=CC(=O)N1CC2(CC(n3nc(-c4ccc(N5CCC5=O)cc4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5029190,=,=,IC50,nM,15000.0,IC50,uM,15.0,C=CC(=O)N1CC2(CC(n3nc(-c4ccc(N5CCC5=O)cc4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
Inhibition of human KRAS G12C mutant incubated for 2 hrs by scintillation counter based covalent competition assay,C=CC(=O)N1CC2(CC(n3nc(-c4ccc(CC(C)(C)O)cc4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5029190,=,=,IC50,nM,12.0,IC50,uM,0.012,C=CC(=O)N1CC2(CC(n3nc(-c4ccc(CC(C)(C)O)cc4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
Inhibition of human KRAS G12C mutant incubated for 2 hrs by scintillation counter based covalent competition assay,C=CC(=O)N1CC2(CC(n3nc(-c4ccc(CC(C)(C)O)cc4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5029190,=,=,IC50,nM,1200.0,IC50,uM,1.2,C=CC(=O)N1CC2(CC(n3nc(-c4ccc(CC(C)(C)O)cc4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
Inhibition of human KRAS G12C mutant incubated for 2 hrs by scintillation counter based covalent competition assay,C=CC(=O)N1CC2(CC(n3nc(-c4ccc(OCCO)cc4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5029190,=,=,IC50,nM,26.0,IC50,uM,0.026000000000000002,C=CC(=O)N1CC2(CC(n3nc(-c4ccc(OCCO)cc4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
Inhibition of human KRAS G12C mutant incubated for 2 hrs by scintillation counter based covalent competition assay,C=CC(=O)N1CC2(CC(n3nc(-c4ccc(OCCO)cc4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5029190,=,=,IC50,nM,2800.0,IC50,uM,2.8,C=CC(=O)N1CC2(CC(n3nc(-c4ccc(OCCO)cc4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
Inhibition of human KRAS G12C mutant incubated for 2 hrs by scintillation counter based covalent competition assay,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(c4)OC(CO)C5)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5029190,=,=,IC50,nM,38.0,IC50,uM,0.038,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(c4)OC(CO)C5)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
Inhibition of human KRAS G12C mutant incubated for 2 hrs by scintillation counter based covalent competition assay,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(c4)OC(CO)C5)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5029190,>,>,IC50,nM,50000.0,IC50,uM,50.0,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(c4)OC(CO)C5)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
Inhibition of human KRAS G12C mutant incubated for 2 hrs by scintillation counter based covalent competition assay,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5nn(CCOC)cc5c4)c(-c4c(Cl)c(C)cc5[nH]nc(N)c45)c3C)C2)C1,CHEMBL5029190,=,=,IC50,nM,9.0,IC50,uM,0.009000000000000001,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5nn(CCOC)cc5c4)c(-c4c(Cl)c(C)cc5[nH]nc(N)c45)c3C)C2)C1,2022
Inhibition of human KRAS G12C mutant incubated for 2 hrs by scintillation counter based covalent competition assay,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5nn(CCOC)cc5c4)c(-c4c(Cl)c(C)cc5[nH]nc(N)c45)c3C)C2)C1,CHEMBL5029190,=,=,IC50,nM,840.0,IC50,uM,0.84,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5nn(CCOC)cc5c4)c(-c4c(Cl)c(C)cc5[nH]nc(N)c45)c3C)C2)C1,2022
Inhibition of human KRAS G12C mutant incubated for 2 hrs by scintillation counter based covalent competition assay,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(c4)CCN5C(=O)CN4CC[C@H](F)C4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5029190,=,=,IC50,nM,15.0,IC50,uM,0.015,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(c4)CCN5C(=O)CN4CC[C@H](F)C4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
Inhibition of human KRAS G12C mutant incubated for 2 hrs by scintillation counter based covalent competition assay,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(c4)CCN5C(=O)CN4CC[C@H](F)C4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5029190,=,=,IC50,nM,13300.0,IC50,uM,13.3,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(c4)CCN5C(=O)CN4CC[C@H](F)C4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
Binding affinity to human AviTEV6His-tagged KRAS isoform 4B wild type (1 to 169 residues) expressed in Escherichia coli BL21 (DE3) assessed as dissociation constant by SPR analysis,CN1CCC[C@H]1COc1nc(N2C[C@H]3CC[C@@H](C2)N3)c2cnc(-c3cc(O)cc4ccccc34)c(F)c2n1,CHEMBL5046237,=,=,Kd,nM,182.0,Kd,nM,182.0,CN1CCC[C@H]1COc1nc(N2C[C@H]3CC[C@@H](C2)N3)c2cnc(-c3cc(O)cc4ccccc34)c(F)c2n1,2022
Binding affinity to human AviTEV6His-tagged KRAS isoform 4B wild type (1 to 169 residues) expressed in Escherichia coli BL21 (DE3) assessed as dissociation constant by SPR analysis,CN1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c(F)c(-c4cc(O)cc5ccccc45)ncc23)CC1,CHEMBL5046237,=,=,Kd,nM,6200.0,Kd,uM,6.2,CN1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c(F)c(-c4cc(O)cc5ccccc45)ncc23)CC1,2022
Binding affinity to human AviTEV6His-tagged KRAS isoform 4B wild type (1 to 169 residues) expressed in Escherichia coli BL21 (DE3) assessed as dissociation constant by SPR analysis,CN1CCC[C@H]1COc1nc(N2CCOCC2)c2cnc(-c3cc(O)cc4ccccc34)c(F)c2n1,CHEMBL5046237,=,=,Kd,nM,560.0,Kd,uM,0.56,CN1CCC[C@H]1COc1nc(N2CCOCC2)c2cnc(-c3cc(O)cc4ccccc34)c(F)c2n1,2022
Binding affinity to human AviTEV6His-tagged KRAS isoform 4B wild type (1 to 169 residues) expressed in Escherichia coli BL21 (DE3) assessed as dissociation constant by SPR analysis,CN1CCC[C@H]1COc1nc(N2CCNCC2)c2cnc(-c3cccc4cccc(Cl)c34)c(F)c2n1,CHEMBL5046237,=,=,Kd,nM,36000.0,Kd,uM,36.0,CN1CCC[C@H]1COc1nc(N2CCNCC2)c2cnc(-c3cccc4cccc(Cl)c34)c(F)c2n1,2022
Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by In-Cell Western assay,CN1CCC[C@H]1COc1nc(N2C[C@H]3CC[C@@H](C2)N3)c2cnc(-c3cc(O)cc4ccccc34)c(F)c2n1,CHEMBL5046237,=,=,IC50,nM,530.0,IC50,uM,0.53,CN1CCC[C@H]1COc1nc(N2C[C@H]3CC[C@@H](C2)N3)c2cnc(-c3cc(O)cc4ccccc34)c(F)c2n1,2022
Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by In-Cell Western assay,CN(C)C1CN(c2nc(N3CC4CCC(C3)N4)c3cnc(-c4cc(O)cc5ccccc45)c(F)c3n2)C1,CHEMBL5046237,=,=,IC50,nM,1300.0,IC50,uM,1.3,CN(C)C1CN(c2nc(N3CC4CCC(C3)N4)c3cnc(-c4cc(O)cc5ccccc45)c(F)c3n2)C1,2022
Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by In-Cell Western assay,Cn1ccnc1CCOc1nc(N2C[C@H]3CC[C@@H](C2)N3)c2cnc(-c3cc(O)cc4ccccc34)c(F)c2n1,CHEMBL5046237,=,=,IC50,nM,3500.0,IC50,uM,3.5,Cn1ccnc1CCOc1nc(N2C[C@H]3CC[C@@H](C2)N3)c2cnc(-c3cc(O)cc4ccccc34)c(F)c2n1,2022
Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by In-Cell Western assay,Oc1cc(-c2ncc3c(N4C[C@H]5CC[C@@H](C4)N5)nc(OCCN4C[C@@H]5C[C@H]4CO5)nc3c2F)c2ccccc2c1,CHEMBL5046237,=,=,IC50,nM,3000.0,IC50,uM,3.0,Oc1cc(-c2ncc3c(N4C[C@H]5CC[C@@H](C4)N5)nc(OCCN4C[C@@H]5C[C@H]4CO5)nc3c2F)c2ccccc2c1,2022
Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by In-Cell Western assay,Oc1cc(-c2ncc3c(N4C[C@H]5CC[C@@H](C4)N5)nc(OCC45CCCN4CCC5)nc3c2F)c2ccccc2c1,CHEMBL5046237,=,=,IC50,nM,270.0,IC50,uM,0.27,Oc1cc(-c2ncc3c(N4C[C@H]5CC[C@@H](C4)N5)nc(OCC45CCCN4CCC5)nc3c2F)c2ccccc2c1,2022
Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by In-Cell Western assay,Oc1cc(-c2ncc3c(N4CC5CCC(C4)N5)nc(OCC45CCCCN4CCC5)nc3c2F)c2ccccc2c1,CHEMBL5046237,=,=,IC50,nM,650.0,IC50,uM,0.65,Oc1cc(-c2ncc3c(N4CC5CCC(C4)N5)nc(OCC45CCCCN4CCC5)nc3c2F)c2ccccc2c1,2022
Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by In-Cell Western assay,Oc1cc(-c2ncc3c(N4C[C@H]5CC[C@@H](C4)N5)nc(OC[C@]45CCCN4C[C@@H](F)C5)nc3c2F)c2ccccc2c1,CHEMBL5046237,=,=,IC50,nM,64.0,IC50,uM,0.064,Oc1cc(-c2ncc3c(N4C[C@H]5CC[C@@H](C4)N5)nc(OC[C@]45CCCN4C[C@@H](F)C5)nc3c2F)c2ccccc2c1,2022
Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by In-Cell Western assay,Oc1cc(-c2ncc3c(N4C[C@H]5CC[C@@H](C4)N5)nc(OC[C@@]45CCCN4C[C@H](F)C5)nc3c2F)c2ccccc2c1,CHEMBL5046237,=,=,IC50,nM,24.0,IC50,uM,0.024,Oc1cc(-c2ncc3c(N4C[C@H]5CC[C@@H](C4)N5)nc(OC[C@@]45CCCN4C[C@H](F)C5)nc3c2F)c2ccccc2c1,2022
Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by In-Cell Western assay,Fc1c(-c2cccc3cccc(F)c23)ncc2c(N3C[C@H]4CC[C@@H](C3)N4)nc(OCC34CCCN3CCC4)nc12,CHEMBL5046237,=,=,IC50,nM,380.0,IC50,uM,0.38,Fc1c(-c2cccc3cccc(F)c23)ncc2c(N3C[C@H]4CC[C@@H](C3)N4)nc(OCC34CCCN3CCC4)nc12,2022
Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by In-Cell Western assay,Fc1c(-c2cccc3cccc(Cl)c23)ncc2c(N3C[C@H]4CC[C@@H](C3)N4)nc(OCC34CCCN3CCC4)nc12,CHEMBL5046237,=,=,IC50,nM,190.0,IC50,uM,0.19,Fc1c(-c2cccc3cccc(Cl)c23)ncc2c(N3C[C@H]4CC[C@@H](C3)N4)nc(OCC34CCCN3CCC4)nc12,2022
Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by In-Cell Western assay,Cc1cccc2cccc(-c3ncc4c(N5C[C@H]6CC[C@@H](C5)N6)nc(OCC56CCCN5CCC6)nc4c3F)c12,CHEMBL5046237,=,=,IC50,nM,2500.0,IC50,uM,2.5,Cc1cccc2cccc(-c3ncc4c(N5C[C@H]6CC[C@@H](C5)N6)nc(OCC56CCCN5CCC6)nc4c3F)c12,2022
Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by In-Cell Western assay,CCc1cccc2cccc(-c3ncc4c(N5C[C@H]6CC[C@@H](C5)N6)nc(OCC56CCCN5CCC6)nc4c3F)c12,CHEMBL5046237,=,=,IC50,nM,200.0,IC50,uM,0.2,CCc1cccc2cccc(-c3ncc4c(N5C[C@H]6CC[C@@H](C5)N6)nc(OCC56CCCN5CCC6)nc4c3F)c12,2022
Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by In-Cell Western assay,COc1cccc2cccc(-c3ncc4c(N5C[C@H]6CC[C@@H](C5)N6)nc(OCC56CCCN5CCC6)nc4c3F)c12,CHEMBL5046237,=,=,IC50,nM,1200.0,IC50,uM,1.2,COc1cccc2cccc(-c3ncc4c(N5C[C@H]6CC[C@@H](C5)N6)nc(OCC56CCCN5CCC6)nc4c3F)c12,2022
Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by In-Cell Western assay,C#Cc1cccc2cccc(-c3ncc4c(N5C[C@H]6CC[C@@H](C5)N6)nc(OCC56CCCN5CCC6)nc4c3F)c12,CHEMBL5046237,=,=,IC50,nM,71.0,IC50,uM,0.071,C#Cc1cccc2cccc(-c3ncc4c(N5C[C@H]6CC[C@@H](C5)N6)nc(OCC56CCCN5CCC6)nc4c3F)c12,2022
Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by In-Cell Western assay,Fc1ccc2cccc(-c3ncc4c(N5C[C@H]6CC[C@@H](C5)N6)nc(OCC56CCCN5CCC6)nc4c3F)c2c1,CHEMBL5046237,=,=,IC50,nM,370.0,IC50,uM,0.37,Fc1ccc2cccc(-c3ncc4c(N5C[C@H]6CC[C@@H](C5)N6)nc(OCC56CCCN5CCC6)nc4c3F)c2c1,2022
Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by In-Cell Western assay,Fc1ccc2cccc(-c3ncc4c(N5C[C@H]6CC[C@@H](C5)N6)nc(OCC56CCCN5CCC6)nc4c3F)c2c1F,CHEMBL5046237,=,=,IC50,nM,97.0,IC50,uM,0.09699999999999999,Fc1ccc2cccc(-c3ncc4c(N5C[C@H]6CC[C@@H](C5)N6)nc(OCC56CCCN5CCC6)nc4c3F)c2c1F,2022
Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by In-Cell Western assay,C#Cc1c(F)ccc2cccc(-c3ncc4c(N5C[C@H]6CC[C@@H](C5)N6)nc(OCC56CCCN5CCC6)nc4c3F)c12,CHEMBL5046237,=,=,IC50,nM,24.0,IC50,uM,0.024,C#Cc1c(F)ccc2cccc(-c3ncc4c(N5C[C@H]6CC[C@@H](C5)N6)nc(OCC56CCCN5CCC6)nc4c3F)c12,2022
Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by In-Cell Western assay,Oc1cc(-c2ncc3c(N4C[C@H]5CC[C@@H](C4)N5)nc(OCC45CCCN4CCC5)nc3c2F)c2c(Cl)cccc2c1,CHEMBL5046237,=,=,IC50,nM,63.0,IC50,uM,0.063,Oc1cc(-c2ncc3c(N4C[C@H]5CC[C@@H](C4)N5)nc(OCC45CCCN4CCC5)nc3c2F)c2c(Cl)cccc2c1,2022
Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by In-Cell Western assay,C#Cc1cccc2cc(O)cc(-c3ncc4c(N5C[C@H]6CC[C@@H](C5)N6)nc(OCC56CCCN5CCC6)nc4c3F)c12,CHEMBL5046237,=,=,IC50,nM,14.0,IC50,uM,0.013999999999999999,C#Cc1cccc2cc(O)cc(-c3ncc4c(N5C[C@H]6CC[C@@H](C5)N6)nc(OCC56CCCN5CCC6)nc4c3F)c12,2022
Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by In-Cell Western assay,C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5C[C@H]6CC[C@@H](C5)N6)nc(OC[C@@]56CCCN5C[C@H](F)C6)nc4c3F)c12,CHEMBL5046237,=,=,IC50,nM,2.0,IC50,nM,2.0,C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5C[C@H]6CC[C@@H](C5)N6)nc(OC[C@@]56CCCN5C[C@H](F)C6)nc4c3F)c12,2022
Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by In-Cell Western assay,Oc1cc(-c2ncc3c(N4CC5CCC(C4)N5)ncnc3c2F)c2ccccc2c1,CHEMBL5046237,>,>,IC50,nM,10000.0,IC50,uM,10.0,Oc1cc(-c2ncc3c(N4CC5CCC(C4)N5)ncnc3c2F)c2ccccc2c1,2022
Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by In-Cell Western assay,CN(C)CCOc1nc(N2C[C@H]3CC[C@@H](C2)N3)c2cnc(-c3cc(O)cc4ccccc34)c(F)c2n1,CHEMBL5046237,>,>,IC50,nM,10000.0,IC50,uM,10.0,CN(C)CCOc1nc(N2C[C@H]3CC[C@@H](C2)N3)c2cnc(-c3cc(O)cc4ccccc34)c(F)c2n1,2022
Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by In-Cell Western assay,O=C1CCC2(COc3nc(N4CC5CCC(C4)N5)c4cnc(-c5cc(O)cc6ccccc56)c(F)c4n3)CCCN12,CHEMBL5046237,>,>,IC50,nM,10000.0,IC50,uM,10.0,O=C1CCC2(COc3nc(N4CC5CCC(C4)N5)c4cnc(-c5cc(O)cc6ccccc56)c(F)c4n3)CCCN12,2022
Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by In-Cell Western assay,Fc1c(-c2cccc3ccccc23)ncc2c(N3C[C@H]4CC[C@@H](C3)N4)nc(OCC34CCCN3CCC4)nc12,CHEMBL5046237,>,>,IC50,nM,10000.0,IC50,uM,10.0,Fc1c(-c2cccc3ccccc23)ncc2c(N3C[C@H]4CC[C@@H](C3)N4)nc(OCC34CCCN3CCC4)nc12,2022
Inhibition of KRAS G12D mutant in human AGS cells assessed as reduction in ERK phosphorylation measured after 3 hrs by In-Cell Western assay,OCc1cccc2cccc(-c3ncc4c(N5C[C@H]6CC[C@@H](C5)N6)nc(OCC56CCCN5CCC6)nc4c3F)c12,CHEMBL5046237,>,>,IC50,nM,10000.0,IC50,uM,10.0,OCc1cccc2cccc(-c3ncc4c(N5C[C@H]6CC[C@@H](C5)N6)nc(OCC56CCCN5CCC6)nc4c3F)c12,2022
Inhibition of human GDP-bound KRAS G12D mutant assessed as inhibition of SOS1-catalyzed nucleotide exchange by measuring KRAS G12D mutant/GTP/c-Raf1 complex formation incubated for 120 mins followed by incubation with SOS1 and GTP for 60 mins followed by addition of c-Raf1 for 60 mins and measured after 60 mins by AlphaLISA assay,C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5C[C@H]6CC[C@@H](C5)N6)nc(OC[C@@]56CCCN5C[C@H](F)C6)nc4c3F)c12,CHEMBL5046237,=,=,IC50,nM,5.0,IC50,nM,5.0,C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5C[C@H]6CC[C@@H](C5)N6)nc(OC[C@@]56CCCN5C[C@H](F)C6)nc4c3F)c12,2022
Inhibition of KRAS G12C mutant (unknown origin),C=CC(=O)N1CC(N2CCN(C(=O)CNc3cc(C4(C)CC4)c(Cl)cc3O)CC2)C1,CHEMBL5046237,=,=,Ki,nM,200000.0,Ki,uM,200.0,C=CC(=O)N1CC(N2CCN(C(=O)CNc3cc(C4(C)CC4)c(Cl)cc3O)CC2)C1,2022
Inhibition of KRAS G12C mutant (2 to 188 residues) (unknown origin) expressed in Escherichia coli assessed as inhibition of SOS mediated nucleotide exchange at 21 degreeC for 15 mins by HTRF assay,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCC2(CCc4ccccc4C2)C3)C[C@@H]1CC#N,CHEMBL5046324,=,=,IC50,nM,142.0,IC50,uM,0.142,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCC2(CCc4ccccc4C2)C3)C[C@@H]1CC#N,2022
Inhibition of KRAS G12C mutant (2 to 188 residues) (unknown origin) expressed in Escherichia coli assessed as inhibition of SOS mediated nucleotide exchange at 21 degreeC for 15 mins by HTRF assay,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CC[C@@]2(CCc4ccccc4C2)C3)C[C@@H]1CC#N,CHEMBL5046324,=,=,IC50,nM,291.0,IC50,uM,0.29100000000000004,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CC[C@@]2(CCc4ccccc4C2)C3)C[C@@H]1CC#N,2022
Inhibition of KRAS G12C mutant (2 to 188 residues) (unknown origin) expressed in Escherichia coli assessed as inhibition of SOS mediated nucleotide exchange at 21 degreeC for 15 mins by HTRF assay,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CC[C@]2(CCc4ccccc4C2)C3)C[C@@H]1CC#N,CHEMBL5046324,=,=,IC50,nM,131.0,IC50,uM,0.131,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CC[C@]2(CCc4ccccc4C2)C3)C[C@@H]1CC#N,2022
Inhibition of KRAS G12C mutant (2 to 188 residues) (unknown origin) expressed in Escherichia coli assessed as inhibition of SOS mediated nucleotide exchange at 4 degreeC for 18 hrs by HTRF assay,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCC2(CCc4ccccc4C2)C3)C[C@@H]1CC#N,CHEMBL5046324,=,=,IC50,nM,46.0,IC50,uM,0.046,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCC2(CCc4ccccc4C2)C3)C[C@@H]1CC#N,2022
Inhibition of KRAS G12C mutant (2 to 188 residues) (unknown origin) expressed in Escherichia coli assessed as inhibition of SOS mediated nucleotide exchange at 4 degreeC for 18 hrs by HTRF assay,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CC[C@@]2(CCc4ccccc4C2)C3)C[C@@H]1CC#N,CHEMBL5046324,=,=,IC50,nM,51.0,IC50,uM,0.051,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CC[C@@]2(CCc4ccccc4C2)C3)C[C@@H]1CC#N,2022
Inhibition of KRAS G12C mutant (2 to 188 residues) (unknown origin) expressed in Escherichia coli assessed as inhibition of SOS mediated nucleotide exchange at 4 degreeC for 18 hrs by HTRF assay,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CC[C@]2(CCc4ccccc4C2)C3)C[C@@H]1CC#N,CHEMBL5046324,=,=,IC50,nM,60.0,IC50,uM,0.06,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CC[C@]2(CCc4ccccc4C2)C3)C[C@@H]1CC#N,2022
Inhibition of KRAS G12C mutant (2 to 188 residues) (unknown origin) expressed in Escherichia coli assessed as inhibition of SOS mediated nucleotide exchange measured after 18 hrs by HTRF assay,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2C[C@@H](C)[C@H](c2c(F)c(N)cc(C)c2C(F)(F)F)C3)[C@@H](C)C1,CHEMBL5046324,<,<,IC50,nM,10.0,IC50,uM,0.01,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2C[C@@H](C)[C@H](c2c(F)c(N)cc(C)c2C(F)(F)F)C3)[C@@H](C)C1,2022
Inhibition of KRAS G12C mutant (2 to 188 residues) (unknown origin) expressed in Escherichia coli assessed as inhibition of SOS mediated nucleotide exchange measured after 18 hrs by HTRF assay,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2C[C@@H](C)[C@H](c2nc(N)cc(C)c2C(F)(F)F)C3)[C@@H](C)C1,CHEMBL5046324,<,<,IC50,nM,10.0,IC50,uM,0.01,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2C[C@@H](C)[C@H](c2nc(N)cc(C)c2C(F)(F)F)C3)[C@@H](C)C1,2022
Inhibition of KRAS G12C mutant (2 to 188 residues) (unknown origin) expressed in Escherichia coli assessed as inhibition of SOS mediated nucleotide exchange measured after 18 hrs by HTRF assay,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2C[C@@H](C)[C@H](c2cc(O)cc4ccccc24)C3)[C@@H](C)C1,CHEMBL5046324,<,<,IC50,nM,10.0,IC50,uM,0.01,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2C[C@@H](C)[C@H](c2cc(O)cc4ccccc24)C3)[C@@H](C)C1,2022
Inhibition of KRAS G12C mutant (2 to 188 residues) (unknown origin) expressed in Escherichia coli assessed as inhibition of SOS mediated nucleotide exchange measured after 18 hrs by HTRF assay,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2C[C@@H](C)[C@H](c2c(C(F)(F)F)ccc(N)c2F)C3)[C@@H](C)C1,CHEMBL5046324,<,<,IC50,nM,10.0,IC50,uM,0.01,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2C[C@@H](C)[C@H](c2c(C(F)(F)F)ccc(N)c2F)C3)[C@@H](C)C1,2022
Inhibition of KRAS G12C mutant (2 to 188 residues) (unknown origin) expressed in Escherichia coli assessed as inhibition of SOS mediated nucleotide exchange measured after 18 hrs by HTRF assay,C=CC(=O)N1CCN(c2nc(OC[C@@H]3C[C@H](F)CN3C)nc3c2C[C@@H](C)[C@H](c2cc(O)cc4ccccc24)C3)[C@@H](C)C1,CHEMBL5046324,=,=,IC50,nM,11.0,IC50,uM,0.011000000000000001,C=CC(=O)N1CCN(c2nc(OC[C@@H]3C[C@H](F)CN3C)nc3c2C[C@@H](C)[C@H](c2cc(O)cc4ccccc24)C3)[C@@H](C)C1,2022
Inhibition of KRAS G12C mutant (2 to 188 residues) (unknown origin) expressed in Escherichia coli assessed as inhibition of SOS mediated nucleotide exchange measured after 18 hrs by HTRF assay,C=CC(=O)N1CCN(c2nc(OCc3cn(C)cn3)nc3c2CC[C@H](c2cc(O)cc4ccccc24)C3)[C@@H](C)C1,CHEMBL5046324,=,=,IC50,nM,470.0,IC50,uM,0.47,C=CC(=O)N1CCN(c2nc(OCc3cn(C)cn3)nc3c2CC[C@H](c2cc(O)cc4ccccc24)C3)[C@@H](C)C1,2022
Inhibition of KRAS G12C mutant in human HCC1171 cells assessed as effect on cell alkylation measured after 18 hrs by western blot analysis,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2C[C@@H](C)[C@H](c2c(F)c(N)cc(C)c2C(F)(F)F)C3)[C@@H](C)C1,CHEMBL5046324,=,=,EC50,nM,3.3,EC50,uM,0.0033,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2C[C@@H](C)[C@H](c2c(F)c(N)cc(C)c2C(F)(F)F)C3)[C@@H](C)C1,2022
Inhibition of KRAS G12C mutant in human HCC1171 cells assessed as effect on cell alkylation measured after 18 hrs by western blot analysis,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2C[C@@H](C)[C@H](c2nc(N)cc(C)c2C(F)(F)F)C3)[C@@H](C)C1,CHEMBL5046324,=,=,EC50,nM,6.0,EC50,uM,0.006,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2C[C@@H](C)[C@H](c2nc(N)cc(C)c2C(F)(F)F)C3)[C@@H](C)C1,2022
Inhibition of KRAS G12C mutant in human HCC1171 cells assessed as effect on cell alkylation measured after 18 hrs by western blot analysis,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2C[C@@H](C)[C@H](c2cc(O)cc4ccccc24)C3)[C@@H](C)C1,CHEMBL5046324,<,<,EC50,nM,6.1,EC50,uM,0.0061,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2C[C@@H](C)[C@H](c2cc(O)cc4ccccc24)C3)[C@@H](C)C1,2022
Inhibition of KRAS G12C mutant in human HCC1171 cells assessed as effect on cell alkylation measured after 18 hrs by western blot analysis,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2C[C@@H](C)[C@H](c2c(C(F)(F)F)ccc(N)c2F)C3)[C@@H](C)C1,CHEMBL5046324,=,=,EC50,nM,6.6,EC50,uM,0.0066,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2C[C@@H](C)[C@H](c2c(C(F)(F)F)ccc(N)c2F)C3)[C@@H](C)C1,2022
Inhibition of KRAS G12C mutant in human HCC1171 cells assessed as effect on cell alkylation measured after 18 hrs by western blot analysis,C=CC(=O)N1CCN(c2nc(OC[C@@H]3C[C@H](F)CN3C)nc3c2C[C@@H](C)[C@H](c2cc(O)cc4ccccc24)C3)[C@@H](C)C1,CHEMBL5046324,=,=,EC50,nM,40.0,EC50,uM,0.04,C=CC(=O)N1CCN(c2nc(OC[C@@H]3C[C@H](F)CN3C)nc3c2C[C@@H](C)[C@H](c2cc(O)cc4ccccc24)C3)[C@@H](C)C1,2022
Inhibition of KRAS G12C mutant in human HCC1171 cells assessed as effect on cell alkylation measured after 18 hrs by western blot analysis,C=CC(=O)N1CCN(c2nc(OCc3cn(C)cn3)nc3c2CC[C@H](c2cc(O)cc4ccccc24)C3)[C@@H](C)C1,CHEMBL5046324,=,=,EC50,nM,3000.0,EC50,uM,3.0,C=CC(=O)N1CCN(c2nc(OCc3cn(C)cn3)nc3c2CC[C@H](c2cc(O)cc4ccccc24)C3)[C@@H](C)C1,2022
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC[C@H](C)C1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@@H](N)Cc2ccccc2)CC#CCSC[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)N2CCC[C@H]2C(N)=O)[C@@H](C)CC)NC1=O,CHEMBL5055671,=,=,IC50,nM,23.0,IC50,uM,0.023,CC[C@H](C)C1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@@H](N)Cc2ccccc2)CC#CCSC[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)N2CCC[C@H]2C(N)=O)[C@@H](C)CC)NC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)CCCCn2cc(nn2)CSC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,CHEMBL5055671,>,>,IC50,nM,100000.0,IC50,uM,100.0,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)CCCCn2cc(nn2)CSC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)CCCCn2cc(nn2)COC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,CHEMBL5055671,>,>,IC50,nM,100000.0,IC50,uM,100.0,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)CCCCn2cc(nn2)COC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccccc2)NC(=O)CCCc2cn(nn2)C[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,CHEMBL5055671,>,>,IC50,nM,100000.0,IC50,uM,100.0,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccccc2)NC(=O)CCCc2cn(nn2)C[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccccc2)NC(=O)CCCc2cn(nn2)CC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,CHEMBL5055671,>,>,IC50,nM,100000.0,IC50,uM,100.0,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccccc2)NC(=O)CCCc2cn(nn2)CC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)CCCCn2nncc2CSC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,CHEMBL5055671,>,>,IC50,nM,100000.0,IC50,uM,100.0,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)CCCCn2nncc2CSC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)CCCCn2nncc2COC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,CHEMBL5055671,>,>,IC50,nM,100000.0,IC50,uM,100.0,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)CCCCn2nncc2COC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccccc2)NC(=O)CCCCn2nncc2COC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,CHEMBL5055671,>,>,IC50,nM,100000.0,IC50,uM,100.0,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccccc2)NC(=O)CCCCn2nncc2COC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](C)NC(=O)CCCCn2nncc2COC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,CHEMBL5055671,>,>,IC50,nM,100000.0,IC50,uM,100.0,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](C)NC(=O)CCCCn2nncc2COC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)CNC(=O)CCCCn2nncc2COC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,CHEMBL5055671,=,=,IC50,nM,100000.0,IC50,uM,100.0,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)CNC(=O)CCCCn2nncc2COC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)CNC(=O)CCCn2nncc2COC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,CHEMBL5055671,>,>,IC50,nM,100000.0,IC50,uM,100.0,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)CNC(=O)CCCn2nncc2COC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)CNC(=O)CCCc2cn(nn2)CC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,CHEMBL5055671,>,>,IC50,nM,100000.0,IC50,uM,100.0,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)CNC(=O)CCCc2cn(nn2)CC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)CNC(=O)CCCc2cnnn2C[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,CHEMBL5055671,>,>,IC50,nM,100000.0,IC50,uM,100.0,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)CNC(=O)CCCc2cnnn2C[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)CCc2cnnn2CC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,CHEMBL5055671,>,>,IC50,nM,100000.0,IC50,uM,100.0,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)CCc2cnnn2CC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)CNC(=O)CCCc2cnnn2CC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,CHEMBL5055671,>,>,IC50,nM,100000.0,IC50,uM,100.0,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)CNC(=O)CCCc2cnnn2CC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,C=C1/C=C/CCCC(=O)N[C@@H](C)C(=O)N2CCC[C@H]2C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)CSC1,CHEMBL5055671,>,>,IC50,nM,100000.0,IC50,uM,100.0,C=C1/C=C/CCCC(=O)N[C@@H](C)C(=O)N2CCC[C@H]2C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)CSC1,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,C=C1/C=C/COC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CCCN2C(=O)CNC(=O)CC1,CHEMBL5055671,>,>,IC50,nM,100000.0,IC50,uM,100.0,C=C1/C=C/COC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CCCN2C(=O)CNC(=O)CC1,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,C=C1/C=C/COC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CCCN2C(=O)CNC(=O)C1,CHEMBL5055671,=,=,IC50,nM,98000.0,IC50,uM,98.0,C=C1/C=C/COC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CCCN2C(=O)CNC(=O)C1,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](C)NC(=O)CCC/C=C/COC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,CHEMBL5055671,>,>,IC50,nM,100000.0,IC50,uM,100.0,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](C)NC(=O)CCC/C=C/COC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](C)NC(=O)CCCC#CC#CCOC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,CHEMBL5055671,>,>,IC50,nM,100000.0,IC50,uM,100.0,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](C)NC(=O)CCCC#CC#CCOC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)CNC(=O)CCCC#CC#CCOC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,CHEMBL5055671,>,>,IC50,nM,100000.0,IC50,uM,100.0,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)CNC(=O)CCCC#CC#CCOC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](C)NC(=O)c2ccccc2/C=C/COC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,CHEMBL5055671,>,>,IC50,nM,100000.0,IC50,uM,100.0,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](C)NC(=O)c2ccccc2/C=C/COC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](CC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)C[C@@H](C)C(=O)C1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,91000.0,IC50,uM,91.0,CC(C)C[C@H](CC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)C[C@@H](C)C(=O)C1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CC2CCCCC2)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,100000.0,IC50,uM,100.0,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CC2CCCCC2)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,60000.0,IC50,uM,60.0,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CCCC[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)CNC(=O)CCCCn2nncc2COC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,CHEMBL5055671,=,=,IC50,nM,48000.0,IC50,uM,48.0,CCCC[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)CNC(=O)CCCCn2nncc2COC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CC2CC2)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,32000.0,IC50,uM,32.0,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CC2CC2)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2ccccc2)C(=O)N1)C(N)=O,CHEMBL5055671,>,>,IC50,nM,38000.0,IC50,uM,38.0,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2ccccc2)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@H](Cc2ccccc2)C(=O)N1)C(N)=O,CHEMBL5055671,>,>,IC50,nM,82000.0,IC50,uM,82.0,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@H](Cc2ccccc2)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](c2ccccc2)C(=O)N1)C(N)=O,CHEMBL5055671,>,>,IC50,nM,100000.0,IC50,uM,100.0,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](c2ccccc2)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,18000.0,IC50,uM,18.0,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,7100.0,IC50,uM,7.1,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,9500.0,IC50,uM,9.5,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccnc2)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,41000.0,IC50,uM,41.0,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccnc2)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccs2)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,53000.0,IC50,uM,53.0,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccs2)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2ccccc2Cl)C(=O)N1)C(N)=O,CHEMBL5055671,>,>,IC50,nM,100000.0,IC50,uM,100.0,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2ccccc2Cl)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2ccc(Cl)cc2)C(=O)N1)C(N)=O,CHEMBL5055671,>,>,IC50,nM,74000.0,IC50,uM,74.0,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2ccc(Cl)cc2)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,7700.0,IC50,uM,7.7,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,32000.0,IC50,uM,32.0,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCCCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,55000.0,IC50,uM,55.0,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCCCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(=O)N[C@@H](Cc1cccc2ccccc12)C(=O)N[C@@H](COCc1cnnn1CCCCC(=O)NCC(N)=O)C(=O)N[C@@H](CC(C)C)C(N)=O,CHEMBL5055671,=,=,IC50,nM,38000.0,IC50,uM,38.0,CC(=O)N[C@@H](Cc1cccc2ccccc12)C(=O)N[C@@H](COCc1cnnn1CCCCC(=O)NCC(N)=O)C(=O)N[C@@H](CC(C)C)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,95000.0,IC50,uM,95.0,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CC[C@@H](O)[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,70000.0,IC50,uM,70.0,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CC[C@@H](O)[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCOC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,6500.0,IC50,uM,6.5,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCOC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N(C)[C@@H](C(C)C)C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,100000.0,IC50,uM,100.0,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N(C)[C@@H](C(C)C)C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)NC(C)(C)C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,20000.0,IC50,uM,20.0,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)NC(C)(C)C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2Cc3ccccc3C[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,5800.0,IC50,uM,5.8,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2Cc3ccccc3C[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,37000.0,IC50,uM,37.0,C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,NC(=O)[C@@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C1CCCCC1,CHEMBL5055671,=,=,IC50,nM,78000.0,IC50,uM,78.0,NC(=O)[C@@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C1CCCCC1,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1,CHEMBL5055671,=,=,IC50,nM,100000.0,IC50,uM,100.0,NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CCCC[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,100000.0,IC50,uM,100.0,CCCC[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,NC(=O)[C@H](CC1CC1)NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1,CHEMBL5055671,=,=,IC50,nM,29000.0,IC50,uM,29.0,NC(=O)[C@H](CC1CC1)NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,NC(=O)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,48000.0,IC50,uM,48.0,NC(=O)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,NC(=O)CC[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,50000.0,IC50,uM,50.0,NC(=O)CC[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@@H](C(N)=O)N(C)C(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1,CHEMBL5055671,=,=,IC50,nM,26000.0,IC50,uM,26.0,CC(C)C[C@@H](C(N)=O)N(C)C(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)N[C@@H](C)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,9700.0,IC50,uM,9.7,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)N[C@@H](C)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)N[C@H](C)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,25000.0,IC50,uM,25.0,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)N[C@H](C)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)N[C@@H](CC(=O)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,66000.0,IC50,uM,66.0,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)N[C@@H](CC(=O)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)N[C@@H](CCC(=O)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,49000.0,IC50,uM,49.0,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)N[C@@H](CCC(=O)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)N[C@H](CC(=O)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,77000.0,IC50,uM,77.0,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)N[C@H](CC(=O)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)N[C@H](CCC(=O)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,100000.0,IC50,uM,100.0,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)N[C@H](CCC(=O)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,9600.0,IC50,uM,9.6,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,7000.0,IC50,uM,7.0,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,10000.0,IC50,uM,10.0,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,48000.0,IC50,uM,48.0,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,12000.0,IC50,uM,12.0,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCCCCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,81000.0,IC50,uM,81.0,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCCCCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCCCCCCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,28000.0,IC50,uM,28.0,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCCCCCCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@H]1CSCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,11000.0,IC50,uM,11.0,CC(C)C[C@H](NC(=O)[C@H]1CSCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@H]1CCCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,19000.0,IC50,uM,19.0,CC(C)C[C@H](NC(=O)[C@H]1CCCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@H]1Cc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,65000.0,IC50,uM,65.0,CC(C)C[C@H](NC(=O)[C@H]1Cc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@H]1Cn2nncc2CCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,31000.0,IC50,uM,31.0,CC(C)C[C@H](NC(=O)[C@H]1Cn2nncc2CCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@H]1CCn2nncc2CCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,13000.0,IC50,uM,13.0,CC(C)C[C@H](NC(=O)[C@H]1CCn2nncc2CCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@H]1COCc2cn(nn2)CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,>,>,IC50,nM,100000.0,IC50,uM,100.0,CC(C)C[C@H](NC(=O)[C@H]1COCc2cn(nn2)CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(N)=O,CHEMBL5055671,=,=,IC50,nM,46000.0,IC50,uM,46.0,CC(C)C[C@H](NC(=O)[C@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@H]1CCCn2nncc2COC[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@H](Cc2cccc3ccccc23)NC(=O)[C@@H]2CCCN2C(=O)CNC1=O,CHEMBL5055671,=,=,IC50,nM,38000.0,IC50,uM,38.0,CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@H]1CCCn2nncc2COC[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@H](Cc2cccc3ccccc23)NC(=O)[C@@H]2CCCN2C(=O)CNC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H]1CCCn2nncc2COC[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@H](Cc2cccc3ccccc23)NC(=O)[C@@H]2CCCN2C(=O)CNC1=O,CHEMBL5055671,=,=,IC50,nM,93000.0,IC50,uM,93.0,CC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H]1CCCn2nncc2COC[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@H](Cc2cccc3ccccc23)NC(=O)[C@@H]2CCCN2C(=O)CNC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@H]1CCCn2nncc2COC[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N2CCC[C@H]2C(N)=O)NC(=O)[C@H](Cc2cccc3ccccc23)NC(=O)[C@@H]2CCCN2C(=O)CNC1=O,CHEMBL5055671,=,=,IC50,nM,40000.0,IC50,uM,40.0,CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@H]1CCCn2nncc2COC[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N2CCC[C@H]2C(N)=O)NC(=O)[C@H](Cc2cccc3ccccc23)NC(=O)[C@@H]2CCCN2C(=O)CNC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H]1CCCn2nncc2COC[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N2CCC[C@H]2C(N)=O)NC(=O)[C@H](Cc2cccc3ccccc23)NC(=O)[C@@H]2CCCN2C(=O)CNC1=O,CHEMBL5055671,>,>,IC50,nM,83000.0,IC50,uM,83.0,CC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H]1CCCn2nncc2COC[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N2CCC[C@H]2C(N)=O)NC(=O)[C@H](Cc2cccc3ccccc23)NC(=O)[C@@H]2CCCN2C(=O)CNC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC[C@@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(C)=O)CCCn2nncc2COC[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(N)=O)NC1=O,CHEMBL5055671,>,>,IC50,nM,89000.0,IC50,uM,89.0,CC[C@@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(C)=O)CCCn2nncc2COC[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(N)=O)NC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC[C@@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC2=NCN=C2)NC(=O)[C@H](Cc2ccccc2)NC(C)=O)CCCn2nncc2COC[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(C)N2CCC[C@H]2C(N)=O)NC1=O,CHEMBL5055671,=,=,IC50,nM,8600.0,IC50,uM,8.6,CC[C@@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC2=NCN=C2)NC(=O)[C@H](Cc2ccccc2)NC(C)=O)CCCn2nncc2COC[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(C)N2CCC[C@H]2C(N)=O)NC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H]1CCCn2nncc2COC[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(C)N2CCC[C@H]2C(N)=O)NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccc(O)cc2)NC1=O,CHEMBL5055671,=,=,IC50,nM,3300.0,IC50,uM,3.3,CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H]1CCCn2nncc2COC[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(C)N2CCC[C@H]2C(N)=O)NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccc(O)cc2)NC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](CC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)C[C@@H](C)C(=O)C1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,91201.08,pIC50,,4.04,CC(C)C[C@H](CC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)C[C@@H](C)C(=O)C1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CC2CCCCC2)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,100000.0,pIC50,,4.0,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CC2CCCCC2)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,60255.96,pIC50,,4.22,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CCCC[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)CNC(=O)CCCCn2nncc2COC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,CHEMBL5055671,=,=,IC50,nM,47863.01,pIC50,,4.32,CCCC[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)CNC(=O)CCCCn2nncc2COC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CC2CC2)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,32359.37,pIC50,,4.49,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CC2CC2)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2ccccc2)C(=O)N1)C(N)=O,CHEMBL5055671,<,>,IC50,nM,39810.72,pIC50,,4.4,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2ccccc2)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@H](Cc2ccccc2)C(=O)N1)C(N)=O,CHEMBL5055671,<,>,IC50,nM,79432.82,pIC50,,4.1,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@H](Cc2ccccc2)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](c2ccccc2)C(=O)N1)C(N)=O,CHEMBL5055671,<,>,IC50,nM,100000.0,pIC50,,4.0,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](c2ccccc2)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,18197.01,pIC50,,4.74,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,7079.46,pIC50,,5.15,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,9549.93,pIC50,,5.02,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2ccc3ccccc3c2)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccnc2)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,40738.03,pIC50,,4.39,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccnc2)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccs2)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,53703.18,pIC50,,4.27,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccs2)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2ccccc2Cl)C(=O)N1)C(N)=O,CHEMBL5055671,<,>,IC50,nM,100000.0,pIC50,,4.0,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2ccccc2Cl)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2ccc(Cl)cc2)C(=O)N1)C(N)=O,CHEMBL5055671,<,>,IC50,nM,79432.82,pIC50,,4.1,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2ccc(Cl)cc2)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,7585.78,pIC50,,5.12,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,32359.37,pIC50,,4.49,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCCCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,54954.09,pIC50,,4.26,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCCCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(=O)N[C@@H](Cc1cccc2ccccc12)C(=O)N[C@@H](COCc1cnnn1CCCCC(=O)NCC(N)=O)C(=O)N[C@@H](CC(C)C)C(N)=O,CHEMBL5055671,=,=,IC50,nM,38018.94,pIC50,,4.42,CC(=O)N[C@@H](Cc1cccc2ccccc12)C(=O)N[C@@H](COCc1cnnn1CCCCC(=O)NCC(N)=O)C(=O)N[C@@H](CC(C)C)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,95499.26,pIC50,,4.02,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CC[C@@H](O)[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,69183.1,pIC50,,4.16,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CC[C@@H](O)[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCOC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,6456.54,pIC50,,5.19,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCOC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N(C)[C@@H](C(C)C)C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,100000.0,pIC50,,4.0,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N(C)[C@@H](C(C)C)C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)NC(C)(C)C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,19498.45,pIC50,,4.71,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)NC(C)(C)C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2Cc3ccccc3C[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,5754.4,pIC50,,5.24,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2Cc3ccccc3C[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,37153.52,pIC50,,4.43,C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,NC(=O)[C@@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C1CCCCC1,CHEMBL5055671,=,=,IC50,nM,77624.71,pIC50,,4.11,NC(=O)[C@@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C1CCCCC1,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1,CHEMBL5055671,=,=,IC50,nM,100000.0,pIC50,,4.0,NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CCCC[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,100000.0,pIC50,,4.0,CCCC[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,NC(=O)[C@H](CC1CC1)NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1,CHEMBL5055671,=,=,IC50,nM,28840.32,pIC50,,4.54,NC(=O)[C@H](CC1CC1)NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,NC(=O)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,48977.88,pIC50,,4.31,NC(=O)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,NC(=O)CC[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,50118.72,pIC50,,4.3,NC(=O)CC[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@@H](C(N)=O)N(C)C(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1,CHEMBL5055671,=,=,IC50,nM,25703.96,pIC50,,4.59,CC(C)C[C@@H](C(N)=O)N(C)C(=O)[C@@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)N[C@@H](C)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,9772.37,pIC50,,5.01,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)N[C@@H](C)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)N[C@H](C)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,25118.86,pIC50,,4.6,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)N[C@H](C)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)N[C@@H](CC(=O)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,66069.34,pIC50,,4.18,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)N[C@@H](CC(=O)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)N[C@@H](CCC(=O)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,48977.88,pIC50,,4.31,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)N[C@@H](CCC(=O)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)N[C@H](CC(=O)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,77624.71,pIC50,,4.11,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)N[C@H](CC(=O)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)N[C@H](CCC(=O)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,100000.0,pIC50,,4.0,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)N[C@H](CCC(=O)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,9549.93,pIC50,,5.02,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,7079.46,pIC50,,5.15,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,10471.29,pIC50,,4.98,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,47863.01,pIC50,,4.32,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,12589.25,pIC50,,4.9,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCCCCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,81283.05,pIC50,,4.09,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCCCCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCCCCCCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,28183.83,pIC50,,4.55,CC(C)C[C@H](NC(=O)[C@@H]1COCc2cnnn2CCCCCCCCCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@H]1CSCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,10471.29,pIC50,,4.98,CC(C)C[C@H](NC(=O)[C@H]1CSCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@H]1CCCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,19498.45,pIC50,,4.71,CC(C)C[C@H](NC(=O)[C@H]1CCCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@H]1Cc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,64565.42,pIC50,,4.19,CC(C)C[C@H](NC(=O)[C@H]1Cc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@H]1Cn2nncc2CCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,31622.78,pIC50,,4.5,CC(C)C[C@H](NC(=O)[C@H]1Cn2nncc2CCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@H]1CCn2nncc2CCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,=,=,IC50,nM,12589.25,pIC50,,4.9,CC(C)C[C@H](NC(=O)[C@H]1CCn2nncc2CCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@H]1COCc2cn(nn2)CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,CHEMBL5055671,<,>,IC50,nM,100000.0,pIC50,,4.0,CC(C)C[C@H](NC(=O)[C@H]1COCc2cn(nn2)CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(C)C[C@H](NC(=O)[C@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(N)=O,CHEMBL5055671,=,=,IC50,nM,45708.82,pIC50,,4.34,CC(C)C[C@H](NC(=O)[C@H]1COCc2cnnn2CCCCC(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2cccc3ccccc23)C(=O)N1)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(N)=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@H]1CCCn2nncc2COC[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@H](Cc2cccc3ccccc23)NC(=O)[C@@H]2CCCN2C(=O)CNC1=O,CHEMBL5055671,=,=,IC50,nM,38018.94,pIC50,,4.42,CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@H]1CCCn2nncc2COC[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@H](Cc2cccc3ccccc23)NC(=O)[C@@H]2CCCN2C(=O)CNC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H]1CCCn2nncc2COC[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@H](Cc2cccc3ccccc23)NC(=O)[C@@H]2CCCN2C(=O)CNC1=O,CHEMBL5055671,=,=,IC50,nM,93325.43,pIC50,,4.03,CC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H]1CCCn2nncc2COC[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@H](Cc2cccc3ccccc23)NC(=O)[C@@H]2CCCN2C(=O)CNC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@H]1CCCn2nncc2COC[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N2CCC[C@H]2C(N)=O)NC(=O)[C@H](Cc2cccc3ccccc23)NC(=O)[C@@H]2CCCN2C(=O)CNC1=O,CHEMBL5055671,=,=,IC50,nM,39810.72,pIC50,,4.4,CC(=O)N[C@@H](CC(=O)O)C(=O)N[C@H]1CCCn2nncc2COC[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N2CCC[C@H]2C(N)=O)NC(=O)[C@H](Cc2cccc3ccccc23)NC(=O)[C@@H]2CCCN2C(=O)CNC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H]1CCCn2nncc2COC[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N2CCC[C@H]2C(N)=O)NC(=O)[C@H](Cc2cccc3ccccc23)NC(=O)[C@@H]2CCCN2C(=O)CNC1=O,CHEMBL5055671,<,>,IC50,nM,79432.82,pIC50,,4.1,CC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H]1CCCn2nncc2COC[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N2CCC[C@H]2C(N)=O)NC(=O)[C@H](Cc2cccc3ccccc23)NC(=O)[C@@H]2CCCN2C(=O)CNC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC[C@@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(C)=O)CCCn2nncc2COC[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(N)=O)NC1=O,CHEMBL5055671,<,>,IC50,nM,79432.82,pIC50,,4.1,CC[C@@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(C)=O)CCCn2nncc2COC[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(N)=O)NC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC[C@@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC2=NCN=C2)NC(=O)[C@H](Cc2ccccc2)NC(C)=O)CCCn2nncc2COC[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(C)N2CCC[C@H]2C(N)=O)NC1=O,CHEMBL5055671,=,=,IC50,nM,8511.38,pIC50,,5.07,CC[C@@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC2=NCN=C2)NC(=O)[C@H](Cc2ccccc2)NC(C)=O)CCCn2nncc2COC[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(C)N2CCC[C@H]2C(N)=O)NC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) measured after 60 mins by HTRF competition binding assay,CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H]1CCCn2nncc2COC[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(C)N2CCC[C@H]2C(N)=O)NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccc(O)cc2)NC1=O,CHEMBL5055671,=,=,IC50,nM,3311.31,pIC50,,5.48,CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H]1CCCn2nncc2COC[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(C)N2CCC[C@H]2C(N)=O)NC(=O)[C@H](Cc2ccc3ccccc3c2)NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccc(O)cc2)NC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) at 100 uM measured after 60 mins by HTRF competition binding assay,CC[C@H](C)C1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@@H](N)Cc2ccccc2)CC#CCSC[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)N2CCC[C@H]2C(N)=O)[C@@H](C)CC)NC1=O,CHEMBL5055671,,,Inhibition,%,,INH,,,CC[C@H](C)C1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@@H](N)Cc2ccccc2)CC#CCSC[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)N2CCC[C@H]2C(N)=O)[C@@H](C)CC)NC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) at 100 uM measured after 60 mins by HTRF competition binding assay,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)CCCCn2cc(nn2)CSC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,CHEMBL5055671,=,=,Inhibition,%,0.0,INH,%,0.0,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)CCCCn2cc(nn2)CSC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) at 100 uM measured after 60 mins by HTRF competition binding assay,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)CCCCn2cc(nn2)COC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,CHEMBL5055671,=,=,Inhibition,%,22.0,INH,%,22.0,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)CCCCn2cc(nn2)COC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) at 100 uM measured after 60 mins by HTRF competition binding assay,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccccc2)NC(=O)CCCc2cn(nn2)C[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,CHEMBL5055671,=,=,Inhibition,%,8.0,INH,%,8.0,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccccc2)NC(=O)CCCc2cn(nn2)C[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) at 100 uM measured after 60 mins by HTRF competition binding assay,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccccc2)NC(=O)CCCc2cn(nn2)CC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,CHEMBL5055671,=,=,Inhibition,%,9.0,INH,%,9.0,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccccc2)NC(=O)CCCc2cn(nn2)CC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) at 100 uM measured after 60 mins by HTRF competition binding assay,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)CCCCn2nncc2CSC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,CHEMBL5055671,=,=,Inhibition,%,20.0,INH,%,20.0,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)CCCCn2nncc2CSC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) at 100 uM measured after 60 mins by HTRF competition binding assay,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)CCCCn2nncc2COC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,CHEMBL5055671,=,=,Inhibition,%,28.0,INH,%,28.0,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)CCCCn2nncc2COC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) at 100 uM measured after 60 mins by HTRF competition binding assay,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccccc2)NC(=O)CCCCn2nncc2COC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,CHEMBL5055671,=,=,Inhibition,%,38.0,INH,%,38.0,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccccc2)NC(=O)CCCCn2nncc2COC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) at 100 uM measured after 60 mins by HTRF competition binding assay,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](C)NC(=O)CCCCn2nncc2COC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,CHEMBL5055671,=,=,Inhibition,%,30.0,INH,%,30.0,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](C)NC(=O)CCCCn2nncc2COC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) at 100 uM measured after 60 mins by HTRF competition binding assay,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)CNC(=O)CCCCn2nncc2COC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,CHEMBL5055671,=,=,Inhibition,%,48.0,INH,%,48.0,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)CNC(=O)CCCCn2nncc2COC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) at 100 uM measured after 60 mins by HTRF competition binding assay,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)CNC(=O)CCCn2nncc2COC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,CHEMBL5055671,=,=,Inhibition,%,39.0,INH,%,39.0,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)CNC(=O)CCCn2nncc2COC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) at 100 uM measured after 60 mins by HTRF competition binding assay,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)CNC(=O)CCCc2cn(nn2)CC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,CHEMBL5055671,=,=,Inhibition,%,6.0,INH,%,6.0,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)CNC(=O)CCCc2cn(nn2)CC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) at 100 uM measured after 60 mins by HTRF competition binding assay,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)CNC(=O)CCCc2cnnn2C[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,CHEMBL5055671,=,=,Inhibition,%,16.0,INH,%,16.0,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)CNC(=O)CCCc2cnnn2C[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) at 100 uM measured after 60 mins by HTRF competition binding assay,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)CCc2cnnn2CC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,CHEMBL5055671,=,=,Inhibition,%,44.0,INH,%,44.0,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2ccc(O)cc2)NC(=O)CCc2cnnn2CC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) at 100 uM measured after 60 mins by HTRF competition binding assay,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)CNC(=O)CCCc2cnnn2CC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,CHEMBL5055671,=,=,Inhibition,%,22.0,INH,%,22.0,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)CNC(=O)CCCc2cnnn2CC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) at 100 uM measured after 60 mins by HTRF competition binding assay,C=C1/C=C/CCCC(=O)N[C@@H](C)C(=O)N2CCC[C@H]2C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)CSC1,CHEMBL5055671,=,=,Inhibition,%,28.0,INH,%,28.0,C=C1/C=C/CCCC(=O)N[C@@H](C)C(=O)N2CCC[C@H]2C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)CSC1,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) at 100 uM measured after 60 mins by HTRF competition binding assay,C=C1/C=C/COC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CCCN2C(=O)CNC(=O)CC1,CHEMBL5055671,=,=,Inhibition,%,21.0,INH,%,21.0,C=C1/C=C/COC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CCCN2C(=O)CNC(=O)CC1,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) at 100 uM measured after 60 mins by HTRF competition binding assay,C=C1/C=C/COC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CCCN2C(=O)CNC(=O)C1,CHEMBL5055671,=,=,Inhibition,%,46.0,INH,%,46.0,C=C1/C=C/COC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CCCN2C(=O)CNC(=O)C1,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) at 100 uM measured after 60 mins by HTRF competition binding assay,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](C)NC(=O)CCC/C=C/COC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,CHEMBL5055671,=,=,Inhibition,%,5.0,INH,%,5.0,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](C)NC(=O)CCC/C=C/COC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) at 100 uM measured after 60 mins by HTRF competition binding assay,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](C)NC(=O)CCCC#CC#CCOC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,CHEMBL5055671,=,=,Inhibition,%,0.0,INH,%,0.0,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](C)NC(=O)CCCC#CC#CCOC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) at 100 uM measured after 60 mins by HTRF competition binding assay,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)CNC(=O)CCCC#CC#CCOC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,CHEMBL5055671,=,=,Inhibition,%,0.0,INH,%,0.0,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)CNC(=O)CCCC#CC#CCOC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,2021
Inhibition of alexa fluor 647-labeled kinase tracer 314 binding to biotinylated-KRAS G12V mutant (unknown origin) at 100 uM measured after 60 mins by HTRF competition binding assay,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](C)NC(=O)c2ccccc2/C=C/COC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,CHEMBL5055671,=,=,Inhibition,%,25.0,INH,%,25.0,CC[C@H](C)[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](C)NC(=O)c2ccccc2/C=C/COC[C@@H](C(=O)N[C@@H](CC(C)C)C(N)=O)NC1=O,2021
Inhibition of biotinylated Avi-tagged GDP-bound KRAS G12C mutant (1 to 185 residues) (unknown origin) assessed as inhibition of KRAS G12C mutant/SOS/GST-tagged c-Raf complex formation incubated for 1 hr and measured by fluorescence based assay,C=CC(=O)N1CCN(c2nc(NC3CCN(C)CC3)nc3c(F)c(-c4c(C)ccc5[nH]ncc45)c(Cl)cc23)CC1,CHEMBL5107997,=,=,IC50,nM,470.0,IC50,uM,0.47,C=CC(=O)N1CCN(c2nc(NC3CCN(C)CC3)nc3c(F)c(-c4c(C)ccc5[nH]ncc45)c(Cl)cc23)CC1,2022
Inhibition of biotinylated Avi-tagged GDP-bound KRAS G12C mutant (1 to 185 residues) (unknown origin) assessed as inhibition of KRAS G12C mutant/SOS/GST-tagged c-Raf complex formation incubated for 1 hr and measured by fluorescence based assay,C=CC(=O)N1CC2(C1)CN(c1nc(NC3CCN(C)CC3)nc3c(F)c(-c4c(C)ccc5[nH]ncc45)c(Cl)cc13)C2,CHEMBL5107997,=,=,IC50,nM,3000.0,IC50,uM,3.0,C=CC(=O)N1CC2(C1)CN(c1nc(NC3CCN(C)CC3)nc3c(F)c(-c4c(C)ccc5[nH]ncc45)c(Cl)cc13)C2,2022
Inhibition of biotinylated Avi-tagged GDP-bound KRAS G12C mutant (1 to 185 residues) (unknown origin) assessed as inhibition of KRAS G12C mutant/SOS/GST-tagged c-Raf complex formation incubated for 1 hr and measured by fluorescence based assay,C=CC(=O)N1CC2(CCN(c3nc(NC4CCN(C)CC4)nc4c(F)c(-c5c(C)ccc6[nH]ncc56)c(Cl)cc34)C2)C1,CHEMBL5107997,=,=,IC50,nM,160.0,IC50,uM,0.16,C=CC(=O)N1CC2(CCN(c3nc(NC4CCN(C)CC4)nc4c(F)c(-c5c(C)ccc6[nH]ncc56)c(Cl)cc34)C2)C1,2022
Inhibition of biotinylated Avi-tagged GDP-bound KRAS G12C mutant (1 to 185 residues) (unknown origin) assessed as inhibition of KRAS G12C mutant/SOS/GST-tagged c-Raf complex formation incubated for 1 hr and measured by fluorescence based assay,C=CC(=O)N1CC2(CCN(c3nc(NC4CCN(C)CC4)nc4c(F)c(-c5c(C)ccc6[nH]ncc56)c(Cl)cc34)CC2)C1,CHEMBL5107997,=,=,IC50,nM,350.0,IC50,uM,0.35,C=CC(=O)N1CC2(CCN(c3nc(NC4CCN(C)CC4)nc4c(F)c(-c5c(C)ccc6[nH]ncc56)c(Cl)cc34)CC2)C1,2022
Inhibition of biotinylated Avi-tagged GDP-bound KRAS G12C mutant (1 to 185 residues) (unknown origin) assessed as inhibition of KRAS G12C mutant/SOS/GST-tagged c-Raf complex formation incubated for 1 hr and measured by fluorescence based assay,C=CC(=O)N1CCC2(C1)CN(c1nc(NC3CCN(C)CC3)nc3c(F)c(-c4c(C)ccc5[nH]ncc45)c(Cl)cc13)C2,CHEMBL5107997,=,=,IC50,nM,18000.0,IC50,uM,18.0,C=CC(=O)N1CCC2(C1)CN(c1nc(NC3CCN(C)CC3)nc3c(F)c(-c4c(C)ccc5[nH]ncc45)c(Cl)cc13)C2,2022
Inhibition of biotinylated Avi-tagged GDP-bound KRAS G12C mutant (1 to 185 residues) (unknown origin) assessed as inhibition of KRAS G12C mutant/SOS/GST-tagged c-Raf complex formation incubated for 1 hr and measured by fluorescence based assay,C=CC(=O)N1CCC2(CC1)CN(c1nc(NC3CCN(C)CC3)nc3c(F)c(-c4c(C)ccc5[nH]ncc45)c(Cl)cc13)C2,CHEMBL5107997,>,>,IC50,nM,30000.0,IC50,uM,30.0,C=CC(=O)N1CCC2(CC1)CN(c1nc(NC3CCN(C)CC3)nc3c(F)c(-c4c(C)ccc5[nH]ncc45)c(Cl)cc13)C2,2022
Inhibition of biotinylated Avi-tagged GDP-bound KRAS G12C mutant (1 to 185 residues) (unknown origin) assessed as inhibition of KRAS G12C mutant/SOS/GST-tagged c-Raf complex formation incubated for 1 hr and measured by fluorescence based assay,C=CC(=O)N1CC2(CCN(c3nc(OC4CCN(C)CC4)nc4c(F)c(-c5c(C)ccc6[nH]ncc56)c(Cl)cc34)CC2)C1,CHEMBL5107997,=,=,IC50,nM,70.0,IC50,uM,0.07,C=CC(=O)N1CC2(CCN(c3nc(OC4CCN(C)CC4)nc4c(F)c(-c5c(C)ccc6[nH]ncc56)c(Cl)cc34)CC2)C1,2022
Inhibition of biotinylated Avi-tagged GDP-bound KRAS G12C mutant (1 to 185 residues) (unknown origin) assessed as inhibition of KRAS G12C mutant/SOS/GST-tagged c-Raf complex formation incubated for 1 hr and measured by fluorescence based assay,C=CC(=O)N1CC2(CCN(c3nc(OC4CCN(CC)CC4)nc4c(F)c(-c5c(C)ccc6[nH]ncc56)c(Cl)cc34)CC2)C1,CHEMBL5107997,=,=,IC50,nM,77.0,IC50,uM,0.077,C=CC(=O)N1CC2(CCN(c3nc(OC4CCN(CC)CC4)nc4c(F)c(-c5c(C)ccc6[nH]ncc56)c(Cl)cc34)CC2)C1,2022
Inhibition of biotinylated Avi-tagged GDP-bound KRAS G12C mutant (1 to 185 residues) (unknown origin) assessed as inhibition of KRAS G12C mutant/SOS/GST-tagged c-Raf complex formation incubated for 1 hr and measured by fluorescence based assay,C=CC(=O)N1CC2(CCN(c3nc(SC4CCN(CC)CC4)nc4c(F)c(-c5c(C)ccc6[nH]ncc56)c(Cl)cc34)CC2)C1,CHEMBL5107997,=,=,IC50,nM,940.0,IC50,uM,0.94,C=CC(=O)N1CC2(CCN(c3nc(SC4CCN(CC)CC4)nc4c(F)c(-c5c(C)ccc6[nH]ncc56)c(Cl)cc34)CC2)C1,2022
Inhibition of biotinylated Avi-tagged GDP-bound KRAS G12C mutant (1 to 185 residues) (unknown origin) assessed as inhibition of KRAS G12C mutant/SOS/GST-tagged c-Raf complex formation incubated for 1 hr and measured by fluorescence based assay,C=CC(=O)N1CC2(CCN(c3nc(N(C)C4CCN(CC)CC4)nc4c(F)c(-c5c(C)ccc6[nH]ncc56)c(Cl)cc34)CC2)C1,CHEMBL5107997,=,=,IC50,nM,3200.0,IC50,uM,3.2,C=CC(=O)N1CC2(CCN(c3nc(N(C)C4CCN(CC)CC4)nc4c(F)c(-c5c(C)ccc6[nH]ncc56)c(Cl)cc34)CC2)C1,2022
Inhibition of biotinylated Avi-tagged GDP-bound KRAS G12C mutant (1 to 185 residues) (unknown origin) assessed as inhibition of KRAS G12C mutant/SOS/GST-tagged c-Raf complex formation incubated for 1 hr and measured by fluorescence based assay,CCN1CCC(Oc2nc(N3CCC4(CC3)CN(C(=O)/C=C/CN3CCOCC3)C4)c3cc(Cl)c(-c4c(C)ccc5[nH]ncc45)c(F)c3n2)CC1,CHEMBL5107997,>,>,IC50,nM,10000.0,IC50,uM,10.0,CCN1CCC(Oc2nc(N3CCC4(CC3)CN(C(=O)/C=C/CN3CCOCC3)C4)c3cc(Cl)c(-c4c(C)ccc5[nH]ncc45)c(F)c3n2)CC1,2022
Inhibition of biotinylated Avi-tagged GDP-bound KRAS G12C mutant (1 to 185 residues) (unknown origin) assessed as inhibition of KRAS G12C mutant/SOS/GST-tagged c-Raf complex formation incubated for 1 hr and measured by fluorescence based assay,C=CC(=O)N1CC2(CCN(c3nc(OCC4CCN(C)CC4)nc4c(F)c(-c5c(C)ccc6[nH]ncc56)c(Cl)cc34)CC2)C1,CHEMBL5107997,=,=,IC50,nM,130.0,IC50,uM,0.13,C=CC(=O)N1CC2(CCN(c3nc(OCC4CCN(C)CC4)nc4c(F)c(-c5c(C)ccc6[nH]ncc56)c(Cl)cc34)CC2)C1,2022
Inhibition of biotinylated Avi-tagged GDP-bound KRAS G12C mutant (1 to 185 residues) (unknown origin) assessed as inhibition of KRAS G12C mutant/SOS/GST-tagged c-Raf complex formation incubated for 1 hr and measured by fluorescence based assay,C=CC(=O)N1CC2(CCN(c3nc(OCCN(C)C)nc4c(F)c(-c5c(C)ccc6[nH]ncc56)c(Cl)cc34)CC2)C1,CHEMBL5107997,=,=,IC50,nM,340.0,IC50,uM,0.34,C=CC(=O)N1CC2(CCN(c3nc(OCCN(C)C)nc4c(F)c(-c5c(C)ccc6[nH]ncc56)c(Cl)cc34)CC2)C1,2022
Inhibition of biotinylated Avi-tagged GDP-bound KRAS G12C mutant (1 to 185 residues) (unknown origin) assessed as inhibition of KRAS G12C mutant/SOS/GST-tagged c-Raf complex formation incubated for 1 hr and measured by fluorescence based assay,C=CC(=O)N1CC2(CCN(c3nc(OCCCN(C)C)nc4c(F)c(-c5c(C)ccc6[nH]ncc56)c(Cl)cc34)CC2)C1,CHEMBL5107997,=,=,IC50,nM,260.0,IC50,uM,0.26,C=CC(=O)N1CC2(CCN(c3nc(OCCCN(C)C)nc4c(F)c(-c5c(C)ccc6[nH]ncc56)c(Cl)cc34)CC2)C1,2022
Inhibition of biotinylated Avi-tagged GDP-bound KRAS G12C mutant (1 to 185 residues) (unknown origin) assessed as inhibition of KRAS G12C mutant/SOS/GST-tagged c-Raf complex formation incubated for 1 hr and measured by fluorescence based assay,C=CC(=O)N1CC2(CCN(c3nc(OC4(CN(C)C)CCC4)nc4c(F)c(-c5c(C)ccc6[nH]ncc56)c(Cl)cc34)CC2)C1,CHEMBL5107997,=,=,IC50,nM,770.0,IC50,uM,0.77,C=CC(=O)N1CC2(CCN(c3nc(OC4(CN(C)C)CCC4)nc4c(F)c(-c5c(C)ccc6[nH]ncc56)c(Cl)cc34)CC2)C1,2022
Inhibition of biotinylated Avi-tagged GDP-bound KRAS G12C mutant (1 to 185 residues) (unknown origin) assessed as inhibition of KRAS G12C mutant/SOS/GST-tagged c-Raf complex formation incubated for 1 hr and measured by fluorescence based assay,C=CC(=O)N1CC2(CCN(c3nc(OCCCN4CCCCC4)nc4c(F)c(-c5c(C)ccc6[nH]ncc56)c(Cl)cc34)CC2)C1,CHEMBL5107997,=,=,IC50,nM,370.0,IC50,uM,0.37,C=CC(=O)N1CC2(CCN(c3nc(OCCCN4CCCCC4)nc4c(F)c(-c5c(C)ccc6[nH]ncc56)c(Cl)cc34)CC2)C1,2022
Inhibition of biotinylated Avi-tagged GDP-bound KRAS G12C mutant (1 to 185 residues) (unknown origin) assessed as inhibition of KRAS G12C mutant/SOS/GST-tagged c-Raf complex formation incubated for 1 hr and measured by fluorescence based assay,C=CC(=O)N1CC2(CCN(c3nc(OCCCN4CCOCC4)nc4c(F)c(-c5c(C)ccc6[nH]ncc56)c(Cl)cc34)CC2)C1,CHEMBL5107997,=,=,IC50,nM,650.0,IC50,uM,0.65,C=CC(=O)N1CC2(CCN(c3nc(OCCCN4CCOCC4)nc4c(F)c(-c5c(C)ccc6[nH]ncc56)c(Cl)cc34)CC2)C1,2022
Inhibition of biotinylated Avi-tagged GDP-bound KRAS G12C mutant (1 to 185 residues) (unknown origin) assessed as inhibition of KRAS G12C mutant/SOS/GST-tagged c-Raf complex formation incubated for 1 hr and measured by fluorescence based assay,C=CC(=O)N1CC2(CCN(c3nc(OC4CCOCC4)nc4c(F)c(-c5c(C)ccc6[nH]ncc56)c(Cl)cc34)CC2)C1,CHEMBL5107997,=,=,IC50,nM,2100.0,IC50,uM,2.1,C=CC(=O)N1CC2(CCN(c3nc(OC4CCOCC4)nc4c(F)c(-c5c(C)ccc6[nH]ncc56)c(Cl)cc34)CC2)C1,2022
Inhibition of biotinylated Avi-tagged GDP-bound KRAS G12C mutant (1 to 185 residues) (unknown origin) assessed as inhibition of KRAS G12C mutant/SOS/GST-tagged c-Raf complex formation at 3 uM incubated for 1 hr and measured by fluorescence based assay relative to control,C=CC(=O)N1CC2(C1)CN(c1nc(NC3CCN(C)CC3)nc3c(F)c(-c4c(C)ccc5[nH]ncc45)c(Cl)cc13)C2,CHEMBL5107997,=,=,Inhibition,%,60.0,INH,%,60.0,C=CC(=O)N1CC2(C1)CN(c1nc(NC3CCN(C)CC3)nc3c(F)c(-c4c(C)ccc5[nH]ncc45)c(Cl)cc13)C2,2022
Binding affinity to N-terminal His tagged recombinant human KRAS G12C mutant (2 to 186 residues) expressed in Escherichia coli assessed as dissociation constant by ITC analysis,COc1ccc(Cl)cc1-c1c(Cl)cc2c(N3CCN(C(=O)c4ccc([N+](=O)[O-])o4)CC3)ncnc2c1F,CHEMBL5108034,=,=,Kd,nM,97.0,Kd,nM,97.0,COc1ccc(Cl)cc1-c1c(Cl)cc2c(N3CCN(C(=O)c4ccc([N+](=O)[O-])o4)CC3)ncnc2c1F,2022
Binding affinity to N-terminal His tagged recombinant human KRAS G12C mutant (2 to 186 residues) expressed in Escherichia coli assessed as change in enthalpy by ITC analysis,COc1ccc(Cl)cc1-c1c(Cl)cc2c(N3CCN(C(=O)c4ccc([N+](=O)[O-])o4)CC3)ncnc2c1F,CHEMBL5108034,=,=,deltaH,kcal/mol,-5.58,deltaH,kcal/mol,-5.58,COc1ccc(Cl)cc1-c1c(Cl)cc2c(N3CCN(C(=O)c4ccc([N+](=O)[O-])o4)CC3)ncnc2c1F,2022
Binding affinity to N-terminal His tagged recombinant human KRAS G12C mutant (2 to 186 residues) expressed in Escherichia coli assessed as change in gibbs free energy by ITC analysis,COc1ccc(Cl)cc1-c1c(Cl)cc2c(N3CCN(C(=O)c4ccc([N+](=O)[O-])o4)CC3)ncnc2c1F,CHEMBL5108034,=,=,deltaG,kcal/mol,-9.58,deltaG,kcal/mol,-9.58,COc1ccc(Cl)cc1-c1c(Cl)cc2c(N3CCN(C(=O)c4ccc([N+](=O)[O-])o4)CC3)ncnc2c1F,2022
Binding affinity to N-terminal His tagged recombinant human KRAS G12C mutant (2 to 186 residues) expressed in Escherichia coli assessed as change in entropy by ITC analysis,COc1ccc(Cl)cc1-c1c(Cl)cc2c(N3CCN(C(=O)c4ccc([N+](=O)[O-])o4)CC3)ncnc2c1F,CHEMBL5108034,=,=,-TdeltaS,kcal/mol,-4.0,-TdeltaS,kcal/mol,-4.0,COc1ccc(Cl)cc1-c1c(Cl)cc2c(N3CCN(C(=O)c4ccc([N+](=O)[O-])o4)CC3)ncnc2c1F,2022
Inhibition of GTP bound KRAS G12C mutant in human NCI-H358 cells assessed as reduction in KRAS G12C-GTP level at 10 to 30 uM incubated for 8 hrs by KRAS-GTP pulldown assay,COc1ccc(Cl)cc1-c1c(Cl)cc2c(N3CCN(C(=O)c4ccc([N+](=O)[O-])o4)CC3)ncnc2c1F,CHEMBL5108034,,,Inhibition,%,,INH,,,COc1ccc(Cl)cc1-c1c(Cl)cc2c(N3CCN(C(=O)c4ccc([N+](=O)[O-])o4)CC3)ncnc2c1F,2022
Inhibition of KRAS in human NCI-H358 cells assessed as reduction in KRAS level at 10 to 30 uM incubated for 8 hrs by KRAS-GTP pulldown assay,COc1ccc(Cl)cc1-c1c(Cl)cc2c(N3CCN(C(=O)c4ccc([N+](=O)[O-])o4)CC3)ncnc2c1F,CHEMBL5108034,,,Inhibition,%,,INH,,,COc1ccc(Cl)cc1-c1c(Cl)cc2c(N3CCN(C(=O)c4ccc([N+](=O)[O-])o4)CC3)ncnc2c1F,2022
Inhibition of GTP bound KRAS G12C mutant in human NCI-H358 cells assessed as reduction in pERK level incubated for 8 hrs by KRAS-GTP pulldown assay,COc1ccc(Cl)cc1-c1c(Cl)cc2c(N3CCN(C(=O)c4ccc([N+](=O)[O-])o4)CC3)ncnc2c1F,CHEMBL5108034,,,Inhibition,%,,INH,,,COc1ccc(Cl)cc1-c1c(Cl)cc2c(N3CCN(C(=O)c4ccc([N+](=O)[O-])o4)CC3)ncnc2c1F,2022
Inhibition of human His-Avi-TEV-tagged KRAS G12D mutant expressed in Escherichia coli BL21(DE3) by TR-FRET assay,CC1CCN(C[C@@H]2NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)CSC[C@@H](CNCC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc3ccccc3)NC2=O)CC1,CHEMBL5108037,=,=,IC50,nM,800.0,IC50,uM,0.8,CC1CCN(C[C@@H]2NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)CSC[C@@H](CNCC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc3ccccc3)NC2=O)CC1,2022
Binding affinity to GppNHp-bound Avidin-tagged KRAS G12D mutant (2 to 169 residues) (unknown origin) up to 100 uM by surface plasmon resonance analysis,C/C=C/C[C@@H](C)[C@@H](O)[C@H](NC(=O)[C@@H]1CCCN1C(=O)C(C)(C)NC(=O)CCCCCCCCC)C(=O)N[C@](C)(CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NC(C)(C)C(=O)NC(C)(C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CO)CC(C)C,CHEMBL5120895,,,Activity,,,Activity,,,C/C=C/C[C@@H](C)[C@@H](O)[C@H](NC(=O)[C@@H]1CCCN1C(=O)C(C)(C)NC(=O)CCCCCCCCC)C(=O)N[C@](C)(CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NC(C)(C)C(=O)NC(C)(C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CO)CC(C)C,2022
Binding affinity to GppNHp-bound Avidin-tagged KRAS G12D mutant (2 to 169 residues) (unknown origin) up to 100 uM by surface plasmon resonance analysis,C/C=C/C[C@@H](C)[C@@H](O)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@](C)(CC)NC(=O)CCCCCCCCC)C(=O)N[C@](C)(CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NC(C)(C)C(=O)NC(C)(C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CO)CC(C)C,CHEMBL5120895,,,Activity,,,Activity,,,C/C=C/C[C@@H](C)[C@@H](O)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@](C)(CC)NC(=O)CCCCCCCCC)C(=O)N[C@](C)(CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NC(C)(C)C(=O)NC(C)(C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CO)CC(C)C,2022
Binding affinity to GppNHp-bound Avidin-tagged KRAS G12D mutant (2 to 169 residues) (unknown origin) up to 100 uM by surface plasmon resonance analysis,C/C=C/C[C@@H](C)[C@@H](O)[C@H](NC(=O)[C@@H]1CCCN1C(=O)C(C)(C)NC(=O)CCCCCCCCC)C(=O)N[C@](C)(CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NC(C)(C)C(=O)N[C@](C)(CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CO)CC(C)C,CHEMBL5120895,,,Activity,,,Activity,,,C/C=C/C[C@@H](C)[C@@H](O)[C@H](NC(=O)[C@@H]1CCCN1C(=O)C(C)(C)NC(=O)CCCCCCCCC)C(=O)N[C@](C)(CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NC(C)(C)C(=O)N[C@](C)(CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CO)CC(C)C,2022
Binding affinity to GppNHp-bound Avidin-tagged KRAS G12D mutant (2 to 169 residues) (unknown origin) up to 100 uM by surface plasmon resonance analysis,C/C=C/C[C@@H](C)[C@@H](O)[C@H](NC(=O)[C@@H]1CCCN1C(=O)C(C)(C)NC(=O)CCCCCCC)C(=O)N[C@](C)(CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NC(C)(C)C(=O)NC(C)(C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CO)CC(C)C,CHEMBL5120895,,,Activity,,,Activity,,,C/C=C/C[C@@H](C)[C@@H](O)[C@H](NC(=O)[C@@H]1CCCN1C(=O)C(C)(C)NC(=O)CCCCCCC)C(=O)N[C@](C)(CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NC(C)(C)C(=O)NC(C)(C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CO)CC(C)C,2022
Binding affinity to GppNHp-bound Avidin-tagged KRAS G12D mutant (2 to 169 residues) (unknown origin) up to 100 uM by surface plasmon resonance analysis,C/C=C/C[C@@H](C)[C@@H](O)[C@H](NC(=O)[C@@H]1CCCN1C(=O)C(C)(C)NC(=O)CCCCCCCCC)C(=O)NC(C)(C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NC(C)(C)C(=O)NC(C)(C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CO)CC(C)C,CHEMBL5120895,,,Activity,,,Activity,,,C/C=C/C[C@@H](C)[C@@H](O)[C@H](NC(=O)[C@@H]1CCCN1C(=O)C(C)(C)NC(=O)CCCCCCCCC)C(=O)NC(C)(C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NC(C)(C)C(=O)NC(C)(C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CO)CC(C)C,2022
Binding affinity to GppNHp-bound Avidin-tagged KRAS G12D mutant (2 to 169 residues) (unknown origin) up to 100 uM by surface plasmon resonance analysis,CCCCCCCCCC(=O)NC(C)(C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@](C)(CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NC(C)(C)C(=O)NC(C)(C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CO)CC(C)C,CHEMBL5120895,,,Activity,,,Activity,,,CCCCCCCCCC(=O)NC(C)(C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@](C)(CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NC(C)(C)C(=O)NC(C)(C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CO)CC(C)C,2022
Binding affinity to GppNHp-bound Avidin-tagged KRAS G12D mutant (2 to 169 residues) (unknown origin) up to 100 uM by surface plasmon resonance analysis,CCCCCCCCCC(=O)N[C@](C)(CC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@](C)(CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NC(C)(C)C(=O)NC(C)(C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CO)CC(C)C,CHEMBL5120895,,,Activity,,,Activity,,,CCCCCCCCCC(=O)N[C@](C)(CC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@](C)(CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NC(C)(C)C(=O)NC(C)(C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CO)CC(C)C,2022
Binding affinity to GppNHp-bound Avidin-tagged wild-type KRAS (1 to 169 residues) (unknown origin) up to 100 uM by surface plasmon resonance analysis,C/C=C/C[C@@H](C)[C@@H](O)[C@H](NC(=O)[C@@H]1CCCN1C(=O)C(C)(C)NC(=O)CCCCCCCCC)C(=O)N[C@](C)(CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NC(C)(C)C(=O)NC(C)(C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CO)CC(C)C,CHEMBL5120895,,,Activity,,,Activity,,,C/C=C/C[C@@H](C)[C@@H](O)[C@H](NC(=O)[C@@H]1CCCN1C(=O)C(C)(C)NC(=O)CCCCCCCCC)C(=O)N[C@](C)(CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NC(C)(C)C(=O)NC(C)(C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CO)CC(C)C,2022
Binding affinity to GppNHp-bound Avidin-tagged wild-type KRAS (1 to 169 residues) (unknown origin) up to 100 uM by surface plasmon resonance analysis,C/C=C/C[C@@H](C)[C@@H](O)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@](C)(CC)NC(=O)CCCCCCCCC)C(=O)N[C@](C)(CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NC(C)(C)C(=O)NC(C)(C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CO)CC(C)C,CHEMBL5120895,,,Activity,,,Activity,,,C/C=C/C[C@@H](C)[C@@H](O)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@](C)(CC)NC(=O)CCCCCCCCC)C(=O)N[C@](C)(CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NC(C)(C)C(=O)NC(C)(C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CO)CC(C)C,2022
Binding affinity to GppNHp-bound Avidin-tagged wild-type KRAS (1 to 169 residues) (unknown origin) up to 100 uM by surface plasmon resonance analysis,C/C=C/C[C@@H](C)[C@@H](O)[C@H](NC(=O)[C@@H]1CCCN1C(=O)C(C)(C)NC(=O)CCCCCCCCC)C(=O)N[C@](C)(CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NC(C)(C)C(=O)N[C@](C)(CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CO)CC(C)C,CHEMBL5120895,,,Activity,,,Activity,,,C/C=C/C[C@@H](C)[C@@H](O)[C@H](NC(=O)[C@@H]1CCCN1C(=O)C(C)(C)NC(=O)CCCCCCCCC)C(=O)N[C@](C)(CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NC(C)(C)C(=O)N[C@](C)(CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CO)CC(C)C,2022
Binding affinity to GppNHp-bound Avidin-tagged wild-type KRAS (1 to 169 residues) (unknown origin) up to 100 uM by surface plasmon resonance analysis,C/C=C/C[C@@H](C)[C@@H](O)[C@H](NC(=O)[C@@H]1CCCN1C(=O)C(C)(C)NC(=O)CCCCCCC)C(=O)N[C@](C)(CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NC(C)(C)C(=O)NC(C)(C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CO)CC(C)C,CHEMBL5120895,,,Activity,,,Activity,,,C/C=C/C[C@@H](C)[C@@H](O)[C@H](NC(=O)[C@@H]1CCCN1C(=O)C(C)(C)NC(=O)CCCCCCC)C(=O)N[C@](C)(CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NC(C)(C)C(=O)NC(C)(C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CO)CC(C)C,2022
Binding affinity to GppNHp-bound Avidin-tagged wild-type KRAS (1 to 169 residues) (unknown origin) up to 100 uM by surface plasmon resonance analysis,C/C=C/C[C@@H](C)[C@@H](O)[C@H](NC(=O)[C@@H]1CCCN1C(=O)C(C)(C)NC(=O)CCCCCCCCC)C(=O)NC(C)(C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NC(C)(C)C(=O)NC(C)(C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CO)CC(C)C,CHEMBL5120895,,,Activity,,,Activity,,,C/C=C/C[C@@H](C)[C@@H](O)[C@H](NC(=O)[C@@H]1CCCN1C(=O)C(C)(C)NC(=O)CCCCCCCCC)C(=O)NC(C)(C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NC(C)(C)C(=O)NC(C)(C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CO)CC(C)C,2022
Binding affinity to GppNHp-bound Avidin-tagged wild-type KRAS (1 to 169 residues) (unknown origin) up to 100 uM by surface plasmon resonance analysis,CCCCCCCCCC(=O)NC(C)(C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@](C)(CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NC(C)(C)C(=O)NC(C)(C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CO)CC(C)C,CHEMBL5120895,,,Activity,,,Activity,,,CCCCCCCCCC(=O)NC(C)(C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@](C)(CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NC(C)(C)C(=O)NC(C)(C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CO)CC(C)C,2022
Binding affinity to GppNHp-bound Avidin-tagged wild-type KRAS (1 to 169 residues) (unknown origin) up to 100 uM by surface plasmon resonance analysis,CCCCCCCCCC(=O)N[C@](C)(CC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@](C)(CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NC(C)(C)C(=O)NC(C)(C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CO)CC(C)C,CHEMBL5120895,,,Activity,,,Activity,,,CCCCCCCCCC(=O)N[C@](C)(CC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@](C)(CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NC(C)(C)C(=O)NC(C)(C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CO)CC(C)C,2022
Binding affinity to KRAS G12D mutant (unknown origin) measured after 30 mins by TAMRA-N3 based In-gel fluorescence scanning analysis,C#Cc1ccc(S(=O)(=O)N(C)C#C)cc1,CHEMBL5120948,,,Activity,,,Activity,,,C#Cc1ccc(S(=O)(=O)N(C)C#C)cc1,2022
Inhibition of BODIPY loaded KRAS G12C mutant (unknown origin) assessed as inhibition of GDP-GTP exchange rate in presence of SOS1/GppNHp incubated for 2 hr by BODIPY fluorescence assay,C=Cc1ncc2n1CCN(c1nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc13)C2,CHEMBL5131529,=,=,IC50,nM,100.0,IC50,nM,100.0,C=Cc1ncc2n1CCN(c1nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc13)C2,2022
Inhibition of BODIPY loaded KRAS G12C mutant (unknown origin) assessed as inhibition of GDP-GTP exchange rate in presence of SOS1/GppNHp incubated for 2 hr by BODIPY fluorescence assay,C=Cc1ncc2n1CCN(c1nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc13)C2,CHEMBL5131529,=,=,IC50,nM,100.0,IC50,nM,100.0,C=Cc1ncc2n1CCN(c1nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc13)C2,2022
Inhibition of BODIPY loaded KRAS G12C mutant (unknown origin) assessed as inhibition of GDP-GTP exchange rate in presence of SOS1/GppNHp incubated for 2 hr by BODIPY fluorescence assay,C=Cc1ncc2n1CCN(c1nc(=O)n(CC3CC3)c3nc(-c4c(O)cccc4F)c(F)cc13)C2,CHEMBL5131529,=,=,IC50,nM,100.0,IC50,nM,100.0,C=Cc1ncc2n1CCN(c1nc(=O)n(CC3CC3)c3nc(-c4c(O)cccc4F)c(F)cc13)C2,2022
Inhibition of BODIPY loaded KRAS G12C mutant (unknown origin) assessed as inhibition of GDP-GTP exchange rate in presence of SOS1/GppNHp incubated for 2 hr by BODIPY fluorescence assay,C=Cc1ncc2n1CCN(c1nc(=O)n(C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc13)C2,CHEMBL5131529,=,=,IC50,nM,100.0,IC50,nM,100.0,C=Cc1ncc2n1CCN(c1nc(=O)n(C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc13)C2,2022
Inhibition of BODIPY loaded KRAS G12C mutant (unknown origin) assessed as inhibition of GDP-GTP exchange rate in presence of SOS1/GppNHp incubated for 2 hr by BODIPY fluorescence assay,C=Cc1ncc2n1CCN(c1nc(OCC3CCCN3C)nc3c(F)c(-c4cc(O)cc5ccccc45)c(Cl)cc13)C2,CHEMBL5131529,<=,<=,IC50,nM,100.0,IC50,nM,100.0,C=Cc1ncc2n1CCN(c1nc(OCC3CCCN3C)nc3c(F)c(-c4cc(O)cc5ccccc45)c(Cl)cc13)C2,2022
Inhibition of BODIPY loaded KRAS G12C mutant (unknown origin) assessed as inhibition of GDP-GTP exchange rate in presence of SOS1/GppNHp incubated for 2 hr by BODIPY fluorescence assay,C=Cc1ncc2n1CCN(c1nc(OCC3CCCN3C)nc3c(F)c(-c4c(O)cccc4F)c(Cl)cc13)C2,CHEMBL5131529,=,=,IC50,nM,100.0,IC50,nM,100.0,C=Cc1ncc2n1CCN(c1nc(OCC3CCCN3C)nc3c(F)c(-c4c(O)cccc4F)c(Cl)cc13)C2,2022
Inhibition of BODIPY loaded KRAS G12C mutant (unknown origin) assessed as inhibition of GDP-GTP exchange rate in presence of SOS1/GppNHp incubated for 2 hr by BODIPY fluorescence assay,C=Cc1ncc2n1CCN(c1nc(OCC3CCCN3C)nc3c(F)c(-c4c(C)ccc5[nH]ncc45)c(Cl)cc13)C2,CHEMBL5131529,=,=,IC50,nM,100.0,IC50,nM,100.0,C=Cc1ncc2n1CCN(c1nc(OCC3CCCN3C)nc3c(F)c(-c4c(C)ccc5[nH]ncc45)c(Cl)cc13)C2,2022
Inhibition of BODIPY loaded KRAS G12C mutant (unknown origin) assessed as inhibition of GDP-GTP exchange rate in presence of SOS1/GppNHp incubated for 2 hr by BODIPY fluorescence assay,C=Cc1ncc2n1CCN(c1nc(OCCN(C)C)nc3c(F)c(-c4cc(O)cc5ccccc45)c(Cl)cc13)C2,CHEMBL5131529,=,=,IC50,nM,100.0,IC50,nM,100.0,C=Cc1ncc2n1CCN(c1nc(OCCN(C)C)nc3c(F)c(-c4cc(O)cc5ccccc45)c(Cl)cc13)C2,2022
Inhibition of BODIPY loaded KRAS G12C mutant (unknown origin) assessed as inhibition of GDP-GTP exchange rate in presence of SOS1/GppNHp incubated for 2 hr by BODIPY fluorescence assay,C=Cc1ncc2n1CCN(c1nc(OC3CCN(C)CC3)nc3c(F)c(-c4cc(O)cc5ccccc45)c(Cl)cc13)C2,CHEMBL5131529,=,=,IC50,nM,100.0,IC50,nM,100.0,C=Cc1ncc2n1CCN(c1nc(OC3CCN(C)CC3)nc3c(F)c(-c4cc(O)cc5ccccc45)c(Cl)cc13)C2,2022
Inhibition of BODIPY loaded KRAS G12C mutant (unknown origin) assessed as inhibition of GDP-GTP exchange rate in presence of SOS1/GppNHp incubated for 2 hr by BODIPY fluorescence assay,C=Cc1ncc2n1CCN(c1nc(OCCN3CCOCC3)nc3c(F)c(-c4cc(O)cc5ccccc45)c(Cl)cc13)C2,CHEMBL5131529,=,=,IC50,nM,100.0,IC50,nM,100.0,C=Cc1ncc2n1CCN(c1nc(OCCN3CCOCC3)nc3c(F)c(-c4cc(O)cc5ccccc45)c(Cl)cc13)C2,2022
Inhibition of BODIPY loaded KRAS G12C mutant (unknown origin) assessed as inhibition of GDP-GTP exchange rate in presence of SOS1/GppNHp incubated for 2 hr by BODIPY fluorescence assay,C=Cc1ncc2n1CCN(c1nc(OC[C@@H]3CCCN3C)nc3c(F)c(-c4cc(O)cc5ccccc45)c(Cl)cc13)C2,CHEMBL5131529,=,=,IC50,nM,100.0,IC50,nM,100.0,C=Cc1ncc2n1CCN(c1nc(OC[C@@H]3CCCN3C)nc3c(F)c(-c4cc(O)cc5ccccc45)c(Cl)cc13)C2,2022
Inhibition of BODIPY loaded KRAS G12C mutant (unknown origin) assessed as inhibition of GDP-GTP exchange rate in presence of SOS1/GppNHp incubated for 2 hr by BODIPY fluorescence assay,C=Cc1ncc2n1CCN(c1nc(OC3CCCN(C)C3)nc3c(F)c(-c4cc(O)cc5ccccc45)c(Cl)cc13)C2,CHEMBL5131529,=,=,IC50,nM,100.0,IC50,nM,100.0,C=Cc1ncc2n1CCN(c1nc(OC3CCCN(C)C3)nc3c(F)c(-c4cc(O)cc5ccccc45)c(Cl)cc13)C2,2022
Inhibition of KRAS G12C mutant in human MIA PaCa-2 cells assessed as reduction in ERK phosphorylation incubated for 2 to 4 hrs by HTRF assay,C=Cc1ncc2n1CCN(c1nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc13)C2,CHEMBL5131529,=,=,IC50,nM,5000.0,IC50,uM,5.0,C=Cc1ncc2n1CCN(c1nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc13)C2,2022
Inhibition of KRAS G12C mutant in human MIA PaCa-2 cells assessed as reduction in ERK phosphorylation incubated for 2 to 4 hrs by HTRF assay,C=Cc1ncc2n1CCN(c1nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc13)C2,CHEMBL5131529,=,=,IC50,nM,5000.0,IC50,uM,5.0,C=Cc1ncc2n1CCN(c1nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc13)C2,2022
Inhibition of KRAS G12C mutant in human MIA PaCa-2 cells assessed as reduction in ERK phosphorylation incubated for 2 to 4 hrs by HTRF assay,C=Cc1ncc2n1CCN(c1nc(=O)n(CC3CC3)c3nc(-c4c(O)cccc4F)c(F)cc13)C2,CHEMBL5131529,=,=,IC50,nM,5000.0,IC50,uM,5.0,C=Cc1ncc2n1CCN(c1nc(=O)n(CC3CC3)c3nc(-c4c(O)cccc4F)c(F)cc13)C2,2022
Inhibition of KRAS G12C mutant in human MIA PaCa-2 cells assessed as reduction in ERK phosphorylation incubated for 2 to 4 hrs by HTRF assay,C=Cc1ncc2n1CCN(c1nc(=O)n(C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc13)C2,CHEMBL5131529,=,=,IC50,nM,5000.0,IC50,uM,5.0,C=Cc1ncc2n1CCN(c1nc(=O)n(C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc13)C2,2022
Inhibition of KRAS G12C mutant in human MIA PaCa-2 cells assessed as reduction in ERK phosphorylation incubated for 2 to 4 hrs by HTRF assay,C=Cc1ncc2n1CCN(c1nc(OCC3CCCN3C)nc3c(F)c(-c4cc(O)cc5ccccc45)c(Cl)cc13)C2,CHEMBL5131529,=,=,IC50,nM,1000.0,IC50,uM,1.0,C=Cc1ncc2n1CCN(c1nc(OCC3CCCN3C)nc3c(F)c(-c4cc(O)cc5ccccc45)c(Cl)cc13)C2,2022
Inhibition of KRAS G12C mutant in human MIA PaCa-2 cells assessed as reduction in ERK phosphorylation incubated for 2 to 4 hrs by HTRF assay,C=Cc1ncc2n1CCN(c1nc(OCC3CCCN3C)nc3c(F)c(-c4c(O)cccc4F)c(Cl)cc13)C2,CHEMBL5131529,=,=,IC50,nM,5000.0,IC50,uM,5.0,C=Cc1ncc2n1CCN(c1nc(OCC3CCCN3C)nc3c(F)c(-c4c(O)cccc4F)c(Cl)cc13)C2,2022
Inhibition of KRAS G12C mutant in human MIA PaCa-2 cells assessed as reduction in ERK phosphorylation incubated for 2 to 4 hrs by HTRF assay,C=Cc1ncc2n1CCN(c1nc(OCC3CCCN3C)nc3c(F)c(-c4c(C)ccc5[nH]ncc45)c(Cl)cc13)C2,CHEMBL5131529,=,=,IC50,nM,5000.0,IC50,uM,5.0,C=Cc1ncc2n1CCN(c1nc(OCC3CCCN3C)nc3c(F)c(-c4c(C)ccc5[nH]ncc45)c(Cl)cc13)C2,2022
Inhibition of KRAS G12C mutant in human MIA PaCa-2 cells assessed as reduction in ERK phosphorylation incubated for 2 to 4 hrs by HTRF assay,C=Cc1ncc2n1CCN(c1nc(OCCN(C)C)nc3c(F)c(-c4cc(O)cc5ccccc45)c(Cl)cc13)C2,CHEMBL5131529,=,=,IC50,nM,1000.0,IC50,uM,1.0,C=Cc1ncc2n1CCN(c1nc(OCCN(C)C)nc3c(F)c(-c4cc(O)cc5ccccc45)c(Cl)cc13)C2,2022
Inhibition of KRAS G12C mutant in human MIA PaCa-2 cells assessed as reduction in ERK phosphorylation incubated for 2 to 4 hrs by HTRF assay,C=Cc1ncc2n1CCN(c1nc(OC3CCN(C)CC3)nc3c(F)c(-c4cc(O)cc5ccccc45)c(Cl)cc13)C2,CHEMBL5131529,=,=,IC50,nM,5000.0,IC50,uM,5.0,C=Cc1ncc2n1CCN(c1nc(OC3CCN(C)CC3)nc3c(F)c(-c4cc(O)cc5ccccc45)c(Cl)cc13)C2,2022
Inhibition of KRAS G12C mutant in human MIA PaCa-2 cells assessed as reduction in ERK phosphorylation incubated for 2 to 4 hrs by HTRF assay,C=Cc1ncc2n1CCN(c1nc(OCCN3CCOCC3)nc3c(F)c(-c4cc(O)cc5ccccc45)c(Cl)cc13)C2,CHEMBL5131529,=,=,IC50,nM,5000.0,IC50,uM,5.0,C=Cc1ncc2n1CCN(c1nc(OCCN3CCOCC3)nc3c(F)c(-c4cc(O)cc5ccccc45)c(Cl)cc13)C2,2022
Inhibition of KRAS G12C mutant in human MIA PaCa-2 cells assessed as reduction in ERK phosphorylation incubated for 2 to 4 hrs by HTRF assay,C=Cc1ncc2n1CCN(c1nc(OC[C@@H]3CCCN3C)nc3c(F)c(-c4cc(O)cc5ccccc45)c(Cl)cc13)C2,CHEMBL5131529,=,=,IC50,nM,1000.0,IC50,uM,1.0,C=Cc1ncc2n1CCN(c1nc(OC[C@@H]3CCCN3C)nc3c(F)c(-c4cc(O)cc5ccccc45)c(Cl)cc13)C2,2022
Inhibition of KRAS G12C mutant in human MIA PaCa-2 cells assessed as reduction in ERK phosphorylation incubated for 2 to 4 hrs by HTRF assay,C=Cc1ncc2n1CCN(c1nc(OC3CCCN(C)C3)nc3c(F)c(-c4cc(O)cc5ccccc45)c(Cl)cc13)C2,CHEMBL5131529,=,=,IC50,nM,5000.0,IC50,uM,5.0,C=Cc1ncc2n1CCN(c1nc(OC3CCCN(C)C3)nc3c(F)c(-c4cc(O)cc5ccccc45)c(Cl)cc13)C2,2022
Inhibition of BODIPY loaded KRAS G12C mutant (unknown origin) assessed as inhibition of GDP-GTP exchange rate preincubated for 2 hrs and measured after 2 hrs in presence of SOS1-GppNHp mixture by BODIPY fluorescence based PHERAstar plate reader analysis,C=CC(=O)N1CC(F)(Cn2c(=O)c(=O)n(-c3c(C(C)C)cccc3C(C)C)c3nc(-c4cc(O)cc5ccccc45)c(Cl)cc32)C1,CHEMBL5131551,<=,<=,IC50,nM,100.0,IC50,nM,100.0,C=CC(=O)N1CC(F)(Cn2c(=O)c(=O)n(-c3c(C(C)C)cccc3C(C)C)c3nc(-c4cc(O)cc5ccccc45)c(Cl)cc32)C1,2022
Inhibition of BODIPY loaded KRAS G12C mutant (unknown origin) assessed as inhibition of GDP-GTP exchange rate preincubated for 2 hrs and measured after 2 hrs in presence of SOS1-GppNHp mixture by BODIPY fluorescence based PHERAstar plate reader analysis,C=CC(=O)N1CC(F)(Cn2c(=O)c(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4ccccc4F)c(Cl)cc32)C1,CHEMBL5131551,<=,<=,IC50,nM,100.0,IC50,nM,100.0,C=CC(=O)N1CC(F)(Cn2c(=O)c(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4ccccc4F)c(Cl)cc32)C1,2022
Inhibition of BODIPY loaded KRAS G12C mutant (unknown origin) assessed as inhibition of GDP-GTP exchange rate preincubated for 2 hrs and measured after 2 hrs in presence of SOS1-GppNHp mixture by BODIPY fluorescence based PHERAstar plate reader analysis,C=CC(=O)N1CC(F)(Cn2c(=O)c(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(N)cccc4F)c(Cl)cc32)C1,CHEMBL5131551,<=,<=,IC50,nM,100.0,IC50,nM,100.0,C=CC(=O)N1CC(F)(Cn2c(=O)c(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(N)cccc4F)c(Cl)cc32)C1,2022
Inhibition of BODIPY loaded KRAS G12C mutant (unknown origin) assessed as inhibition of GDP-GTP exchange rate preincubated for 2 hrs and measured after 2 hrs in presence of SOS1-GppNHp mixture by BODIPY fluorescence based PHERAstar plate reader analysis,C=CC(=O)N1CC(F)(Cn2c(=O)c(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(F)ccc(F)c4O)c(Cl)cc32)C1,CHEMBL5131551,<=,<=,IC50,nM,100.0,IC50,nM,100.0,C=CC(=O)N1CC(F)(Cn2c(=O)c(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(F)ccc(F)c4O)c(Cl)cc32)C1,2022
Inhibition of BODIPY loaded KRAS G12C mutant (unknown origin) assessed as inhibition of GDP-GTP exchange rate preincubated for 2 hrs and measured after 2 hrs in presence of SOS1-GppNHp mixture by BODIPY fluorescence based PHERAstar plate reader analysis,C=CC(=O)N1CC(F)(Cn2c(=O)c(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4cccc(Cl)c4Cl)c(Cl)cc32)C1,CHEMBL5131551,<=,<=,IC50,nM,100.0,IC50,nM,100.0,C=CC(=O)N1CC(F)(Cn2c(=O)c(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4cccc(Cl)c4Cl)c(Cl)cc32)C1,2022
Inhibition of BODIPY loaded KRAS G12C mutant (unknown origin) assessed as inhibition of GDP-GTP exchange rate preincubated for 2 hrs and measured after 2 hrs in presence of SOS1-GppNHp mixture by BODIPY fluorescence based PHERAstar plate reader analysis,C=CC(=O)N1CC(F)(Cn2c(=O)c(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(Cl)ccc5c4OCO5)c(Cl)cc32)C1,CHEMBL5131551,<=,<=,IC50,nM,100.0,IC50,nM,100.0,C=CC(=O)N1CC(F)(Cn2c(=O)c(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(Cl)ccc5c4OCO5)c(Cl)cc32)C1,2022
Inhibition of KRAS G12C mutant in human MIA PaCa-2 cells assessed as reduction in phosphorylated ERK level incubation for 2 to 4 hrs by HTRF assay,C=CC(=O)N1CC(F)(Cn2c(=O)c(=O)n(-c3c(C(C)C)cccc3C(C)C)c3nc(-c4cc(O)cc5ccccc45)c(Cl)cc32)C1,CHEMBL5131551,<=,<=,IC50,nM,100.0,IC50,nM,100.0,C=CC(=O)N1CC(F)(Cn2c(=O)c(=O)n(-c3c(C(C)C)cccc3C(C)C)c3nc(-c4cc(O)cc5ccccc45)c(Cl)cc32)C1,2022
Inhibition of KRAS G12C mutant in human MIA PaCa-2 cells assessed as reduction in phosphorylated ERK level incubation for 2 to 4 hrs by HTRF assay,C=CC(=O)N1CC(F)(Cn2c(=O)c(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4ccccc4F)c(Cl)cc32)C1,CHEMBL5131551,<=,<=,IC50,nM,100.0,IC50,nM,100.0,C=CC(=O)N1CC(F)(Cn2c(=O)c(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4ccccc4F)c(Cl)cc32)C1,2022
Inhibition of KRAS G12C mutant in human MIA PaCa-2 cells assessed as reduction in phosphorylated ERK level incubation for 2 to 4 hrs by HTRF assay,C=CC(=O)N1CC(F)(Cn2c(=O)c(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(N)cccc4F)c(Cl)cc32)C1,CHEMBL5131551,<=,<=,IC50,nM,100.0,IC50,nM,100.0,C=CC(=O)N1CC(F)(Cn2c(=O)c(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(N)cccc4F)c(Cl)cc32)C1,2022
Inhibition of KRAS G12C mutant in human MIA PaCa-2 cells assessed as reduction in phosphorylated ERK level incubation for 2 to 4 hrs by HTRF assay,C=CC(=O)N1CC(F)(Cn2c(=O)c(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(F)ccc(F)c4O)c(Cl)cc32)C1,CHEMBL5131551,<=,<=,IC50,nM,100.0,IC50,nM,100.0,C=CC(=O)N1CC(F)(Cn2c(=O)c(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(F)ccc(F)c4O)c(Cl)cc32)C1,2022
Inhibition of KRAS G12C mutant in human MIA PaCa-2 cells assessed as reduction in phosphorylated ERK level incubation for 2 to 4 hrs by HTRF assay,C=CC(=O)N1CC(F)(Cn2c(=O)c(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4cccc(Cl)c4Cl)c(Cl)cc32)C1,CHEMBL5131551,<=,<=,IC50,nM,100.0,IC50,nM,100.0,C=CC(=O)N1CC(F)(Cn2c(=O)c(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4cccc(Cl)c4Cl)c(Cl)cc32)C1,2022
Inhibition of KRAS G12C mutant in human MIA PaCa-2 cells assessed as reduction in phosphorylated ERK level incubation for 2 to 4 hrs by HTRF assay,C=CC(=O)N1CC(F)(Cn2c(=O)c(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(Cl)ccc5c4OCO5)c(Cl)cc32)C1,CHEMBL5131551,<=,<=,IC50,nM,100.0,IC50,nM,100.0,C=CC(=O)N1CC(F)(Cn2c(=O)c(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(Cl)ccc5c4OCO5)c(Cl)cc32)C1,2022
Inhibition of recombinant biotinylated KRAS G12D mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL5131563,=,=,IC50,nM,54.0,IC50,nM,54.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2022
Inhibition of recombinant biotinylated KRAS G12D mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,CCC[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL5131563,>,>,IC50,nM,11110.0,IC50,nM,11110.0,CCC[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2022
Inhibition of recombinant biotinylated KRAS G12D mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](CC2CCCC2)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C1=O,CHEMBL5131563,>,>,IC50,nM,11110.0,IC50,nM,11110.0,CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](CC2CCCC2)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C1=O,2022
Inhibition of recombinant biotinylated KRAS G12D mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(C)C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C1=O,CHEMBL5131563,>,>,IC50,nM,11110.0,IC50,nM,11110.0,CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(C)C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C1=O,2022
Inhibition of recombinant biotinylated KRAS G12D mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,CC[C@H](C)[C@@H]1NC(=O)[C@H](CCc2ccccc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL5131563,=,=,IC50,nM,1387.0,IC50,nM,1387.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](CCc2ccccc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2022
Inhibition of recombinant biotinylated KRAS G12D mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,CCC[C@@H]1NC(=O)[C@H](CCc2ccccc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL5131563,>,>,IC50,nM,11110.0,IC50,nM,11110.0,CCC[C@@H]1NC(=O)[C@H](CCc2ccccc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2022
Inhibition of recombinant biotinylated KRAS G12D mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](CC2CCCC2)NC(=O)[C@H](CCc2ccccc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C1=O,CHEMBL5131563,>,>,IC50,nM,11110.0,IC50,nM,11110.0,CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](CC2CCCC2)NC(=O)[C@H](CCc2ccccc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C1=O,2022
Inhibition of recombinant biotinylated KRAS G12D mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(C)C)NC(=O)[C@H](CCc2ccccc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C1=O,CHEMBL5131563,>,>,IC50,nM,11110.0,IC50,nM,11110.0,CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(C)C)NC(=O)[C@H](CCc2ccccc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C1=O,2022
Inhibition of recombinant biotinylated KRAS G12D mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL5131563,=,=,IC50,nM,7.0,IC50,nM,7.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2022
Inhibition of recombinant biotinylated KRAS G12D mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,CCC[C@@H]1NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL5131563,=,=,IC50,nM,604.0,IC50,nM,604.0,CCC[C@@H]1NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2022
Inhibition of recombinant biotinylated KRAS G12D mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,CC(C)C[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(N)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](CC2CCCC2)NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC1=O,CHEMBL5131563,>,>,IC50,nM,11110.0,IC50,nM,11110.0,CC(C)C[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(N)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](CC2CCCC2)NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC1=O,2022
Inhibition of recombinant biotinylated KRAS G12D mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(C)C)NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C1=O,CHEMBL5131563,>,>,IC50,nM,11110.0,IC50,nM,11110.0,CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(C)C)NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C1=O,2022
Inhibition of recombinant biotinylated KRAS G12D mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,CC[C@H](C)[C@@H]1NC(=O)[C@H](CC2CCCCC2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL5131563,=,=,IC50,nM,161.0,IC50,nM,161.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](CC2CCCCC2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2022
Inhibition of recombinant biotinylated KRAS G12D mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,CCC[C@@H]1NC(=O)[C@H](CC2CCCCC2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL5131563,>,>,IC50,nM,11110.0,IC50,nM,11110.0,CCC[C@@H]1NC(=O)[C@H](CC2CCCCC2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2022
Inhibition of recombinant biotinylated KRAS G12D mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](CC2CCCC2)NC(=O)[C@H](CC2CCCCC2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C1=O,CHEMBL5131563,>,>,IC50,nM,11110.0,IC50,nM,11110.0,CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](CC2CCCC2)NC(=O)[C@H](CC2CCCCC2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C1=O,2022
Inhibition of recombinant biotinylated KRAS G12D mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(C)C)NC(=O)[C@H](CC2CCCCC2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C1=O,CHEMBL5131563,>,>,IC50,nM,11110.0,IC50,nM,11110.0,CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(C)C)NC(=O)[C@H](CC2CCCCC2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C1=O,2022
Inhibition of recombinant biotinylated KRAS G12D mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](C(c2ccccc2)c2ccccc2)NC(=O)[C@H](CO)NC1=O,CHEMBL5131563,=,=,IC50,nM,251.0,IC50,nM,251.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](C(c2ccccc2)c2ccccc2)NC(=O)[C@H](CO)NC1=O,2022
Inhibition of recombinant biotinylated KRAS G12D mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2cc(F)c(F)c(F)c2)NC(=O)[C@H](CO)NC1=O,CHEMBL5131563,=,=,IC50,nM,193.0,IC50,nM,193.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2cc(F)c(F)c(F)c2)NC(=O)[C@H](CO)NC1=O,2022
Inhibition of recombinant biotinylated KRAS G12D mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2CCCCC2)NC(=O)[C@H](CO)NC1=O,CHEMBL5131563,=,=,IC50,nM,1474.0,IC50,nM,1474.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2CCCCC2)NC(=O)[C@H](CO)NC1=O,2022
Inhibition of recombinant biotinylated KRAS G12D mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](C(c2ccccc2)c2ccccc2)NC(=O)[C@H](CCN)NC1=O,CHEMBL5131563,>,>,IC50,nM,11110.0,IC50,nM,11110.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](C(c2ccccc2)c2ccccc2)NC(=O)[C@H](CCN)NC1=O,2022
Inhibition of recombinant biotinylated KRAS G12D mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,CCCC[C@@H]1NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O,CHEMBL5131563,>,>,IC50,nM,11110.0,IC50,nM,11110.0,CCCC[C@@H]1NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O,2022
Inhibition of recombinant biotinylated KRAS G12D mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,CCCC[C@@H]1NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2CCCCC2)NC1=O,CHEMBL5131563,>,>,IC50,nM,11110.0,IC50,nM,11110.0,CCCC[C@@H]1NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC2CCCCC2)NC1=O,2022
Inhibition of recombinant biotinylated KRAS G12D mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2cscn2)NC1=O,CHEMBL5131563,=,=,IC50,nM,2269.0,IC50,nM,2269.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](Cc2cscn2)NC1=O,2022
Inhibition of recombinant biotinylated KRAS G12D mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2cc(F)c(F)c(F)c2)NC(=O)[C@H](Cc2cscn2)NC1=O,CHEMBL5131563,>,>,IC50,nM,11110.0,IC50,nM,11110.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2cc(F)c(F)c(F)c2)NC(=O)[C@H](Cc2cscn2)NC1=O,2022
Inhibition of recombinant biotinylated KRAS G12D mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,CC[C@H](C)[C@@H]1NC(=O)[C@@H](Cc2ccc(-c3ccccc3)cc2)C(=O)[C@H](COC)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL5131563,=,=,IC50,nM,1133.0,IC50,nM,1133.0,CC[C@H](C)[C@@H]1NC(=O)[C@@H](Cc2ccc(-c3ccccc3)cc2)C(=O)[C@H](COC)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2022
Inhibition of recombinant biotinylated KRAS G12D mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,C=CCO[C@H]1CCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](Cc3ccc(-c4ccccc4)cc3)NC(=O)[C@H]12,CHEMBL5131563,=,=,IC50,nM,1.0,IC50,nM,1.0,C=CCO[C@H]1CCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](Cc3ccc(-c4ccccc4)cc3)NC(=O)[C@H]12,2022
Inhibition of recombinant biotinylated KRAS G12D mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,C=CCO[C@H]1CCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](Cc3ccc(-c4ccccc4)cc3)NC(=O)[C@H](CC3CCC3)NC(=O)[C@H]12,CHEMBL5131563,=,=,IC50,nM,2.0,IC50,nM,2.0,C=CCO[C@H]1CCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](Cc3ccc(-c4ccccc4)cc3)NC(=O)[C@H](CC3CCC3)NC(=O)[C@H]12,2022
Inhibition of recombinant biotinylated KRAS G12D mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2[C@@H](c3ccccc3)CCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL5131563,=,=,IC50,nM,1.0,IC50,nM,1.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2[C@@H](c3ccccc3)CCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2022
Inhibition of recombinant biotinylated KRAS G12D mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC2CCC2)NC(=O)[C@@H]2[C@@H](c3ccccc3)CCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL5131563,=,=,IC50,nM,7.0,IC50,nM,7.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC2CCC2)NC(=O)[C@@H]2[C@@H](c3ccccc3)CCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2022
Inhibition of recombinant biotinylated KRAS G12D mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H]2[C@@H](c3ccccc3)CCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL5131563,=,=,IC50,nM,20.0,IC50,nM,20.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H]2[C@@H](c3ccccc3)CCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2022
Inhibition of recombinant biotinylated KRAS G12D mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2[C@H]3CC[C@H](C3)N2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL5131563,=,=,IC50,nM,201.0,IC50,nM,201.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2[C@H]3CC[C@H](C3)N2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2022
Inhibition of recombinant biotinylated KRAS G12D mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,CCCCC[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC1=O,CHEMBL5131563,=,=,IC50,nM,5.0,IC50,nM,5.0,CCCCC[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC1=O,2022
Inhibition of recombinant biotinylated KRAS G12D mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](CCC#N)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL5131563,=,=,IC50,nM,24.0,IC50,nM,24.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](CCC#N)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2022
Inhibition of recombinant biotinylated KRAS G12D mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](CCCC(=O)O)NC(=O)[C@@H]2[C@@H](C)CCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL5131563,=,=,IC50,nM,43.0,IC50,nM,43.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](CCCC(=O)O)NC(=O)[C@@H]2[C@@H](C)CCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2022
Inhibition of recombinant biotinylated KRAS G12D mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,CCCCC[C@@H]1NC(=O)[C@@H]2C[C@H](OCC(=O)O)CN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC1=O,CHEMBL5131563,=,=,IC50,nM,23.0,IC50,nM,23.0,CCCCC[C@@H]1NC(=O)[C@@H]2C[C@H](OCC(=O)O)CN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC1=O,2022
Inhibition of recombinant biotinylated KRAS G12D mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](CC2CCCCC2)NC(=O)[C@@H]2C[C@H](OCC(=O)O)CN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL5131563,=,=,IC50,nM,25.0,IC50,nM,25.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](CC2CCCCC2)NC(=O)[C@@H]2C[C@H](OCC(=O)O)CN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2022
Inhibition of recombinant biotinylated KRAS G12D mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](Cc2ccc(Cl)cc2)NC(=O)[C@@H]2C[C@H](OCC(=O)O)CN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL5131563,=,=,IC50,nM,33.0,IC50,nM,33.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](Cc2ccc(Cl)cc2)NC(=O)[C@@H]2C[C@H](OCC(=O)O)CN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2022
Inhibition of recombinant biotinylated KRAS G12D mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CC[C@@H](c3ccccc3)N2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL5131563,=,=,IC50,nM,94.0,IC50,nM,94.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CC[C@@H](c3ccccc3)N2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2022
Inhibition of recombinant biotinylated KRAS G12D mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2[C@@H](c3ccccc3)CCN2CC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL5131563,<,<,IC50,nM,1.0,IC50,nM,1.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2[C@@H](c3ccccc3)CCN2CC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2022
Inhibition of recombinant biotinylated KRAS G12D mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,C=CC[C@H]1CCN2CC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](Cc3ccc(-c4ccccc4)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]12,CHEMBL5131563,<,<,IC50,nM,1.0,IC50,nM,1.0,C=CC[C@H]1CCN2CC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](Cc3ccc(-c4ccccc4)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]12,2022
Inhibition of recombinant biotinylated KRAS G12D mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,CCCCC[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2[C@@H](c3ccccc3)CCN2CC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC1=O,CHEMBL5131563,<,<,IC50,nM,1.0,IC50,nM,1.0,CCCCC[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2[C@@H](c3ccccc3)CCN2CC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC1=O,2022
Inhibition of recombinant biotinylated KRAS G12D mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,C=CC[C@H]1CCN2CC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](CCCCC)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](Cc3ccc(-c4ccccc4)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]12,CHEMBL5131563,<,<,IC50,nM,1.0,IC50,nM,1.0,C=CC[C@H]1CCN2CC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](CCCCC)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](Cc3ccc(-c4ccccc4)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]12,2022
Inhibition of recombinant biotinylated KRAS G12D mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2[C@H](c3ccccc3)CCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN=[N+]=[N-])NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL5131563,<,<,IC50,nM,1.0,IC50,nM,1.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2[C@H](c3ccccc3)CCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN=[N+]=[N-])NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2022
Inhibition of recombinant biotinylated KRAS G12D mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2[C@H](c3ccccc3)CCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC1=O,CHEMBL5131563,<,<,IC50,nM,1.0,IC50,nM,1.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2[C@H](c3ccccc3)CCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC1=O,2022
Inhibition of recombinant biotinylated KRAS G12D mutant (unknown origin) assessed as inhibition of SOS-catalyzed nucleotide exchange preincubated for 60 mins followed by addition of human SOS protein and unlabeled GTP and measured after 60 mins by TR-FRET analysis,CC(=O)N[C@@H](CCCCN=[N+]=[N-])C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2[C@@H](c3ccccc3)CCN2C1=O,CHEMBL5131563,<,<,IC50,nM,1.0,IC50,nM,1.0,CC(=O)N[C@@H](CCCCN=[N+]=[N-])C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2[C@@H](c3ccccc3)CCN2C1=O,2022
Inhibition of KRAS in human ASPC1 cells harboring KRAS G12D mutant assessed as inhibition of ERK phosphorylation incubated for 2 hrs by AlphaScreen-based LDH membrane integrity assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2[C@@H](c3ccccc3)CCN2CC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL5131563,=,=,IC50,nM,3300.0,IC50,uM,3.3,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2[C@@H](c3ccccc3)CCN2CC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2022
Inhibition of KRAS in human ASPC1 cells harboring KRAS G12D mutant assessed as inhibition of ERK phosphorylation incubated for 2 hrs by AlphaScreen-based LDH membrane integrity assay,C=CC[C@H]1CCN2CC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](Cc3ccc(-c4ccccc4)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]12,CHEMBL5131563,=,=,IC50,nM,28000.0,IC50,uM,28.0,C=CC[C@H]1CCN2CC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](Cc3ccc(-c4ccccc4)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]12,2022
Inhibition of KRAS in human ASPC1 cells harboring KRAS G12D mutant assessed as inhibition of ERK phosphorylation incubated for 2 hrs by AlphaScreen-based LDH membrane integrity assay,CCCCC[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2[C@@H](c3ccccc3)CCN2CC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC1=O,CHEMBL5131563,=,=,IC50,nM,6800.0,IC50,uM,6.8,CCCCC[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2[C@@H](c3ccccc3)CCN2CC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC1=O,2022
Inhibition of KRAS in human ASPC1 cells harboring KRAS G12D mutant assessed as inhibition of ERK phosphorylation incubated for 2 hrs by AlphaScreen-based LDH membrane integrity assay,C=CC[C@H]1CCN2CC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](CCCCC)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](Cc3ccc(-c4ccccc4)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]12,CHEMBL5131563,=,=,IC50,nM,30000.0,IC50,uM,30.0,C=CC[C@H]1CCN2CC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](CCCCC)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](Cc3ccc(-c4ccccc4)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]12,2022
Inhibition of KRAS in human ASPC1 cells harboring KRAS G12D mutant assessed as inhibition of ERK phosphorylation incubated for 2 hrs by AlphaScreen-based LDH membrane integrity assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2[C@H](c3ccccc3)CCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN=[N+]=[N-])NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL5131563,=,=,IC50,nM,2700.0,IC50,uM,2.7,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2[C@H](c3ccccc3)CCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN=[N+]=[N-])NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2022
Inhibition of KRAS in human ASPC1 cells harboring KRAS G12D mutant assessed as inhibition of ERK phosphorylation incubated for 2 hrs by AlphaScreen-based LDH membrane integrity assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2[C@H](c3ccccc3)CCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC1=O,CHEMBL5131563,=,=,IC50,nM,3800.0,IC50,uM,3.8,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2[C@H](c3ccccc3)CCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC1=O,2022
Inhibition of KRAS in human ASPC1 cells harboring KRAS G12D mutant assessed as inhibition of ERK phosphorylation incubated for 2 hrs by AlphaScreen-based LDH membrane integrity assay,CC(=O)N[C@@H](CCCCN=[N+]=[N-])C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2[C@@H](c3ccccc3)CCN2C1=O,CHEMBL5131563,=,=,IC50,nM,6200.0,IC50,uM,6.2,CC(=O)N[C@@H](CCCCN=[N+]=[N-])C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2[C@@H](c3ccccc3)CCN2C1=O,2022
Inhibition of KRAS in human ASPC1 cells harboring KRAS G12D mutant assessed as inhibition of ERK phosphorylation incubated for 18 hrs by AlphaScreen-based LDH membrane integrity assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2[C@@H](c3ccccc3)CCN2CC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL5131563,=,=,IC50,nM,33000.0,IC50,uM,33.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2[C@@H](c3ccccc3)CCN2CC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2022
Inhibition of KRAS in human ASPC1 cells harboring KRAS G12D mutant assessed as inhibition of ERK phosphorylation incubated for 18 hrs by AlphaScreen-based LDH membrane integrity assay,C=CC[C@H]1CCN2CC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](Cc3ccc(-c4ccccc4)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]12,CHEMBL5131563,>,>,IC50,nM,50000.0,IC50,uM,50.0,C=CC[C@H]1CCN2CC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](Cc3ccc(-c4ccccc4)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]12,2022
Inhibition of KRAS in human ASPC1 cells harboring KRAS G12D mutant assessed as inhibition of ERK phosphorylation incubated for 18 hrs by AlphaScreen-based LDH membrane integrity assay,CCCCC[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2[C@@H](c3ccccc3)CCN2CC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC1=O,CHEMBL5131563,=,=,IC50,nM,29000.0,IC50,uM,29.0,CCCCC[C@@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2[C@@H](c3ccccc3)CCN2CC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC1=O,2022
Inhibition of KRAS in human ASPC1 cells harboring KRAS G12D mutant assessed as inhibition of ERK phosphorylation incubated for 18 hrs by AlphaScreen-based LDH membrane integrity assay,C=CC[C@H]1CCN2CC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](CCCCC)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](Cc3ccc(-c4ccccc4)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]12,CHEMBL5131563,>,>,IC50,nM,50000.0,IC50,uM,50.0,C=CC[C@H]1CCN2CC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](CCCCC)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](Cc3ccc(-c4ccccc4)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]12,2022
Inhibition of KRAS in human ASPC1 cells harboring KRAS G12D mutant assessed as inhibition of ERK phosphorylation incubated for 18 hrs by AlphaScreen-based LDH membrane integrity assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2[C@H](c3ccccc3)CCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN=[N+]=[N-])NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,CHEMBL5131563,=,=,IC50,nM,19000.0,IC50,uM,19.0,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2[C@H](c3ccccc3)CCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN=[N+]=[N-])NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC1=O,2022
Inhibition of KRAS in human ASPC1 cells harboring KRAS G12D mutant assessed as inhibition of ERK phosphorylation incubated for 18 hrs by AlphaScreen-based LDH membrane integrity assay,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2[C@H](c3ccccc3)CCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC1=O,CHEMBL5131563,=,=,IC50,nM,3900.0,IC50,uM,3.9,CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2[C@H](c3ccccc3)CCN2C(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(C)=O)CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC1=O,2022
Inhibition of KRAS in human ASPC1 cells harboring KRAS G12D mutant assessed as inhibition of ERK phosphorylation incubated for 18 hrs by AlphaScreen-based LDH membrane integrity assay,CC(=O)N[C@@H](CCCCN=[N+]=[N-])C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2[C@@H](c3ccccc3)CCN2C1=O,CHEMBL5131563,=,=,IC50,nM,6800.0,IC50,uM,6.8,CC(=O)N[C@@H](CCCCN=[N+]=[N-])C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](Cc2ccc(-c3ccccc3)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2[C@@H](c3ccccc3)CCN2C1=O,2022
Binding affinity to KRAS (unknown origin) assessed as inhibition constant,C=CC(=O)N1CC(N2CCN(C(=O)CNc3cc(C4(C)CC4)c(Cl)cc3O)CC2)C1,CHEMBL5143589,=,=,Ki,nM,200000.0,Ki,uM,200.0,C=CC(=O)N1CC(N2CCN(C(=O)CNc3cc(C4(C)CC4)c(Cl)cc3O)CC2)C1,2022
Binding affinity to KRAS (unknown origin) assessed as inhibition constant,C=CC(=O)N1CCN(c2ncnc3c(F)c(-c4c(O)cccc4F)c(Cl)cc23)CC1,CHEMBL5143589,=,=,Ki,nM,31000.0,Ki,uM,31.0,C=CC(=O)N1CCN(c2ncnc3c(F)c(-c4c(O)cccc4F)c(Cl)cc23)CC1,2022
Binding affinity to KRAS (unknown origin) assessed as inhibition constant,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1,CHEMBL5143589,=,=,Ki,nM,86000.0,Ki,uM,86.0,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1,2022
Binding affinity to KRAS (unknown origin) assessed as inhibition constant,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,CHEMBL5143589,=,=,Ki,nM,3700.0,Ki,uM,3.7,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,2022
Binding affinity to KRAS (unknown origin) assessed as inactivation constant,C=CC(=O)N1CC(N2CCN(C(=O)CNc3cc(C4(C)CC4)c(Cl)cc3O)CC2)C1,CHEMBL5143589,=,=,Kinact,/s,0.05,Kinact,/s,0.05,C=CC(=O)N1CC(N2CCN(C(=O)CNc3cc(C4(C)CC4)c(Cl)cc3O)CC2)C1,2022
Binding affinity to KRAS (unknown origin) assessed as inactivation constant,C=CC(=O)N1CCN(c2ncnc3c(F)c(-c4c(O)cccc4F)c(Cl)cc23)CC1,CHEMBL5143589,=,=,Kinact,/s,0.03,Kinact,/s,0.03,C=CC(=O)N1CCN(c2ncnc3c(F)c(-c4c(O)cccc4F)c(Cl)cc23)CC1,2022
Binding affinity to KRAS (unknown origin) assessed as inactivation constant,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1,CHEMBL5143589,=,=,Kinact,/s,0.85,Kinact,/s,0.85,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1,2022
Binding affinity to KRAS (unknown origin) assessed as inactivation constant,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,CHEMBL5143589,=,=,Kinact,/s,0.13,Kinact,/s,0.13,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,2022
Binding affinity to KRAS (unknown origin) assessed as ratio of inactivation constant to inhibition constant,C=CC(=O)N1CC(N2CCN(C(=O)CNc3cc(C4(C)CC4)c(Cl)cc3O)CC2)C1,CHEMBL5143589,=,=,Ratio,/mM/s,0.2,Ratio,/mM/s,0.2,C=CC(=O)N1CC(N2CCN(C(=O)CNc3cc(C4(C)CC4)c(Cl)cc3O)CC2)C1,2022
Binding affinity to KRAS (unknown origin) assessed as ratio of inactivation constant to inhibition constant,C=CC(=O)N1CCN(c2ncnc3c(F)c(-c4c(O)cccc4F)c(Cl)cc23)CC1,CHEMBL5143589,=,=,Ratio,/mM/s,2.4,Ratio,/mM/s,2.4,C=CC(=O)N1CCN(c2ncnc3c(F)c(-c4c(O)cccc4F)c(Cl)cc23)CC1,2022
Binding affinity to KRAS (unknown origin) assessed as ratio of inactivation constant to inhibition constant,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1,CHEMBL5143589,=,=,Ratio,/mM/s,9.9,Ratio,/mM/s,9.9,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1,2022
Binding affinity to KRAS (unknown origin) assessed as ratio of inactivation constant to inhibition constant,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,CHEMBL5143589,=,=,Ratio,/mM/s,35.0,Ratio,/mM/s,35.0,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,2022
Binding affinity to wild type KRAS (unknown origin) assessed as dissociation constant,CN1CCC[C@H]1COc1nc(N2CCNCC2)c2cnc(-c3cccc4cccc(Cl)c34)c(F)c2n1,CHEMBL5143589,=,=,Kd,nM,36000.0,Kd,uM,36.0,CN1CCC[C@H]1COc1nc(N2CCNCC2)c2cnc(-c3cccc4cccc(Cl)c34)c(F)c2n1,2022
Binding affinity to KRAS (unknown origin) assessed as dissociation constant,C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OC[C@@]56CCCN5C[C@H](F)C6)nc4c3F)c12,CHEMBL5143589,<,<,Kd,nM,0.0002,Kd,nM,0.0002,C#Cc1c(F)ccc2cc(O)cc(-c3ncc4c(N5CC6CCC(C5)N6)nc(OC[C@@]56CCCN5C[C@H](F)C6)nc4c3F)c12,2022
Binding affinity to GDP-bound KRAS G12V RAS mutant (unknown origin),O=S(=O)(NCCOc1ccc2ccccc2c1)c1ccc(NO)cc1,CHEMBL5149962,=,=,IC50,nM,500.0,IC50,uM,0.5,O=S(=O)(NCCOc1ccc2ccccc2c1)c1ccc(NO)cc1,2021
Binding affinity to GDP-bound KRAS G12V RAS mutant (unknown origin),O=S(=O)(c1ccc(NO)cc1)N(CCOc1ccc2ccccc2c1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,CHEMBL5149962,=,=,IC50,nM,700.0,IC50,uM,0.7,O=S(=O)(c1ccc(NO)cc1)N(CCOc1ccc2ccccc2c1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,2021
Binding affinity to GDP-bound KRAS G12V RAS mutant (unknown origin),Nc1nc2c(ncn2CCN(CCOc2ccc3ccccc3c2)S(=O)(=O)c2ccc(NO)cc2)c(=O)[nH]1,CHEMBL5149962,=,=,IC50,nM,500.0,IC50,uM,0.5,Nc1nc2c(ncn2CCN(CCOc2ccc3ccccc3c2)S(=O)(=O)c2ccc(NO)cc2)c(=O)[nH]1,2021
Binding affinity to GDP-bound KRAS G12D mutant (unknown origin) assessed as dissociation constant,Nc1ccc2nc(Cc3c[nH]c4ccccc34)[nH]c2c1,CHEMBL5149962,=,=,Kd,nM,1300000.0,Kd,uM,1300.0,Nc1ccc2nc(Cc3c[nH]c4ccccc34)[nH]c2c1,2021
Binding affinity to GDP-bound KRAS G12D mutant (unknown origin) assessed as dissociation constant,O=C(Nc1ccc2nc(Cc3c[nH]c4ccccc34)[nH]c2c1)[C@@H]1CCCN1,CHEMBL5149962,=,=,Kd,nM,340000.0,Kd,uM,340.0,O=C(Nc1ccc2nc(Cc3c[nH]c4ccccc34)[nH]c2c1)[C@@H]1CCCN1,2021
Binding affinity to GDP-bound KRAS G12D mutant (unknown origin) assessed as dissociation constant,CC[C@H](C)[C@H](N)C(=O)NC1=Cc2[nH]c(Cc3c[nH]c4ccccc34)nc2CC1,CHEMBL5149962,=,=,Kd,nM,190000.0,Kd,uM,190.0,CC[C@H](C)[C@H](N)C(=O)NC1=Cc2[nH]c(Cc3c[nH]c4ccccc34)nc2CC1,2021
Binding affinity to KRAS (unknown origin) assessed as dissociation constant,Cc1[nH]c2cc(Cl)cc(Cl)c2c1CCN,CHEMBL5149962,=,=,Kd,nM,1100000.0,Kd,mM,1.1,Cc1[nH]c2cc(Cl)cc(Cl)c2c1CCN,2021
Binding affinity to KRAS (unknown origin) assessed as dissociation constant,c1ccc2[nH]cnc2c1,CHEMBL5149962,=,=,Kd,nM,1500000.0,Kd,mM,1.5,c1ccc2[nH]cnc2c1,2021
Inhibition of KRAS G12C mutant (unknown origin),C=CC(=O)N1CCN(c2nc(NCCC(=O)N(C)C)nc3c(F)c(-c4cc(O)cc5ccccc45)c(Cl)cc23)CC1,CHEMBL5149962,=,=,IC50,nM,726.0,IC50,uM,0.726,C=CC(=O)N1CCN(c2nc(NCCC(=O)N(C)C)nc3c(F)c(-c4cc(O)cc5ccccc45)c(Cl)cc23)CC1,2021
Antiproliferative activity against human COLO 320DM cells harboring wild type KRAS assessed as reduction in cell viability incubated for 24 hrs in presence of MVA,CCCC[C@@H](C)/C=C(C)/C=C(\C)C(=O)NC1=C[C@@](O)(/C=C/C=C/C=C/C(=O)NC2=C(O)CCC2=O)[C@@H]2O[C@@H]2C1=O,CHEMBL5149962,=,=,IC50,nM,3580.0,IC50,uM,3.58,CCCC[C@@H](C)/C=C(C)/C=C(\C)C(=O)NC1=C[C@@](O)(/C=C/C=C/C=C/C(=O)NC2=C(O)CCC2=O)[C@@H]2O[C@@H]2C1=O,2021
Inhibition of KRAS G12V mutant (unknown origin) expressed in mouse NIH3T3 cells assessed as inhibition of post-translational modification processing,CSCC[C@H](CC(=O)[C@H](/C=C\[C@@H](/C=C/[C@@H](N)CS)C(C)C)Cc1ccccc1)C(=O)O,CHEMBL5149962,=,=,IC50,nM,25000.0,IC50,uM,25.0,CSCC[C@H](CC(=O)[C@H](/C=C\[C@@H](/C=C/[C@@H](N)CS)C(C)C)Cc1ccccc1)C(=O)O,2021
Inhibition of K-Ras (unknown origin) geranylgeranylation,N#Cc1ccc2c(c1)CN(S(=O)(=O)c1cccs1)[C@H](Cc1ccccc1)CN2Cc1c[nH]cn1,CHEMBL5149962,=,=,IC50,nM,2300.0,IC50,uM,2.3,N#Cc1ccc2c(c1)CN(S(=O)(=O)c1cccs1)[C@H](Cc1ccccc1)CN2Cc1c[nH]cn1,2021
Inhibition of K-Ras (unknown origin) farnesylation,N#Cc1ccc2c(c1)CN(S(=O)(=O)c1cccs1)[C@H](Cc1ccccc1)CN2Cc1c[nH]cn1,CHEMBL5149962,=,=,IC90,nM,108.0,IC90,nM,108.0,N#Cc1ccc2c(c1)CN(S(=O)(=O)c1cccs1)[C@H](Cc1ccccc1)CN2Cc1c[nH]cn1,2021
Inhibition of K-Ras (unknown origin) farnesylation,N#Cc1ccc2c(c1)CN(S(=O)(=O)c1cccs1)[C@H](Cc1ccccc1)CN2Cc1c[nH]cn1,CHEMBL5149962,=,=,IC50,nM,8.4,IC50,nM,8.4,N#Cc1ccc2c(c1)CN(S(=O)(=O)c1cccs1)[C@H](Cc1ccccc1)CN2Cc1c[nH]cn1,2021
Inhibition of recombinant full length FLAG tagged KRAS G12C mutant (1 to 169 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3),C=CC(=O)N1CC(N2CCN(C(=O)CNc3cc(C4(C)CC4)c(Cl)cc3O)CC2)C1,CHEMBL5149962,=,=,IC50,nM,1700.0,IC50,nM,1700.0,C=CC(=O)N1CC(N2CCN(C(=O)CNc3cc(C4(C)CC4)c(Cl)cc3O)CC2)C1,2021
Inhibition of recombinant full length FLAG tagged KRAS G12C mutant (1 to 169 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3),C=CC(=O)N1CCN(c2ncnc3c(F)c(-c4c(O)cccc4F)c(Cl)cc23)CC1,CHEMBL5149962,=,=,IC50,nM,120.0,IC50,nM,120.0,C=CC(=O)N1CCN(c2ncnc3c(F)c(-c4c(O)cccc4F)c(Cl)cc23)CC1,2021
Inhibition of KRAS (unknown origin) dependent signal transduction,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,CHEMBL5149962,=,=,EC50,nM,10.0,EC50,nM,10.0,C=C(F)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,2021
Inhibition of human K-ras,N#Cc1ccc2c(c1)CN(S(=O)(=O)c1cccs1)[C@H](Cc1ccccc1)CN2Cc1c[nH]cn1,CHEMBL5150007,=,=,IC50,nM,8.4,IC50,nM,8.4,N#Cc1ccc2c(c1)CN(S(=O)(=O)c1cccs1)[C@H](Cc1ccccc1)CN2Cc1c[nH]cn1,2021
Inhibition of KRAS G12C mutant (unknown origin) assessed as inhibition of SOS1-catalyzed nucleotide exchange measured by HTRF assay,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1,CHEMBL5154696,=,=,IC50,nM,9.66,IC50,nM,9.66,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1,2022
Inhibition of KRAS G12C mutant (unknown origin) assessed as inhibition of SOS1-catalyzed nucleotide exchange measured by HTRF assay,CC=C(C#N)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,CHEMBL5154696,=,=,IC50,nM,96.32,IC50,nM,96.32,CC=C(C#N)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,2022
Inhibition of KRAS G12C mutant (unknown origin) assessed as inhibition of SOS1-catalyzed nucleotide exchange measured by HTRF assay,CCC=C(C#N)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,CHEMBL5154696,=,=,IC50,nM,270.88,IC50,nM,270.88,CCC=C(C#N)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,2022
Inhibition of KRAS G12C mutant (unknown origin) assessed as inhibition of SOS1-catalyzed nucleotide exchange measured by HTRF assay,CC(C)C=C(C#N)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,CHEMBL5154696,=,=,IC50,nM,283.84,IC50,nM,283.84,CC(C)C=C(C#N)C(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,2022
Inhibition of KRAS G12C mutant (unknown origin) assessed as inhibition of SOS1-catalyzed nucleotide exchange measured by HTRF assay,CN1CCC[C@H]1COc1nc2c(c(N3CCN(C(=O)C(C#N)=CC4CC4)[C@@H](CC#N)C3)n1)CCN(c1cccc3cccc(Cl)c13)C2,CHEMBL5154696,=,=,IC50,nM,25.44,IC50,nM,25.44,CN1CCC[C@H]1COc1nc2c(c(N3CCN(C(=O)C(C#N)=CC4CC4)[C@@H](CC#N)C3)n1)CCN(c1cccc3cccc(Cl)c13)C2,2022
Inhibition of KRAS G12C mutant (unknown origin) assessed as inhibition of SOS1-catalyzed nucleotide exchange measured by HTRF assay,CN1CCC[C@H]1COc1nc2c(c(N3CCN(C(=O)C(C#N)=CC(C)(C)C)[C@@H](CC#N)C3)n1)CCN(c1cccc3cccc(Cl)c13)C2,CHEMBL5154696,=,=,IC50,nM,639.91,IC50,nM,639.91,CN1CCC[C@H]1COc1nc2c(c(N3CCN(C(=O)C(C#N)=CC(C)(C)C)[C@@H](CC#N)C3)n1)CCN(c1cccc3cccc(Cl)c13)C2,2022
Reversible covalent binding affinity to KRAS G12C mutant (unknown origin) incubated for 2 hrs and measured by MALDI-TOF-MS analysis,CN1CCC[C@H]1COc1nc2c(c(N3CCN(C(=O)C(C#N)=CC4CC4)[C@@H](CC#N)C3)n1)CCN(c1cccc3cccc(Cl)c13)C2,CHEMBL5154696,,,Activity,,,Activity,,,CN1CCC[C@H]1COc1nc2c(c(N3CCN(C(=O)C(C#N)=CC4CC4)[C@@H](CC#N)C3)n1)CCN(c1cccc3cccc(Cl)c13)C2,2022
Inhibition of KRAS G12D mutant (unknown origin) downstream signalling in human SW1990 cells assessed as suppression of Raf phosphorylation incubated for 24 hrs by pull down based Western blotting analysis,COc1ccc(C(F)(F)F)cc1-c1cc2c(N3CC4CCC(C3)N4)ncnc2s1,CHEMBL5154793,,,Activity,,,Activity,,,COc1ccc(C(F)(F)F)cc1-c1cc2c(N3CC4CCC(C3)N4)ncnc2s1,2022
Inhibition of wild type KRAS (unknown origin) downstream signalling in human HCT-116 cells assessed as suppression of Raf phosphorylation incubated 24 hrs by pull down based Western blotting analysis,COc1ccc(C(F)(F)F)cc1-c1cc2c(N3CC4CCC(C3)N4)ncnc2s1,CHEMBL5154793,,,Activity,,,Activity,,,COc1ccc(C(F)(F)F)cc1-c1cc2c(N3CC4CCC(C3)N4)ncnc2s1,2022
Binding affinity to human his-tagged KRAS G12D mutant assessed as dissociation constant by isothermal titration calorimetry,COc1ccc(C(F)(F)F)cc1-c1cc2c(N3CC4CCC(C3)N4)ncnc2s1,CHEMBL5154793,=,=,Kd,nM,33.0,Kd,nM,33.0,COc1ccc(C(F)(F)F)cc1-c1cc2c(N3CC4CCC(C3)N4)ncnc2s1,2022
Binding affinity to human his-tagged KRAS G12D mutant assessed as change in enthalpy by isothermal titration calorimetry,COc1ccc(C(F)(F)F)cc1-c1cc2c(N3CC4CCC(C3)N4)ncnc2s1,CHEMBL5154793,=,=,deltaH,kcal/mol,-26.6,deltaH,kcal/mol,-26.6,COc1ccc(C(F)(F)F)cc1-c1cc2c(N3CC4CCC(C3)N4)ncnc2s1,2022
Binding affinity to human his-tagged KRAS G12D mutant assessed as gibbs free energy change by isothermal titration calorimetry,COc1ccc(C(F)(F)F)cc1-c1cc2c(N3CC4CCC(C3)N4)ncnc2s1,CHEMBL5154793,=,=,deltaG,kcal/mol,-10.2,deltaG,kcal/mol,-10.2,COc1ccc(C(F)(F)F)cc1-c1cc2c(N3CC4CCC(C3)N4)ncnc2s1,2022
Binding affinity to human his-tagged KRAS G12D mutant assessed as change in entropy by isothermal titration calorimetry,COc1ccc(C(F)(F)F)cc1-c1cc2c(N3CC4CCC(C3)N4)ncnc2s1,CHEMBL5154793,=,=,-TdeltaS,kcal/mol,16.4,-TdeltaS,kcal/mol,16.4,COc1ccc(C(F)(F)F)cc1-c1cc2c(N3CC4CCC(C3)N4)ncnc2s1,2022
Inhibition of KRAS G12D mutant downstream signalling in human SW1990 cells assessed as suppression of ERK phosphorylation incubated for 24 hrs by pull down based Western blotting analysis,COc1ccc(C(F)(F)F)cc1-c1cc2c(N3CC4CCC(C3)N4)ncnc2s1,CHEMBL5154793,,,Activity,,,Activity,,,COc1ccc(C(F)(F)F)cc1-c1cc2c(N3CC4CCC(C3)N4)ncnc2s1,2022
Inhibition of wild type KRAS (unknown origin) downstream signalling in human HCT-116 cells assessed as suppression of ERK phosphorylation incubated for 24 hrs by pull down based Western blotting analysis,COc1ccc(C(F)(F)F)cc1-c1cc2c(N3CC4CCC(C3)N4)ncnc2s1,CHEMBL5154793,,,Activity,,,Activity,,,COc1ccc(C(F)(F)F)cc1-c1cc2c(N3CC4CCC(C3)N4)ncnc2s1,2022
Binding affinity to KRAS G12C mutant in human NCI-H338 cell lysate assessed as trypsin-mediated biotinylated cysteine residues digestion by measuring reduction in protein level at 4 uM pretreated for 2 hrs followed by labelled with iodoacetamide-desthiobiotin by MS analysis,C=CC(=O)N1C[C@@H]2CCOc3c(Cl)c(-c4c(O)cccc4F)c(F)c4ncnc(c34)N2C[C@H]1C,CHEMBL5154891,,,Activity,,,Activity,,,C=CC(=O)N1C[C@@H]2CCOc3c(Cl)c(-c4c(O)cccc4F)c(F)c4ncnc(c34)N2C[C@H]1C,2022
Inhibition of C-terminal Avi and 6His-tagged human KRAS 2B G12C mutant (1 to 166 residues) expressed in Escherichia coli BL21 (DE3) assessed as inhibition of SOS mediated nucleotide exchange preincubated for 4 hrs followed by SOS1 addition by HTRF assay,C=CC(=O)N1C[C@@H]2CCOc3c(Cl)c(-c4c(O)cccc4F)c(F)c4ncnc(c34)N2C[C@H]1C,CHEMBL5154891,=,=,IC50,nM,3.0,IC50,uM,0.003,C=CC(=O)N1C[C@@H]2CCOc3c(Cl)c(-c4c(O)cccc4F)c(F)c4ncnc(c34)N2C[C@H]1C,2022
Inhibition of C-terminal Avi and 6His-tagged human KRAS 2B G12C mutant (1 to 166 residues) expressed in Escherichia coli BL21 (DE3) assessed as inhibition of SOS mediated nucleotide exchange preincubated for 4 hrs followed by SOS1 addition by HTRF assay,C=CC(=O)N1CCN(c2ncnc3cc(-c4c(C)ccc5[nH]ncc45)c(Cl)cc23)CC1,CHEMBL5154891,=,=,IC50,nM,496.0,IC50,uM,0.496,C=CC(=O)N1CCN(c2ncnc3cc(-c4c(C)ccc5[nH]ncc45)c(Cl)cc23)CC1,2022
Inhibition of C-terminal Avi and 6His-tagged human KRAS 2B G12C mutant (1 to 166 residues) expressed in Escherichia coli BL21 (DE3) assessed as inhibition of SOS mediated nucleotide exchange preincubated for 4 hrs followed by SOS1 addition by HTRF assay,C=CC(=O)N1CCN2c3ncnc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)c(c34)OC[C@@H]2C1,CHEMBL5154891,=,=,IC50,nM,82.0,IC50,uM,0.08199999999999999,C=CC(=O)N1CCN2c3ncnc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)c(c34)OC[C@@H]2C1,2022
Inhibition of C-terminal Avi and 6His-tagged human KRAS 2B G12C mutant (1 to 166 residues) expressed in Escherichia coli BL21 (DE3) assessed as inhibition of SOS mediated nucleotide exchange preincubated for 4 hrs followed by SOS1 addition by HTRF assay,C=CC(=O)N1CCN2c3ncnc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)c(c34)OC[C@@H]2C1,CHEMBL5154891,=,=,IC50,nM,27090.0,IC50,uM,27.09,C=CC(=O)N1CCN2c3ncnc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)c(c34)OC[C@@H]2C1,2022
Inhibition of C-terminal Avi and 6His-tagged human KRAS 2B G12C mutant (1 to 166 residues) expressed in Escherichia coli BL21 (DE3) assessed as inhibition of SOS mediated nucleotide exchange preincubated for 4 hrs followed by SOS1 addition by HTRF assay,C=CC(=O)N1CCN2c3ncnc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)c(c34)OC[C@H]2C1,CHEMBL5154891,=,=,IC50,nM,171.0,IC50,uM,0.171,C=CC(=O)N1CCN2c3ncnc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)c(c34)OC[C@H]2C1,2022
Inhibition of C-terminal Avi and 6His-tagged human KRAS 2B G12C mutant (1 to 166 residues) expressed in Escherichia coli BL21 (DE3) assessed as inhibition of SOS mediated nucleotide exchange preincubated for 4 hrs followed by SOS1 addition by HTRF assay,C=CC(=O)N1CCN2c3ncnc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)c(c34)OC[C@H]2C1,CHEMBL5154891,=,=,IC50,nM,17784.0,IC50,uM,17.784000000000002,C=CC(=O)N1CCN2c3ncnc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)c(c34)OC[C@H]2C1,2022
Inhibition of C-terminal Avi and 6His-tagged human KRAS 2B G12C mutant (1 to 166 residues) expressed in Escherichia coli BL21 (DE3) assessed as inhibition of SOS mediated nucleotide exchange preincubated for 4 hrs followed by SOS1 addition by HTRF assay,C=CC(=O)N1CCN2c3ncnc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)c(c34)OCC[C@@H]2C1,CHEMBL5154891,=,=,IC50,nM,15460.0,IC50,uM,15.46,C=CC(=O)N1CCN2c3ncnc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)c(c34)OCC[C@@H]2C1,2022
Inhibition of C-terminal Avi and 6His-tagged human KRAS 2B G12C mutant (1 to 166 residues) expressed in Escherichia coli BL21 (DE3) assessed as inhibition of SOS mediated nucleotide exchange preincubated for 4 hrs followed by SOS1 addition by HTRF assay,C=CC(=O)N1CCN2c3ncnc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)c(c34)OCC[C@H]2C1,CHEMBL5154891,=,=,IC50,nM,9.0,IC50,uM,0.009000000000000001,C=CC(=O)N1CCN2c3ncnc4cc(-c5c(C)ccc6[nH]ncc56)c(Cl)c(c34)OCC[C@H]2C1,2022
Inhibition of C-terminal Avi and 6His-tagged human KRAS 2B G12C mutant (1 to 166 residues) expressed in Escherichia coli BL21 (DE3) assessed as inhibition of SOS mediated nucleotide exchange preincubated for 4 hrs followed by SOS1 addition by HTRF assay,C=CC(=O)N1CCN2c3ncnc4c(F)c(-c5c(O)cccc5F)c(Cl)c(c34)OC[C@@H]2C1,CHEMBL5154891,=,=,IC50,nM,19.0,IC50,uM,0.019,C=CC(=O)N1CCN2c3ncnc4c(F)c(-c5c(O)cccc5F)c(Cl)c(c34)OC[C@@H]2C1,2022
Inhibition of C-terminal Avi and 6His-tagged human KRAS 2B G12C mutant (1 to 166 residues) expressed in Escherichia coli BL21 (DE3) assessed as inhibition of SOS mediated nucleotide exchange preincubated for 4 hrs followed by SOS1 addition by HTRF assay,C=CC(=O)N1C[C@H]2COc3c(Cl)c(-c4c(O)cccc4F)c(F)c4ncnc(c34)N2C[C@H]1C,CHEMBL5154891,=,=,IC50,nM,117.0,IC50,uM,0.11699999999999999,C=CC(=O)N1C[C@H]2COc3c(Cl)c(-c4c(O)cccc4F)c(F)c4ncnc(c34)N2C[C@H]1C,2022
Inhibition of C-terminal Avi and 6His-tagged human KRAS 2B G12C mutant (1 to 166 residues) expressed in Escherichia coli BL21 (DE3) assessed as inhibition of SOS mediated nucleotide exchange preincubated for 4 hrs followed by SOS1 addition by HTRF assay,C=CC(=O)N1C[C@H]2COc3c(Cl)c(-c4c(O)cccc4F)c(F)c4ncnc(c34)N2C[C@@H]1C,CHEMBL5154891,=,=,IC50,nM,135.0,IC50,uM,0.135,C=CC(=O)N1C[C@H]2COc3c(Cl)c(-c4c(O)cccc4F)c(F)c4ncnc(c34)N2C[C@@H]1C,2022
Inhibition of C-terminal Avi and 6His-tagged human KRAS 2B G12C mutant (1 to 166 residues) expressed in Escherichia coli BL21 (DE3) assessed as inhibition of SOS mediated nucleotide exchange preincubated for 4 hrs followed by SOS1 addition by HTRF assay,C=CC(=O)N1C[C@H]2COc3c(Cl)c(-c4c(O)cccc4F)c(F)c4ncnc(c34)N2C[C@H]1C,CHEMBL5154891,=,=,IC50,nM,64.0,IC50,uM,0.064,C=CC(=O)N1C[C@H]2COc3c(Cl)c(-c4c(O)cccc4F)c(F)c4ncnc(c34)N2C[C@H]1C,2022
Inhibition of C-terminal Avi and 6His-tagged human KRAS 2B G12C mutant (1 to 166 residues) expressed in Escherichia coli BL21 (DE3) assessed as inhibition of SOS mediated nucleotide exchange preincubated for 4 hrs followed by SOS1 addition by HTRF assay,C=CC(=O)N1CCN2c3ncnc4c(F)c(-c5c(O)cccc5F)c(Cl)c(c34)OCC[C@H]2C1,CHEMBL5154891,<,<,IC50,nM,5.0,IC50,uM,0.005,C=CC(=O)N1CCN2c3ncnc4c(F)c(-c5c(O)cccc5F)c(Cl)c(c34)OCC[C@H]2C1,2022
Inhibition of C-terminal Avi and 6His-tagged human KRAS 2B G12C mutant (1 to 166 residues) expressed in Escherichia coli BL21 (DE3) assessed as inhibition of SOS mediated nucleotide exchange preincubated for 4 hrs followed by SOS1 addition by HTRF assay,C=CC(=O)N1C[C@@H]2CCOc3c(Cl)c(-c4c(O)cccc4F)c(F)c4ncnc(c34)N2C[C@@H]1C,CHEMBL5154891,=,=,IC50,nM,138.0,IC50,uM,0.138,C=CC(=O)N1C[C@@H]2CCOc3c(Cl)c(-c4c(O)cccc4F)c(F)c4ncnc(c34)N2C[C@@H]1C,2022
Binding affinity to KRAS G12V mutant (unknown origin) assessed as dissociation constant by HSQC NMR spectroscopy analysis,CC1(C)CCCc2sc(N)c(C#N)c21,CHEMBL5214993,=,=,Kd,nM,15000.0,Kd,uM,15.0,CC1(C)CCCc2sc(N)c(C#N)c21,2022
Binding affinity to KRAS G12V mutant (unknown origin) assessed as dissociation constant by HSQC NMR spectroscopy analysis,N#Cc1c(N)sc2c1C(C(=O)Nc1ccccc1)CCC2,CHEMBL5214993,=,=,Kd,nM,1270000.0,Kd,uM,1270.0,N#Cc1c(N)sc2c1C(C(=O)Nc1ccccc1)CCC2,2022
Binding affinity to KRAS G12V mutant (unknown origin) assessed as dissociation constant by HSQC NMR spectroscopy analysis,CNC(=O)C1(C)CCCc2sc(N)c(C#N)c21,CHEMBL5214993,>,>,Kd,nM,2000000.0,Kd,uM,2000.0,CNC(=O)C1(C)CCCc2sc(N)c(C#N)c21,2022
Binding affinity to KRAS G12V mutant (unknown origin) assessed as dissociation constant by HSQC NMR spectroscopy analysis,CC1(C(=O)Nc2ccccc2)CCCc2sc(N)c(C#N)c21,CHEMBL5214993,=,=,Kd,nM,1180000.0,Kd,uM,1180.0,CC1(C(=O)Nc2ccccc2)CCCc2sc(N)c(C#N)c21,2022
Binding affinity to KRAS G12V mutant (unknown origin) assessed as dissociation constant by HSQC NMR spectroscopy analysis,CC1(C(=O)O)CCCc2sc(N)c(C#N)c21,CHEMBL5214993,=,=,Kd,nM,1160000.0,Kd,uM,1160.0,CC1(C(=O)O)CCCc2sc(N)c(C#N)c21,2022
Binding affinity to KRAS G12V mutant (unknown origin) assessed as dissociation constant by HSQC NMR spectroscopy analysis,Cc1noc(C2(C)CCCc3sc(N)c(C#N)c32)n1,CHEMBL5214993,=,=,Kd,nM,20000.0,Kd,uM,20.0,Cc1noc(C2(C)CCCc3sc(N)c(C#N)c32)n1,2022
Binding affinity to KRAS G12V mutant (unknown origin) assessed as dissociation constant by HSQC NMR spectroscopy analysis,C[C@]1(c2nc(-c3ccc(N)cc3)no2)CCCc2sc(N)c(C#N)c21,CHEMBL5214993,<,<,Kd,nM,10000.0,Kd,uM,10.0,C[C@]1(c2nc(-c3ccc(N)cc3)no2)CCCc2sc(N)c(C#N)c21,2022
Binding affinity to KRAS G12V mutant (unknown origin) assessed as dissociation constant by HSQC NMR spectroscopy analysis,C[C@]1(c2nc(-c3cccc(N)c3)no2)CCCc2sc(N)c(C#N)c21,CHEMBL5214993,<,<,Kd,nM,10000.0,Kd,uM,10.0,C[C@]1(c2nc(-c3cccc(N)c3)no2)CCCc2sc(N)c(C#N)c21,2022
Binding affinity to KRAS G12D mutant (unknown origin) assessed as dissociation constant by HSQC NMR spectroscopy analysis,C[C@]1(c2nc(-c3ccc(N)cc3)no2)CCCc2sc(N)c(C#N)c21,CHEMBL5214993,>,>,Kd,nM,2000000.0,Kd,mM,2.0,C[C@]1(c2nc(-c3ccc(N)cc3)no2)CCCc2sc(N)c(C#N)c21,2022
Binding affinity to KRAS G12D mutant (unknown origin) assessed as dissociation constant by HSQC NMR spectroscopy analysis,C[C@]1(c2nc(-c3cccc(N)c3)no2)CCCc2sc(N)c(C#N)c21,CHEMBL5214993,>,>,Kd,nM,2000000.0,Kd,mM,2.0,C[C@]1(c2nc(-c3cccc(N)c3)no2)CCCc2sc(N)c(C#N)c21,2022
Binding affinity to KRAS G12C mutant (unknown origin) assessed as Kinact/Ki incubated for 24 hrs by LC-MS analysis,C=CC(=O)Nc1ccc(-c2noc([C@@]3(C)CCCc4sc(N)c(C#N)c43)n2)cc1,CHEMBL5214993,=,=,K,1/M.sec,8.4,K,1/M.sec,8.4,C=CC(=O)Nc1ccc(-c2noc([C@@]3(C)CCCc4sc(N)c(C#N)c43)n2)cc1,2022
Binding affinity to KRAS G12C mutant (unknown origin) assessed as Kinact/Ki incubated for 24 hrs by LC-MS analysis,C=CC(=O)Nc1cccc(-c2noc([C@@]3(C)CCCc4sc(N)c(C#N)c43)n2)c1,CHEMBL5214993,=,=,K,1/M.sec,34.5,K,1/M.sec,34.5,C=CC(=O)Nc1cccc(-c2noc([C@@]3(C)CCCc4sc(N)c(C#N)c43)n2)c1,2022
Binding affinity to KRAS G12C mutant (unknown origin) assessed as Kinact/Ki incubated for 24 hrs by LC-MS analysis,C=CC(=O)N1CCN(c2cccc(-c3noc([C@@]4(C)CCCc5sc(N)c(C#N)c54)n3)c2)CC1,CHEMBL5214993,=,=,K,1/M.sec,12.8,K,1/M.sec,12.8,C=CC(=O)N1CCN(c2cccc(-c3noc([C@@]4(C)CCCc5sc(N)c(C#N)c54)n3)c2)CC1,2022
Binding affinity to KRAS G12C mutant (unknown origin) assessed as Kinact/Ki incubated for 24 hrs by LC-MS analysis,C=CC(=O)N1CCN(c2cc(-c3noc([C@@]4(C)CCCc5sc(N)c(C#N)c54)n3)nc(N3CCN(C)C[C@@H]3C)c2)CC1,CHEMBL5214993,=,=,K,1/M.sec,15220.0,K,1/M.sec,15220.0,C=CC(=O)N1CCN(c2cc(-c3noc([C@@]4(C)CCCc5sc(N)c(C#N)c54)n3)nc(N3CCN(C)C[C@@H]3C)c2)CC1,2022
Binding affinity to KRAS G12C mutant (unknown origin) assessed as Kinact/Ki incubated for 24 hrs by LC-MS analysis,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1,CHEMBL5214993,=,=,K,1/M.sec,2870.0,K,1/M.sec,2870.0,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1,2022
Binding affinity to KRAS G12C mutant (unknown origin) assessed as inactivation constant incubated for 24 hrs by LC-MS analysis,C=CC(=O)Nc1ccc(-c2noc([C@@]3(C)CCCc4sc(N)c(C#N)c43)n2)cc1,CHEMBL5214993,=,=,Kinact,/hr,0.7,Kinact,/hr,0.7,C=CC(=O)Nc1ccc(-c2noc([C@@]3(C)CCCc4sc(N)c(C#N)c43)n2)cc1,2022
Binding affinity to KRAS G12C mutant (unknown origin) assessed as inactivation constant incubated for 24 hrs by LC-MS analysis,C=CC(=O)Nc1cccc(-c2noc([C@@]3(C)CCCc4sc(N)c(C#N)c43)n2)c1,CHEMBL5214993,=,=,Kinact,/hr,1.1,Kinact,/hr,1.1,C=CC(=O)Nc1cccc(-c2noc([C@@]3(C)CCCc4sc(N)c(C#N)c43)n2)c1,2022
Binding affinity to KRAS G12C mutant (unknown origin) assessed as inactivation constant incubated for 24 hrs by LC-MS analysis,C=CC(=O)N1CCN(c2cccc(-c3noc([C@@]4(C)CCCc5sc(N)c(C#N)c54)n3)c2)CC1,CHEMBL5214993,=,=,Kinact,/hr,0.3,Kinact,/hr,0.3,C=CC(=O)N1CCN(c2cccc(-c3noc([C@@]4(C)CCCc5sc(N)c(C#N)c54)n3)c2)CC1,2022
Binding affinity to KRAS G12C mutant (unknown origin) assessed as inactivation constant incubated for 24 hrs by LC-MS analysis,C=CC(=O)N1CCN(c2cc(-c3noc([C@@]4(C)CCCc5sc(N)c(C#N)c54)n3)nc(N3CCN(C)C[C@@H]3C)c2)CC1,CHEMBL5214993,=,=,Kinact,/hr,133.0,Kinact,/hr,133.0,C=CC(=O)N1CCN(c2cc(-c3noc([C@@]4(C)CCCc5sc(N)c(C#N)c54)n3)nc(N3CCN(C)C[C@@H]3C)c2)CC1,2022
Binding affinity to KRAS G12C mutant (unknown origin) assessed as inactivation constant incubated for 24 hrs by LC-MS analysis,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1,CHEMBL5214993,=,=,Kinact,/hr,126.0,Kinact,/hr,126.0,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1,2022
Binding affinity to KRAS G12C mutant (unknown origin) assessed as inhibition constant incubated for 24 hrs by LC-MS analysis,C=CC(=O)Nc1ccc(-c2noc([C@@]3(C)CCCc4sc(N)c(C#N)c43)n2)cc1,CHEMBL5214993,=,=,Ki,nM,24100.0,Ki,uM,24.1,C=CC(=O)Nc1ccc(-c2noc([C@@]3(C)CCCc4sc(N)c(C#N)c43)n2)cc1,2022
Binding affinity to KRAS G12C mutant (unknown origin) assessed as inhibition constant incubated for 24 hrs by LC-MS analysis,C=CC(=O)Nc1cccc(-c2noc([C@@]3(C)CCCc4sc(N)c(C#N)c43)n2)c1,CHEMBL5214993,=,=,Ki,nM,8600.0,Ki,uM,8.6,C=CC(=O)Nc1cccc(-c2noc([C@@]3(C)CCCc4sc(N)c(C#N)c43)n2)c1,2022
Binding affinity to KRAS G12C mutant (unknown origin) assessed as inhibition constant incubated for 24 hrs by LC-MS analysis,C=CC(=O)N1CCN(c2cccc(-c3noc([C@@]4(C)CCCc5sc(N)c(C#N)c54)n3)c2)CC1,CHEMBL5214993,=,=,Ki,nM,7500.0,Ki,uM,7.5,C=CC(=O)N1CCN(c2cccc(-c3noc([C@@]4(C)CCCc5sc(N)c(C#N)c54)n3)c2)CC1,2022
Binding affinity to KRAS G12C mutant (unknown origin) assessed as inhibition constant incubated for 24 hrs by LC-MS analysis,C=CC(=O)N1CCN(c2cc(-c3noc([C@@]4(C)CCCc5sc(N)c(C#N)c54)n3)nc(N3CCN(C)C[C@@H]3C)c2)CC1,CHEMBL5214993,=,=,Ki,nM,2500.0,Ki,uM,2.5,C=CC(=O)N1CCN(c2cc(-c3noc([C@@]4(C)CCCc5sc(N)c(C#N)c54)n3)nc(N3CCN(C)C[C@@H]3C)c2)CC1,2022
Binding affinity to KRAS G12C mutant (unknown origin) assessed as inhibition constant incubated for 24 hrs by LC-MS analysis,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1,CHEMBL5214993,=,=,Ki,nM,12200.0,Ki,uM,12.2,C=CC(=O)N1CCN(c2nc(=O)n(-c3c(C)ccnc3C(C)C)c3nc(-c4c(O)cccc4F)c(F)cc23)[C@@H](C)C1,2022
Induction of KRAS G12C mutant degradation in human NCI-H2030 cells,C=C(F)C(=O)N1CCC(c2nc(OC[C@@H]3CCCN3CCCOCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCc3ccc(-c4scnc4C)cc3)C(C)(C)C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,CHEMBL5223100,=,=,DC50,uM,0.59,DC50,uM,0.59,C=C(F)C(=O)N1CCC(c2nc(OC[C@@H]3CCCN3CCCOCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCc3ccc(-c4scnc4C)cc3)C(C)(C)C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,2022
Induction of KRAS G12C mutant degradation in human NCI-H2030 cells assessed as maximum degradation relative to control,C=C(F)C(=O)N1CCC(c2nc(OC[C@@H]3CCCN3CCCOCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCc3ccc(-c4scnc4C)cc3)C(C)(C)C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,CHEMBL5223100,=,=,Emax,%,80.0,Emax,%,80.0,C=C(F)C(=O)N1CCC(c2nc(OC[C@@H]3CCCN3CCCOCCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCc3ccc(-c4scnc4C)cc3)C(C)(C)C)nc3c2CCN(c2cccc4cccc(Cl)c24)C3)C[C@@H]1CC#N,2022
"Displacement of [acrylamide-2,3-3H2]-N-(3-fluoro-4-(2-methyl-3-(5-methyl-1H- indazole-4-yl)-1H-pyrrolo[ 2,3-b]pyridin-1-yl)-phenyl from KRAS G12C mutant (unknown origin) assessed as ratio of Kinact/Ki by competitive scintillation proximity assay",C=CC(=O)Nc1ccc(-n2nc(C)c(-c3c(C)ccc4[nH]ncc34)c2C)cc1,CHEMBL5236595,=,=,Ratio,/mM/s,0.1,Ratio,/mM/s,0.1,C=CC(=O)Nc1ccc(-n2nc(C)c(-c3c(C)ccc4[nH]ncc34)c2C)cc1,2022
"Displacement of [acrylamide-2,3-3H2]-N-(3-fluoro-4-(2-methyl-3-(5-methyl-1H- indazole-4-yl)-1H-pyrrolo[ 2,3-b]pyridin-1-yl)-phenyl from KRAS G12C mutant (unknown origin) assessed as ratio of Kinact/Ki by competitive scintillation proximity assay",C=CC(=O)Nc1ccc(-n2nc(C)c(-c3c(C)ccc4[nH]ncc34)c2C)c(F)c1,CHEMBL5236595,=,=,Ratio,/mM/s,0.5,Ratio,/mM/s,0.5,C=CC(=O)Nc1ccc(-n2nc(C)c(-c3c(C)ccc4[nH]ncc34)c2C)c(F)c1,2022
"Displacement of [acrylamide-2,3-3H2]-N-(3-fluoro-4-(2-methyl-3-(5-methyl-1H- indazole-4-yl)-1H-pyrrolo[ 2,3-b]pyridin-1-yl)-phenyl from KRAS G12C mutant (unknown origin) assessed as ratio of Kinact/Ki by competitive scintillation proximity assay",C=CC(=O)Nc1ccc(-n2nc(C(C)C)c(-c3c(C)ccc4[nH]ncc34)c2C)c(F)c1,CHEMBL5236595,=,=,Ratio,/mM/s,6.0,Ratio,/mM/s,6.0,C=CC(=O)Nc1ccc(-n2nc(C(C)C)c(-c3c(C)ccc4[nH]ncc34)c2C)c(F)c1,2022
"Displacement of [acrylamide-2,3-3H2]-N-(3-fluoro-4-(2-methyl-3-(5-methyl-1H- indazole-4-yl)-1H-pyrrolo[ 2,3-b]pyridin-1-yl)-phenyl from KRAS G12C mutant (unknown origin) assessed as ratio of Kinact/Ki by competitive scintillation proximity assay",C=CC(=O)Nc1ccc(-c2nn(C(C)C)c(-c3c(C)ccc4[nH]ncc34)c2C)c(F)c1,CHEMBL5236595,=,=,Ratio,/mM/s,0.2,Ratio,/mM/s,0.2,C=CC(=O)Nc1ccc(-c2nn(C(C)C)c(-c3c(C)ccc4[nH]ncc34)c2C)c(F)c1,2022
"Displacement of [acrylamide-2,3-3H2]-N-(3-fluoro-4-(2-methyl-3-(5-methyl-1H- indazole-4-yl)-1H-pyrrolo[ 2,3-b]pyridin-1-yl)-phenyl from KRAS G12C mutant (unknown origin) assessed as ratio of Kinact/Ki by competitive scintillation proximity assay",C=CC(=O)Nc1ccc(-n2nc(C(C)C)c(-c3c(C)ccc4[nH]ncc34)c2C)c(C)c1,CHEMBL5236595,=,=,Ratio,/mM/s,1.7,Ratio,/mM/s,1.7,C=CC(=O)Nc1ccc(-n2nc(C(C)C)c(-c3c(C)ccc4[nH]ncc34)c2C)c(C)c1,2022
"Displacement of [acrylamide-2,3-3H2]-N-(3-fluoro-4-(2-methyl-3-(5-methyl-1H- indazole-4-yl)-1H-pyrrolo[ 2,3-b]pyridin-1-yl)-phenyl from KRAS G12C mutant (unknown origin) assessed as ratio of Kinact/Ki by competitive scintillation proximity assay",C=CC(=O)Nc1ccc(-n2nc(C(C)C)c(-c3c(C)ccc4[nH]ncc34)c2C)cc1,CHEMBL5236595,=,=,Ratio,/mM/s,0.6,Ratio,/mM/s,0.6,C=CC(=O)Nc1ccc(-n2nc(C(C)C)c(-c3c(C)ccc4[nH]ncc34)c2C)cc1,2022
"Displacement of [acrylamide-2,3-3H2]-N-(3-fluoro-4-(2-methyl-3-(5-methyl-1H- indazole-4-yl)-1H-pyrrolo[ 2,3-b]pyridin-1-yl)-phenyl from KRAS G12C mutant (unknown origin) assessed as ratio of Kinact/Ki by competitive scintillation proximity assay",C=CC(=O)N1CC2(CC(n3nc(C(C)C)c(-c4c(C)ccc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,=,=,Ratio,/mM/s,0.4,Ratio,/mM/s,0.4,C=CC(=O)N1CC2(CC(n3nc(C(C)C)c(-c4c(C)ccc5[nH]ncc45)c3C)C2)C1,2022
"Displacement of [acrylamide-2,3-3H2]-N-(3-fluoro-4-(2-methyl-3-(5-methyl-1H- indazole-4-yl)-1H-pyrrolo[ 2,3-b]pyridin-1-yl)-phenyl from KRAS G12C mutant (unknown origin) assessed as ratio of Kinact/Ki by competitive scintillation proximity assay",C=CC(=O)N1CC2(CC(n3nc(C4CCCCC4)c(-c4c(C)ccc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,=,=,Ratio,/mM/s,0.3,Ratio,/mM/s,0.3,C=CC(=O)N1CC2(CC(n3nc(C4CCCCC4)c(-c4c(C)ccc5[nH]ncc45)c3C)C2)C1,2022
"Displacement of [acrylamide-2,3-3H2]-N-(3-fluoro-4-(2-methyl-3-(5-methyl-1H- indazole-4-yl)-1H-pyrrolo[ 2,3-b]pyridin-1-yl)-phenyl from KRAS G12C mutant (unknown origin) assessed as ratio of Kinact/Ki by competitive scintillation proximity assay",C=CC(=O)N1CC2(CC(n3nc(C4CCCCC4)c(-c4c(Cl)ccc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,=,=,Ratio,/mM/s,0.9,Ratio,/mM/s,0.9,C=CC(=O)N1CC2(CC(n3nc(C4CCCCC4)c(-c4c(Cl)ccc5[nH]ncc45)c3C)C2)C1,2022
"Displacement of [acrylamide-2,3-3H2]-N-(3-fluoro-4-(2-methyl-3-(5-methyl-1H- indazole-4-yl)-1H-pyrrolo[ 2,3-b]pyridin-1-yl)-phenyl from KRAS G12C mutant (unknown origin) assessed as ratio of Kinact/Ki by competitive scintillation proximity assay",C=CC(=O)N1CC2(CC(n3nc(-c4cccnc4)c(-c4c(Cl)ccc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,=,=,Ratio,/mM/s,1.3,Ratio,/mM/s,1.3,C=CC(=O)N1CC2(CC(n3nc(-c4cccnc4)c(-c4c(Cl)ccc5[nH]ncc45)c3C)C2)C1,2022
"Displacement of [acrylamide-2,3-3H2]-N-(3-fluoro-4-(2-methyl-3-(5-methyl-1H- indazole-4-yl)-1H-pyrrolo[ 2,3-b]pyridin-1-yl)-phenyl from KRAS G12C mutant (unknown origin) assessed as ratio of Kinact/Ki by competitive scintillation proximity assay",C=CC(=O)N1CC2(CC(n3nc(-c4cccnc4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,=,=,Ratio,/mM/s,10.0,Ratio,/mM/s,10.0,C=CC(=O)N1CC2(CC(n3nc(-c4cccnc4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
"Displacement of [acrylamide-2,3-3H2]-N-(3-fluoro-4-(2-methyl-3-(5-methyl-1H- indazole-4-yl)-1H-pyrrolo[ 2,3-b]pyridin-1-yl)-phenyl from KRAS G12C mutant (unknown origin) assessed as ratio of Kinact/Ki by competitive scintillation proximity assay",C=CC(=O)N1CC2(CC(n3nc(-c4cccnc4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C(F)F)C2)C1,CHEMBL5236595,=,=,Ratio,/mM/s,3.0,Ratio,/mM/s,3.0,C=CC(=O)N1CC2(CC(n3nc(-c4cccnc4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C(F)F)C2)C1,2022
"Displacement of [acrylamide-2,3-3H2]-N-(3-fluoro-4-(2-methyl-3-(5-methyl-1H- indazole-4-yl)-1H-pyrrolo[ 2,3-b]pyridin-1-yl)-phenyl from KRAS G12C mutant (unknown origin) assessed as ratio of Kinact/Ki by competitive scintillation proximity assay",C=CC(=O)N1CC2(CC(n3nc(-c4cccnc4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3CC#N)C2)C1,CHEMBL5236595,=,=,Ratio,/mM/s,0.2,Ratio,/mM/s,0.2,C=CC(=O)N1CC2(CC(n3nc(-c4cccnc4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3CC#N)C2)C1,2022
"Displacement of [acrylamide-2,3-3H2]-N-(3-fluoro-4-(2-methyl-3-(5-methyl-1H- indazole-4-yl)-1H-pyrrolo[ 2,3-b]pyridin-1-yl)-phenyl from KRAS G12C mutant (unknown origin) assessed as ratio of Kinact/Ki by competitive scintillation proximity assay",C=CC(=O)N1CC2(CC(n3nc(-c4ccccn4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,=,=,Ratio,/mM/s,7.0,Ratio,/mM/s,7.0,C=CC(=O)N1CC2(CC(n3nc(-c4ccccn4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
"Displacement of [acrylamide-2,3-3H2]-N-(3-fluoro-4-(2-methyl-3-(5-methyl-1H- indazole-4-yl)-1H-pyrrolo[ 2,3-b]pyridin-1-yl)-phenyl from KRAS G12C mutant (unknown origin) assessed as ratio of Kinact/Ki by competitive scintillation proximity assay",C=CC(=O)N1CC2(CC(n3nc(-c4ccccc4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,=,=,Ratio,/mM/s,60.0,Ratio,/mM/s,60.0,C=CC(=O)N1CC2(CC(n3nc(-c4ccccc4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
"Displacement of [acrylamide-2,3-3H2]-N-(3-fluoro-4-(2-methyl-3-(5-methyl-1H- indazole-4-yl)-1H-pyrrolo[ 2,3-b]pyridin-1-yl)-phenyl from KRAS G12C mutant (unknown origin) assessed as ratio of Kinact/Ki by competitive scintillation proximity assay",C=CC(=O)N1CC2(CC(n3nc(-c4ccc5[nH]ncc5c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,=,=,Ratio,/mM/s,116.0,Ratio,/mM/s,116.0,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5[nH]ncc5c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
"Displacement of [acrylamide-2,3-3H2]-N-(3-fluoro-4-(2-methyl-3-(5-methyl-1H- indazole-4-yl)-1H-pyrrolo[ 2,3-b]pyridin-1-yl)-phenyl from KRAS G12C mutant (unknown origin) assessed as ratio of Kinact/Ki by competitive scintillation proximity assay",C=CC(=O)N1CC2(CC(n3nc(-c4ccc5cn[nH]c5c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,=,=,Ratio,/mM/s,19.0,Ratio,/mM/s,19.0,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5cn[nH]c5c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
"Displacement of [acrylamide-2,3-3H2]-N-(3-fluoro-4-(2-methyl-3-(5-methyl-1H- indazole-4-yl)-1H-pyrrolo[ 2,3-b]pyridin-1-yl)-phenyl from KRAS G12C mutant (unknown origin) assessed as ratio of Kinact/Ki by competitive scintillation proximity assay",C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(c4)ncn5C)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,=,=,Ratio,/mM/s,24.0,Ratio,/mM/s,24.0,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(c4)ncn5C)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
"Displacement of [acrylamide-2,3-3H2]-N-(3-fluoro-4-(2-methyl-3-(5-methyl-1H- indazole-4-yl)-1H-pyrrolo[ 2,3-b]pyridin-1-yl)-phenyl from KRAS G12C mutant (unknown origin) assessed as ratio of Kinact/Ki by competitive scintillation proximity assay",C=CC(=O)N1CC2(CC(n3nc(-c4ccc5nnccc5c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,=,=,Ratio,/mM/s,25.0,Ratio,/mM/s,25.0,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5nnccc5c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
"Displacement of [acrylamide-2,3-3H2]-N-(3-fluoro-4-(2-methyl-3-(5-methyl-1H- indazole-4-yl)-1H-pyrrolo[ 2,3-b]pyridin-1-yl)-phenyl from KRAS G12C mutant (unknown origin) assessed as ratio of Kinact/Ki by competitive scintillation proximity assay",C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5C)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,=,=,Ratio,/mM/s,141.0,Ratio,/mM/s,141.0,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5C)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
"Displacement of [acrylamide-2,3-3H2]-N-(3-fluoro-4-(2-methyl-3-(5-methyl-1H- indazole-4-yl)-1H-pyrrolo[ 2,3-b]pyridin-1-yl)-phenyl from KRAS G12C mutant (unknown origin) assessed as ratio of Kinact/Ki by competitive scintillation proximity assay",C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5CCN(C)C)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,=,=,Ratio,/mM/s,150.0,Ratio,/mM/s,150.0,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5CCN(C)C)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
"Displacement of [acrylamide-2,3-3H2]-N-(3-fluoro-4-(2-methyl-3-(5-methyl-1H- indazole-4-yl)-1H-pyrrolo[ 2,3-b]pyridin-1-yl)-phenyl from KRAS G12C mutant (unknown origin) assessed as ratio of Kinact/Ki by competitive scintillation proximity assay",C=CC(=O)N1CC2(CC(n3nc(-c4ccc5nn(CCN6CCOCC6)cc5c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,=,=,Ratio,/mM/s,190.0,Ratio,/mM/s,190.0,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5nn(CCN6CCOCC6)cc5c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
"Displacement of [acrylamide-2,3-3H2]-N-(3-fluoro-4-(2-methyl-3-(5-methyl-1H- indazole-4-yl)-1H-pyrrolo[ 2,3-b]pyridin-1-yl)-phenyl from KRAS G12C mutant (unknown origin) assessed as ratio of Kinact/Ki by competitive scintillation proximity assay",C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5CCOC)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,=,=,Ratio,/mM/s,190.0,Ratio,/mM/s,190.0,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5CCOC)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
"Displacement of [acrylamide-2,3-3H2]-N-(3-fluoro-4-(2-methyl-3-(5-methyl-1H- indazole-4-yl)-1H-pyrrolo[ 2,3-b]pyridin-1-yl)-phenyl from KRAS G12C mutant (unknown origin) assessed as ratio of Kinact/Ki by competitive scintillation proximity assay",C=CC(=O)N1CC2(CC(n3nc(-c4ccc5nn(CCOC)cc5c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,=,=,Ratio,/mM/s,225.0,Ratio,/mM/s,225.0,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5nn(CCOC)cc5c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
"Displacement of [acrylamide-2,3-3H2]-N-(3-fluoro-4-(2-methyl-3-(5-methyl-1H- indazole-4-yl)-1H-pyrrolo[ 2,3-b]pyridin-1-yl)-phenyl from KRAS G12C mutant (unknown origin) assessed as ratio of Kinact/Ki by competitive scintillation proximity assay",C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5C)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,<,<,Ratio,/mM/s,0.2,Ratio,/mM/s,0.2,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5C)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 6 hrs by MSD assay,C=CC(=O)Nc1ccc(-n2nc(C)c(-c3c(C)ccc4[nH]ncc34)c2C)cc1,CHEMBL5236595,,,IC50,,,IC50,,,C=CC(=O)Nc1ccc(-n2nc(C)c(-c3c(C)ccc4[nH]ncc34)c2C)cc1,2022
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 6 hrs by MSD assay,C=CC(=O)Nc1ccc(-n2nc(C)c(-c3c(C)ccc4[nH]ncc34)c2C)c(F)c1,CHEMBL5236595,,,IC50,,,IC50,,,C=CC(=O)Nc1ccc(-n2nc(C)c(-c3c(C)ccc4[nH]ncc34)c2C)c(F)c1,2022
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 6 hrs by MSD assay,C=CC(=O)Nc1ccc(-n2nc(C(C)C)c(-c3c(C)ccc4[nH]ncc34)c2C)c(F)c1,CHEMBL5236595,=,=,IC50,nM,500.0,IC50,uM,0.5,C=CC(=O)Nc1ccc(-n2nc(C(C)C)c(-c3c(C)ccc4[nH]ncc34)c2C)c(F)c1,2022
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 6 hrs by MSD assay,C=CC(=O)Nc1ccc(-c2nn(C(C)C)c(-c3c(C)ccc4[nH]ncc34)c2C)c(F)c1,CHEMBL5236595,,,IC50,,,IC50,,,C=CC(=O)Nc1ccc(-c2nn(C(C)C)c(-c3c(C)ccc4[nH]ncc34)c2C)c(F)c1,2022
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 6 hrs by MSD assay,C=CC(=O)Nc1ccc(-n2nc(C(C)C)c(-c3c(C)ccc4[nH]ncc34)c2C)c(C)c1,CHEMBL5236595,=,=,IC50,nM,1500.0,IC50,uM,1.5,C=CC(=O)Nc1ccc(-n2nc(C(C)C)c(-c3c(C)ccc4[nH]ncc34)c2C)c(C)c1,2022
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 6 hrs by MSD assay,C=CC(=O)Nc1ccc(-n2nc(C(C)C)c(-c3c(C)ccc4[nH]ncc34)c2C)cc1,CHEMBL5236595,,,IC50,,,IC50,,,C=CC(=O)Nc1ccc(-n2nc(C(C)C)c(-c3c(C)ccc4[nH]ncc34)c2C)cc1,2022
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 6 hrs by MSD assay,C=CC(=O)N1CC2(CC(n3nc(C(C)C)c(-c4c(C)ccc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,=,=,IC50,nM,3900.0,IC50,uM,3.9,C=CC(=O)N1CC2(CC(n3nc(C(C)C)c(-c4c(C)ccc5[nH]ncc45)c3C)C2)C1,2022
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 6 hrs by MSD assay,C=CC(=O)N1CC2(CC(n3nc(C4CCCCC4)c(-c4c(C)ccc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,,,IC50,,,IC50,,,C=CC(=O)N1CC2(CC(n3nc(C4CCCCC4)c(-c4c(C)ccc5[nH]ncc45)c3C)C2)C1,2022
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 6 hrs by MSD assay,C=CC(=O)N1CC2(CC(n3nc(C4CCCCC4)c(-c4c(Cl)ccc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,=,=,IC50,nM,700.0,IC50,uM,0.7,C=CC(=O)N1CC2(CC(n3nc(C4CCCCC4)c(-c4c(Cl)ccc5[nH]ncc45)c3C)C2)C1,2022
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 6 hrs by MSD assay,C=CC(=O)N1CC2(CC(n3nc(-c4cccnc4)c(-c4c(Cl)ccc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,=,=,IC50,nM,500.0,IC50,uM,0.5,C=CC(=O)N1CC2(CC(n3nc(-c4cccnc4)c(-c4c(Cl)ccc5[nH]ncc45)c3C)C2)C1,2022
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 6 hrs by MSD assay,C=CC(=O)N1CC2(CC(n3nc(-c4cccnc4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,=,=,IC50,nM,90.0,IC50,uM,0.09,C=CC(=O)N1CC2(CC(n3nc(-c4cccnc4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 6 hrs by MSD assay,C=CC(=O)N1CC2(CC(n3nc(-c4cccnc4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C(F)F)C2)C1,CHEMBL5236595,,,IC50,,,IC50,,,C=CC(=O)N1CC2(CC(n3nc(-c4cccnc4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C(F)F)C2)C1,2022
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 6 hrs by MSD assay,C=CC(=O)N1CC2(CC(n3nc(-c4cccnc4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3CC#N)C2)C1,CHEMBL5236595,,,IC50,,,IC50,,,C=CC(=O)N1CC2(CC(n3nc(-c4cccnc4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3CC#N)C2)C1,2022
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 6 hrs by MSD assay,C=CC(=O)N1CC2(CC(n3nc(-c4ccccn4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,,,IC50,,,IC50,,,C=CC(=O)N1CC2(CC(n3nc(-c4ccccn4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 6 hrs by MSD assay,C=CC(=O)N1CC2(CC(n3nc(-c4ccccc4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,=,=,IC50,nM,20.0,IC50,uM,0.02,C=CC(=O)N1CC2(CC(n3nc(-c4ccccc4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 6 hrs by MSD assay,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5[nH]ncc5c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,=,=,IC50,nM,20.0,IC50,uM,0.02,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5[nH]ncc5c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 6 hrs by MSD assay,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5cn[nH]c5c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,=,=,IC50,nM,50.0,IC50,uM,0.05,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5cn[nH]c5c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 6 hrs by MSD assay,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(c4)ncn5C)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,=,=,IC50,nM,140.0,IC50,uM,0.14,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(c4)ncn5C)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 6 hrs by MSD assay,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5C)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,=,=,IC50,nM,20.0,IC50,uM,0.02,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5C)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 6 hrs by MSD assay,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5CCN(C)C)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,=,=,IC50,nM,30.0,IC50,uM,0.03,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5CCN(C)C)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 6 hrs by MSD assay,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5nn(CCN6CCOCC6)cc5c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,=,=,IC50,nM,10.0,IC50,uM,0.01,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5nn(CCN6CCOCC6)cc5c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 6 hrs by MSD assay,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5CCOC)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,=,=,IC50,nM,8.0,IC50,uM,0.008,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5CCOC)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 6 hrs by MSD assay,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5nn(CCOC)cc5c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,=,=,IC50,nM,4.0,IC50,uM,0.004,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5nn(CCOC)cc5c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
"Invivo target occupancy at KRAS G12C mutant in human MIA PaCa-2 cells xenografted mouse assessed as decrease in free KRAS G12C level at 100 mg/kg, po after 3 hrs",C=CC(=O)N1CC2(CC(n3nc(-c4ccccc4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,=,=,Occ,%,20.0,Occ,%,20.0,C=CC(=O)N1CC2(CC(n3nc(-c4ccccc4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
"Invivo target occupancy at KRAS G12C mutant in human MIA PaCa-2 cells xenografted mouse assessed as decrease in free KRAS G12C level at 100 mg/kg, po after 24 hrs",C=CC(=O)N1CC2(CC(n3nc(-c4ccccc4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,=,=,Occ,%,40.0,Occ,%,40.0,C=CC(=O)N1CC2(CC(n3nc(-c4ccccc4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
"Invivo target occupancy at KRAS G12C mutant in human MIA PaCa-2 cells xenografted mouse assessed as decrease in free KRAS G12C level at 30 mg/kg, po after 3 hrs",C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5C)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,=,=,Occ,%,3.0,Occ,%,3.0,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5C)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
"Invivo target occupancy at KRAS G12C mutant in human MIA PaCa-2 cells xenografted mouse assessed as decrease in free KRAS G12C level at 30 mg/kg, po after 3 hrs",C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5CCN(C)C)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,,,Occ,,,Occ,,,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5CCN(C)C)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
"Invivo target occupancy at KRAS G12C mutant in human MIA PaCa-2 cells xenografted mouse assessed as decrease in free KRAS G12C level at 30 mg/kg, po after 3 hrs",C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5CCOC)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,=,=,Occ,%,100.0,Occ,%,100.0,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5CCOC)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
"Invivo target occupancy at KRAS G12C mutant in human MIA PaCa-2 cells xenografted mouse assessed as decrease in free KRAS G12C level at 30 mg/kg, po after 3 hrs",C=CC(=O)N1CC2(CC(n3nc(-c4ccc5nn(CCOC)cc5c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,,,Occ,,,Occ,,,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5nn(CCOC)cc5c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
"Invivo target occupancy at KRAS G12C mutant in human MIA PaCa-2 cells xenografted mouse assessed as decrease in free KRAS G12C level at 30 mg/kg, po after 6 hrs",C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5C)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,=,=,Occ,%,2.0,Occ,%,2.0,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5C)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
"Invivo target occupancy at KRAS G12C mutant in human MIA PaCa-2 cells xenografted mouse assessed as decrease in free KRAS G12C level at 30 mg/kg, po after 6 hrs",C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5CCN(C)C)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,,,Occ,,,Occ,,,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5CCN(C)C)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
"Invivo target occupancy at KRAS G12C mutant in human MIA PaCa-2 cells xenografted mouse assessed as decrease in free KRAS G12C level at 30 mg/kg, po after 6 hrs",C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5CCOC)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,,,Occ,,,Occ,,,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5CCOC)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
"Invivo target occupancy at KRAS G12C mutant in human MIA PaCa-2 cells xenografted mouse assessed as decrease in free KRAS G12C level at 30 mg/kg, po after 6 hrs",C=CC(=O)N1CC2(CC(n3nc(-c4ccc5nn(CCOC)cc5c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,=,=,Occ,%,37.0,Occ,%,37.0,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5nn(CCOC)cc5c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
"Invivo target occupancy at KRAS G12C mutant in human MIA PaCa-2 cells xenografted mouse assessed as decrease in free KRAS G12C level at 30 mg/kg, po after 24 hrs",C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5C)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,=,=,Occ,%,23.0,Occ,%,23.0,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5C)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
"Invivo target occupancy at KRAS G12C mutant in human MIA PaCa-2 cells xenografted mouse assessed as decrease in free KRAS G12C level at 30 mg/kg, po after 24 hrs",C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5CCN(C)C)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,,,Occ,,,Occ,,,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5CCN(C)C)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
"Invivo target occupancy at KRAS G12C mutant in human MIA PaCa-2 cells xenografted mouse assessed as decrease in free KRAS G12C level at 30 mg/kg, po after 24 hrs",C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5CCOC)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,=,=,Occ,%,100.0,Occ,%,100.0,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5CCOC)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
"Invivo target occupancy at KRAS G12C mutant in human MIA PaCa-2 cells xenografted mouse assessed as decrease in free KRAS G12C level at 30 mg/kg, po after 24 hrs",C=CC(=O)N1CC2(CC(n3nc(-c4ccc5nn(CCOC)cc5c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,=,=,Occ,%,78.0,Occ,%,78.0,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5nn(CCOC)cc5c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
"Invivo target occupancy at KRAS G12C mutant in human MIA PaCa-2 cells xenografted mouse assessed as decrease in DUSPS6 expression at 30 mg/kg, po after 3 hrs",C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5C)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,=,=,Occ,%,27.0,Occ,%,27.0,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5C)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
"Invivo target occupancy at KRAS G12C mutant in human MIA PaCa-2 cells xenografted mouse assessed as decrease in DUSPS6 expression at 30 mg/kg, po after 3 hrs",C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5CCN(C)C)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,,,Occ,,,Occ,,,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5CCN(C)C)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
"Invivo target occupancy at KRAS G12C mutant in human MIA PaCa-2 cells xenografted mouse assessed as decrease in DUSPS6 expression at 30 mg/kg, po after 3 hrs",C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5CCOC)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,=,=,Occ,%,100.0,Occ,%,100.0,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5CCOC)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
"Invivo target occupancy at KRAS G12C mutant in human MIA PaCa-2 cells xenografted mouse assessed as decrease in DUSPS6 expression at 30 mg/kg, po after 3 hrs",C=CC(=O)N1CC2(CC(n3nc(-c4ccc5nn(CCOC)cc5c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,,,Occ,,,Occ,,,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5nn(CCOC)cc5c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
"Invivo target occupancy at KRAS G12C mutant in human MIA PaCa-2 cells xenografted mouse assessed as decrease in DUSPS6 expression at 30 mg/kg, po after 6 hrs",C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5C)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,=,=,Occ,%,37.0,Occ,%,37.0,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5C)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
"Invivo target occupancy at KRAS G12C mutant in human MIA PaCa-2 cells xenografted mouse assessed as decrease in DUSPS6 expression at 30 mg/kg, po after 6 hrs",C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5CCN(C)C)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,,,Occ,,,Occ,,,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5CCN(C)C)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
"Invivo target occupancy at KRAS G12C mutant in human MIA PaCa-2 cells xenografted mouse assessed as decrease in DUSPS6 expression at 30 mg/kg, po after 6 hrs",C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5CCOC)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,,,Occ,,,Occ,,,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5CCOC)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
"Invivo target occupancy at KRAS G12C mutant in human MIA PaCa-2 cells xenografted mouse assessed as decrease in DUSPS6 expression at 30 mg/kg, po after 6 hrs",C=CC(=O)N1CC2(CC(n3nc(-c4ccc5nn(CCOC)cc5c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,=,=,Occ,%,45.0,Occ,%,45.0,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5nn(CCOC)cc5c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
"Invivo target occupancy at KRAS G12C mutant in human MIA PaCa-2 cells xenografted mouse assessed as decrease in DUSPS6 expression at 30 mg/kg, po after 24 hrs",C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5C)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,=,=,Occ,%,100.0,Occ,%,100.0,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5C)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
"Invivo target occupancy at KRAS G12C mutant in human MIA PaCa-2 cells xenografted mouse assessed as decrease in DUSPS6 expression at 30 mg/kg, po after 24 hrs",C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5CCN(C)C)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,,,Occ,,,Occ,,,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5CCN(C)C)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
"Invivo target occupancy at KRAS G12C mutant in human MIA PaCa-2 cells xenografted mouse assessed as decrease in DUSPS6 expression at 30 mg/kg, po after 24 hrs",C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5CCOC)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,=,=,Occ,%,100.0,Occ,%,100.0,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5CCOC)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
"Invivo target occupancy at KRAS G12C mutant in human MIA PaCa-2 cells xenografted mouse assessed as decrease in DUSPS6 expression at 30 mg/kg, po after 24 hrs",C=CC(=O)N1CC2(CC(n3nc(-c4ccc5nn(CCOC)cc5c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,=,=,Occ,%,59.0,Occ,%,59.0,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5nn(CCOC)cc5c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
"Displacement of [acrylamide-2,3-3H2]-N-(3-fluoro-4-(2-methyl-3-(5-methyl-1H- indazole-4-yl)-1H-pyrrolo[ 2,3-b]pyridin-1-yl)-phenyl from KRAS G12C mutant (unknown origin) assessed as ratio of Kinact/Ki by MS based assay",C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5C)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,CHEMBL5236595,=,=,Ratio,/mM/s,24.3,Ratio,/mM/s,24.3,C=CC(=O)N1CC2(CC(n3nc(-c4ccc5c(cnn5C)c4)c(-c4c(Cl)c(C)cc5[nH]ncc45)c3C)C2)C1,2022
Binding affinity to KRAS G12C mutant (unknown origin) assessed as covalent bond formation by measuring Kobs/[I] ratio,C=CC(=O)N1CC(NC(=O)COc2ccc(Br)cc2NC(=O)c2cc(C)no2)C1,CHEMBL5241099,=,=,Ratio,/M/s,2.0,Ratio,/M/s,2.0,C=CC(=O)N1CC(NC(=O)COc2ccc(Br)cc2NC(=O)c2cc(C)no2)C1,2021
Binding affinity to KRAS G12C mutant (unknown origin) assessed as covalent bond formation by measuring Kobs/[I] ratio,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)ccc32)C1,CHEMBL5241099,=,=,Ratio,/M/s,230.0,Ratio,/M/s,230.0,C=CC(=O)N1CC(NC(=O)Cn2cc(C(=O)N3CCc4c(cccc4OC)C3)c3cc(Br)ccc32)C1,2021
Covalent modification of KRAS G12C mutant (unknown origin) at 5 uM incubated for 3 hrs relative to control,C=CC(=O)N1CCN(c2ncnc3c2CCN(c2cccc4ccccc24)C3)CC1,CHEMBL5241099,=,=,Activity,%,13.0,Activity,%,13.0,C=CC(=O)N1CCN(c2ncnc3c2CCN(c2cccc4ccccc24)C3)CC1,2021
Covalent modification of KRAS G12C mutant (unknown origin) at 5 uM incubated for 3 hrs relative to control,C=CC(=O)N1CCN(c2ncnc3c2CCN(c2cc(O)cc4ccccc24)C3)CC1,CHEMBL5241099,=,=,Activity,%,99.0,Activity,%,99.0,C=CC(=O)N1CCN(c2ncnc3c2CCN(c2cc(O)cc4ccccc24)C3)CC1,2021
Covalent modification of KRAS G12C mutant (unknown origin) at 3 uM incubated for 15 mins relative to control,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cc(O)cc4ccccc24)C3)CC1,CHEMBL5241099,=,=,Activity,%,84.0,Activity,%,84.0,C=CC(=O)N1CCN(c2nc(OC[C@@H]3CCCN3C)nc3c2CCN(c2cc(O)cc4ccccc24)C3)CC1,2021
Inhibition of KRAS G12C mutant in human NCI-H358 cells incubated for 6 hrs by LC-MS/MS analysis,C=CC(=O)N1CC(N2CCN(C(=O)CNc3cc(C4(C)CC4)c(Cl)cc3O)CC2)C1,CHEMBL5241099,=,=,IC50,nM,1600.0,IC50,uM,1.6,C=CC(=O)N1CC(N2CCN(C(=O)CNc3cc(C4(C)CC4)c(Cl)cc3O)CC2)C1,2021
Inhibition of KRAS G12C mutant in human NCI-H358 cells incubated for 6 hrs by LC-MS/MS analysis,C=CC(=O)N1CCN(C(=O)CNc2cc(I)c(Cl)cc2O)CC1,CHEMBL5241099,=,=,IC50,nM,100000.0,IC50,uM,100.0,C=CC(=O)N1CCN(C(=O)CNc2cc(I)c(Cl)cc2O)CC1,2021
Inhibition of KRAS G12C mutant in human NCI-H358 cells incubated for 6 hrs by LC-MS/MS analysis,C=CC(=O)N1CC(N2CCN(C(=O)CNc3cc(Cl)c(Cl)cc3O)CC2)C1,CHEMBL5241099,=,=,IC50,nM,50000.0,IC50,uM,50.0,C=CC(=O)N1CC(N2CCN(C(=O)CNc3cc(Cl)c(Cl)cc3O)CC2)C1,2021
Inhibition of KRAS G12C mutant in human NCI-H358 cells assessed as reduction in ERK phosphorylation incubated for 24 hrs by immunoblot analysis,C=CC(=O)N1CCN(c2ncnc3c(F)c(-c4c(O)cccc4F)c(Cl)cc23)CC1,CHEMBL5241099,=,=,IC50,nM,120.0,IC50,uM,0.12,C=CC(=O)N1CCN(c2ncnc3c(F)c(-c4c(O)cccc4F)c(Cl)cc23)CC1,2021
Binding affinity to GppNHp-tagged KRAS G12V mutant (unknown origin),O=C(NCC1COc2ccccc2O1)c1ccco1,CHEMBL5241099,=,=,Kd,nM,235000.0,Kd,uM,235.0,O=C(NCC1COc2ccccc2O1)c1ccco1,2021
Binding affinity to GppNHp-tagged KRAS G12V mutant (unknown origin),COc1nc(-c2cccc3c2OCCO3)ccc1Nc1ccc(CN(C)C)cc1,CHEMBL5241099,=,=,Kd,nM,51.0,Kd,uM,0.051,COc1nc(-c2cccc3c2OCCO3)ccc1Nc1ccc(CN(C)C)cc1,2021
Binding affinity to GDP-bound KRAS G12D mutant (unknown origin) by 1H/15N HSQC spectra analysis,CC[C@H](C)[C@H](N)C(=O)Nc1ccc2[nH]c(Cc3cc4ccccc4[nH]3)nc2c1,CHEMBL5241099,=,=,Kd,nM,190000.0,Kd,uM,190.0,CC[C@H](C)[C@H](N)C(=O)Nc1ccc2[nH]c(Cc3cc4ccccc4[nH]3)nc2c1,2021
Inhibition of recombinant GDP-bound KRAS G12D mutant (unknown origin) expressed in Escherichia coli Rosetta 2 (DE3) assessed as inhibition of SOS mediated nucleotide exchange at 1 mM relative to control,CC[C@H](C)[C@H](N)C(=O)Nc1ccc2[nH]c(Cc3cc4ccccc4[nH]3)nc2c1,CHEMBL5241099,=,=,Inhibition,%,78.0,INH,%,78.0,CC[C@H](C)[C@H](N)C(=O)Nc1ccc2[nH]c(Cc3cc4ccccc4[nH]3)nc2c1,2021
Covalent binding affinity to 6His tagged GDP bound human KRAS G12C mutant (1 to 169 residues) expressed in Escherichia coli BL21 (DE3) cells at 200 uM incubated for 24 hrs by LC-MS /MS analysis,O=C(Nc1ccc(Cl)cc1)NC1CCN(C(=O)CCl)CC1,CHEMBL5247585,,,Activity,,,Activity,,,O=C(Nc1ccc(Cl)cc1)NC1CCN(C(=O)CCl)CC1,2022
Covalent binding affinity to 6His tagged GDP bound human KRAS G12C mutant (1 to 169 residues) expressed in Escherichia coli BL21 (DE3) cells at 200 uM incubated for 24 hrs by LC-MS /MS analysis,O=C(Nc1ccc(Cl)c(C(F)(F)F)c1)NC1CCN(C(=O)CCl)CC1,CHEMBL5247585,,,Activity,,,Activity,,,O=C(Nc1ccc(Cl)c(C(F)(F)F)c1)NC1CCN(C(=O)CCl)CC1,2022
Covalent binding affinity to 6His tagged GDP bound human KRAS G12C mutant (1 to 169 residues) expressed in Escherichia coli BL21 (DE3) cells at 200 uM incubated for 24 hrs by LC-MS /MS analysis,O=C(CCl)N1CCN(C(=O)Nc2ccc(Cl)c(-c3ccccc3F)c2)CC1,CHEMBL5247585,,,Activity,,,Activity,,,O=C(CCl)N1CCN(C(=O)Nc2ccc(Cl)c(-c3ccccc3F)c2)CC1,2022
Covalent binding affinity to 6his tagged GDP bound human wildtype KRAS expressed in Escherichia coli BL21 (DE3) cells at 200 uM incubated for 24 hrs by LC-MS/MS analysis,O=C(Nc1ccc(Cl)cc1)NC1CCN(C(=O)CCl)CC1,CHEMBL5247585,,,Activity,,,Activity,,,O=C(Nc1ccc(Cl)cc1)NC1CCN(C(=O)CCl)CC1,2022
Covalent binding affinity to 6his tagged GDP bound human wildtype KRAS expressed in Escherichia coli BL21 (DE3) cells at 200 uM incubated for 24 hrs by LC-MS/MS analysis,O=C(Nc1ccc(Cl)c(C(F)(F)F)c1)NC1CCN(C(=O)CCl)CC1,CHEMBL5247585,,,Activity,,,Activity,,,O=C(Nc1ccc(Cl)c(C(F)(F)F)c1)NC1CCN(C(=O)CCl)CC1,2022
Covalent binding affinity to 6his tagged GDP bound human wildtype KRAS expressed in Escherichia coli BL21 (DE3) cells at 200 uM incubated for 24 hrs by LC-MS/MS analysis,O=C(CCl)N1CCN(C(=O)Nc2ccc(Cl)c(-c3ccccc3F)c2)CC1,CHEMBL5247585,,,Activity,,,Activity,,,O=C(CCl)N1CCN(C(=O)Nc2ccc(Cl)c(-c3ccccc3F)c2)CC1,2022
Inhibition of 6His tagged Mant-GDP loaded human KRAS G12C mutant (1 to 169 residues) expressed in Escherichia coli BL21 (DE3) cells assessed as inhibition of SOS1-mediated nucleotide exchange at 10 uM preincubated with compound for 1 hrs followed by addition of GTP and SOS1 protein and measured every 90 sec for 2 hrs by fluorescence based assay,O=C(Nc1ccc(Cl)cc1)NC1CCN(C(=O)CCl)CC1,CHEMBL5247585,,,Inhibition,%,,INH,,,O=C(Nc1ccc(Cl)cc1)NC1CCN(C(=O)CCl)CC1,2022
Inhibition of 6His tagged Mant-GDP loaded human KRAS G12C mutant (1 to 169 residues) expressed in Escherichia coli BL21 (DE3) cells assessed as inhibition of SOS1-mediated nucleotide exchange at 10 uM preincubated with compound for 1 hrs followed by addition of GTP and SOS1 protein and measured every 90 sec for 2 hrs by fluorescence based assay,O=C(Nc1ccc(Cl)c(C(F)(F)F)c1)NC1CCN(C(=O)CCl)CC1,CHEMBL5247585,,,Inhibition,%,,INH,,,O=C(Nc1ccc(Cl)c(C(F)(F)F)c1)NC1CCN(C(=O)CCl)CC1,2022
Inhibition of 6His tagged Mant-GDP loaded human KRAS G12C mutant (1 to 169 residues) expressed in Escherichia coli BL21 (DE3) cells assessed as inhibition of SOS1-mediated nucleotide exchange at 10 uM preincubated with compound for 1 hrs followed by addition of GTP and SOS1 protein and measured every 90 sec for 2 hrs by fluorescence based assay,O=C(CCl)N1CCN(C(=O)Nc2ccc(Cl)c(-c3ccccc3F)c2)CC1,CHEMBL5247585,,,Inhibition,%,,INH,,,O=C(CCl)N1CCN(C(=O)Nc2ccc(Cl)c(-c3ccccc3F)c2)CC1,2022
Inhibition of 6His tagged Mant-GDP loaded human KRAS G12C mutant (1 to 169 residues) expressed in Escherichia coli BL21 (DE3) cells assessed as inhibition of GDP-catalyed nucleotide exchange at 10 uM preincubated with compound for 1 hrs followed by addition of GTP and EDTA and measured every 90 sec for 2 hrs by fluorescence based assay,O=C(Nc1ccc(Cl)cc1)NC1CCN(C(=O)CCl)CC1,CHEMBL5247585,,,Inhibition,%,,INH,,,O=C(Nc1ccc(Cl)cc1)NC1CCN(C(=O)CCl)CC1,2022
Inhibition of 6His tagged Mant-GDP loaded human KRAS G12C mutant (1 to 169 residues) expressed in Escherichia coli BL21 (DE3) cells assessed as inhibition of GDP-catalyed nucleotide exchange at 10 uM preincubated with compound for 1 hrs followed by addition of GTP and EDTA and measured every 90 sec for 2 hrs by fluorescence based assay,O=C(Nc1ccc(Cl)c(C(F)(F)F)c1)NC1CCN(C(=O)CCl)CC1,CHEMBL5247585,,,Inhibition,%,,INH,,,O=C(Nc1ccc(Cl)c(C(F)(F)F)c1)NC1CCN(C(=O)CCl)CC1,2022
Inhibition of 6His tagged Mant-GDP loaded human KRAS G12C mutant (1 to 169 residues) expressed in Escherichia coli BL21 (DE3) cells assessed as inhibition of GDP-catalyed nucleotide exchange at 10 uM preincubated with compound for 1 hrs followed by addition of GTP and EDTA and measured every 90 sec for 2 hrs by fluorescence based assay,O=C(CCl)N1CCN(C(=O)Nc2ccc(Cl)c(-c3ccccc3F)c2)CC1,CHEMBL5247585,,,Inhibition,%,,INH,,,O=C(CCl)N1CCN(C(=O)Nc2ccc(Cl)c(-c3ccccc3F)c2)CC1,2022
Inhibition of KRAS signaling in human NCI-H2228 cells harboring wildtype KRAS at 0.5 to 8 uM incubated for 6 hrs by Western blot analysis,O=C(CCl)N1CCN(C(=O)Nc2ccc(Cl)c(-c3ccccc3F)c2)CC1,CHEMBL5247585,,,Inhibition,%,,INH,,,O=C(CCl)N1CCN(C(=O)Nc2ccc(Cl)c(-c3ccccc3F)c2)CC1,2022
"Invivo inhibition of KRAS signaling in BALB/C mouse xenografted with human NCI-H358 cells harboring KRAS G12C mutant assessed as decrease in ERK phosphorylation in tumor at 10 to 15 mg/kg, ip administered for 21 days by IHC staining based analysis",O=C(CCl)N1CCN(C(=O)Nc2ccc(Cl)c(-c3ccccc3F)c2)CC1,CHEMBL5247585,,,Inhibition,%,,INH,,,O=C(CCl)N1CCN(C(=O)Nc2ccc(Cl)c(-c3ccccc3F)c2)CC1,2022
